<SEC-DOCUMENT>0001069530-23-000017.txt : 20230501
<SEC-HEADER>0001069530-23-000017.hdr.sgml : 20230501
<ACCEPTANCE-DATETIME>20230501092513
ACCESSION NUMBER:		0001069530-23-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230501
DATE AS OF CHANGE:		20230501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CASSAVA SCIENCES INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29959
		FILM NUMBER:		23870623

	BUSINESS ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
		BUSINESS PHONE:		512-501-2444

	MAIL ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PAIN THERAPEUTICS INC
		DATE OF NAME CHANGE:	20000309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sava-20230331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Inline XBRL document created by Certent Disclosure Management 1.0.0.0-->
<!--Created on: 05/01/2023 13:20:06 PM-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:sava="http://www.cassavasciences.com/20230331" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <head>
    <title>sava-20230331x10q</title>
    <meta http-equiv="Content-Type" content="text/html" /></head>
  <body xml:lang="en-US">
    <div style="display:none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="ct-nonNumeric-ba1ff8d6-a35f-4bf9-9151-555a3dd11e7f" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="ct-nonNumeric-23e35512-eeb5-449f-a1c2-4f98e71b33ea" contextRef="Duration_1_1_2023_To_3_31_2023">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="ct-nonNumeric-180d411d-6d07-43b7-9c3e-f51316c20bf4" contextRef="Duration_1_1_2023_To_3_31_2023">Q1</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="ct-nonNumeric-0bbbc5fb-8925-4c27-a029-2ee86f047dcf" contextRef="Duration_1_1_2023_To_3_31_2023">2023</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="ct-nonNumeric-13a290a7-15eb-4798-83c2-21753cdb54a3" contextRef="Duration_1_1_2023_To_3_31_2023">0001069530</ix:nonNumeric><ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="ct-nonNumeric-2ee72825-f424-4cad-989d-4fdf3594c244" contextRef="Duration_1_1_2023_To_3_31_2023">Yes</ix:nonNumeric><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="ct-nonNumeric-5a52fcd1-2225-4e77-80d9-13ca85140cc1" contextRef="Duration_1_1_2023_To_3_31_2023">Yes</ix:nonNumeric><ix:nonFraction id="ct-nonFraction-cbc88618-b081-4619-b685-3e0fad376ad5" name="us-gaap:CommitmentsAndContingencies" contextRef="As_Of_12_31_2022" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-dc8da0e0-df89-4507-a6dd-b30ddbfcd92f" name="us-gaap:CommitmentsAndContingencies" contextRef="As_Of_3_31_2023" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-cf2a5b87-8893-455d-a0c1-91fb0a2ee367" name="us-gaap:PreferredStockValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-e8e3c658-e35d-4eea-99f7-fdbacb758fa7" name="us-gaap:PreferredStockValue" contextRef="As_Of_3_31_2023" unitRef="Unit12" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-b786222f-0c6a-455c-9a63-3cd0d3ae33f5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-05eb815c-fd10-48c9-8d79-99d6ee0a77d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-a22d958c-bef2-4f73-8328-e8bfeb74d56d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-4c45888e-635f-47a9-8d16-d034a6483bd4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="ct-nonFraction-dd238c04-f83e-48b9-bb8b-2c297a0680b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sava-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_5_2022_To_5_5_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:StockOptionAndPerformanceAwardActivity2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2023_To_4_30_2023_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-30</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_OperatingLeasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:OperatingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sava:TwoBuildingOfficeComplexAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2021_To_11_4_2021_srt_LitigationCaseAxis_sava_ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_28_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-28</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_OperatingLeasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:OperatingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_5_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:StockOptionAndPerformanceAwardActivity2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sava:TwoBuildingOfficeComplexAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_1_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2022_To_6_30_2022_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_TitleOfIndividualAxis_sava_IndependentDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:IndependentDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:FirstValuationMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_27_2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit17"><xbrli:measure>sava:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit16"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit15"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit14"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit13"><xbrli:measure>sava:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit12"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit1"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
    <div class="headerContainer"></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 14pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.21in;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 14pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">UNITED STATES</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 14pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 14pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SECURITIES AND EXCHANGE COMMISSION</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Washington, D.C. 20549</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_____________________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 16pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 16pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Form </span><ix:nonNumeric name="dei:DocumentType" id="ct-nonNumeric-db49bb90-90c1-4054-b075-883e7fe336f6" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 16pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">10-Q</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_____________________</span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 9.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 79.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 79.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 3.20in;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Mark One)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 11.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 79.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="ct-nonNumeric-1658005c-f64d-4906-992b-5fd6ef864ec3" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt:booleantrue"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#254;</span></span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 11.8%;"><p dir="ltr" style="font-family: Wingdings;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 79.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 11.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">For the Quarterly Period Ended </span><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="ct-nonNumeric-e4c724dc-6981-4f37-bed5-3c9d05c148d5" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt:datemonthdayyearen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31, 2023</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">or</span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 79.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 11.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 79.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="ct-nonNumeric-fe7fe05a-bb50-4472-a93c-e16248ef9c7c" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 11.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 9.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 79.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the Transition Period from ___________ to ___________</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 11.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Commission File Number: </span><ix:nonNumeric name="dei:EntityFileNumber" id="ct-nonNumeric-6a7c56e7-384f-4484-b81a-e1cbc253b3d0" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">000-29959</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_______________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Sansation;font-size: 22pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityRegistrantName" id="ct-nonNumeric-357e6b00-3a5f-4492-b430-7ef8bccfd707" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; color: #1F497D;font-family: Sansation;font-size: 22pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cassava Sciences, Inc.</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 22pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 22pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(Exact name of registrant as specified in its charter)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 3pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 3pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 22.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 27.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 25.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 24.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 22.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 27.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="ct-nonNumeric-4114d034-ebf5-48a0-b11d-02ae9f3d039d" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt-sec:stateprovnameen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Delaware</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 25.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="ct-nonNumeric-eea3cce6-72a0-43d7-83bd-b02220492110" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">91-1911336</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 24.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 22.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 27.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(State</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">or</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">other</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">jurisdiction</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">of</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 25.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(I.R.S.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Employer</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 24.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 22.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 27.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">incorporation</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">or</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">organization)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 25.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Identification</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Number)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 24.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="ct-nonNumeric-9c223c3f-d3f3-41ed-9f76-d0cce480ba27" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6801 N. Capital of Texas Highway</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, </span><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="ct-nonNumeric-a89c59e1-95c7-4be4-8bb7-c0c1e7faae99" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Building 1; Suite 300</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, </span><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="ct-nonNumeric-b60e1356-2b66-4049-9acf-9cd7a3cfb0c9" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Austin</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, </span><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="ct-nonNumeric-a164ed87-c135-4254-af64-1a53c58610d2" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">TX</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="ct-nonNumeric-fecb4b23-92f7-42da-98f7-96108b55fa99" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">78731</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><ix:nonNumeric name="dei:CityAreaCode" id="ct-nonNumeric-fdc8ed95-f5e2-4d70-b800-056098db3db4" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">512</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) </span><ix:nonNumeric name="dei:LocalPhoneNumber" id="ct-nonNumeric-42e2f4d9-7f90-49d5-8c65-c08980296962" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">501-2444</span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">(Address, including zip code, of registrant&#8217;s principal executive offices and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">telephone number, including area code)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Securities registered pursuant to Section 12(b) of the Act:</span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 38.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0</span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 38.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Title of each class</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Trading</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Symbol(s)</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Name of each exchange on which registered</span></p></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: top;width: 38.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="ct-nonNumeric-ca4e16c7-6570-4b11-8b6e-e81d0ffb0172" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common Stock, $0.001 par value</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 15.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="ct-nonNumeric-07b676e3-21b0-46ae-a5a3-707cbc0e419c" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SAVA</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-top: 0;vertical-align: bottom;width: 45.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="ct-nonNumeric-5e01c39d-0ecb-4708-846e-95405e4e1452" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt-sec:exchnameen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Nasdaq</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Capital Market </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-2ee72825-f424-4cad-989d-4fdf3594c244;">&#254;</span></span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160; &#160;No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonNumeric-5a52fcd1-2225-4e77-80d9-13ca85140cc1;">&#254;</span></span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;No&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See </span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;">the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; </span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;">&#8220;smaller</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reporting company,</span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;">&#8221; and &#8220;emerging growth company&#8221;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in Rule 12b-2 of the Exchange Act.</span></p><div style="padding-left: 0;text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 37.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 62.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 30.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="dei:EntityFilerCategory" id="ct-nonNumeric-44f1e2a9-0ee5-4184-a9de-3bc703541586" contextRef="Duration_1_1_2023_To_3_31_2023"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Large Accelerated Filer</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  </span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#254;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 62.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accelerated Filer </span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 30.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Non-accelerated Filer  </span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 62.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Smaller Reporting Company   </span><ix:nonNumeric name="dei:EntitySmallBusiness" id="ct-nonNumeric-9220927f-348e-4445-a0d7-57cec8e1174d" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></ix:nonNumeric></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 7.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 30.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 62.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Emerging Growth Company  </span><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="ct-nonNumeric-49fb2261-58da-42af-acbe-922e0c58f308" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></ix:nonNumeric></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 6pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 6pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span></p><p dir="ltr" style="font-family: Wingdings;font-size: 9pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2</span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> of the Exchange Act</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">). Yes&#160;</span><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#168;</span></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;&#160;&#160;No&#160;</span><ix:nonNumeric name="dei:EntityShellCompany" id="ct-nonNumeric-94125644-9401-407b-a10e-e9d83f19de3c" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt:booleanfalse"><span style="white-space:pre-wrap; font-family: Wingdings;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; font-family: &quot;Wingdings&quot;">&#254;</span></span></ix:nonNumeric></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Indicate the number of shares outstanding of each of</span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> the</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> issuer&#8217;s classes of common stock, as of the latest practicable date.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="padding-left: 0;text-align:center"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: auto;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #FFFFFF;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #FFFFFF;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 41.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 39.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 41.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 39.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Common Stock, $0.001 par value</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 41.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;"><ix:nonFraction id="ct-nonFraction-7b2cad65-3bcd-4bcf-b49c-1fd7ba4c1abc" name="dei:EntityCommonStockSharesOutstanding" contextRef="As_Of_4_27_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">41,749,435</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 39.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 41.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares&#160;Outstanding&#160;as&#160;of&#160;April 27,&#160;2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 8.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 2pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 2pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">1</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">TABLE OF CONTENTS</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="padding-left: 0;text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 74.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Page No.</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PART I.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FINANCIAL INFORMATION</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 1.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial Statements</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Balance_Sheets" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Condensed C</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">onsolidated </span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Balance Sheets &#8211; </span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">March</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;"> 31, 2023 and December 31, 2022</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Statements_of_Operations" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Condensed Consolidated Statements of Operations &#8211; Three</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"></span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Months Ended </span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">March</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;"> 31, 2</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">023 and 2022</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Stock_Holders_Equity" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity - Three Months Ended March 31, 2023 and 2022</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Statements_of_Cash_Flows" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Condensed Consolidated Statements of Cash Flows &#8211; </span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Three </span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Months Ende</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">d March</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;"> 31, 2023 and 2022</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Notes_To_Financial_Statements" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 2.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#MDA" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">16</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 3.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Quantitative_And_Qualitative_Disclosures" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">31</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 4.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Controls_And_Procedures" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Controls and Procedures</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">31</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">PART II.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">OTHER INFORMATION</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 1.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Legal_Proceedings" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Legal Proceedings</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">32</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 1A</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Risk_Factors" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Risk Factors</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 2.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Unregistered_Sales" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 3.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Defaults_Upon_Senior_Securities" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Defaults Upon Senior Securities</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 4.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Mine_Safety" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Mine Safety Disclosures</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 5.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Other_Information" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Other Information</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">33</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">   Item 6.</span></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Exhibits" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Exhibits</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 12.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 73.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="3" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 86.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="#Signatures" style="text-decoration: none;"><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Signatures</span></a></p></td><td colspan="2" style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 13.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">35</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">2</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Times;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: Times;font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART I.  FINANCIAL</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> INFORMATION</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="Balance_Sheets" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Financial Statements</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sub> </sub></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.19in;margin-right: 0.02in;margin-top: 0;text-align: center;text-indent: -0.19in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.02in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p></td></tr><tr style="height: 0.07in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.22in;"><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></p></td></tr><tr style="height: 0.18in;"><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Unaudited, In thousands, except share and par value data)</span></p></td></tr><tr style="height: 0.18in;"><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.35in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31, </span><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr style="height: 0.15in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">ASSETS</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current assets:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-284d8c79-d3b3-43b8-8949-62c992b4c363" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">187,467</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-daf94512-cdde-4bbb-8d57-f6415c02b8b2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">201,015</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid expenses and other current assets</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8b4d1fbc-f112-41fa-a600-4d730e039641" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,532</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-46d8bb3b-6a32-4913-bc67-977275ccde7a" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,211</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total current assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0de1f0dd-c983-4494-a6b1-1658e0c06b33" name="us-gaap:AssetsCurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">194,999</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a66db293-d1b1-4c20-9aba-3d73b94fae1e" name="us-gaap:AssetsCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">211,226</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-50cc5f27-b929-45b3-b2eb-bf5142e2ecd2" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">122</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment, net</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-35933e12-12d6-48d8-8f21-5e9c25e44e81" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,609</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9c14825f-5aca-46d1-ad8d-5918de7210b4" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,864</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets, net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-608d3135-cb50-4ba9-87e7-f9964f4965cf" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">503</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bd687735-5cad-4ece-820a-24d6963b995e" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">622</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total assets</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3b63652f-bdd3-496d-b7d6-f64841a0711d" name="us-gaap:Assets" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">218,111</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2830550d-a0e2-4fd9-80f0-2ff99575746e" name="us-gaap:Assets" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">234,834</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.18in;"><td colspan="6" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">LIABILITIES AND STOCKHOLDERS&apos; EQUITY</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Current liabilities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts payable and accrued expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a29293d9-835c-4560-af26-7e57a7295731" name="us-gaap:AccountsPayableCurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">8,242</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a30e50db-bc46-46ba-97b4-3172c8b70909" name="us-gaap:AccountsPayableCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,017</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued development expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3f998460-8fe6-4d64-af7b-f5741286cc9d" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">5,276</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4dfcf56f-5a41-428c-b898-ca7534f06165" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,280</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued compensation and benefits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d1b6d2fb-2760-474f-b449-c47da3bdad8a" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">212</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-066181d2-9415-4342-9fbe-d9201c2b6f14" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">170</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, current</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-215601da-ad4f-4774-b217-d94dea41aed0" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">104</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other current liabilities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e59def4-be2c-43fb-a559-961acf45bb6d" name="us-gaap:OtherLiabilitiesCurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">179</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6ec0d1e2-2d19-48a8-a82b-0d099e7a903f" name="us-gaap:OtherLiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">492</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total current liabilities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-82061396-0a17-4de5-a924-1f5a99f33650" name="us-gaap:LiabilitiesCurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13,909</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-15491824-5da1-4eda-832f-9cda25b392e1" name="us-gaap:LiabilitiesCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,063</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, non-current</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6f7735c2-698d-4946-98cb-11be73cc6a95" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">35</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other non-current liabilities</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a827be24-87ef-429d-bcda-27d586dcd399" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">197</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-168c6178-2d1e-423c-8684-0be3c6a475f6" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">197</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total liabilities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-eb37df70-d629-46b4-aaba-dbf3f16ebfb0" name="us-gaap:Liabilities" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,106</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b74fb81a-e4e5-4e9b-b2b9-6e7ecbd5c638" name="us-gaap:Liabilities" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,295</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Commitments and contingencies (Notes 10, 11 and 12)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-dc8da0e0-df89-4507-a6dd-b30ddbfcd92f;">&#160;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-cbc88618-b081-4619-b685-3e0fad376ad5;">&#160;</span></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stockholders&apos; equity:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Preferred stock, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-21ad2be7-8289-4f2c-adb8-3af2d4c95694" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2022" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-2ed3a297-0251-4ecf-a811-ba62e3a76d84" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="As_Of_3_31_2023" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value; </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1d236f44-14a5-4ac2-aa51-9cf5ddf2713f" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-11b2a8b7-2da2-47ff-8e5e-97ed2df22833" name="us-gaap:PreferredStockSharesAuthorized" contextRef="As_Of_3_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares authorized, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37211f3c-60f7-400e-815a-0c00ed267645" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-aa88cb0e-73cc-484d-a3de-e9082462f6d3" name="us-gaap:PreferredStockSharesIssued" contextRef="As_Of_3_31_2023" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-e01cccfb-416e-4b27-a0fc-be84d009db0e" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="ct-nonFraction-3a4d3b14-3897-4b39-be90-9ba8d5b66028" name="us-gaap:PreferredStockSharesOutstanding" contextRef="As_Of_3_31_2023" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> issued and outstanding</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-e8e3c658-e35d-4eea-99f7-fdbacb758fa7;">&#8212;</span></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-cf2a5b87-8893-455d-a0c1-91fb0a2ee367;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Common stock, $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8f8bca4e-210c-4502-8d65-27f81a791343" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_12_31_2022" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-67c603b6-cb4b-457c-a7bf-a97731ffeae2" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_3_31_2023" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> par value; </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1b033372-0544-4067-b8cd-4458c4045dad" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-121bc351-05e8-461e-8c76-097c0f094acb" name="us-gaap:CommonStockSharesAuthorized" contextRef="As_Of_3_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">120,000,000</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares authorized; </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f07c1b8d-ffc3-457f-b116-719f58187a3a" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_3_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-32c75f56-f63e-4bd8-a2f2-f63146fbfe00" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_3_31_2023" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">41,749,435</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a31f77dd-d01c-483b-8f76-968b94a91262" name="us-gaap:CommonStockSharesIssued" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="ct-nonFraction-31e5dd03-7ff0-416b-ac64-adc3a6ca30ca" name="us-gaap:CommonStockSharesOutstanding" contextRef="As_Of_12_31_2022" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">41,735,557</ix:nonFraction></ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9f5c87f6-3f60-416c-9204-0cdaf47eb6f8" name="us-gaap:CommonStockValue" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">42</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b59ca39c-5af6-4ed0-9689-5c061c2f6cf9" name="us-gaap:CommonStockValue" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">42</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Additional paid-in capital</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7700dbb6-1588-4f31-ac1a-90dd73e8596e" name="us-gaap:AdditionalPaidInCapital" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">511,786</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0095a48b-21a7-4183-a5a0-9ebdfb84c32f" name="us-gaap:AdditionalPaidInCapital" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">511,049</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated deficit</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-93179a7c-a6bf-42c6-b620-02386e92537e" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">307,823</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-42b0d102-a88a-4b6f-95ab-65c5b5b70f91" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">283,552</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stockholders&apos; equity </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-549496ec-61be-454e-80d6-35d6af091d04" name="us-gaap:StockholdersEquity" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">204,005</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4052fe62-8e0f-40c6-a226-b3904ad7348a" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">227,539</ix:nonFraction></span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total liabilities and stockholders&apos; equity</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-08cb176e-4d77-41f7-92be-2555ef0c5db2" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">218,111</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2c9fe665-26f1-4f33-aeb9-208bfeb9c844" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">234,834</ix:nonFraction></span></p></td></tr><tr style="height: 0.07in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 70.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.19in;margin-right: 0.02in;margin-top: 0;text-align: center;text-indent: -0.19in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.19in;margin-right: 0.02in;margin-top: 0;text-align: center;text-indent: -0.19in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> See accompanying notes to condensed consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">3</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span id="Statements_of_Operations" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: Times;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Times;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Times;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Enstivity</span></p><p dir="ltr" style="font-family: Times;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></p></td></tr><tr><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Unaudited, in thousands, except per share data)</span></p></td></tr><tr><td colspan="8" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating expenses:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development, net of grant reimbursement</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-39d101f4-1c7c-49d3-ba04-eaa37d145a37" name="sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,120</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ee1c01ee-bd83-4778-b807-d4b7b3659605" name="sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">14,906</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b30e9751-2e51-4298-8bce-c4a4e2adc9d7" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,392</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0422f7f5-1153-4a5a-912b-edffda8a6443" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,915</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total operating expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-224cca01-d471-47bd-977e-cc021e03b008" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">26,512</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1e058e37-aa6b-4f06-8a5e-51690d1f114c" name="us-gaap:OperatingExpenses" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17,821</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating loss</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d3180f6d-8a9b-466c-835b-7ba6e4cd35e8" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">26,512</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-01eb3002-fc93-4f3a-8568-d6d7cbe2b958" name="us-gaap:OperatingIncomeLoss" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">17,821</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest income</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3167b6a5-faba-49b4-9e72-dbbc4ca626cf" name="us-gaap:InterestAndOtherIncome" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,051</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-20c513d6-4e23-4a4c-a593-756f4c6b358f" name="us-gaap:InterestAndOtherIncome" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">31</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other income, net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-84859641-80e9-4d6d-97eb-f99ab4b4388a" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">190</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bb8f2718-092c-420d-b591-1bd97c19abb2" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">263</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2cc2d1df-c515-4c12-8383-c22fc48860e5" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">24,271</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-14254f39-1161-44fc-a1e9-b5cb54d6e6ff" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">17,527</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b1464ff1-c5a1-49a9-95eb-9485e483303e" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" sign="-">0.58</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-906a1442-84cb-48dc-82eb-f38280589574" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" sign="-">0.44</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-faccc685-51e1-4fa7-a1b6-8bb239465fb0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">41,739</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-afcf1627-4d83-4fbd-84c2-ed880c2eab57" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">39,962</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.8%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: Times;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Times;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: Times;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying notes to condensed </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">consolidated </span><span style="white-space:pre-wrap; font-family: Times;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">financial stateme</span><span style="white-space:pre-wrap; font-family: Times;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">nts.</span></p><p dir="ltr" style="font-family: Times;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Times;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span id="Stock_Holders_Equity" style="text-decoration: none;"></span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">4</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: Times;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: Times;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="14" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="14" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</span></p></td></tr><tr><td colspan="14" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Unaudited, in thousands, except share data)</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="4" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Common stock</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Additional</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Accumulated</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">stockholders&apos;</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Shares</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Par value</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">paid-in capital</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">deficit</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 7pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 7pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 7pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">equity</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Balance at December 31, 2021</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ff7a2c18-f1d9-4b39-b3e0-507ef131baec" name="us-gaap:SharesIssued" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">40,016,792</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a5d6e7c9-0884-4583-a537-b2e03cc8d93e" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">40</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f0504b58-7fac-46e9-b7ac-ad5a86359a3a" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">461,181</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d2acae48-3e55-4e48-961d-11d182167e69" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">207,306</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4a9e2eb2-53c4-4caf-9326-89501d20b6c1" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">253,915</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation for:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for employees</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d40afa37-53e3-4ddc-8c5f-254ac3b51586" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">471</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-32b6fa1b-9471-4bf4-b9a4-92c6382d5bb8" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">471</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for non-employees</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1415f7d0-26a4-45c5-9403-76e5e5c8aaf3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3043b68e-d149-4091-b232-1bb72c5737a1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock pursuant to exercise of stock options</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d4591aeb-4d02-48bc-b090-04ed8271434a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">14,488</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-13fd85ac-bb77-4f8f-bcf1-0b4ba8f977b7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">211</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-064694e0-231c-4a99-9b5f-d4a68b4fb222" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">211</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0c26c1a6-f53e-41c6-a9c8-2257e3388079" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">17,527</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1e903e94-fa2c-4167-9433-7e6dee877999" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">17,527</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Balance at March 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-76b7dac3-ed20-499f-9595-b8e045e7d13b" name="us-gaap:SharesIssued" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">40,031,280</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b05b99aa-3b52-4759-a779-5ffdd5dfee3d" name="us-gaap:StockholdersEquity" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">40</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2ab5eef9-ab28-49fb-9586-e43138dd20d0" name="us-gaap:StockholdersEquity" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">461,887</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e6bb3f6d-5ddc-496c-9374-8ec04a310d9e" name="us-gaap:StockholdersEquity" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">224,833</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1b0c409e-7b6d-4e04-af30-6a80c52a6f26" name="us-gaap:StockholdersEquity" contextRef="As_Of_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">237,094</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Balance at December 31, 2022</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5eb2e7cf-714b-4c1e-913a-a2fe14938751" name="us-gaap:SharesIssued" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">41,735,557</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c3aecad7-1d61-4b92-be3e-cca6fcf0cb30" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">42</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bc05f4c1-1e5c-4c61-a6f7-2bce643f067d" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">511,049</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1fec2147-d3f4-414b-8404-a3cc3fe75f07" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">283,552</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a9765cab-f677-441f-86a0-61eb82d32876" name="us-gaap:StockholdersEquity" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">227,539</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation for:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for employees</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-127819f2-75af-4e46-a3c7-afbf0311beb0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">650</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-688cb02d-b4cb-4355-93da-11af192b85ed" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">650</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock options for non-employees</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f05745d4-fa48-44c8-8913-434f685b226e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">23</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e4986608-40e0-44cb-9312-eb02aca1b6df" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">23</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Issuance of common stock pursuant to exercise of stock options</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0c131113-522a-499b-8625-c1318231039f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">13,878</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-33b39368-0be3-4b60-bb14-54d0779d8a80" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">64</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8669b04d-3afe-4da5-aea2-1fcab0c79d93" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">64</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> &#8212;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d007b72-8d17-42d2-bcf6-ec778fee9663" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">24,271</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a19f8224-112f-462a-9e65-2a9238ffed1b" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">24,271</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 51.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Balance at March 31, 2023</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-42b2dc13-785a-4d6f-93ac-b4ca4f91d134" name="us-gaap:SharesIssued" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">41,749,435</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 5.3%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a828bd37-e6bd-4f38-9883-500428bb25df" name="us-gaap:StockholdersEquity" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">42</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 8.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-130b7549-c963-4bcc-a00c-7a33f81d9fc4" name="us-gaap:StockholdersEquity" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">511,786</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.00in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7e19bef6-87c5-43b3-bf41-5f93a9d7bb64" name="us-gaap:StockholdersEquity" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">307,823</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.05in;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7260df80-5e60-4196-b43e-ccaa579e2765" name="us-gaap:StockholdersEquity" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">204,005</ix:nonFraction></span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Times;font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying notes to condensed consolidated financial statements.</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">5</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span id="Statements_of_Cash_Flows" style="text-decoration: none;"></span></p><div style="border-bottom-style: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CASSAVA SCIENCES, INC.</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 12pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p></td></tr><tr><td colspan="6" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(Unaudited, in thousands)</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from operating activities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-94b372ab-5779-47ac-a6cc-1e38a6ad3eaf" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">24,271</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2e691f4f-6e5e-40f2-87b5-e89ba37d5d3d" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">17,527</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.17in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Stock-based compensation</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.17in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-92594fa4-0c05-40e1-9f8b-2e1bd8111a8b" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">673</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-336f8214-77a4-486d-9f3e-e8119fa06550" name="us-gaap:ShareBasedCompensation" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">495</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.17in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.17in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a3b6fd3-cdf4-4d97-b678-3c7551cf8646" name="us-gaap:Depreciation" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">272</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-bbadb172-7a8b-4531-94c7-c2b6a1b84514" name="us-gaap:Depreciation" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">178</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.17in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization of intangible assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.17in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c3d729c2-3340-40b1-bdcf-bfea14f1c9f2" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">119</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-256c35b7-d5fb-416e-9377-5e4edb95873b" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">135</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.17in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Changes in operating assets and liabilities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.17in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid and other current assets</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9030b596-5c1f-4cf2-b3d6-b1c6813b100e" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">2,679</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a01ee60b-91ac-4f89-86be-47c0c9a2a5e5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,063</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease right-of-use assets and liabilities</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7ef4cafd-8b43-43e8-958b-b6dfeebd8281" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">17</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1f2535f9-86e5-4eea-9158-cc4174995a3c" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accounts payable and accrued expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b7bffbd4-02a7-4b77-8d31-2772b40093f9" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4,565</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d3a28ac-f79b-479e-88ff-6b3090cdec33" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">3,794</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued development expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2ed4bcd4-f5b0-4e30-a758-016f542e6932" name="sava:IncreaseDecreaseInDevelopmentExpense" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">2,996</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-59cae46e-8697-4d6a-8dfd-f0819b22e032" name="sava:IncreaseDecreaseInDevelopmentExpense" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">122</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accrued compensation and benefits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d50561df-85e8-42e9-b8a8-22d769c1f63d" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">42</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d6b8342e-b98f-40a5-b77e-e1f245d0ba13" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">1,705</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other liabilities</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.25in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c67dcfac-ea60-4f3e-93f7-d56c0fdad65b" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">313</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6deb50e1-c884-4951-9924-25bfcdecede4" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">370</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.33in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.33in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1c9c1b72-89a7-44c2-a3d6-d23b601c6796" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">13,255</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.33in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3c293e28-cbdc-44d1-b6b4-613273440577" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">23,530</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from investing activities:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Purchase of property and equipment</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6501dcf3-db4f-4bac-959d-60f1f4535f0b" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">357</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2314d03e-07dc-4a56-ad8d-c301f1348056" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">425</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.33in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in investing activities</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.33in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-80158669-b365-4c38-af07-db8427a43556" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">357</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ab820bf3-f6b1-4b18-baaf-3f40c77ed83c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">425</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cash flows from financing activities:</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.08in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Proceeds from issuance of common stock upon exercise of stock options</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0efb16e0-7d5b-4142-86fc-91044c142401" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">64</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9b5c3ed1-ed5e-4522-b44d-a5c6c26d0d13" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">211</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.33in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0.33in;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3960c6d6-1408-4287-b465-39c78649f112" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">64</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9cdfb84c-4f78-44e7-bcc6-5ec03608c074" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">211</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net decrease in cash and cash equivalents</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-30867167-ee4d-4d36-9d6d-10ef1feca90f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">13,548</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.00in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c49c2a85-f802-4e53-9a68-3cb34518dd39" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">23,744</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents at beginning of period</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9159d760-5420-439e-87c4-bf9d80ca852d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">201,015</ix:nonFraction></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1b02e340-b302-4849-9d73-c183c23a0893" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_12_31_2021" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">233,437</ix:nonFraction></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash and cash equivalents at end of period</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-13e2630c-6d3e-4d8b-8612-65fa39af9cb9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">187,467</ix:nonFraction></span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0.05in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3c818366-c70a-4520-9a1f-2e5a27cd79fc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="As_Of_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">209,693</ix:nonFraction></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 72.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 10.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.2%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: 0.05pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">See accompanying notes to condensed </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">consolidated </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">6</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cassava Sciences, Inc.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Notes to Condensed Consolidated Financial Statements</span><span id="Notes_To_Financial_Statements" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Unaudited)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ct-nonNumeric-7a4f0676-bfd9-4063-87e5-244ef394eecd" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-7a4f0676-bfd9-4063-87e5-244ef394eecd-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 1.  General and Liquidity</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-7a4f0676-bfd9-4063-87e5-244ef394eecd-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discover and develop proprietary pharmaceutical product candidates that may offer significant improvements to patients and healthcare professionals. The Company generally focuses its discovery and product development efforts on disorders of the nervous system. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions to the Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All intercompany transactions and balances have been eliminated in consolidation.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for any other interim period or for the year 2023</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Liquidity</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4449fd82-cf2c-493e-a07f-f1d5823deed5" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6" sign="-">307.8</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million at March 31, 2023. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company may seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are no assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next 12 months.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 2.&#160;&#160;Significant Accounting Policies</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-0" continuedAt="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="ct-nonNumeric-4693fe08-5099-4611-bc5b-c00c02904eef" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-4693fe08-5099-4611-bc5b-c00c02904eef-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-4693fe08-5099-4611-bc5b-c00c02904eef-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and assumptions.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ct-nonNumeric-35f92385-ba87-4ea2-9673-25aedb475563" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-35f92385-ba87-4ea2-9673-25aedb475563-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cash and Cash Equivalents and Concentration of Credit Risk</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-35f92385-ba87-4ea2-9673-25aedb475563-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at one financial institution. </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">7</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <ix:continuation id="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-1" continuedAt="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-2"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ct-nonNumeric-6a5583ba-8455-4d0e-86eb-97d81deecd13" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-6a5583ba-8455-4d0e-86eb-97d81deecd13-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value Measurements </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-6a5583ba-8455-4d0e-86eb-97d81deecd13-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 1 includes quoted prices in active markets.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company does not have any financial instruments where the fair value is based on Level 2 inputs.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any financial instruments where the fair value is based on Level 3 inputs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at March 31, 2023 and December 31, 2022.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ct-nonNumeric-41b2c1bd-10eb-4f17-9a02-870909487f59" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-41b2c1bd-10eb-4f17-9a02-870909487f59-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Business Segments</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-41b2c1bd-10eb-4f17-9a02-870909487f59-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-38b16210-3dbb-419c-8d23-c0eac0498bca" name="us-gaap:NumberOfOperatingSegments" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit17" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> business segment: the development of novel drugs and diagnostics.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="sava:ProceedsFromGrantsPolicyPolicyTextBlock" id="ct-nonNumeric-f5de3718-0c78-4be0-aac6-988b0f795712" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-f5de3718-0c78-4be0-aac6-988b0f795712-continuation-0"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Proceeds from Grants</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-f5de3718-0c78-4be0-aac6-988b0f795712-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended March 31, 2023,&#160;there were </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4e3f95cc-c8ec-4518-a52b-d421a69f2ed1" name="sava:ReductionToResearchAndDevelopmentExpense" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three months ended March 31, 2022</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, the Company received reimbursements totaling $</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e7b73f4c-11a9-4746-bebd-796e11dbd364" name="sava:ReductionToResearchAndDevelopmentExpense" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.1</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million pursuant to NIH research grants. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records the proceeds from these grants as reductions to its research and development expenses.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="ct-nonNumeric-20d2f389-e805-40d1-9f87-75f5cb7e7b43" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-20d2f389-e805-40d1-9f87-75f5cb7e7b43-continuation-0"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-20d2f389-e805-40d1-9f87-75f5cb7e7b43-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </span><span id="_cp_text_1_372" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&apos;s judgment. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-e06138a8-277d-4a4a-9bcf-5ce5d0e4cbeb" contextRef="Duration_1_1_2023_To_3_31_2023" format="ixt-sec:durwordsen"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">8</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <ix:continuation id="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-2" continuedAt="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-3"><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="ct-nonNumeric-2b872ce6-131d-41f5-94a1-8d960de65332" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-2b872ce6-131d-41f5-94a1-8d960de65332-continuation-0"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Net Loss per Share </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-2b872ce6-131d-41f5-94a1-8d960de65332-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">method. Potential dilutive common shares consist of outstanding common stock options.&#160;&#160;There is no difference between the Company&#8217;s net loss and comprehensive loss. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ct-nonNumeric-5df35553-4478-4ea9-bf01-cfc4efa5ee98" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerator:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-04e54472-2d97-450e-ae8e-c38bf291dbee" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">24,271</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aeef729d-55ae-40cb-9042-627d1390528b" name="us-gaap:NetIncomeLoss" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3" sign="-">17,527</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denominator:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a82913c9-bba2-4bda-bb60-bb1b61429f8c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">41,739</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e286c69c-bdb2-4f11-a9d1-eb79b3faddcf" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">39,962</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-15cb17e5-e0c2-4fab-aff4-7559ee746ac5" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" sign="-">0.58</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-81fc2270-5243-4cbd-8aec-2efdd3f97069" name="us-gaap:EarningsPerShareDiluted" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal" sign="-">0.44</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Dilutive common stock options excluded from net loss per share, diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cdf20db9-94a4-4d2f-a21e-9dff7af571ad" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">2,034</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1b4a5934-7840-4bab-a6f5-9032f9d2ed1a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-3" format="ixt:numdotdecimal" scale="3">2,086</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">dilutive. The Company also excluded </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-21f87bed-e4f3-44a7-8e13-d985ebac7c90" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">57,143</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted stock awards from the calculation of net loss per share, diluted, until their expiration in June 2022 because the effect of including restricted stock awards would have been anti</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">dilutive.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="ct-nonNumeric-4396299f-e30e-4961-b139-348d45815afc" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-4396299f-e30e-4961-b139-348d45815afc-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160; &#160; </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-4396299f-e30e-4961-b139-348d45815afc-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:nonNumeric name="sava:ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" id="ct-nonNumeric-61e4eb64-6671-4759-aa00-610a1d638a23" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-61e4eb64-6671-4759-aa00-610a1d638a23-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Research Contract Costs and Accruals </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-61e4eb64-6671-4759-aa00-610a1d638a23-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have not been materially different from actual costs.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ct-nonNumeric-a5f4cfba-a4b6-46c0-8e92-52058c395fe9" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-a5f4cfba-a4b6-46c0-8e92-52058c395fe9-continuation-0"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Incentive Bonus Plan</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-a5f4cfba-a4b6-46c0-8e92-52058c395fe9-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#8220;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note 10 for further discussion of the Plan.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div></ix:continuation>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">9</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><ix:continuation id="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-3" continuedAt="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-4"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="ct-nonNumeric-968df001-b19d-4701-86de-5ea32edb4d8e" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-968df001-b19d-4701-86de-5ea32edb4d8e-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Leases</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-968df001-b19d-4701-86de-5ea32edb4d8e-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ct-nonNumeric-6d9ccbd7-3a68-44c2-be3c-38987bc4cfcb" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-6d9ccbd7-3a68-44c2-be3c-38987bc4cfcb-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Property and equipment</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-6d9ccbd7-3a68-44c2-be3c-38987bc4cfcb-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-991c40a2-c81b-456a-b3b0-b972926f2875" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years and approximately </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-d4302cee-7837-4910-bf38-146df965ccbb" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately </span><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ct-nonNumeric-ac54698e-4a1f-41ea-a40c-cd3a1c5b1c19" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.1</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ct-nonNumeric-781f6395-158f-4499-a062-858a3ff6d5dd" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-781f6395-158f-4499-a062-858a3ff6d5dd-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Intangible assets</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-781f6395-158f-4499-a062-858a3ff6d5dd-continuation-0"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately </span><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ct-nonNumeric-4d391b39-8a3b-4aa1-a146-2e6b6d42c571" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.0</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years at March 31, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to be impaired, an impairment loss is recognized.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="ct-nonNumeric-55947cd2-c0fa-4609-9bb1-f2f5809df4a9" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-55947cd2-c0fa-4609-9bb1-f2f5809df4a9-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Income Taxes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-55947cd2-c0fa-4609-9bb1-f2f5809df4a9-continuation-0" continuedAt="ct-nonNumeric-55947cd2-c0fa-4609-9bb1-f2f5809df4a9-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-55947cd2-c0fa-4609-9bb1-f2f5809df4a9-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">condensed</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></ix:continuation></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082-continuation-4"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">10</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="sava:PrepaidAndOtherAssetsDisclosureTextBlock" id="ct-nonNumeric-40a3b4f1-4965-4952-98ae-0d94cf20e464" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-40a3b4f1-4965-4952-98ae-0d94cf20e464-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 3.  Prepaid Expenses and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Other Current Assets</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-40a3b4f1-4965-4952-98ae-0d94cf20e464-continuation-0" continuedAt="ct-nonNumeric-40a3b4f1-4965-4952-98ae-0d94cf20e464-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid expenses and other current assets at March 31, 2023 and December 31, 2022 consisted of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ct-nonNumeric-0371b82f-48e2-4264-a1e0-bec78c32ad49" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid insurance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-33965396-3e1d-4f77-98a2-04f700b8ba02" name="us-gaap:PrepaidInsurance" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">439</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3b0f4606-9abc-4c71-b7ba-87fad14f1ef2" name="us-gaap:PrepaidInsurance" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">874</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contract research organization and other deposits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c1367525-abb8-4183-9750-3791ab330edd" name="us-gaap:DepositContractsAssets" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">6,816</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8d898ad5-316f-4115-8209-317775b1378e" name="us-gaap:DepositContractsAssets" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">9,177</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-16dd4b76-bee6-46f0-bf67-f0d7bfbf8089" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">277</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3160f5ec-fb18-4ebe-97c4-ce107bb968ac" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">160</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total prepaid expenses and other current assets</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-72a30f92-e9e8-4935-96ea-49df6da3b3dd" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">7,532</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-711abfcb-5327-4e70-9f79-82512462e80e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">10,211</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-40a3b4f1-4965-4952-98ae-0d94cf20e464-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">       Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" id="ct-nonNumeric-ae6301ad-7712-42b8-a60f-2f3183ee647f" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-ae6301ad-7712-42b8-a60f-2f3183ee647f-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 4. Real Property</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-ae6301ad-7712-42b8-a60f-2f3183ee647f-continuation-0" continuedAt="ct-nonNumeric-ae6301ad-7712-42b8-a60f-2f3183ee647f-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company owns a two-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#8217;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are being outsourced to professional real-estate managers. The office complex measures approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c18e2753-83fd-48e9-98f4-53b2d63ca5dd" name="us-gaap:NetRentableArea" contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember" unitRef="Unit16" decimals="0" format="ixt:numdotdecimal">90,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> rentable square feet. At March 31, 2023, the property was over </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-327cf1dd-6af9-4bfa-bca3-1fdd8e42eaff" name="sava:PercentageOfCurrentlyLeased" contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" scale="-2">60</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% leased. The Company also occupies approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-fa5f1ae9-2d1e-42a3-949d-b3c9a1172f10" name="sava:PercentageOfOccupancy" contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" scale="-2">25</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the property.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records the net income from building operations and leases as other income, net, as leasing is not core to the Company&#8217;s operations. Building depreciation and amortization for space not occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ct-nonNumeric-e750b05b-d06b-4768-8351-160168ec8758" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4863db93-f0a0-4dd5-a92e-2f8ac9db09ad" name="us-gaap:OtherNonoperatingIncome" contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">557</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d23653a0-c4ab-4831-8ff9-8022ef92fdab" name="us-gaap:OtherNonoperatingIncome" contextRef="Duration_1_1_2022_To_3_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">573</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property operating expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c4d081d8-5669-4c08-8cdf-3107731cf263" name="us-gaap:OtherNonoperatingExpense" contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">367</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-69da07ed-4266-46cc-adb4-a17b6e507f89" name="us-gaap:OtherNonoperatingExpense" contextRef="Duration_1_1_2022_To_3_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">310</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Other income, net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8871c8f2-1c4f-4e62-ab54-e55dbdda6e89" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">190</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-16ffc434-4d21-4e6d-9d9d-3ad13a5ce44a" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="Duration_1_1_2022_To_3_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">263</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-ae6301ad-7712-42b8-a60f-2f3183ee647f-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ct-nonNumeric-e3c2e436-f19a-4f9e-a332-7bf567ac33be" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-e3c2e436-f19a-4f9e-a332-7bf567ac33be-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 5.  Property and equipment</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-e3c2e436-f19a-4f9e-a332-7bf567ac33be-continuation-0" continuedAt="ct-nonNumeric-e3c2e436-f19a-4f9e-a332-7bf567ac33be-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of property and equipment, net, as of March 31, 2023&#160;and&#160;December 31, 2022&#160;were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ct-nonNumeric-79e47a16-9746-448b-b33a-9c1c55c64b81" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Land</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9d66f3fb-1d38-438d-89bf-c47692370907" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,734</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-694d03a3-5ec5-4878-aeb2-ca361f54caa7" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,734</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Buildings</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-819dcec5-4800-4e9a-b59b-cc45f21ff537" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,980</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2a83f01c-25fd-4b87-8abf-4a682843f756" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">15,980</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Site improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e59d6d3-cf69-4655-b8ae-56fc1cc2e936" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">470</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-313c7cfd-a69b-428f-94fc-16598e7ac439" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">470</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tenant improvements</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37ea943d-ee17-4415-9673-2a01865f47ba" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,016</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-aa4fd562-ddad-418a-8ad8-703235c62c9f" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">3,016</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-df07f382-abde-42e6-bcf9-8e06ce44c0e2" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">868</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-7659169d-93ba-460c-9f92-6d46b43045e7" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">851</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Construction in progress</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-af1a6d25-ceca-4265-a7ef-e3fa9309a648" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4bb5e26d-a5d9-4bbc-8dc1-116c7a6ef3d0" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a68a04ab-907f-4ddb-b40c-1be0da224edb" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,081</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-365397c9-6901-4f12-9945-335d6efaeebf" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">24,064</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated depreciation</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-577a5622-45dd-431d-bc5d-4faaa82dc340" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,472</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e02201d7-d6b6-47e8-991e-37a8e8ed87b5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,200</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Property and equipment, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6adba2e6-aaba-459e-9fe0-3dcf09a6efd5" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,609</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c4bed00a-bc06-4143-bc1b-5fbdebab4236" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">22,864</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-e3c2e436-f19a-4f9e-a332-7bf567ac33be-continuation-1"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation expense for property and equipment was&#160;$</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-449f68c2-f3cf-4342-946a-45d2c8030e23" name="us-gaap:Depreciation" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">272,000</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;and&#160;$</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e4ff8499-faa5-4125-875c-510e617ebb87" name="us-gaap:Depreciation" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">178,000</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;for the three months ended&#160;March 31, 2023&#160;and 2022, respectively.</span></ix:continuation></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">11</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ct-nonNumeric-5fbae18e-5077-4f1f-9f74-abd7c21661ab" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-5fbae18e-5077-4f1f-9f74-abd7c21661ab-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 6.  Intangible assets</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-5fbae18e-5077-4f1f-9f74-abd7c21661ab-continuation-0" continuedAt="ct-nonNumeric-5fbae18e-5077-4f1f-9f74-abd7c21661ab-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of intangible assets, net, as of March 31, 2023&#160;and&#160;December 31, 2022&#160;were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ct-nonNumeric-99d12ba2-2072-4cdb-b86e-eb493d1baeae" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease-in-place agreements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3a0ef5ed-57cd-44de-a2f6-e8653f7d6fab" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,053</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5d9b6969-4219-4919-bf56-f71dd669d9f0" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,053</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasing commissions and other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a7e639f2-785b-4d70-b739-8cb97d68d4cf" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">290</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a5c1643-b3d8-4ec6-aafe-646a53a8564c" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">290</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4417d074-a5a2-480f-95f9-d3db1357b56b" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,343</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c8581035-b048-4ccb-93ca-2a4a8e7684ac" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">1,343</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated amortization</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8a203ce5-202a-40b4-b586-373ca7fa3ffb" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">840</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-788829df-5d02-4be8-966c-5e518c96b21d" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">721</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Intangible assets, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f6012e3e-694f-4c4c-ae29-d549db808773" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">503</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-48743a24-a76a-425f-bfba-acbbf70a583c" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_12_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">622</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization expense for intangible assets was&#160;$</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-067c17a5-6695-45db-bfe3-f5e914cf504c" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">119,000</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4c4ed742-a6f7-407d-828a-b4798b1aeceb" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">135,000</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the three months ended&#160;March 31, 2023 and 2022, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization expense for finite-lived intangible assets as of March 31, 2023 is expected to be as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ct-nonNumeric-2f566bb9-a436-45f9-a8f2-3539c8a6b71c" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">For the year ending December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-70b33d0b-f0ee-4fcd-ba29-a2798c29209a" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">332</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e809fed7-43d1-4e1c-bc5b-9220f138c81c" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">167</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4a050361-51e8-4d10-9d3a-98884049f955" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">4</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total amortization</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-384a035e-be17-430b-945d-46f690e50627" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="As_Of_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">503</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><ix:continuation id="ct-nonNumeric-5fbae18e-5077-4f1f-9f74-abd7c21661ab-continuation-1"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ct-nonNumeric-67b6e6d7-c5df-4197-89b8-4e1dac2d3739" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-67b6e6d7-c5df-4197-89b8-4e1dac2d3739-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 7.  Stockholders&#8217; Equity and Stock-Based Compensation Expense</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-67b6e6d7-c5df-4197-89b8-4e1dac2d3739-continuation-0" continuedAt="ct-nonNumeric-67b6e6d7-c5df-4197-89b8-4e1dac2d3739-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2022 Registered Direct Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November&#160;22, 2022, the Company completed a common stock offering pursuant to which certain investors purchased </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c3337d22-2397-441a-aad3-3bccfcefc39c" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">1,666,667</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock at a price of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-d30cd964-f152-4d1c-b2d4-06079df223d0" name="us-gaap:SaleOfStockPricePerShare" contextRef="As_Of_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal">30.00</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. Net proceeds of the offering were approximately $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e7fedaec-accc-43ac-9fed-aa6b329d3184" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">47.3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million after deducting offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">At-the-Market Common Stock Offering </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2020, the Company established an at-the-market offering program (&#8220;2020 Program&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-28fc557d-4f5e-4ea8-93cb-18a5cd4545d4" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="Duration_3_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">100</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in transactions pursuant to a shelf registration statement that was declared effective by the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> on May 5, 2020</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company gave notice of termination for the 2020 Program on April 26, 2023, which is effective May 1, 2023. There were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b371a7ba-614b-4c35-a377-30a3481e0361" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="Duration_4_30_2023_To_4_30_2023_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember" unitRef="Unit1" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> common stock sales under the 2020 Program through its termination. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock Option and Performance Award Activity in 2023</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023, stock options and unvested Performance Awards outstanding under the Company&#8217;s stock option plans changed as follows:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="sava:StockOptionAndPerformanceAwardActivity" id="ct-nonNumeric-888a7289-24a2-4a0b-918d-abd4591138a4" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock Options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Performance Awards</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e8a794d0-8f01-4fd0-a3cc-4dd6acf940d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,529,448</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-35f1c435-63ec-44a0-898b-75583ae4d20b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">7,142</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-dd238c04-f83e-48b9-bb8b-2c297a0680b7;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-05eb815c-fd10-48c9-8d79-99d6ee0a77d4;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-27841093-0c84-4cc7-b5ed-3e99f06b4aa7" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">19,017</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a22d958c-bef2-4f73-8328-e8bfeb74d56d;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-4c45888e-635f-47a9-8d16-d034a6483bd4;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-b786222f-0c6a-455c-9a63-3cd0d3ae33f5;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of March 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-6af35ecf-d3a4-448f-9e8c-de5154d8bcfd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">2,510,431</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-71cb1c72-2bf2-4af7-ab0f-f2f5ce757f34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">7,142</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The weighted average exercise price of options outstanding at </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023 was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-95585ba3-491e-4236-b786-841550f3c9a5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember" unitRef="Unit15" decimals="2" format="ixt:numdotdecimal">12.15</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. As outstanding options vest over the current remaining vesting period of </span><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ct-nonNumeric-b492c77d-d562-4f75-a26c-263eb8b481db" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.3</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #FF0000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">years, the Company expects to recognize stock-based </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">12</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><ix:continuation id="ct-nonNumeric-67b6e6d7-c5df-4197-89b8-4e1dac2d3739-continuation-1" continuedAt="ct-nonNumeric-67b6e6d7-c5df-4197-89b8-4e1dac2d3739-continuation-2"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">compensation expense of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-ab343e3e-360f-4d4b-9b1a-a75332309002" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">7.0</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million. If and when outstanding Performance Awards vest, the Company will recognize stock-based compensation expense of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0d914c20-2371-451a-803c-913174ea0be8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">0.1</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million over the implicit service period.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023, there were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3094861b-7268-49f6-8f96-4836af9ded6e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">19,017</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options exercised. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Of the stock options exercised, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-37984c12-b252-4610-9e4f-fae1f34f858c" name="sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">5,139</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options were net settled in satisfaction of the exercise price, with </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-be6e2690-f366-4b6a-ae4c-6149214b3a3d" name="sava:ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> cash proceeds received. Cash proceeds</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to the Company </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">for options not net settled</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> totaled $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-081d10b9-4b9b-430b-9053-1441fbda8cea" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">64,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> during the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended March 31, 2022, there were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-dc91ec4c-3245-4a78-baa7-aacd9f43627c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">19,609</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options exercised. Of the stock options exercised, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-67de9249-4f95-4a61-bd80-708468b82d06" name="sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF" format="ixt:numdotdecimal">5,121</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options were net settled in satisfaction of the exercise price, with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8c5a3a4e-d791-45f7-ad6e-66ef2212f00f" name="sava:ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> cash proceeds received. Cash proceeds to the Company for options not net settled totaled $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9fd2b9e7-47f1-43dc-bbc9-b7b276b2d4d1" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="INF" format="ixt:numdotdecimal">211,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> during the three months ended March 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock-based Compensation Expense in 2023</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.21in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three and nine months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023 and 2022, the Company&#8217;s stock-based compensation expense was as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ct-nonNumeric-7447cfe3-7ab6-41b6-882d-f383f5a28d78" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-2f4e8efa-e0c9-4f20-8e1f-58ac9de5c2f2" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">389</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-e376d1fe-9f43-4292-bedb-c2f34ff9a3ac" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">422</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c74ed195-037f-4974-92e3-4a4235c723e2" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">284</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a32db236-729b-4408-9020-4cb4664f9cd1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">73</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3ee311bd-bad9-4f19-bb1d-bd0915e260cb" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">673</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-518323b1-1005-4806-a9aa-dba9e1082812" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal" scale="3">495</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div></ix:nonNumeric><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2018 Equity Incentive Plan </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or a designated committee of the Board is responsible for administration of the Company&#8217;s 2018 Omnibus Incentive Plan, as amended (the &#8220;2018 Plan&#8221;) and determines the terms and conditions of each option granted, consistent with the terms of the 2018 Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the 2018 Plan, including grants of stock options and Performance Awards. Share-based awards generally expire </span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ct-nonNumeric-00a1b241-90d9-4a60-8845-d3e9386715f2" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember" format="ixt-sec:duryear"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years from the date of grant. The 2018 Plan, as amended on May 5, 2022, provides for issuance of up to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-c61c2421-c89b-4251-b861-80f65df8de6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="Duration_5_5_2022_To_5_5_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember" unitRef="Unit1" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock, par value $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-96d13e1d-4f84-4616-b3f2-fe7010ebb5b5" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="As_Of_5_5_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember" unitRef="Unit15" decimals="INF" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share, subject to adjustment as provided in the 2018 Plan. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279; </span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-67b6e6d7-c5df-4197-89b8-4e1dac2d3739-continuation-2"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses&#160;its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="ct-nonNumeric-cf069b86-66c1-4463-962a-6c0702242feb" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-cf069b86-66c1-4463-962a-6c0702242feb-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 8.  Income Taxes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-cf069b86-66c1-4463-962a-6c0702242feb-continuation-0" continuedAt="ct-nonNumeric-cf069b86-66c1-4463-962a-6c0702242feb-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company did </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0e844b72-b580-4f55-ad45-80ce7c2d5a9b" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t provide for income taxes during the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, because it has projected a net loss for the full year 2023 </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">for which any benefit will be offset by an increase in the valuation allowance</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. There was also </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-82171521-daff-47cf-be37-5fe9f850cfb7" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> provision for income taxes for the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">,</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 2022.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-cf069b86-66c1-4463-962a-6c0702242feb-continuation-1"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:CommitmentsDisclosureTextBlock" id="ct-nonNumeric-950acc6a-cbba-4964-9ffe-91a438e03c89" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-950acc6a-cbba-4964-9ffe-91a438e03c89-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 9.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Commitments</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-950acc6a-cbba-4964-9ffe-91a438e03c89-continuation-0" continuedAt="ct-nonNumeric-950acc6a-cbba-4964-9ffe-91a438e03c89-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Right-of-use Asset and Liability</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company had an operating lease for approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8ef8ccad-cdf8-48ca-ac97-b14f60a14633" name="us-gaap:NetRentableArea" contextRef="As_Of_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_OperatingLeasesMember" unitRef="Unit16" decimals="0" format="ixt:numdotdecimal">6,000</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> square feet of office space in Austin, Texas with an expiration of </span><ix:nonNumeric name="us-gaap:LeaseExpirationDate1" id="ct-nonNumeric-ba012256-84ed-48b2-8f49-b2046e88763d" contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_OperatingLeasesMember" format="ixt:datemonthdayyearen"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">April 30, 2024</span></ix:nonNumeric><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company and the landlord consented to early terminate this lease on February 22, 2023 with no continuing obligations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Rent expense for the </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three months ended&#160;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023&#160;and 2022&#160;totaled $</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-32c983b9-86df-461a-8160-4154aefd868a" name="us-gaap:OperatingLeaseExpense" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">24,000</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-29ac622b-7c2a-4d83-91dc-d8fc5068cef5" name="us-gaap:OperatingLeaseExpense" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="Unit12" decimals="0" format="ixt:numdotdecimal">41,000</ix:nonFraction></span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">13</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><ix:continuation id="ct-nonNumeric-950acc6a-cbba-4964-9ffe-91a438e03c89-continuation-1" continuedAt="ct-nonNumeric-950acc6a-cbba-4964-9ffe-91a438e03c89-continuation-2"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash paid for operating lease liabilities during the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023 and 2022 totaled $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-1a6b38db-29b5-417b-81bf-c95fa272a485" name="us-gaap:OperatingLeasePayments" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">24,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-63315068-9ff8-4c51-a618-e76feccf921f" name="us-gaap:OperatingLeasePayments" contextRef="Duration_1_1_2022_To_3_31_2022" unitRef="Unit12" decimals="-3" format="ixt:numdotdecimal">41,000</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Other Commitments</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-950acc6a-cbba-4964-9ffe-91a438e03c89-continuation-2"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="sava:CashIncentiveBonusPlanTextBlock" id="ct-nonNumeric-30d43a08-7dcb-43e4-86c0-48bb7c09f9c1" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-30d43a08-7dcb-43e4-86c0-48bb7c09f9c1-continuation-0"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note&#160;10.&#160; 2020 Cash Incentive Bonus Plan</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-30d43a08-7dcb-43e4-86c0-48bb7c09f9c1-continuation-0" continuedAt="ct-nonNumeric-30d43a08-7dcb-43e4-86c0-48bb7c09f9c1-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2020, the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has not occurred&#160;as of </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2022, the Company&#8217;s independent directors were participants in the Plan. However, effective March 16, 2023, the Board of Directors amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the Plan were completely forfeited to the Company and will not be allocated to any other participant under the Plan. The Company&#8217;s independent directors have </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-4399b6ec-ef12-47cd-aaf7-0ac3de515ec9" name="sava:CashIncentiveBonusAward" contextRef="As_Of_3_31_2023_srt_TitleOfIndividualAxis_sava_IndependentDirectorsMember" unitRef="Unit12" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t received, and as a result of such amendment will never receive, any payments under the Plan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (1) the closing price&#160;of one share&#160;of the Company&#8217;s common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (2) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;This constitutes a market condition under applicable accounting guidance.&#160; &#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0b4f3888-fd57-4aae-9959-8db74f4d7953" name="sava:PerformancePlanValuationAmount" contextRef="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-9" format="ixt:numdotdecimal" scale="9">5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-8111b617-e837-43d6-8725-81b02f08e5a1" name="sava:PerformancePlanValuationAmount" contextRef="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-6" format="ixt:numdotdecimal" scale="6">200</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million and&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-5596c97a-dd7a-4a79-a247-db001783c06b" name="sava:PerformancePlanValuationAmount" contextRef="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-9" format="ixt:numdotdecimal" scale="9">5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for no less than </span><ix:nonNumeric name="sava:MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" id="ct-nonNumeric-7638dfab-b210-4caa-b346-b5e18267faa1" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" format="ixt-sec:durday"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20</span></ix:nonNumeric><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-cc7b4332-a0b9-450b-96e9-172e03d7a2e3" name="sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit14" decimals="2" format="ixt:numdotdecimal" scale="-2">67</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;not awarded by the Compensation Committee&#160;are&#160;no longer available for distribution.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the Company were to exceed a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0cbe67e3-b122-47ed-96fb-fa8c4c0af60b" name="sava:PerformancePlanValuationAmount" contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-9" format="ixt:numdotdecimal" scale="9">5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-26dd58e7-6865-4fe0-99f9-f706f382cc68" name="sava:CashIncentiveBonusAward" contextRef="As_Of_3_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">111.4</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-f9a3faac-c087-41f6-ad04-82880b354154" name="sava:CashIncentiveBonusAward" contextRef="As_Of_3_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">289.7</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(1)&#160;the Company completes a Merger Transaction, or&#160;(2)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which may ever occur. Accordingly, there can be no assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">14</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><ix:continuation id="ct-nonNumeric-30d43a08-7dcb-43e4-86c0-48bb7c09f9c1-continuation-1" continuedAt="ct-nonNumeric-30d43a08-7dcb-43e4-86c0-48bb7c09f9c1-continuation-2"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9834886b-cc83-4fc2-937b-22af0386dc29" name="sava:MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense" contextRef="Duration_1_1_2023_To_3_31_2023" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">14</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2020, the Company&#160;achieved&#160;the first&#160;Valuation&#160;Milestone.&#160;Subsequently, the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-be6942cc-7c5e-40d3-b2e5-64bd69f23e49" name="sava:CashIncentiveBonusAward" contextRef="As_Of_10_31_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">6.5</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;in total&#160;for&#160;all Plan participants (after the March 2023 Plan amendment), subject to future satisfaction of a Performance Condition.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the year ended December&#160;31, 2021, the Company achieved </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a9ffc803-1f7b-458a-9dfe-69feb8df7971" name="sava:NumberOfValuationMilestonesAchieved" contextRef="Duration_1_1_2021_To_12_31_2021" unitRef="Unit13" decimals="INF" format="ixt:numdotdecimal">11</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-0a670dee-6297-4fe2-8e5a-9f25d4dbab39" name="sava:CashIncentiveBonusAward" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">74.9</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million up to a hypothetical maximum of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-3e994f94-5e8b-4a09-a8bf-674d6efab850" name="sava:CashIncentiveBonusAward" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt:numdotdecimal" scale="6">202.3</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million (after the March 2023 Plan amendment), to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b4e9c259-91d8-4b44-ac0f-29afd336a875" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember" unitRef="Unit12" decimals="-5" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;compensation expense was recorded&#160;since no&#160;grant date has occurred and no&#160;Performance Conditions are considered probable of being met.&#160;There is no continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No Valuation Milestones were achieved during 2022 or the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 31, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-16780f2d-0dfe-41e3-b95d-6d8efc8cbaba" name="sava:PaymentsForCashIncentiveBonus" contextRef="Duration_5_1_2023_To_5_1_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5" format="ixt-sec:numwordsen" scale="6">No</ix:nonFraction></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> actual cash payments were authorized or made to participants under the Plan through May 1, 2023.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><ix:continuation id="ct-nonNumeric-30d43a08-7dcb-43e4-86c0-48bb7c09f9c1-continuation-2"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></ix:continuation></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><ix:nonNumeric name="us-gaap:LossContingencyDisclosures" id="ct-nonNumeric-a33425ed-3770-4a8c-a52b-f3ecd441d748" contextRef="Duration_1_1_2023_To_3_31_2023" escape="true" continuedAt="ct-nonNumeric-a33425ed-3770-4a8c-a52b-f3ecd441d748-continuation-0"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 11. Contingencies</span></ix:nonNumeric></p><ix:continuation id="ct-nonNumeric-a33425ed-3770-4a8c-a52b-f3ecd441d748-continuation-0" continuedAt="ct-nonNumeric-a33425ed-3770-4a8c-a52b-f3ecd441d748-continuation-1"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">From time to time, the Company may become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and Citizen Petitions submitted to FDA, and may receive inquiries from government authorities relating to matters arising from the ordinary course of business</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to the Company. No information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, no accrual for these matters has been recorded within the condensed consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Government Investigations</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 15, 2021, the Company disclosed that certain government agencies had asked it to provide them with corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and will continue to cooperate with government authorities. No government agency has informed the Company that it has found evidence of research misconduct. No government agency has informed the Company that any wrongdoing has occurred by any party. No government agency has filed any charges against the Company, or anyone associated with it. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency may pursue an enforcement action against the Company or others.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Securities Class Actions and Shareholder Derivative Actions</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Between August 27, 2021 and October 26, 2021, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-b24d63be-de73-417f-ba4e-12cc1e01ea33" name="us-gaap:LossContingencyNewClaimsFiledNumber" contextRef="Duration_8_28_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember" unitRef="Unit13" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On June 30, 2022, a federal judge consolidated the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-a75cc3af-d31f-4669-829b-e47e71cc9b28" name="us-gaap:LossContingencyNewClaimsFiledNumber" contextRef="Duration_8_28_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember" unitRef="Unit13" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> class action lawsuits into </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-9715dfa0-f571-4719-8d3a-1c565b6d3519" name="sava:NumberOfClassActionsConvertedToCase" contextRef="Duration_6_30_2022_To_6_30_2022_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember" unitRef="Unit13" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of the Company&#8217;s securities between September 14, 2020 and July 26, 2022. Briefing on defendants&#8217; motion to dismiss was completed on January 23, 2023</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and an argument on defendants&#8217; motion was held </span></p></ix:continuation></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">15</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><ix:continuation id="ct-nonNumeric-a33425ed-3770-4a8c-a52b-f3ecd441d748-continuation-1"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">on April 26, 2023</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The Company believes the claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s board of directors. This complaint relies on the allegations made in Citizen Petitions that were submitted to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(and subsequently denied by) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since November 4, 2021, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><ix:nonFraction id="ct-nonFraction-69d5669e-9173-4349-ba01-fd631d0b2d87" name="us-gaap:LossContingencyNewClaimsFiledNumber" contextRef="Duration_11_4_2021_To_11_4_2021_srt_LitigationCaseAxis_sava_ShareholderDerivativeActionsMember" unitRef="Unit13" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, and one in Texas state court (Travis County District Court). </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All four actions have</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> been stayed pending the resolution of the motions to dismiss in the securities class actions. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July 5, 2022, the three federal court actions were consolidated into a single action.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s board of directors. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the 2020 Cash Incentive Bonus Plan in August 2020. The complaints seek unspecified compensatory damages and other relief. On </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">January 6, 2023, the plaintiffs filed an amended complaint. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Defendants filed a partial answer to the amended complaint on March 10, 2023, and moved to partially dismiss the amended complaint on March 14, 2023. Defendants&#8217; motion to dismiss remains pending. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although the plaintiffs in this derivative case do</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p></ix:continuation><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 2.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Management&#8217;s Discu</span><span id="MDA" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">ssion and Analysis of Financial Condition and Results of Operations</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This discussion and analysis should be read in conjunction with Cassava Sciences, Inc.&#8217;s (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) condensed consolidated financial statements and accompanying notes included elsewhere in this Quarterly Report on Form 10-Q. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> results are not necessarily indicative of results that may occur in future periods.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This Quarterly Report on Form 10-Q contains certain statements that are considered forward-looking statements within the meaning of the Private Securities Reform Act of 1995. We intend that such statements be protected by the safe harbor created thereby. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and &#8220;would&#8221; or the negatives of these terms or other comparable terminology.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance, taking into account all information currently available to us. Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Examples of such forward-looking statements include, but are not limited to statements about:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">number of patients with Alzheimer&#8217;s disease we expect to enroll in our on-going Phase 3 studies, the enrollment rates for these studies, and the length of time to complete patient enrollment for our studies and the expected safety profile or treatment benefits of simufilam for people with Alzheimer&#8217;s disease</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our reliance on third-party contractors to conduct the clinical trials and make drug supply on a large-scale for our Phase 3 clinical program, or their ability to do so on-time or on-budget;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">16</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">limitations around data interpretation from results of our long-term open-label study, as compared to efficacy results from a fully completed, randomized controlled study design;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the ability of clinical scales to assess cognition or health in our trials of Alzheimer&#8217;s disease;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">any significant changes we may make, or anticipate making, to the design of any of our on-going studies of simufilam in patients with Alzheimer&#8217;s disease;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to initiate, conduct or analyze additional clinical and non-clinical studies with our product candidates targeted at Alzheimer&#8217;s disease and other neurodegenerative diseases;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the impact of pre-clinical findings on our ability to develop our product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the interpretation of results from our  pre-clinical or early clinical studies, such as Phase 1 and Phase 2 studies;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our plans to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">further develop </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SavaDx, our investigational blood-based diagnostic, and to evaluate a non-antibody approach for SavaDx;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability or willingness to expand therapeutic indications for simufilam outside of Alzheimer&#8217;s disease;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the safety, efficacy, or potential therapeutic benefits of our product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our ability to file for and obtain regulatory approval of our product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our strategy and ability to establish an infrastructure to commercialize any product candidates, if approved;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the potential future revenues of our product candidates, if approved and commercialized;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the market acceptance of our product candidates, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">if approved and commercialized;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the pricing and reimbursement of our product candidates, if approved and commercialized;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the utility of protection, or the sufficiency, of our intellectual property;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our potential competitors or competitive products for the treatment of Alzheimer&#8217;s disease;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our need to raise new capital from time to time to continue our operations or to expand our operations;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our use of multiple third-party vendors, including a Clinical Research Organization (CRO), to conduct clinical studies of our lead product candidate;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">expectations regarding trade secrets, technological innovations, licensing agreements and outsourcing of certain business functions;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our expenses increasing by unanticipated amounts due to inflation;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">fluctuations in our financial or operating results;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our operating losses, anticipated operating and capital expenditures and legal expenses;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">expectations regarding the issuance of shares of common stock, options or other equity to employees or directors pursuant to equity compensation awards, net of employment taxes;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the development and maintenance of our internal information systems and infrastructure;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our need to hire additional personnel and our ability to attract and retain such personnel;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">existing regulations and regulatory developments in the United States and other jurisdictions in which we operate;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our plans to expand the size and scope of our operations;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the sufficiency of our current resources to continue to fund our operations;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">potential future agreements with third parties in connection with the commercialization of our product candidates;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the accuracy of our estimates regarding expenses, capital requirements, and needs for additional financing;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">assumptions and estimates used for our disclosures regarding stock-based compensation;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the expense, timing and outcome of pending or future litigation or other legal proceedings and claims, including U.S. government inquiries</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">litigation, claims or other uncertainties that may arise from allegations made against us or our collaborators.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Such forward-looking statements and our business involve risks and uncertainties, including, but not limited to the following: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have a limited operating history in our business&#160;targeting Alzheimer&#8217;s disease and no products approved for commercial sale.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development of biopharmaceutical products is a highly uncertain undertaking and involves a substantial degree of risk </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and our</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> business is heavily dependent on the successful development of our product candidates</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are concentrating a substantial portion of our research and development efforts on the diagnosis and treatment of Alzheimer&#8217;s disease, an area of research that has recorded many clinical failures.</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">17</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our clinical trials may fail to demonstrate evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and the commercialization of our product candidates.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may need to obtain substantial additional financing to complete the development and any commercialization of our product candidates</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are a small company with no sales force and may not be successful in our efforts to commercialize any product candidates which are approved.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our CRO and contract manufacturers may fail to perform as anticipated</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may be unable to protect our intellectual property rights or trade secrets</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may be subject to third-party claims of intellectual property infringement</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may not succeed in our maintenance or pursuit of licensing rights or third-party intellectual property necessary for the development of our product candidates</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Enacted or future legislation or regulatory actions may adversely affect our product pricing, or limit the reimbursement we may receive for our products</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A significant breakdown, security breach or interruption affecting our internal computer systems, or those used by our third-party research collaborators, may compromise the confidentiality of our financial or proprietary information, result in material disruptions of our products and operations and adversely affect our reputation.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may be&#160;unsuccessful at hiring and retaining qualified personnel</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We and certain of our directors and executive officers have been named as defendants in lawsuits that could result in substantial costs and divert management&#8217;s attention.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Adverse and lingering circumstances caused by disease epidemics or pandemics, such as COVID-19.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Please also refer to the section entitled </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8220;Risk Factors</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as such risk factors may be amended, updated or modified periodically in our reports filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) for further information on these and other risks affecting us. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We caution you not to place undue reliance on forward-looking statements because our future results may differ materially from those expressed or implied by them. We do not intend to update any forward-looking statement, whether written or oral, relating to the matters discussed in this Quarterly Report on Form 10-Q, except as required by law.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This Form 10-Q may also contain statistical data and drug information based on independent industry publications or other publicly available information. We have not independently verified the accuracy or completeness of the data contained in these publicly available sources of data and information. Accordingly, we make no representations as to the accuracy or completeness of such information. You are cautioned not to give undue weight to such data.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our research programs in neurodegeneration have benefited from longstanding scientific and financial support from the National </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Institutes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of Health (&#8220;NIH&#8221;). The contents of this </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Quarterly Report on Form 10-Q</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> are solely our responsibility and do not necessarily represent any official views of NIH, the Department of Health and Human Services, or the United States government.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Overview</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#8217;s disease. Our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the brain. Our lead therapeutic drug candidate, simufilam, is being evaluated for the proposed treatment of Alzheimer&#8217;s disease dementia in Phase 3 clinical studies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Over the past 10 years, we have combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer&#8217;s disease and other neurodegenerative diseases. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our strategy is to leverage our </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">18</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">unique scientific/clinical platform to develop a first-in-class program for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">treating neurodegenerative diseases, such as Alzheimer&#8217;s</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We currently have two </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">biopharmaceutical </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">assets under development: </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our lead therapeutic product candidate, called simufilam, is a novel oral treatment for Alzheimer&#8217;s disease dementia; and </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer&#8217;s disease from a small sample of blood.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our scientific approach for the treatment of Alzheimer&#8217;s disease seeks to simultaneously suppress </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">both</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> neurodegeneration and neuroinflammation. We believe our ability to improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our lead product candidate, simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer&#8217;s brain. Published studies have demonstrated that the altered form of FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation. We are currently conducting </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">a Phase 3 program with simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe simufilam improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering the downstream toxic effects of altered FLNA. We have generated and published experimental and clinical evidence of improved brain health with simufilam. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Importantly, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">simufilam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> is not dependent on clearing amyloid from the brain. S</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ince simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with those of other therapeutic candidates aiming to treat neurodegeneration.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam has demonstrated a multitude of treatment effects in animal models of disease, including normalizing neurotransmission, decreasing neuroinflammation, suppressing neurodegeneration, and restoring memory and cognition.  </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date. SavaDx is being developed in-house with outside collaborators. We own exclusive, worldwide rights to drug and diagnostic assets and related technologies, without royalty obligations to any third party. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our patent protection with respect to simufilam and use of simufilam for Alzheimer&#8217;s disease and other neurodegenerative diseases currently runs through 2039 and includes seven issued U.S. patents. In addition, we have patent protection with respect to simufilam for use in treating certain cancers that runs through 2034. Our patent estate further includes patents and patent applications for related compounds and treatments. Corresponding foreign filings have been made for each of the U.S. filings.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">About Alzheimer&#8217;s Disease</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s disease is a progressive neurodegenerative disorder that affects cognition, function and behavior. As of 2021, there were approximately 55&#160;million people worldwide living with dementia, a figure expected to increase to 139&#160;million by 2050 according to outside sources. The annual global cost of dementia is now above $1 trillion, according to Alzheimer&#8217;s Disease International, a charitable organization.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 2a Study</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2019, we completed a small, first-in-patient, clinical-proof-of-concept, open-label Phase 2a study of simufilam in the U.S., with substantial support from the National Institute on Aging (NIA), a division of the NIH. Treatment with simufilam for 28 days significantly improved certain key biomarkers of Alzheimer&#8217;s pathology, neurodegeneration and neuroinflammation (p&lt;0.001). Biomarkers effects were seen in all patients in both cerebrospinal fluid (CSF) and plasma.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 2b Study</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In September 2020, we announced final results of a Phase 2b study with simufilam in Alzheimer&#8217;s disease. In this clinical study funded by the NIH, Alzheimer&#8217;s patients treated with 50 mg or 100 mg of simufilam twice-daily for 28 </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">19</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">days showed statistically significant (p&lt;0.05) improvements in CSF biomarkers of disease pathology, neurodegeneration and neuroinflammation, versus Alzheimer&#8217;s patients who took placebo. In addition, Alzheimer&#8217;s patients treated with simufilam showed improvements in validated tests of episodic memory and spatial working memory, versus patients on placebo. Cognitive improvements correlated most strongly with decreases in levels of P-tau181, an exploratory &#8216;research use only&#8217; non-safety related biomarker that suggests brain changes from Alzheimer&#8217;s disease. Materials labeled as Research Use Only are intended for products that are still under development and are not commercially distributed.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Open-label Study Strategy</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Much of the value of our open-label study is to support simufilam&#8217;s long-term safety profile in patients. We believe a well-designed, long-term, open-label study is an exercise in prudent risk-management. Clinical results serve as a tool to help inform and manage the inherent risks and uncertainties of drug development for undertaking a large, expensive Phase 3 clinical testing program.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Open-label Study Top-line Results</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2020, we initiated a long-term, open-label study to evaluate&#160;simufilam, our lead drug candidate,&#160;in patients with Alzheimer&#8217;s disease.&#160;This study&#160;was funded in part by a research grant award from NIH. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The study </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">was designed to evaluate the long-term safety and tolerability of&#160;simufilam&#160;100 mg twice daily for 12 or more months. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Another study objective was to assess exploratory efficacy endpoints, such as changes in cognition, and biomarkers.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In January 2023, we announced positive top-line Phase 2 results for our open-label study. The study enrolled over 200 patients with mild-to-moderate Alzheimer&#8217;s disease (MMSE 16-26). Endpoints were measured at baseline (study entry) and month 12.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s is a degenerative disease of the brain. Over time, cognition progressively worsens in the mild-to-moderate stages of Alzheimer&#8217;s as the disease takes its toll. ADAS-Cog scores that change minimally (or improve) over 1 year is a highly desirable outcome in a clinical study of patients with mild-to-moderate Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Top-line Results &#8211; mean scores, baseline to month 12 </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">lower is better, except for MMSE)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">:</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ADAS-Cog11 scores changed from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19.1 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.2) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19.6 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13.3)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">MMSE scores changed from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">21.5 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.6) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20.2 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.4)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">NPI10 scores changed from 3.2 (&#177;4.6) to 2.9 (&#177;4.6)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 12pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">GDS scores changed from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.8 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.8) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.4 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.9)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Response Analysis &#8211; baseline to month 12</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">ADAS-Cog scores improved in 47% of patients; this group had a mean change of -4.7 (&#177;3.8) points (lower is better).</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In an additional 23% of patients, ADAS-Cog declined less than 5 points; this group had a mean change of 2.5 (&#177;1.4) points.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients with an NPI10 score of zero increased from 42% to 54%, indicating reduced dementia-related neuropsychiatric symptoms after 1 year on simufilam.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Analysis of Efficacy Endpoints</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Efficacy outcomes were analyzed by an independent, outside biostatistical consulting firm led by Suzanne Hendrix, PhD. The pre-specified primary efficacy endpoint was change in baseline on ADAS-Cog11, a cognitive scale widely used in Alzheimer&#8217;s clinical research. Exploratory endpoints included the Mini-Mental State Examination (MMSE) to assess disease stage by cognitive impairment; the Neuropsychiatric Inventory (NPI10) to assess dementia </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">20</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">related behavior; and the Geriatric Depression Scale (GDS). The Full Analysis Set (FAS) population (N=216) was used for the statistical analysis of efficacy endpoints.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Alzheimer&#8217;s is a progressive disease. Severity of disease is typically assessed by MMSE score. In this study, mild patients are MMSE 21-26; moderate patients are MMSE 16-20. Mild and moderate sub-groups showed notable differences on changes in ADAS-Cog mean scores, baseline to month 12 (lower is better):</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">mild</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> sub-group, ADAS-Cog scores improved, from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15.0 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.3) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.6 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.8)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 12pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">moderate</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> sub-group, ADAS-Cog scores worsened, from </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25.7 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9.2) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">30.1 (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#177;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13.1)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe the improvement in ADAS-Cog over 1 year in mild patients taking simufilam is well outside the expected range of historic placebo decline rates from numerous other studies. Figure 1 presents a model of historical declines on ADAS-Cog in early disease (MCI + mild) and mild disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"><img src="sava-20230331x10qg001.jpg" style="width: 6.520139in; height: 2.115972in" alt="Chart&#xA;&#xA;Description automatically generated with low confidence" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Figure 1:</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> Statistical model of simufilam versus historical 1-year placebo declines on ADAS-Cog in early disease and mild disease</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Safety Data</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Simufilam 100 mg twice daily was generally safe and well tolerated in this open-label study. There were no drug-related serious adverse events. Three treatment-emergent adverse events (TEAEs) occurred in 7% or more of study patients: COVID-19 (12%), urinary tract infection (10%) and headache (9%). Reported TEAEs are based on all study patients who received at least one dose of drug. The top three reasons for patient discontinuations were withdrawal of informed consent (N=14), adverse events (N=13) and patient non-compliance (N=7).</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">____________________________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>1 </sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Figure 1: Forest plot</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> model by Pentara Corporation. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Data was sourced from non-randomized studies (i.e., ADNI) and randomized, controlled trials </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">conducted by other sponsors in patients with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">early (i.e., MCI + mild) and mild Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Biomarker Data</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Exploratory biomarkers were analyzed from cerebrospinal fluid (CSF) collected from 25 patients in the open-label study who agreed to undergo a lumbar puncture at baseline and again after 6 months of treatment. CSF samples were analyzed blind by our academic collaborator at City University of New York. All CSF biomarkers were &#8216;research use only&#8217;, non-safety-related exploratory biomarkers. We previously announced results of this bioanalysis in a press release dated July 29, 2021.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> P-values shown below are baseline vs. 6-month levels by paired t-test:</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">21</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF biomarkers of disease pathology, t-tau and p-tau181, decreased 38% and 18%, respectively (both p&lt;0.00001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF biomarkers of neurodegeneration, neurogranin and neurofilament light chain (NfL), decreased 72% and 55%, respectively (both p&lt;0.00001)</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CSF biomarkers of neuroinflammation, sTREM2 and YKL-40, decreased 65% and 44% (both p&lt;0.00001)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Limitations of Open-label Study and Top-line Results</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 12pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 12pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Data results from our open-label safety study do not constitute, and should not be interpreted as, regulatory evidence of safety or efficacy for simufilam in Alzheimer&#8217;s disease. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Rigorous evidence for drug safety and efficacy is derived from one or more large, randomized, placebo-controlled studies. The open-label design and size of this study may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our open-label study add complexity or limitations to the scope of data interpretation. In addition, &#8216;top-line data&#8217; is a summary of the clinical data prior to the completion of a full and final audit or quality-control of the clinical database. We communicated top-line data so that stakeholders had timely access to a summary of the study&#8217;s findings prior to us receiving the final dataset. Final data may change from initial top-line data.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Cognition Maintenance Study</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In May 2021, we initiated a Cognition Maintenance Study (CMS). The CMS is a randomized, withdrawal study design. ICH</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> defines this type of study design as follows: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#8220;In a randomized withdrawal trial, subjects receiving a test&#160;treatment for a specified time are randomly assigned to continued treatment with the test treatment or to placebo (i.e., withdrawal of active therapy)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> &#8230;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#160;Any difference that emerges between the group receiving continued treatment and the group randomized to placebo would demonstrate the effect of the active treatment</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#8221;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The CMS study design is intended to evaluate simufilam&#8217;s effects on cognition and health outcomes in Alzheimer&#8217;s patients who continue with drug treatment versus patients who discontinue drug treatment. It is a double-blind, randomized, placebo-controlled study of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease. Study patients are randomized (1:1) to simufilam or placebo for six months. To enroll in this study, patients must have previously completed 12 months or more of open-label treatment with simufilam. Figure 2.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 2. Cognition Maintenance Study Design</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="sava-20230331x10qg002.jpg" style="width: 6.520139in; height: 2.022917in" alt="Graphical user interface&#xA;&#xA;Description automatically generated with low confidence" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patient enrollment for this study is closed. As of April 26, 2023, over 125 patients have completed this study. A small number of enrolled patients are still being treated in the randomized portion of this study. All randomized clinical data remain blinded. Our goal is to announce top-line clinical results for the CMS approximately third-quarter 2023. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">____________________________</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">22</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2  </sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), Topic E10, Choice of Control Group in Clinical Trials.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">End-of-Phase 2 (EOP2) Meeting with FDA</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In January </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2021</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, we held an End-of-phase 2 (EOP2) meeting for simufilam with the U.S. Food and Drug Administration (FDA). The purpose of this EOP2 meeting was to gain general agreement around key elements of a pivotal Phase 3 program to treat Alzheimer&#8217;s disease dementia. FDA attendees included Robert Temple, MD, Deputy Center Director for Clinical Science and Senior Advisor in the Office of New Drugs; Billy Dunn, MD, Director, Office of Neuroscience; Eric Bastings, MD, Director, Division of Neurology, and others.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In February 2021, we announced the successful completion of our EOP2 meeting. Official meeting minutes confirm that we and FDA are aligned on key elements of a Phase 3 clinical program for simufilam. FDA has agreed that the completed Phase 2 program, together with an ongoing and well-defined Phase 3 clinical program, are sufficient to show evidence of clinical efficacy for simufilam in Alzheimer&#8217;s disease. There is also agreement that the use of separate clinical scales to assess cognition (ADAS-cog</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) and function (ADCS-ADL</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) are appropriate co-primary endpoints of efficacy. A clinical scale that combines cognition and function, such as iADRS</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, is a secondary efficacy endpoint.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_____________________________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADAS-Cog = The Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive Subscale, a measure of cognition </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADCS-ADL = Alzheimer&#8217;s Disease Cooperative Study &#8211; Activities of Daily Living, a measure of health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> iADRS =</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">integrated Alzheimer&#8217;s Disease Rating Scale, a composite measure of cognition and health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">23</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Special Protocol Assessments</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2021, we announced we had reached agreement with FDA under a Special Protocol Assessment (SPA) for both </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Phase</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 3 studies. These SPA agreements document that FDA has reviewed and agreed upon the key design features of our Phase 3 study protocols of simufilam for the treatment of patients with Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">An SPA agreement indicates concurrence by the FDA with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, etc.). These elements are critical to ensure that our planned Phase 3 studies of simufilam in Alzheimer&#8217;s disease can be considered adequate and well-controlled studies in support of a future regulatory submission and marketing application.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The first clinical study protocol under the SPA is titled &#8220;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">A Phase 3, Randomized, Double-Blind, Placebo-</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Controlled</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of One Dose of Simufilam in Subjects with Mild-to-Moderate Alzheimer&apos;s Disease.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The second clinical study protocol under the SPA is titled &#8220;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects with Mild-to-Moderate Alzheimer&#8217;s Disease.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 3 Drug Supply</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have entered into a drug supply agreement with Evonik Industries AG for simufilam. Under </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> agreement, Evonik supplies and is expected to continue to supply us with large-scale, clinical-grade quantities of simufilam. Evonik is one of the world&#8217;s largest contract development and manufacturing organizations for pharmaceutical ingredients. Other vendors supply excipients, the finished dosage form (i.e., simufilam tablets), drug packaging, package labeling and other critical steps in the supply chain for Phase 3 drug supply.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 3 Clinical Program Overview</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our Phase 3 program consists of two large, double-blind, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Highlights of this clinical program are summarized in Figure 3. In June 2021, we announced the selection of Premier Research International as our CRO to help conduct our Phase 3 clinical program.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Figure 3. Summary of Our Phase 3 Clinical Program</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><img src="sava-20230331x10qg003.jpg" style="width: 6.404861in; height: 1.167361in" alt="Graphical user interface&#xA;&#xA;Description automatically generated with medium confidence" /></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">RETHINK-ALZ and REFOCUS-ALZ</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In Fall 2021, we </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">announced initiation of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our two Phase 3 studies </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">of simufilam</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of May 1, 2023, a total of over 1,244 patients have been enrolled in our Phase 3 program. The target patient enrollment for the Phase 3 program is over 1,750 patients. We anticipate the completion of patient enrollment for both of our Phase 3 studies by yearend 2023. Patients continue to be screened in clinical trial sites in the U.S., Canada, Puerto Rico, Australia, and South Korea.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">24</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg in enhancing cognition and slowing cognitive and functional decline over 52 weeks. Secondary objectives include the assessment of simufilam&apos;s effect on neuropsychiatric symptoms and caregiver burden. </span><span id="_Hlk96769600" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This randomized, double-blind, placebo-controlled study plans to enroll approximately 750 patients with mild-to-moderate Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Details of the RETHINK-ALZ Phase 3 study include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Approximately 750 patients with mild-to-moderate Alzheimer&#8217;s disease to be enrolled.</span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients to be randomized (1:1) to simufilam 100 mg or placebo twice daily. </span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients to be treated for 12 months.</span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The co-primary efficacy endpoints are ADAS-Cog12</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a cognitive scale, and ADCS-ADL</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a functional scale; both are standard clinical tools in trials of Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A secondary efficacy endpoint is iADRS</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a standard clinical tool in trials of Alzheimer&#8217;s disease that combines cognitive and functional scores from ADAS-Cog &amp; ADCS-ADL. </span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other secondary endpoints include plasma biomarkers of disease and NPI</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>4</sup></span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a clinical tool that assesses the presence and severity of dementia-related behavior.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In November 2021, we announced initiation of a second Phase 3 study, called REFOCUS-ALZ, designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 76 weeks. This randomized, double-blind, placebo-controlled study plans to enroll approximately 1,000 patients with mild-to-moderate Alzheimer&#8217;s disease.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Details of the REFOCUS-ALZ Phase 3 study include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Approximately 1,000 patients with mild-to-moderate Alzheimer&#8217;s disease to be enrolled.</span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients to be randomized (1:1:1) to simufilam 100 mg, 50 mg, or placebo BID. </span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Patients to be treated for 76 weeks.</span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The co-primary efficacy endpoints are ADAS-Cog</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a cognitive scale, and ADCS-ADL</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a functional scale; both are widely used clinical tools in trials of Alzheimer&#8217;s disease. </span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A secondary efficacy endpoint is iADRS</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a widely used clinical tool in trials of Alzheimer&#8217;s disease that combines cognitive and functional scores from ADAS-Cog &amp; ADCS-ADL. </span></p><p dir="ltr" style="font-family: CG Times (WN);font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Wingdings;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61656;</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other secondary endpoints include CSF, plasma and imaging biomarkers of disease and NPI</span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>4</sup></span><span style="white-space:pre-wrap; font-family: CG Times (WN);font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, a clinical tool that assesses the presence and severity of dementia-related behavior.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_____________________________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADAS-Cog = The Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive Subscale, a measure of cognition </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADCS-ADL = Alzheimer&#8217;s Disease Cooperative Study &#8211; Activities of Daily Living, a measure of health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> iADRS = integrated Alzheimer&#8217;s Disease Rating Scale, a composite measure of cognition and health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>4</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> Neuropsychiatric Inventory (NPI)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">25</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Phase 3 Entry Criteria Includes a Plasma Assay for Phosphorylated Tau (p-Tau)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We believe plasma levels of pTau proteins can provide independent confirmation of Alzheimer&#8217;s  neuropathology. RETHINK-ALZ and REFOCUS-ALZ studies use a &#8216;research use only&#8217;, non-safety related exploratory P-tau181 plasma assay to qualify mild-to-moderate Alzheimer&#8217;s patients. At the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>th</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> International Conference on Clinical Trials on Alzheimer&#8217;s Disease</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(CTAD)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 2022, a poster presentation indicated a 30 ng/L cut-point showed 100% sensitivity and 88% specificity for Alzheimer&#8217;s  diagnosis in 22 autopsy-confirmed samples</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><sup>5</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The plasma assay we use does not rely on age, APOE-gene status or complex algorithms to provide a result.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Open-label Extension Study for the Phase 3 Program</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2022, we announced the initiation of an open-label extension study for our Phase 3 program. This study is designed to provide no-cost access to simufilam for one year to Alzheimer&#8217;s patients who have successfully completed a Phase 3 study of simufilam.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The open-label extension study is expected to generate long-term safety and tolerability data for (oral) simufilam 100 mg twice daily over 52 weeks. There is no obligation for a patient or a physician to participate in the open-label extension study.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Each clinical investigational site and each patient chooses whether to participate in this open-label extension study. Patient enrollment for this study began November 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">_____________________________</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>1</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADAS-Cog = The Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive Subscale, a measure of cognition </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>2</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> ADCS-ADL = Alzheimer&#8217;s Disease Cooperative Study &#8211; Activities of Daily Living, a measure of health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>3</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> iADRS = integrated Alzheimer&#8217;s Disease Rating Scale, a composite measure of cognition and health function</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>4</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> Neuropsychiatric Inventory (NPI)</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"><sup>5</sup></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Source: </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">pTau181 Plasma Biomarker Performance as an Inclusion Criterion in the RETHINK-ALZ and REFOCUS-ALZ trials in mild-to-moderate Alzheimer&#8217;s disease, Mammel et al., CTAD 2022</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 150.0%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SavaDx</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our investigational product candidate, called SavaDx, is early-stage program focused on detecting the presence of Alzheimer&#8217;s disease from a small sample of blood. For business, technical and personnel reasons, we continue to prioritize the </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">development of simufilam, our novel drug candidate, over SavaDx, our novel diagnostic candidate. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SavaDx is a research-use only, non-safety related exploratory biomarker.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The regulatory pathway for SavaDx may eventually include formal analytical validation studies and clinical studies that sup</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">port evidence of sensitivity, specificity and other variables in various healthy and diseased patient populations. We have not conducted such studies and do not expect to conduct such studies in 2023. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">SavaDx is currently designed as an antibody-based detection system for altered filamin A (FLNA). Working with third parties, we </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">are evaluating the exploratory use of mass spectrometry </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">to detect FLNA, i.e., without the use of antibodies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span id="_Hlk33446796" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Financial Overview</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have yet to generate any revenues from product sales. We have an accumulated deficit of $307.8 million at March 31, 2023. These losses have resulted principally from costs incurred in connection with research and development activities, salaries and other personnel-related costs and general corporate expenses. Research and development activities include costs of clinical and preclinical trials as well as clinical supplies associated with our product candidates. Salaries and other personnel-related costs include stock-based compensation associated with stock options and other equity awards granted to employees and non-employees. Our operating results may fluctuate substantially from period to period as a result of enrollment rates of clinical trials for our product candidates, timing of preclinical activities and our need for clinical supplies.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">26</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect to continue to use significant cash resources in our operations for the next several years. Our cash requirements for operating activities and capital expenditures may increase in the future as we:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">continue our ongoing Phase 3 program with simufilam;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">manufacture large-scale supplies for simufilam;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">conduct other preclinical and clinical studies for our product candidates;&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">seek regulatory approvals for our product candidates; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">develop, formulate, manufacture and commercialize our product candidates; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">implement additional internal systems and develop new infrastructure;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">acquire or in-license additional products or technologies, or expand the use of our technology; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">maintain, defend and expand the scope of our intellectual property;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">incur costs related to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">legal proceedings and claims, including U.S. government inquiries; and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">hire additional personnel.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our product candidates. If our development efforts result in regulatory approval and successful commercialization of our product candidates, we expect to generate revenue from direct sales of our drugs and/or, if we license our drugs to future collaborators, from the receipt of license fees and royalties from sales of licensed products. We conduct our research and development programs through a combination of internal and collaborative programs. We rely on arrangements with universities, certain collaborators, </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">contract development and manufacturing organizations (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">CDMOs), CROs and clinical research sites for a significant portion of our product development efforts.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We focus substantially all of our research and development efforts in the area of neurology. The following table summarizes expenses </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">by category for research and development efforts </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(in thousands): </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Compensation</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 1,814&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 1,898&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contractor fees and supplies</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 20,048&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 12,856&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other common costs</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 258&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 152&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 22,120&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 14,906&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expenses include compensation, contractor fees and supplies as well as allocated common costs. Contractor fees and supplies generally include expenses for clinical studies and preclinical studies and costs for formulation and manufacturing activities. Other common costs include the allocation of common costs such as facilities.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023, we did not receive reimbursement from NIH research grants. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2022, we received $0.1 million from NIH research grants. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">These reimbursements were recorded as a reduction to our research and development expenses.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our technology has been applied across certain of our product candidates. Data, know-how, personnel, clinical results, research results and other matters related to the research and development of any one of our product candidates also relate to, and further the development of, our other product candidates. As a result, costs allocated to a specific drug candidate may not necessarily reflect the actual costs surrounding research and development of that product candidate due to cross application of the foregoing</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Estimating the dates of completion of clinical development, and the costs to complete development, of our product candidates would be highly speculative, subjective and potentially misleading. Pharmaceutical product candidates take a significant amount of time to research, develop and commercialize. The clinical trial portion of the development of a new drug alone usually spans several years. The cost and pace of our future research and development activities are linked and subject to change</span><span style="white-space:pre-wrap; color: #0000FF;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">27</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Critical Accounting Estimates</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. GAAP</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses and net loss incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.35in;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There have been no material changes to our critical accounting estimates during the three months ended&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on&#160;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">February 28, 2023</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Results of Operations &#8211; Three Months Ended </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">,</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> 2023 and 2022</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Research and Development Expense</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expenses consist primarily of costs of drug development work associated with our product candidates, including:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">clinical trials,</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">pre-clinical testing,</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">clinical supplies and related formulation and design costs, and</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">compensation and other personnel-related expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development expenses were $22.1 million and $14.9 million during the three months ended March 31, 2023 and 2022, respectively. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This 48% increase was due primarily to increasing enrollment and costs to conduct the ongoing Phase 3 clinical program as well as open-label studies in simufilam compared to the prior year. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect research and development expense to increase in 2023 compared to 2022 as we conduct a Phase 3 clinical program and other clinical studies with simufilam, continue to hire new personnel, manufacture drug supply, and continue our development efforts.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">General and Administrative Expense</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Allocated expenses consist primarily of facility costs for </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">our Company owned</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> office complex in Austin, Texas</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Depreciation and amortization for office space leased but not occupied by the Company is included in general and administrative expense. Depreciation and amortization for office space occupied by the Company is allocated between general and administrative expense and research and development expense. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also incur expenses associated with operating as a public company, including additional legal fees, expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance and audit expenses, investor relations activities, Sarbanes-Oxley compliance expenses and other administrative expenses and professional services.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative expenses were $4.4 million and $2.9 million during the three months ended March 31, 2023 and 2022, respectively. The 51% increase was due primarily to $0.9 million in higher legal expenses </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">as well as a $0.2 million increase in stock-based compensation expense</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">as compared to the prior year.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect general and administrative expense for 2023 will increase compared to 2022 due primarily to anticipated higher legal and professional fees related to ongoing securities class action and derivative lawsuits, </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">28</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">governmental investigations as well the Company&#8217;s lawsuit against a hedge fund and certain individuals who we believe executed a &#8220;short and distort&#8221; campaign against Cassava Sciences.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Interest Income </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Interest income was $2.1 million and $31,000 during the three months ended </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023 and 2022, respectively. </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The increase in interest income was due to increases in interest rates compared to the prior period.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We expect interest income to increase in 2023 compared to 2022 due to the increases in interest rates.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Other income, net </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">record the activities related to leasing office space to third parties in buildings we own as other income, net, as leasing is not core to the Company&#8217;s operations. Other income, net, was $190,000 and $263,000 </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">during</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> the three months ended </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023 and 2022, respectively. Other income, net, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">was lower in the three months ended March 31, 2023 as operating expenses were higher in 2023 compared to the prior year</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation and amortization for the office complex is included in general and administrative and research and development expense, and thus not reflected in other income, net.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Liquidity and Capital Resources</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Since inception, we have financed our operations primarily through public and private stock offerings, payments received under collaboration agreements and interest earned on our cash and cash equivalents balances. We intend to continue to use our capital resources to fund research and development activities, capital expenditures, working capital requirements and other general corporate purposes. As of March 31, 2023, cash and cash equivalents were $187.5 million.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2022 Registered Direct Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 22, 2022, we completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">At-the-Market Common Stock Offering </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2020, we established an at-the-market offering program (&#8220;2020 Program&#8221;) to sell, from time to time, shares of our common stock having an aggregate offering price of up to $100 million </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in transactions pursuant to a shelf registration statement that was declared effective by the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> on May 5, 2020</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. We gave notice of termination for the 2020 Program effective on April 26, 2023, which is effective May 1, 2023. There were no common stock sales under the 2020 Program through its termination. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2020 Cash Incentive Bonus Plan Obligations</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2020, the Board approved the 2020 Cash Incentive Bonus Plan (the Plan). The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee&#160;determines the Company has sufficient cash on hand, as defined in the Plan. Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">29</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2022, the Company&#8217;s independent directors were participants in the Plan. However, effective March 16, 2023, the Board of Directors amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the Plan were completely forfeited to the Company and will not be allocated to any other participant under the Plan. Our independent directors have not received, and as a result of such amendment will never receive, any payments under the Plan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s market capitalization, including all outstanding stock options, was $89.4&#160;million at the inception of the Plan in August 2020. If the Company were to exceed a $5&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, and conditions noted above for payment are met, all&#160;Plan milestones would be deemed achieved, in which case total cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s potential financial obligation to plan participants at </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023 totaled $6.5&#160;million (after the March 2023 Plan amendment), based upon the achievement of one Plan milestone in the Company&#8217;s market capitalization in 2020. No actual cash bonus payments have been made to any Plan participant, as the Company has not yet satisfied all the conditions necessary for amounts to be paid under the Plan. During the year ended December&#160;31, 2021, the Company&#8217;s market capitalization increased substantially. These increases triggered the achievement of 11 additional Plan milestones. Collectively, the achievement of such milestones could trigger potential Company obligations to Plan participants ranging from a minimum of $74.9&#160;million up to a hypothetical maximum of $202.3&#160;million, with exact amounts to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No Valuation Milestones were achieved during the 2022 or the three months ended March 31, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No actual cash payments were authorized or made to participants under the Plan as of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023, or through the filing date of this Form 10-Q.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Cash</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities was $13.3 million for the three months ended March 31, 2023, resulting primarily from the net loss of $24.3 million, partially offset by an increase in accounts payable and accrued expenses of $4.6 million, an increase in accrued developmental expenses of $3.0 million, a decrease in in prepaid and other current assets of $2.7 million and stock-based compensation expense of $0.7 million.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in operating activities was $23.5 million for the three months ended March 31, 2022, resulting primarily from the net loss of $17.5 million, a decrease in accounts payable and accrued expenses of $3.8 million and accrued compensation and benefits of $1.7 million as well as an increase in prepaid and other current assets of $1.1 million, partially offset by stock-based compensation expense of $0.5 million.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in investing activities during the three months ended March 31, 2023 was $0.4 million as final payment was made on renovations and fixtures for</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> our corporate headquarters</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash used in investing activities during the three months ended March 31, 2022 was $0.4 million related to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">renovations and fixtures for</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> our corporate headquarters</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities during the three months ended March 31, 2023 was $0.1 million from the exercise of stock options.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net cash provided by financing activities during the three months ended March 31, 2022 was $0.2 million, from the exercise of stock options.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Property and Leases</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We own an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. This property is intended to accommodate our anticipated growth and expansion of our operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">30</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet. The property is currently over 60% leased. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We also occupied approximately 25% of the property beginning late August 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We leased approximately 6,000 square feet of office space pursuant to an operating lease in Austin, Texas expiring in April 2024. We and the landlord consented to early terminate this lease on February 22, 2023 with no continuing obligations.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.00in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Other Commitments</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We have an accumulated deficit of $307.8 million as of March 31, 2023. We expect our cash requirements to be significant in the future. The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our drug candidates, the resources we devote to researching and developing, formulating, manufacturing, commercializing and supporting our products and other corporate needs. We believe that our current cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months. We may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to us. However, there are no assurances that additional financing will be available on favorable terms, or at all.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 3.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Quantitative and Qualitative Disclosures About Market Risk</span><span id="Quantitative_And_Qualitative_Disclosures" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are exposed to market risks in the ordinary course of our business, primarily related to interest rate sensitivities and, to a lesser extent, currency fluctuations related to our clinical operations outside the U.S.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Interest Rate Sensitivity</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are exposed to market risk related to changes in interest rates. We had cash and cash equivalents of $187.5 million as of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023, which consisted primarily of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. Treasury securities and money market accounts</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 13.5pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-size: 13.5pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="background: #FFFFFF;font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.38in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain investment vehicles with high credit quality and short-term duration, in accordance with our board-approved investment policy. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Such interest-earning instruments carry a degree of interest rate risk. However, due to the generally short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point increase or decrease in interest rates </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">during any of the periods presented would increase or decrease our annual net loss by less than $2 million in our condensed consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 4.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Controls and Procedures</span><span id="Controls_And_Procedures" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Evaluation of disclosure controls and procedures. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer (as Principal Executive Officer) and our Chief Financial Officer (as Principal Financial Officer) have concluded that our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (the &#8220;Exchange Act&#8221;)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms</span><span style="white-space:pre-wrap; color: black;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosures</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.20in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">31</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Changes in internal control over financial reporting.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) identified during the three months ended </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> that has materially affected, or is reasonable likely to materially affect, our internal control over financial reporting.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">PART II &#8211; OTHER INFORMATION</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="Legal_Proceedings" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Legal Proceedings</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">From time to time, we may become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and Citizen Petitions submitted to FDA, and may receive inquiries from government authorities relating to matters arising from the ordinary course of business</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to us. No information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, no accrual for these matters has been recorded within the condensed consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Government Investigations</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 15, 2021, we disclosed that certain government agencies had asked us to provide them with corporate information and documents. These were confidential requests. We have been voluntarily cooperating and will continue to cooperate with government authorities. No government agency has informed us that it has found evidence of research misconduct. No government agency has informed us that any wrongdoing has occurred by any party. No government agency has filed any charges against us, or anyone associated with us. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency may pursue an enforcement action against us or others.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 105.8%;margin-bottom: 5pt;margin-left: 0;margin-right: 0;margin-top: 5pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Securities Class Actions and Shareholder Derivative Actions</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Between August 27, 2021 and October 26, 2021, four putative class action lawsuits were filed alleging violations of the federal securities laws by us and certain named officers. The complaints rely on allegations contained in Citizen Petitions that were submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On June 30, 2022, a federal judge consolidated the four class action lawsuits into one case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of our securities between September 14, 2020 and July 26, 2022. Briefing on defendants&#8217; motion to dismiss was completed on January 23, 2023 </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and an argument on defendants&#8217; motion was held on April 26, 2023</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> We believe the claims are without merit and intend to defend against these lawsuits vigorously. We are unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s board of directors. This complaint relies on allegations made in Citizen Petitions that were submitted to</span><span id="OLE_LINK1" style="text-decoration: none;"></span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (and subsequently denied by)</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since November 4, 2021, three additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">32</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Court for the Western District of Texas, and one in Texas state court (Travis County District Court). </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All four actions have</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> been stayed pending the resolution of the motions to dismiss in the securities class actions. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July 5, 2022, the three federal court actions were consolidated into a single action.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s board of directors. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the 2020 Cash Incentive Bonus Plan</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> in August 2020. The complaints seek unspecified compensatory damages and other relief. On </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">January 6, 2023, the plaintiffs filed an amended complaint. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Defendants filed a partial answer to the amended complaint on March 10, 2023, and moved to partially dismiss the amended complaint on March 14, 2023. Defendants&#8217; motion to dismiss remains pending. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although the plaintiffs in this derivative case do</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We are unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 1A.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Risk Factors</span><span id="Risk_Factors" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span id="_cp_text_1_506" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">There have been no material changes to our risk factors from those disclosed under &#8220;Risk Factors&#8221; in Part I, Item 1A of our 2022 Annual Report</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> on Form 10</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">K</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">. The risks and uncertainties described in our 2022&#160;Annual Report </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">on Form 10</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">K</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"> are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition or results of operations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 2.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Unregistered Sales of Equity Securities and Use of Proceeds</span><span id="Unregistered_Sales" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 3.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Defaults Upon Senior Securities</span><span id="Defaults_Upon_Senior_Securities" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><h1 dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 4.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Mine Safety Disclosures</span><span id="Mine_Safety" style="text-decoration: none;"></span></h1><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Not applicable.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><h1 dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 5.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Other Information</span><span id="Other_Information" style="text-decoration: none;"></span></h1><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">None.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br />&#8206;</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">33</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Item 6.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Exhibits </span><span id="Exhibits" style="text-decoration: none;"></span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 1.69in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -1.54in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following exhibits have been filed with this report:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Incorporated by</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 19.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Reference</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"> Description</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filing</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Exhibit</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Filed</span></p></td></tr><tr><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">No.</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Form</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Date</span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">No.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Herewith</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.1</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Certificate of Incorporation.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-Q</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7/29/2005</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.2</span></a></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certificate of Amendment of Restated Certificate of Incorporation.</span></a></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">8-K</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5/8/2017</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.3</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certificate of Amendment of Restated Certificate of Incorporation.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3/29/2019</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.3</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000009/sava-20221231xex3_4.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">3.4</span></a></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000009/sava-20221231xex3_4.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Amended and Restated Bylaws of Cassava Sciences, Inc.</span></a></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10-K</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2/28/2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.4</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="sava-20230331xex31_1.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">31.1</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="sava-20230331xex31_1.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  </span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="sava-20230331xex31_2.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">31.2</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="sava-20230331xex31_2.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="sava-20230331xex32_1.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">32.1 +</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><a href="sava-20230331xex32_1.htm"><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-decoration: underline;">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #0563C1;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.INS</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inline XBRL Instance Document</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> - </span><span style="white-space:pre-wrap; color: #0563C1;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(the instant document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.SCH</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inline XBRL Taxonomy Extension Schema Document.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.CAL</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.DEF</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.LAB</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">101.PRE</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">104.</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 63.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cover Page Interactive Data File &#8211;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(formatted as Inline XBRL and contained in Exhibit 101)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 9.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 1.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 5.0%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.2%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 7.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">X</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">+The certification furnished in Exhibit&#160;32.1 hereto is deemed to accompany this Quarterly Report on Form&#160;10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.</span><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><br />&#8206;</span></p></div>
    <div><div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">34</span></p></div><hr class="pageBreak" style="margin:18pt 0pt; ct-page-break: true; page-break-after: always;" /><div class="headerContainer"></div></div>
    <div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span id="Signatures" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">SIGNATURES</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="padding-left: 0;text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 160.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.8pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 160.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cassava Sciences, Inc.</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.8pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Registrant)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 160.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/s/ </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">REMI BARBIER</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.8pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Remi Barbier,</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chairman of the Board of Directors,</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">President and Chief Executive Officer</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Date: May 1, 2023</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Principal Executive Officer)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="padding-left: 0;text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 160.75pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.8pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.01in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid windowtext 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 160.75pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">/</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">s/ ERIC J. SCHOEN</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 11.8pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid windowtext 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Eric J. Schoen,</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Chief Financial Officer</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 297pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Date: May 1, 2023</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: top;width: 172.55pt;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(Principal Financial and Accounting Officer)</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div>
    <div class="footerContainer"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;" class="ctHeaderFooterPage">35</span></p></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sava-20230331xex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.4.0.9-->
<!--Created on: 5/1/2023 8:20:15 AM-->
<html>
	<head>
		<title>
			Exhibit 311
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 0pt 0pt 10.6pt;text-indent: -18pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Exhibit 31.1</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">CERTIFICATION OF THE </font><font style="display: inline;font-size:10pt;">PRINCIPAL </font><font style="display: inline;font-size:10pt;">EXECUTIVE OFFICER</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;text-align:left;font-weight:bold;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">I, Remi Barbier, certify that: </font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">I have reviewed this </font><font style="display: inline;font-size:10pt;color:#000000;">Quarterly </font><font style="display: inline;font-size:10pt;color:#000000;">Report on Form 10-Q of </font><font style="display: inline;font-size:10pt;color:#000000;">Cassava Sciences</font><font style="display: inline;font-size:10pt;color:#000000;">, Inc.;&nbsp;&nbsp; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))</font><font style="color:#0000FF;display: inline;color:#000000;font-size:10pt;text-decoration:none;"> and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) </font><font style="display: inline;font-size:10pt;color:#000000;">for the registrant and have: </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="color:#0000FF;display: inline;color:#000000;font-size:10pt;text-decoration:none;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> c.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> d.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;line-height:100%;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;line-height:100%;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;line-height:100%;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:212.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-bottom:1pt none #D9D9D9 ;width:166.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-bottom:1pt none #D9D9D9 ;width:90.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:166.60pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:90.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:166.60pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">/s/ REMI BARBIER</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:90.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Remi Barbier,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Chairman of the Board of Directors,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">(Principal Executive Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Dat</font><font style="display: inline;font-size:10pt;color:#000000;">e</font><font style="display: inline;font-size:10pt;color:#000000;">: &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">May</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">1</font><font style="display: inline;font-size:10pt;color:#000000;">, 20</font><font style="display: inline;font-size:10pt;color:#000000;">2</font><font style="display: inline;font-size:10pt;color:#000000;">3</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sava-20230331xex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.4.0.9-->
<!--Created on: 5/1/2023 8:20:23 AM-->
<html>
	<head>
		<title>
			Exhibit 312
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 0pt 0pt 10.6pt;text-indent: -18pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Exhibit 31.</font><font style="display: inline;">2</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">CERTIFICATION OF THE </font><font style="display: inline;font-size:10pt;">PRINCIPAL </font><font style="display: inline;font-size:10pt;">FINANCIAL</font><font style="display: inline;font-size:10pt;"> OFFICER</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;text-align:left;font-weight:bold;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">I, </font><font style="display: inline;font-size:10pt;">Eric J. Schoen</font><font style="display: inline;font-size:10pt;">, certify that: </font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">I have reviewed this </font><font style="display: inline;font-size:10pt;color:#000000;">Quarterly </font><font style="display: inline;font-size:10pt;color:#000000;">Report on Form 10-Q of </font><font style="display: inline;font-size:10pt;color:#000000;">Cassava Sciences</font><font style="display: inline;font-size:10pt;color:#000000;">, Inc.;&nbsp;&nbsp; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))</font><font style="color:#0000FF;display: inline;color:#000000;font-size:10pt;text-decoration:none;"> and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) </font><font style="display: inline;font-size:10pt;color:#000000;">for the registrant and have: </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="color:#0000FF;display: inline;color:#000000;font-size:10pt;text-decoration:none;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> c.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> d.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;line-height:100%;;"> a.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
				<font style="margin:3pt 0pt 0pt;font-family:Times New Roman;font-size:10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;line-height:100%;;"> b.</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:3pt 0pt 0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;line-height:100%;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:211.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-bottom:1pt none #D9D9D9 ;width:166.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-bottom:1pt none #D9D9D9 ;width:89.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:211.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:166.10pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:89.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:211.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.05pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:211.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.05pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:211.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:166.10pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">/s/ </font><font style="display: inline;font-size:10pt;color:#000000;">ERIC J. SCHOEN</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:89.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:211.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.05pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Eric J. Schoen</font><font style="display: inline;font-size:10pt;color:#000000;">,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:211.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.05pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Chief </font><font style="display: inline;font-size:10pt;color:#000000;">Financial</font><font style="display: inline;font-size:10pt;color:#000000;"> Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:211.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:256.05pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">(Principal </font><font style="display: inline;font-size:10pt;color:#000000;">Financial</font><font style="display: inline;font-size:10pt;color:#000000;"> Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Dat</font><font style="display: inline;font-size:10pt;color:#000000;">e</font><font style="display: inline;font-size:10pt;color:#000000;">: &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">May</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">1</font><font style="display: inline;font-size:10pt;color:#000000;">, 20</font><font style="display: inline;font-size:10pt;color:#000000;">2</font><font style="display: inline;font-size:10pt;color:#000000;">3</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sava-20230331xex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 22.4.0.9-->
<!--Created on: 5/1/2023 8:20:31 AM-->
<html>
	<head>
		<title>
			Exhibit 321
		</title>
	</head>
	<body><div style="margin-left:70pt;margin-right:71pt;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">Exhibit 32.1</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;font-size:11pt;">CERTIFICATION</font><font style="display: inline;font-size:11pt;"> OF THE CHIEF EXECUTIVE OFFICER</font><font style="display: inline;font-size:11pt;">&nbsp;</font><font style="display: inline;font-size:11pt;">AND CHIEF FINANCIAL OFFICER</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-size:11pt;">PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">(18 U.S.C. Section 1350)</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the </font><font style="display: inline;font-size:10pt;">Sarbanes-Oxley Act of 2002, </font><font style="display: inline;font-size:10pt;">each of the undersigned officers</font><font style="display: inline;font-size:10pt;"> of </font><font style="display: inline;font-size:10pt;">Cassava Sciences</font><font style="display: inline;font-size:10pt;">, Inc. (the &#x201C;Company&#x201D;), hereb</font><font style="display: inline;font-size:10pt;">y certif</font><font style="display: inline;font-size:10pt;">ies</font><font style="display: inline;font-size:10pt;"> that to the be</font><font style="display: inline;font-size:10pt;">st of </font><font style="display: inline;font-size:10pt;">such officer&#x2019;s</font><font style="display: inline;font-size:10pt;"> knowledge:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size:10pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">The Company&#x2019;s </font><font style="display: inline;font-size:10pt;color:#000000;">Quarterly</font><font style="display: inline;font-size:10pt;color:#000000;"> Report on Form 10-Q for the period ended </font><font style="display: inline;font-size:10pt;color:#000000;">March 31</font><font style="display: inline;font-size:10pt;color:#000000;">, 20</font><font style="display: inline;font-size:10pt;color:#000000;">2</font><font style="display: inline;font-size:10pt;color:#000000;">3</font><font style="display: inline;font-size:10pt;color:#000000;">, and to which this certification is attached as Exhibit 32.1 (the &#x201C;Periodic Report&#x201D;), fully complies with the requirements of Section 13</font><font style="display: inline;font-size:10pt;color:#000000;">-</font><font style="display: inline;font-size:10pt;color:#000000;">(a) or 15</font><font style="display: inline;font-size:10pt;color:#000000;">-</font><font style="display: inline;font-size:10pt;color:#000000;">(d) of the Securities Exchange Act of 1934, and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size:10pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;font-size:10pt;color:#000000;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 180pt;text-indent:36pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">Date</font><font style="display: inline;font-size:10pt;color:#000000;">: &nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">May</font><font style="display: inline;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-size:10pt;color:#000000;">1</font><font style="display: inline;font-size:10pt;color:#000000;">, 20</font><font style="display: inline;font-size:10pt;color:#000000;">2</font><font style="display: inline;font-size:10pt;color:#000000;">3</font>
		</p>
		<p style="margin:0pt 0pt 0pt 288pt;text-indent:36pt;line-height:100%;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;line-height:100%;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:212.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-bottom:1pt none #D9D9D9 ;width:166.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-bottom:1pt none #D9D9D9 ;width:90.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:166.60pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:90.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:166.60pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">/s/ REMI BARBIER</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:90.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Remi Barbier,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Chairman of the Board of Directors,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">/s/ ERIC J. SCHOEN</font><font style="display: inline;font-size:10pt;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;color:#000000;"></font><font style="display: inline;font-size:10pt;color:#000000;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;color:#000000;"></font><font style="display: inline;font-size:10pt;color:#000000;"></font><font style="display: inline;font-size:10pt;color:#000000;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Eric J. Schoen,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:212.75pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:256.90pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;color:#000000;">Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>sava-20230331x10qg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20230331x10qg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@<_QEG.&_P"^,"A+H#VN>RBEH%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#(]>P44 >/_P#"/?'/_H<M#_[\K_\ (]'_  CWQS_Z'+0_^_*__(]>P44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA7F>DZ/>S>(=-MUAU>&STRYDG$-Y$!#""&&(Y!_K<EAC/09KTP4= ZBT444
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M@RU_]&35U%<O9?\ )3-8_P"P9:_^C)J .HHHHH **** "BBB@ HHHH ****
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M_P!\"C^SK+_GUA_[X% !_:5E_P _</\ WV*DBN8+C/DRI)MZ[6SBH_[.LO\
MGUA_[X%2Q6\,&?)B1,]=JXS0!+10** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2@_I110!RW@M(4
M?7_)E:3.JS%]R;=K?+D#DY^O'TKJ:Y;P7)'(^O\ EP+%MU696VL3O(QECD\$
M^U=344_A.K&_QW\OR"BD;CFL?1/$5OK:WC1H8EMI-H9FR'3JKCV(JSE-FBN5
MA\?Z%<ZFUM;WD4MO%;M/-=!\)& <<\?K6^=2LA=&U-S$)Q#YY0MR(\XW?3/>
MCI<"W16';^+_  _=V-S>PZM;O;VW^N?=C9^?-.C\5Z#+I?\ :2ZI;_8_,\KS
M2V!O_N\\Y]J -NBLBU\2:-?6D-W;ZC \$\WV>-P?O2'^'GOQ4D^OZ3:I<//?
MP1K;RB&4LWW'(R%/OCF@#3I*P(_&OAN5;<QZQ;-]H?9'\QY;CCVZCKBK%UXG
MT6RU6/3+G4H([V3&V)CSSTSV'XT ;%)7/#QCI*:[-H]W<1VUTD@CC61O]:2
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MV#+7_P!&34 =11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!14$]Y;6I43S)&6Z!CUJ'^UM/_Y^XO\ OJ@"[15+^UM/_P"?N+_OJC^UM/\
M^?N+_OJ@"[15+^UM/_Y^XO\ OJC^UM/_ .?N+_OJ@"[16/J?B;2=*TNZU"XN
ME,%M&99/+&YL#T'K6)X7^)_AGQ=<7$.FW$RM;H'?SXM@P3CB@#LZ*I?VMI__
M #]Q?]]4?VMI_P#S]Q?]]4 7:*I?VMI__/W%_P!]4?VMI_\ S]Q?]]4 7:*I
M?VMI_P#S]Q?]]4HU6P9@HNXB2<  ]30!<HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**#2<T
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M16UW_A';<:4@:1G_ +0_>"-206V;,9P"<9K:U#Q3;6+Z9MB:1;W:Q.<&*-L
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MN/,)E,H)'S)C 4E6P<^E"U ZVBL+7=9O[*\L]/TJRBNKZY5Y )Y3'&J)C))
M)R<C'%8EWX](TS2Y[>.P@N+QI4<:C=^1'$8SM<;L'//3UI#L=N57<&(&0, T
MM9]G=W4NBK=S0PR7!C+^79S;T?T".<9SZG'6LO2M>U.36AI>L:=!:SRP&X@\
MB<RC:" 0^0,-R.F1UYIVZ"OI<Z2BN;\0:WK&DM-<VVE0RZ=:Q^;<337&QF7N
M(U .2!GKCM5/4_%M]#+</INEI<6=C;)=7CRS&-@C#=A%P<MM!/)%" ZU8HUD
M:1456?&Y@!DX]:DK&L]=2YU5+-HMB7%LMS;29^^O&X'T(R*V: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y>R_Y*9K'_
M &#+7_T9-745R]E_R4S6/^P9:_\ HR:@#J**** "BBB@ HHHH **AN+F&TC\
MR>0(OJ:J?VYIW_/R/^^30!HT5G?VYIW_ #\C_ODT?VYIW_/R/^^30!HT5G?V
MYIW_ #\C_ODT?VYIW_/R/^^30!HT5G?VYIW_ #\C_ODT?VYIW_/R/^^30!HT
M5G?VYIW_ #\C_ODUS'C#XIZ#X,%F;R.ZN?M6[;]F0';MQUW$>M '<45SNA>,
M])U_1+75())(HKE2RI*N&&"1SC([>M:/]N:=_P _(_[Y- &C16=_;FG?\_(_
M[Y-']N:=_P _(_[Y- &C16=_;FG?\_(_[Y-']N:=_P _(_[Y- &C16=_;FG?
M\_(_[Y-']N:=_P _(_[Y- &C16=_;FG?\_(_[Y-7HW66-9$.589!]10 ^BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ;,(;X3V=]=NT-A<I',R2N2K*S?+TQD'UK4T;PW>V6H^'9?LLJ0V\5VT_G7
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MYK_WS3Z* &>5'_SS7_OFCRH_^>:_]\T^B@!GE1_\\U_[YH\J/_GFO_?-/HH
M9Y4?_/-?^^:Y?QA\/="\;BT&KI./LF[R_(DV?>QG/'/W175T4 9>@Z!8>'=$
MM=)L4;[-;*5C\T[FP23R?QK1\J/_ )YK_P!\T^B@!GE1_P#/-?\ OFCRH_\
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MIEUI'A6RL+U EQ$&#JK!@,L2.1[$50=-#>HHHI %%%% !1110 4444 %%%%
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MH(M5E77AIEU$B^9;B:"1"2'Q@./P)&/:M:N3M[9_^$ETNR5S(-+LSY\O;<P
M5?J1D_A764"%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N7LO^2F:Q_P!@RU_]&35U%<O9?\E,UC_L&6O_ *,FH ZBBBB@
M HHHH **** "BBB@ I#2T4 4[G4[2TE\N:3#XS@*34/]NZ?_ ,]6_P"^#6CM
M4]5!_"DV+_='Y4 9_P#;NG_\]6_[X-']NZ?_ ,]6_P"^#6AL7^Z/RHV+_='Y
M4 9_]NZ?_P ]6_[X-']NZ?\ \]6_[X-:&Q?[H_*C8O\ ='Y4 9_]NZ?_ ,]6
M_P"^#1_;NG_\]6_[X-:&Q?[H_*C8O]T?E0!G_P!NZ?\ \]6_[X-']NZ?_P ]
M6_[X-:&Q?[H_*C8O]T?E0!G_ -NZ?_SU;_O@T?V[I_\ SU;_ +X-:&Q?[H_*
MC8O]T?E0!G_V[I__ #U;_O@US7C/XG:3X-L;6ZGM[F[6XE,86$ %<#.3NQ7:
M[%_NC\JY#X@?#^T\?Z?9V=S>RVBVTIE#1("6)&,<T 3>%O'NE^*- AU:&.>W
MCE=T$<JY8;3CMD5L_P!NZ?\ \]6_[X-4/!GA2W\&^&H-%@N'N8X7=A)(H!.Y
MB>WUK?V+_='Y4 9_]NZ?_P ]6_[X-']NZ?\ \]6_[X-:&Q?[H_*C8O\ ='Y4
M 9_]NZ?_ ,]6_P"^#1_;NG_\]6_[X-:&Q?[H_*C8O]T?E0!G_P!NZ?\ \]6_
M[X-']NZ?_P ]6_[X-:&Q?[H_*C8O]T?E0!G_ -NZ?_SU;_O@T?V[I_\ SU;_
M +X-:&Q?[H_*C8O]T?E0!G_V[I__ #U;_O@T?V[I_P#SU;_O@UH;%_NC\J-B
M_P!T?E0!G_V[I_\ SU;_ +X-3VNI6UY(R0.691DY4BK.Q?[H_*E"@= !0 HH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!#6+XHCTJ31)?[8E,-J"I$BL0R/GY2N.<YZ8K:KG/&MBEYHB2M>06;V<Z7
M,4MP?W8=3P&]CG'XU,_A9OADG6C=VUW,BT\,Z)H.LV;7FIWEQ-<W#36T=RWR
M&8@98X4#=CIG\.:[H5YD=9'B+5-*BU'5=&BAMKI)5CM)VEDFE!PH&0,#)]Z]
M,Z\U%)K7E.C'JHG%U6W(6BJ&MZHFBZ+>:E)$TJ6L32E%/+ <X%6H9UEM8Y\;
M59 _)Z9&:U\S@)J*S-,U_2=8CFDT[4+>Y2 XD:-\[3[U!;^*] N[.YO(-7M)
M+>V_U\@D&$^M &S161%XHT.;3/[235;5K+?Y?G;\+N]/K3X/$6CW.DR:K#J-
MO)81YWW ?Y5QUS0!J45EIXAT>72UU--2MC8NVU9PXVD^F?7@U6C\8^')5MV3
M6K-A<.8XOW@^9AV^O- &[165=>(]&LM3BTVZU*VBO)<;(7?#'/2JO_"7:3'K
MDVD7=U%;72R".-9' ,I(!X_.EY ;]%9FMZS!HMFLSQ23RRR"*""(9:60]%'^
M/8#-8_\ PF%S:+=KK&ASV$\-L]S$GG+*LRH,L Z\!NG!]:8'5T5AR>+-%M+>
MQ>_OX+.2]C62**9P&.<<?J*?J/B?2M.DDMGOK;[:L1E6W:8*6&">O0# ZT ;
M-+7,Z?XVTF_\0W6C>?''=0+'@&0$2%ADA?ITKH+>Z@N@Y@E201N8W*G.&'4?
M44!Y$U%%% !1110 4444 %%%% !1110 4444 %%%% "&BL'6_$-QIU['8Z?I
M<FI7C0M.T22K'MC!P3EN"<D#%4;GQKNATU]*TXWSWT)G5'N$@V(..2W4YXQ0
M%CK:*YB_\47UJUM;0:#-=:@]N;F:V2X0"%!Q]\\,<\ #K6WI>HV^KZ9;ZA:D
MF"= Z$C!P?44 7**** "BBB@ HHHH ***0T %%<U!XIN#K%O:7VBW%C;7;M'
M:W$LBYE<#."G5<@$\^GO5C7M8U/25,UIHOVVV2,O+,;M(1&!U^]UXI>8=;&]
M16;H.I2ZOHMMJ$UE)9/.N_R)&#,H[9(X]ZTJ8!1110 4444 %%%% "$ ]1FB
ML_5-533FMHO*::>YD\N.)2 3ZGZ =:Q4\8R&]B+Z/<)I4UP;:._,B\ODCF/[
MP7((S_C0@.KI*Q-<UZ;3)[6TLM.EU"^N0S) D@C 5?O$LW ZCCO5 ^,_M%C8
M/I>ES7M[=K(PM?,6,IY9PX+'C(;@>M '548K/T758=;TB#4(%94E!RK]58$@
M@_0@U4L/$UIJ/B6^T6W1VDLHU>2;^#)_A'N*.M@Z7-NBL7Q+XDM/#.GI=7*O
M(TDJQ1Q1_>8L<<?3J:J^(/&6GZ!+9V\J2SW5U)&JPQ#)4.P7>QZ!03UH6H'2
M #.<<FEK.CU5#K<FER1M'*(1-$Q/$BYP<?0D#\:T: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y>R_Y*9K'_ &#+7_T9
M-745R]E_R4S6/^P9:_\ HR:@#J**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBD) Y- "T54_M.Q_P"?N+_OJC^U+'_G[B_[ZH M
MT54_M2Q_Y^XO^^J/[4L?^?N+_OJ@"W15&35]/CB>1KJ/:BECALG &:Y7P]\6
M?"?B?5!IVG7<WV@HSCS82BX'7DT =Q15/^U+#_G[B_[ZI?[4L?\ G[B_[ZH
MMT54_M2Q_P"?N+_OJC^U+'_G[B_[ZH MT56CO[2:01QW$;.>BAN35F@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *,FKJ*Y>R_Y*9K'_8,M?_1DU '3]J**.] '.:QXPL=)U 6(M;V]N0H>5+.
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ME%ZZ]?/;[COQTI:0=*6MSR@HHHH **** "BBB@ HHHH *1E#*58 J1@@TM%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS%]N<G(P,=Z .SI*S="U>/7-'AOXXVCWY5XV/*,I(8>_(/-4=-\40:IXGO\
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M ("I_A5ZG-:GW?W?\$V<CU%)D>HK'_X1'P[_ - /3O\ P%3_  H_X1'P[_T
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MTRUVQQ(%49DF)X''6GJ*2C;1_@=?1113("BBB@ HHHH **** "BBB@ HHHH
M**:[K&I9R%4#))JE_;6G?\_:?K0!?HJA_;6G?\_:?K1_;6G?\_:?K0!?HJA_
M;6G?\_:?K1_;6G?\_:?K0!?HJA_;6G?\_:?K1_;6G?\ /VGZT 7Z*H?VUIW_
M #]I^M']M:=_S]I^M %^BJ']M:=_S]I^M<]XL^)&@^#[.WNKXW$Z3R&-1;(&
M((&><D4 =A17->'/'.B^)M$BU6UDDAAD9E"3KM<%3@Y )'ZUK?VUIW_/VGZT
M 7Z*H?VUIW_/VGZT?VUIW_/VGZT 7Z*H?VUIW_/VGZT?VUIW_/VGZT 7Z*H?
MVUIW_/VGZT?VUIW_ #]I^M %^BJ']M:=_P _:?K1_;6G?\_:?K0!?HJBNL:?
M(ZHETA9CA1SR:O"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 2B@TG- '.>$?M1?6_M,F__ (F<OE_O VU.
M,#@\?0]*Z2N6\%I"LFO^3*TF=5F+[DV[6^7(')S]>/I74]ZBG\)U8S^,_E^1
M4U1+J33;A+(0FY,9$8G!*$XZ-CM7$:3I-P^NP7%AH%[H9^<WSR3*8I00?E10
MS?Q8(X7'Z5Z$:*LY;GG6G:-J[_V3ITNF20)HR3*;MW4K<;D*C9@YYSDY JN^
ME^(K/0-'L5L[^.-=.6*5M-:(3I,/X69SCR\'H,\UZ;11Y#N>=^'_  ]JMJ8&
MN;$QM'X?6R)+J3YH9LKU^E9]UX8UBWL]%F\C5F9-(2QG@TZXC1U8<G>7X*G.
M..1BO5**=[A<X%?[3TV^TZRD\/:I=:?IMO&D!@EB=6DP 68LRD[>@X]:HV>E
MZX!I.F-HUPB6>L&\DNFD388V9V&,-G(W 'C\Z],HH3L).QQ":!>_V190/9*7
M363=.IVGY-SD/Z=Q[U!=Z;KMI)K=Q:64C+<:HLP,10S&'R@I:+<<!\]S[UWU
M%(=SS&PT?6[;1KIY-+O+J3^V%O4CO)(VFDC" ?,0=NX8X_"NK\-VEZ/[3O[R
MU:T:^N#*ELY&]%"@?-@D9..Q/;FNCHH>HCRCPWH$6F1VJWW@K5WU".<L]U'<
M+Y>2Y(;'FCC&.WX5;U+2K^U?Q+KDUAY<6I6%Q$Z9&Z *AVL><?-@YQWVUZ93
M7570JRAE88((X(H \YTK2]1U[2X5.F-I<<>BM91R.RD2,ZC&W:2=@QGG'/:H
M]'\+:C=VM_%<1ZO;SMIK6*2ZA=1NH)[(J#[O'4\^U>E!550J@*!T '2G4>8'
ME^JZ;KVMB95\/26ODZ1)9J\DD>9)#C 7!^[QWQ]*LWFA:PVN3A-/D>&6]T^Y
M68.NT+$ K@\YR,9Z5Z/10G8=SS]]'U4W;Z.-.D:%M7_M'^T2R^6$W[\8SNW#
M[O3%)%X>U--(M8?L9$J^(3>. R_ZKS6._KZ8]Z]!HIIBN5-2BDGTJ[BB4M(\
M+JHSU)4UD:9I]W!\/[?3I(2MVNG"$QY'#^7C&>G6NBHI >3S>$M=;0OL(L<K
M'80-&N\9,YV*Z=?X0F<^];#^']4.L/,+0^4?$$5V&W+_ *D0[2WYUZ!13O8=
MSSAM*UJ%-/T-=&DG2VU7[6VH%T\LH69LCG=N&['3M7HXZ444A=1:*** "BBB
M@#FO%9EF@^Q3^'[C5M/G7YUM9@KA@> 067CW!_"LF>TU"#PS9Z1JV@SZQ;M%
MB46DRAD8'Y5.67( [@_A7=44 >9:AX>U40::NK:5/K$$5D81!:2JK139R&8D
MKD;>.I^E=SX<MKZS\.V%MJ4BR7D<*K,RXQN_"M2BB^E@%HHHH **** "BBB@
M K*UZ>Y@L?W&F2:C&^4FABD"2;",97. 3^(K4HI- <GX5M;O1[!XAIEQ!:3W
M#&VM2RLULFW/SG/<CU/45EZ1+K6H:^+W7?#^I17.YDM3F)K>T7H&X?+,>YQW
MP*] HI];@>>Z?X4\1Z;XLTR=]4M[NRB28S2_8@CL6(.&._)8^N.U>A44M'2P
M=;A1110 4444 %%%% '-:Z/LOBC0M1E.+9/-MW8]$9P-N?K@C-/U+3[N?QKH
MM]%"6M;>"X65\CY2VS;QUYP:Z!T21=KJ&7T(S2T(#FO$5O>:YH<-G':3Q+<W
M2QW",5#+"&)+<'H<#WP:K^+=/E=M/N+33K^9X-RB739TBFC! ^7#_*4.,'N,
M#%=;128'':)I]QI/AVV\-@R6UY<P32+<HH=8"6SSDY+#</Q!JCH7A[Q#H7B2
M>YN+F&\L8K!8U$%HL32L"3M'S\-DYR>#GM7?%1N!P,C@&EI];ATL<#X@T::;
M4;ZY30'O9=5M$ABF_=DV;@$ MN/&-P.5R?E-9^O>'-5>[D6;3+C5)VLXHK"[
MAE55MI57#-("1D;L-T;H>*].I*%H.YRR+-/XJTJW9A)-869>ZD7H&8!0/QY/
MX5U5,$:*[.% 9NI Z_6GT"%HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M])TJ[U"5'>.VB:5E098@#/%86DZ_K=Q=V/\ :&FVIL;]"T-Q8S-*$.,@294
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MY:?W%_*@"A_;FG?\_'_CIH_MS3O^?C_QTU?\M/[B_E1Y:?W%_*@"A_;FG?\
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ME1>%(9].T^6!K"]BL[JZ;[-',N98D*\F4YR,D'DDGD5E:5IVIRS:'H\^G7$
MT:[>>:Z=?W4JX<+L;/).\9],&JZBZ&Q#XHUC_A(+/2KSPWY!N=S>8E^DA1%Z
MNR@9QG ^IKK!TKG=%LK@^(M:U2[AD1GD6WM]X_Y9(.J^S$_I714N@=1:***
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M6?VSIW_/W'0!?HJA_;.G?\_<=']LZ=_S]QT 7Z*H?VSIW_/W'1_;.G?\_<=
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M<NK+@D'H%'/%=M]F@_YX1_\ ? J6B@"+[-!_SPB_[X%'V:#_ )X1?]\"I:*
M(OLT'_/"+_O@4?9H/^>$7_? J6B@"+[-!_SPB_[X%'V:#_GA%_WP*EHH B^S
M0?\ /"+_ +X%'V:#_GA%_P!\"I:* (OLT'_/"+_O@4?9H/\ GA%_WP*EHH C
M6&*-LI&BGU"@5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN2Y\@L"8PP "DCC/'.#3Z#5B.T\7I+X-M=?GL;@-<)E;6!3*Y;) 7@8'3J<
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MKQ/X]T;PMHK:I=--/$KK&4@7+9/3J1QQ4'A+XCZ'XOTZ>]L_M%O'#+Y16Y0
MDX!R,$\<UI^*/"6E^+=&;2M2206S.LA\E@C9'3G%0>$O!&C>"].FLM*24PS2
M^:WGOO.[ '!QTX% &G_;>F_\_2_D:7^V]-_Y^E_(U<\F+_GDG_?(H\F+_GDG
M_?(H I_VWIO_ #]+^1I5UG3V956Y4L3@#!ZU;\F+_GDG_?(I?)C!R(T'_ 10
M \4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI:XS3?%VHW%[I\MY86\6EZI(\5F\<I:56&2/,&, $*>A-=D* %HHHH ****
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M!2UC6NM&;64LI8?+2XMA<VS\Y8<;@?0C(XK8%,!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE[+_DIFL?]@RU_P#1DU=1
M7+V7_)3-8_[!EK_Z,FH ZBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BJUW?6UGM\^3:6Z#&35;^W=/\ ^>Q_[X-
M&E16;_;NG_\ /8_]\&C^W=/_ .>Q_P"^#0!I45YQXQ^,>B>#]4AL9[*]NFEA
M$P>$*  21CYB.>*Z'PYXWTOQ%H%KJT0F@CN Q$<J_,N&(YQQVH Z:BLW^W=/
M_P">Q_[X-']NZ?\ \]C_ -\&@#2HK-_MW3_^>Q_[X-7+6ZANXO-A;<F2,XQ0
M!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6([O1;*[L5@M-$,FV[\U6^T@J5&U1RO7)R*I_P#"QO$'_0BZA^<G_P ;I?\
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M:R?^%C>(/^A%U#\Y/_C='_"QO$'_ $(NH?G)_P#&Z'7A_28?V5BK[+_P*/\
MF6TT?Q#HIL+N"T34[C[ ;*=!.$*'=N5MS=0.A[TZ71;[3_#=AH,F@1:[9) J
MR 3K&5D!SDAR!CTQS5+_ (6-X@_Z$74/SD_^-T?\+&\0?]"+J'YR?_&Z'7@_
M^&8?V5BNR_\  H_YG:Z!9W>GZ%9VM]-YUS%&%=\YR?J>M:5><?\ "QO$'_0B
MZA^<G_QNE_X6-X@_Z$74/SD_^-T_;P_I,%E.)[+_ ,"C_F>C45YS_P +&\0?
M]"+J'YR?_&Z/^%C>(/\ H1=0_.3_ .-T>WA_28?V5BNR_P# H_YGHU%><_\
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M&9(OL,H&"^TGU(;Y<_=I_P#PL;Q!_P!"+J'YR?\ QND_X6-X@_Z$;4/SD_\
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M7Z*EQ'$%9%  7T'''3TIBU-; ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH
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M )^X?^^J=]@L_P#GUA_[X%'V"S_Y]8?^^!0 W^T['_G[A_[ZH_M.Q_Y^X?\
MOJG?8+/_ )]8?^^!1]@L_P#GUA_[X% #?[3L?^?N'_OJC^T['_G[A_[ZIWV"
MS_Y]8?\ O@4?8+/_ )]8?^^!0 W^T['_ )^X?^^JP_$WC[P[X3MH+C5+MA'.
MY1/)0R'(&><5O?8+/_GUA_[X%<KXX^'&E^.+*TM;F:6S6VD,@:V506)&,'(H
M UM"\7Z+XBTB/4["[!MI&95,@*-D'!X-:7]IV/\ S]P_]]5C>$O!FG>$_#L&
MCP9NHXF=A+.B[CN8GG ]ZV_L%G_SZP_]\"@!O]IV/_/W#_WU1_:=C_S]P_\
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M_BJ/^%8^$?\ H%M_X$R__%47K=D'+EW\T_N7^9J_\)=X=_Z#FG?^!2?XT?\
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M?[1'N /;.:D_X2[P[_T'-._\"D_QK+_X5CX1_P"@6W_@3+_\51_PK'PC_P!
MMO\ P)E_^*HO6[(.7+OYI_<O\S5_X2[P[_T'-._\"D_QH_X2[P[_ -!S3O\
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M_P#GZ\.?^ T__P 71Y?CO_GZ\.?^ T__ ,77444 <OY?CO\ Y^O#G_@-/_\
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M8=#T6TTNW=WAMHQ&K28W$>^*OT <OY?CO_GZ\.?^ T__ ,71Y?CO_GZ\.?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M??)M"*3@M[GVK70[E!]:K:C8Q:C:-;3%@C$$[3@\'-65&U0/2DNH/<=1113
M**** "D-+2&@#G/M^M0^*(K:9K![*?<4@C5O.10!\[-G&,YXQ_(UT=<_8^&#
M8:_=:JFL:C(;E]TEO(R-'TP /EW #L,XY/K704= ZBT444 %%%% !69KMQ>V
MNDS36+V\<J#<9+A69$4<DE5Y/'85IU1U33_[2M#"MU<6D@.Y)[=@'4^V01^8
M-)WMH->9%X?U"35="M+V8())8PS; 0,_0\CZ5IU3TO3HM+L5MHG>3!+/)(1N
M=CU8XXR:N53\B5>VH4444AA1110 AKF$\6)<>-TT*V-N\*1OYTAD&\2KM(0+
M]#G-=.:RF\.Z6=;AUA+.&.\B5QYB1*"^[&2QQD]/UHZ@:HZ4M(*6@ HHHH *
M*** *&M7DNGZ->7<$1EFBB9HXPI8LP' P.3S5'PMJ=[J6EEM2PE\C8DB^SF$
MH#T!4LW;WK5O;87EK) 9)(]ZX#Q-M93V(/K5;2=*72H&0W,UU,[;I+B<C>Y[
M9P /TH74&: Z4M(*6@ HHHH *0TM)0!QVI^*-2MO%*6=O;#^SHG6.YE>$D L
M,_ZS< O4?PG-=B*Q;OPY#=ZHEX;NYCCR&EM4*^5,PZ%@1G/T(Z5M"A; ]Q:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** $HJCK-Y+I^EW%W#$DCQ)O
M*NY4$#KR ><=!CDUF^$]3U'4]+W:E (YX3Y3$M\[./O%E"@+[ 9X-3S*_*:J
MC)TW4Z(Z"BL>\U>Y&H&PTVS2ZN(T#S-)-Y<<8.< D*Q+''3'3J1QFG-XJ^RV
M4S7-D8[RWFBAFMS)P [!0ZMCYEY)Z \$$"CF01H5);(Z2BJ5EJMAJ,3R65[;
MW"H<.895<*??%-L=8TW4VD6QO[:Y:/EQ#,K[?K@\4[HAPDNA?HJC:ZOIU]-)
M#:WUM/+%_K$CE5BGU /%-MM:TN\N?LUMJ%K-/MW>5',K-CUP#TY'YT70<DNQ
MH451N-7TZUCEEN+ZVB2)_+D9Y5 1B,@')X."#5/4/$^F:>M@[W4#1WL@2*3S
M5"E<9W9SR.@X[D>M%T5&E.3LD;5%48M1A-K/<SRV\<4+NK.LVY5"G^(D#!]1
MV]:6+5M.GM/M<-];R6^[;YJRJ4R3C&<XSD@471/)+L7:.U4K75M.O8))[6^M
MYX8B1(\<JL%QSR0>*K2Z_8MHU]J-A<6]ZEK$[D0S @E5S@D9Q_\ 7HNMQJG.
M]K&M14-O*9[>.;&W>@;'ID55;6],2_\ L#:A:B\_YX&9=_3/W<YZ<T76XN25
M[6-"BL;2O$VFZL)#!=096X:!5\U26()P1CU"DCU J_)?V<*3O+=0HMO_ *XM
M( (^,_-Z<$'GUH4E:XY4YQ?*UJ6J*YV/Q5;75_/!:-:RPQQQ2+<FY C;>Y7&
M0",C;QZD@<=:U+O5M.L)HHKN^MX))?N)+*JEOH">:.9,<J,XNS1>HJC?:QIN
MF;/M]_;6OF9*>=*J;L>F35Q&5T#(0589!'>GH0XM*]API:04M @HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRWMXT>25%%GX@EDN26_U*L9 K-Z [AR:C>ZM[K6;C4=WFZ9#JL<DT@&5VBW
M5_\ =#;3GIT/09KT? ]!0 /05/LGW-_KJWY?Q_X!YAJ%S87FN:O<Z:R21/\
M8"\L?*NPGP2#T;L,CTQVJ[?.UGK>M+J&J:=91W04(+ZV,GFP[ ,*=Z@@'=\N
M"<GW%>A8'H*,9ZT>S\P>-V26GX]/+R. D\C1EM95\0P079T](F_M*V94N%7.
MT@,RL&Y.1DXR,CI77Z%)YFA6+_8Q9[H5/V=5VB/CIC Q^5:! ]*4=*J,;&%6
MO[2-FM?Z\D+10**LYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>sava-20230331x10qg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20230331x10qg002.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_X0!:17AI9@  34T *@    @  8=I  0
M   !    &@       9*&  <    F    +     !53DE#3T1%  !, $4 00!$
M %0 3P!/ $P 4P @ '8 ,@ P "X ,/_; $, !04%" 4(# <'# P)"0D,#0P,
M# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#?_; $,!!0@("@<*# <'# T,"@P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#?_  !$( 4$$#@,!$0 "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /LN@ H
MRM5UB'1_L_GAV^UW,5JFP*<22[MI;++A!M.XC<W3"FMZ=*5;GY;+DA*;O?:-
MKVLGKKILO,SG-4^6]_>DHJW=_H:M8&@4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 95YK$-E>VNGR!S+?^=Y94+L'D()'WDL",@X7:K9/7 YK>-*4X3JJUJ?+
M?>_O.RMI]]VC-S491@[WE>W;17=S5K T"@ H * "@ H * "@ H * "@ H *
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M6_/3C/:UN:^F[O:V^GH8TY^TYM+<LG'UMU-VN4V"@ H X7QS_P PO_L,6?\
M[4KU,'_R_P#^P>I^AQU_^7?_ %]A^IW5>6=@4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 %  >1QQ0!PS^-H=*O3INM+]DEZQSC)MYD.=K@_>C/9E;<JL"/,( )]-825
M6'ML,^==8_;B^J[/R:LVNAQ^W4)>SJ^Z^C^RUW\OZU(M:E2?7]#DB971AJ!5
ME(92/LR\@C((^E523CA\2FK->RT>C7OL4VG5HM;>_P#^DG?5Y1VA0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M& ,DECQW))]Z\^4Y3DZDG>3=V_/\CI45%**V2LO0X_\ X5IX=_Y]/_(]S_\
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M>:9V>['_ &\R_P"-'UZKVA_X!$/JT.\O_ F'_"O=/'26\'_;U)1]>J?RT_\
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M#?\ E6?^0>SJ_P#/W_R2(?V!XB_Z#7_E/MO_ (JCVV&_Z!O_ "K/_(/9U?\
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M3+7J4/\ =L3_ -PO_2V<=3^+2_[?_P#23NJ\L[ H * "@ H * "@ H * "@
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M\BN9(Z<$,,CD'D$5!0M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MP==P!VL.C#/1AV(Y':J3<;V;5U9VZKMZ":3W]22I&% !0 4 % !0 4 % !0
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MWZNUK_<5%./IT6]CMZS+"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MSI?">JWMQXVU2SFN)I+:**8QPO*[1(1-;@%(RQ12 S $ 8!([FIDDH1:6O\
MPY46^9HL?%O7KRT6RT?2I9(;R^F'S0NZ2!00B*&0A@))'[==A%*E%:REL@FV
MK);LB^%&NWKW%_H.K32W%U9REE:9VD<JK>5( SDMM5@C*,D?O#CW*B5E*.B8
M0;UB]T8OQIUO4-)NK(6%S<6H>.4L(99(PQ#)C<$8!L=L@^E522:=TA5&U:QN
MWWC-]?\ !5QJEK(UO>0I''*8G*/',)8@Q4J0RK(IW+@_=;;DX-2H<LU%[#YK
MQNMR?2_%\F@^"H-8NF>ZN2C*AE=F:25II%3>Y)8A0,GG.Q< CBAQO-Q6B_X
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M:5F6% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M4G=R_KH)JW*=I\7]2EU76;31;6&2\^RKYTD$09GD9_F9 %5VXA3.0IVAV)!
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MSGHE)^S3ZLQ27/;L?3]<1TA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M'25!1G:OJD6B6<U_.&:*V0R.$ +$+U"AF4$_5@/>FE=V0F[*X:/JD6M6<-_
M&6*Y02(' # -T#!68 _1B/>AKE=GT!.ZN:-(84 % !0 4 % !0!@7?B!(;EK
M&U@N+ZXB4/*L B A#8V>9)<2P1!G'*QJ[2;06*!<$THZ7;27G_P+DWZ+4N:5
MJT&L1&6#>IC<QRQR*4DBE4*6BD4]&4,.061@0R,RD,1KET&G?8TZD84 % &7
M+J\,5_'I9#^=/#).K #8%B9%8$[MVXF08 4C&<D<9JVE_D*^MB[=7"V<,EPX
M)6%&=@,9(12QQD@9P.,D#/<4EKH/8CT^]34K6&\B#+'<11RJ&P&"R*'4, 2
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M7-*]GS/6UPWLK75MKV.P\+:]J_AO0W*63ZJ(KXP00V]U'=/# 8B^QI;9;CB
MJJ894/[U>%7:ISE%2EO;2^JMK\[;E)N*VOKWO^1B*L7C+Q9 -:@EL5NK [[-
MY)(V9D>4)&[ 0R$$*)PH"YVK]Y0<W\$'RN]GO_5_07Q2UTTV,#4R;31M=TJW
MD:33["_MEM06+A \LID16R> 54D#^(LQRS,32^*,GNT[DO122V35CKD_Y&AO
M^P#_ .T%K/['_;WZE?:_[=.(AT"U3P6->'F"_@N1Y,HED'E+YZKM1 VQ1DM)
MN"A_,).[M6MWS\O2WZ$V]WFZG=P65OXS\3SV^O,SI:65O);1>:T2@R10R22K
MY90YW,7.",<!LB, 97Y(IQZMW+^*5I=%H7OA)?VFF:??27-Q&D1U)T2:>5%$
MA,:;?G8@,[@%N.6Y(I5$VU9=.@X62?J=[\0_^1=O_P#KW;^8K*'Q+U+E\+/)
M9=*TOP[X1AU)TN#=ZI#;V\KPW!CDE67]YY+22K,D,/EQA&V1#<J+&QV,QK>[
ME.VEE=[?B9648WZLK>'+.;0/$%[IXCBL8YM,EDDM()Y9U3Y-\:S/*S;KB-6P
M63"88F/"2'<Y/FBGOKNU;^D)>ZVMM-CG(= M4\%C7AY@OX+D>3*)9!Y2^>J[
M40-L49+2;@H?S"3N[5=WS\O2WZ"M[O-U.[@LK?QGXGGM]>9G2TLK>2VB\UHE
M!DBADDE7RRASN8N<$8X#9$8 ROR13CU;N7\4K2Z+0X.POI;30Y;6&=X[2\UL
MP7-TK'=Y#1IDF0<8D7+.3PX!!RI8'5KWKVU4;I>9FM%;I?<[F^TZW\'Z]#IW
MA]F2WOK&X-W;>:TB82*1DF.]FVN=N5;(X!5,"1E;)/FC>6Z:LS2W*[1ZK5'G
MHTB*T\)VNNPM+'J"W_EQS++(#%'^]^2-0P11O'F;E4/O)^;!(K:]YN/2QG:T
M5+K<] &E0>%_%,VGZ>9$@N=)FDE#2.YDDVRDR.6)RQ*;NP!9MH )%8WYH7?2
M1I;EE9=CF[0Z/%X-M9=3M_MEYYUU%80B29"99'7<2L+H61=L9;.23M12IDS5
MN_.^5V6ER-.57WUL3ZGX=O/ _AF"#<XFU>[B6]5)/* C:-]MJ9#\J;@2)7.4
MSN4[HQ\PI*<GY+3_ #&TXQ]7K_D6[+^U/"\NIK86JZ5"-.EE-F-0AO)(95"X
MNE02&9?E(^9D*]"S%=BA.TK7=]=[6^78>L;V5M-KW^9AZYX?TRS\*6.K6\CF
M]O98S.YF=O/<F0R!HRVPF!\J&501@[RS,2:4GSN+V6WE_P .2TE%-;GT'X^N
M)+3P_?R1$A_L[KD=0'^1B/0[6//4=01UKEA\2]3>6B9AZ#X3T[6] TA+U/.B
MMH8;A8\X1I)(MQ$@'+*K.25R Q&'#*2IIR<92MZ"44TKG/\ PNMH+SPA/;W;
M^3;S&[CFDW*FR-TVN^Y@57:I)W,"HQD@@5532::WT)A\.OF=#=>#M&N]'MT1
MC>VNFP3O;,9$='+*2'<QJ%DVE> ,(>0RM4\TE)]&[7*Y5;R6Q@^!(5G\"R12
M8VO!? Y]"TW/X=:J>E3YHF/P?>;OPWU>%/#NFQWDT<4TZRQ0I)(JO)Y4[QJL
M:L07*KL&%!P"OJ*FHO>=E_5BH/W5<H?&C_D7C_U\0_\ LU.E\7R%4^$YV[TJ
MR\*:[HL^ARN9-38K='SGE^U1/Y9,\@9FSYFYI,C"%E#( R9JTW*,E+IMY>1-
ME%KEZ_B<=87\%KH-Y;3K/+]LUHQ"&"9;?S<HI*2RO'(%B.!N  ).T;E7<1HU
M[R:MI'U(6S7GZ%S13>^%K[6K:U6*V>'2WF%O:RS31Q2 Q;6+2LS-/"DC%VSM
M#;MH"8%)VDHM]]WI_2&KQ;2[=#HO#6@Z-91Z+K;7KV=]=LS2OYCL;V5@6DAD
M=F:.,+)\CG:/,R8R?.9'6).3YHVNE^!225G>S_,X9H[[6TO]5>V,E[#=E4U)
M]3BM?L)21/+C6&5T4+D[%9B =VV,JZDUKI&T;Z6VM>Y&KN[:WWO:QUL&FP>)
M?%BVVMG/VC2;=Y8HYMJ3S"."1H]\#J)$5@TZB-BA,*N,JM9WY87CTD_EOW^X
MJUY6?8P)=6NM(TG4=,L+B0:?#JT=I',&+-%;2>>9 D@/"DQQYVX4[W_YZ'-6
M3:;6O+?YZ$WLFEM>WR.T?2K7P9XATFV\..ZIJ*L+N 2M*LT*#*7#@LPSM:5E
M9<(-C% !O!SNYQDY]-O\B[<K2CUW*?B7X@:Y>Z1=K_9=WH^V-#]I<S# ::-&
M52UO#M9@Q&X,2!G SR'&$4U[R?E_3!R=GHT:VG:'H_A*\@NM)NC%<S:8\D=G
MO=DOG"$I*[,S Y))6&/868!XL*DBM+<I)J2TOOV&DHNZ?3;N<1%IMG<^%I/%
MDUS*VN"4M]J\]Q(DJR"-( H8+_J0K ;=P5AM(C 4:W:G[.WN]K?B19<O-U[F
MM#IJ>*O%5O'JZLPGTBWEN(E9X@[F)&9'\MD;:)#OV@@;D7/ Q4WY(/E_F=AV
MYI:]CC-2LD7P_J$'S,FEZNT=KN9CY4<A*NHYP0VQ200<,688+,3HG[R\XZD/
M9KL]#N;WPEIUQXIT[1O+9;!=*W-"))1N'G74NTOO\P@RL'(W]@!@ "LU)J#E
MUYO\B^5<R72W^99M="L/$'B*]T?5LK9:1;QQV-GYLD<:1;5W3##AF8#:S.6.
M[>"^X*N%=QBI1W;U8[)MI[+9'$W-_<W>A6L4TC7%O::X(+69SEGA5"5&[JRK
MN^4] #L7Y4"KI9*3MHW&[(Z+UT.AUB_N=+U?Q-<V;-'.EM;A77AE#FW1F4]0
M51F(8<J1N!! -2DFH)]W^I3T<K=B'PK97FEZEI5S9VJZ>MTJBX=]4MYC?Q.%
MW2BW9U?<I)DVQ*Q!(&T,,DDTU)-WMM[K5OF*-TU96^>Y0M-,M-<\.ZIXCU&6
M0ZN)) TAF93']Q4AV!@FR4'R0C*PV$1QA=H =W&48+X0LG%R>Y[QX _Y%[3_
M /KVC_E7-/XGZFT=D=?6984 % !0 4 % !0!P.G7]OX:OK^'59([3[9<F[@G
MF98XIHVCBCV"5]J>;"R$-$6W[2L@4HVZM6N9+EULK-$+W6[Z=3BO$9BNX;G5
MIA(FG7NI:6%;:Z/+#"$62=  'V2!B(G'S.J!EP"I.D=+16Z4OO?0S??I="ZJ
M$ OCX=*KHY%E]J-LN^U#>:?M9B2!X]P^R^7]K6W=&9.&=6Y NG/\6MK[^6_G
MM<;Z\NVE[;>?X;E;5;6UCT[4C87=G-$]M")(=-MGAM5<W,864NMS<0"X*@J4
M4I*4".RE54EJ]U=/?J]=O1.PGL[-?):;G;0V2Z+K[V^D00QB33%D,.XP122)
M=;1)(R1RGS CN#(8W=N QQR,[WC>3Z^O0O9V7;]3-UV]N;75$N;R'$L6D:@Q
MBM)Y'8@/!CRYC% ZN1_$L>Y#RI8@4TE:R_F6Z]?43T>O9['(6\EK%?Q?8/[/
MC2;3M161-.5MBJ(@\44]SOVW4ZJF]LPPR)RS(0Z,--;:WW6_Z+HB.NEMGM_6
MIJ:.MF(=*_X1K9_:8@?[7Y>-_E_9&WB]SSG[5Y'D"?@$?NOD%2[^]S[7T^_I
M\KWL4K:<N_7[NOS'^&+>W\ZPD6\M8M1#_P"DQ0V<XU&1\'[3#?O]KD?;Y@)D
MEN(1$)%1X]@V"B771VZ:JWE;3\@7357]-?.^IWGP]_Y -I])/_1TE93^)EQV
M0:+_ ,A[5_I8?^B9*'\,?F"W?R/-[?3(K?PS8W4210B>Z7^T)WA,@:V$EP +
MG8\4DENL@A#(9518QAOD# [7]YKRT7GIMY[F=O=7KK_P30)L[&TNWBEM-0LI
M9[.-X;9);+2X)&)!DDF66ZA,39C-U''N7*QB=!YI++5M;IV>^LOT^7X#T2>S
M6GDOU^9R\\=O);:U"@LIH!!83I]C@\JU#I+)'++;HTDJD+\T<D\9PQ0@[2K"
MKZQWW:U>OS_R)[[=-MCI=3TW3;[^WKF..&6.UTZ![-TVF.(+9R-&]OM^1,>6
MFUX\':H4';Q4)M<J[MW^_J4TO>]-/N)+RTFT^5ET1/*NKK0)96,(Q++.LMN!
M*Q'S2W&)9-LC$RLS?>+&DG?XME+\-?P#;X?Y2O:V]BL;RZ;>61SIUUYEO86<
ML32)Y!VF^;[7<A)(V(*&Y59F<R(&+%P'KU3W6K?GTT7X!IT:V>R_/7\S4TO2
M;.SET)888U^WV4\=W\H)N4:SCD*W&?\ 7#<,@2;@HR% !Q2;;YO)JWEKT&DE
MR^:U^XZ+X9BW3P_:K;^6&5,3"/:")A]\2!>1+C;N#?/C&>U14^)W^14-E8[R
MLBPH * "@#SWQ9\2M-\&W:6-]'<R221+,#"D3+M9W0 EYHSNS&<C!&".>H'=
M1PLZ\7.#BDG;5OLGT3[G/4K1I/EDGM?2W^9R_P#PO;0O^>%__P!^X/\ Y)KH
M^H5>\/OE_P#(F7UF':7W+_,/^%[:%_SPO_\ OW!_\DT?4*O>'WR_^1#ZS#M+
M[E_F'_"]M"_YX7__ '[@_P#DFCZA5[P^^7_R(?68=I?<O\P_X7MH7_/"_P#^
M_<'_ ,DT?4*O>'WR_P#D0^LP[2^Y?YA_PO;0O^>%_P#]^X/_ ))H^H5>\/OE
M_P#(A]9AVE]R_P P_P"%[:%_SPO_ /OW!_\ )-'U"KWA]\O_ )$/K,.TON7^
M8?\ "]M"_P">%_\ ]^X/_DFCZA5[P^^7_P B'UF':7W+_,/^%[:%_P \+_\
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M+_(/^%M>%_\ G]_\E[K_ .,4?5ZG:/\ X'#_ .2#VL//_P !E_D'_"VO"_\
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MT_PYX3TIUELQ:PND4D(9;ELF.7=O#DS'S"=Q :3<ZKM56"HH#>,I/>M3_P#
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M*T+POH<WVBP%M!)Y)@)%P2&B9MS*ZM*5D).,LX9\!1NPH 'BZ3T=6GW^./\
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M G_D&NV/A'Q*ZRZG)9321C"N+I8WV_W6:*5&91U56)"DDJ!N.18NE'X:M/\
M\#C_ )@\)6>]&I_X!+_(=<VWA.ZM8+"26Q%M9.)((TNEC5'&?F_=RJ6)+,6W
M%MS$LV6)-'UNDFW[6G=_WX_YA]4K;>QJ:?W)?Y$\3>%X;JXOUGLC/?)Y=PS7
M2.LJ8"[6C>5H\%0 0$&1USDT?6J5DO:T[+;WX_YA]5K+7V537^Y+_(SM&TWP
M;X>N#>:?)8PSD%=YNQ(5#==GF3.$R."4"G:2N<$BF\73EHZL+?XX_P"8EA*L
M=51J?^ 2_P BM?:'X'U&YDO;EM/:>?<9&%X%#%AAFV).J!SDL7"A]Y\S=O\
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M  +@_P#CE'L:O_/N?_@,O\@]I#^:/WH/^$QT+_H(V'_@7!_\<H]C5_Y]S_\
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MWH/^$QT+_H(V'_@7!_\ '*/8U?\ GW/_ ,!E_D'M(?S1^]!_PF.A?]!&P_\
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M .@:A7KTO]TJ?XU_[8<$_P"/'_#_ /)'L&ZO-.L-U !NH -U !NH -U !NH
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MNHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL ;J+
M&ZBP!NHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL ;J+ &ZBP!NHL!\^_'8Y.F_P#;
MW_[;5ZN$^"M_A7Y2.*M\4/7]4> 5B6% 'J?@V1;S3)--AOKG3KK[5Y_^B6]S
M.\D7E*F'^S ':K<KEL [LJ<J1A+1WLFK6U:7YFL=K7L[]+_H<OXM3R;E8C?S
MZFZ*0YN(IXGB.?\ 5[;AF?D?-Q@<]*N.VR7I;]"9>MSE*T("@#Z*^ /74_\
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MJ>S]OR_N[VO==[;7OOY&*KT_:?5^;]Y:_+9]K[VMMYD5CI5UJ;%;6,R%>3R
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M75ON^\T6UKV90\7ZA%>/;0K<?VA-:V_E3W>''G/YLCA09 '=8D98UE8 N!G
M4+3BK7TM=Z(4GMUMU.0K0@* /5OAAXZL?!7VS[?'/)]J\C9Y"QMCRO.W;M\D
M>,^8N,9Z'..,Q4BYQBET<OQ4?\BX246[]4OPO_F=EJWQRVWD4NE0N]H$(GAN
M52-BV[(:*2)Y-IV\98,O^P3S7.J.GO;]+&KJ:Z;#OB!XMMO%WAN&ZM8YH=M]
M$&66-E&?(N<[)!F.09!^ZVX#!=$R ?G<UBX4HI_SK_TF1]%E,N:M)K_GV_\
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MM2="M%*</Y;VT=GNWW(/#UJ+J^B1AE5)<_\  06'Z@"L\)#VE:">R=W\E?\
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M W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4 &Z@#/\
M#?\ Q\:G_P!?Z?\ INL*=7:G_@?_ *7,=/[7^+_VV)U-<IN% 'AOB;CX@Z9_
MUX/_ .@W]>S1_P!UJ?X__D#SZG\:/^'_ .2/4=U<1J&Z@ W4 &Z@ W4 &Z@
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M/;(4C1SF,9;<2R='/L^Y<?PYYKB4G%66AT.*>K//_C2BQ:';H@"JM[$ H
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M[6J3;=DMDDOQS/"$@L_"^K7$A 20/",_WFB" ?B95%9X5\F$KS>SO'YN-O\
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M_P"ZU/\ '_\ ('G5?XT?\/\ \D>F;JY+&@;J+ &ZBP!NHL ;J+ &ZBP!NHL
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M_P#XBOF/J];_ )]S_P# )?Y'U?UBC_S]I_\ @<?\R9?"FM#_ )<+W_P&F_\
MB*7U>M_S[G_X!+_(?UBC_P _:?\ X''_ #)E\*ZS_P ^%[_X#3?_ !%+ZO6_
MY]U/_ )?Y#^LT/\ G[3_ / X_P"9*OA;6!_RX7G_ (#3?_$4OJ];_GU4_P#
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M53_P"7^1'UJA_P _J?\ X''_ #)5T:_'_+M<?]^9/_B:M8:O_P ^JG_@$O\
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MQE_[X;_"H]C4_DE_X"_\BU6I_P \/_ E_F1-IUU_SQE_[]O_ (5/L:G\D_\
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M?U]T? '+>,?^0</^OS3O_3C:UTT/C_[=G_Z1(QJ_#\X_^E(CW5N<P;J #=0
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MW.BV5W8C2IH]UFJ1QB/>X^2(J8QO#!_E*+SNR<<DY.3S UMU( W4 &Z@ W4
M&Z@!/"O^MU+_ *_U_P#3?85E7^Q_@_\ ;YF]+:7^+_VV)UU<AT!0!X1XMX\?
M:;_UX-_*_KVZ'^[3_P ?_P @>;6_BQ_P_P#R1Z%NKG&&Z@ W4 &Z@ W4 &Z@
M W4 &Z@#'UO6DT2 3-').\CB***)2SO(RLRJ .@(4Y8]/0G )8#%\%:S>ZS!
M=2Z@ DT5[+"(P !$J)%^[R/O;6+98DDGOC !8#+M;W6/$[W%UIUTEC:P2O#
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M[.+#3[,[@WF6T,D<G&?EW-,XVG/(V^G-4HVUNWZB;OI9(]B^ /74_P#MS_\
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M^&+QMJYE%X7) ^8J'"YXYP ,9Z=J974B%O$/!& JC,'F=!]_S<[O][WZ]NE
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MNL>'K*1[ZUCCAE>,&5F@DD1EWX5"DC.@?)WX&&VKD\"A2C)Z/\P<7%:H]9^
M/74_^W/_ -NJFO\ !#_%/\H%TOBEZ1_.1]%UYYU&5J/^OL_^OEO_ $DNJY*W
MQT/^OC_],U3LH_!7_P"O2_\ 3U$U:ZSC"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,K5ONP_]?,/_H8%
M<E?:'_7R'_I1V8?>?_7JI_Z2:M=9QG*^-/\ D&_]OFG?^G"UKJP_\3_MV?\
MZ1(PJ_ _6/\ Z4C.W5UV.,-U%@#=18#SGX@Z9:PZ1?7J1(+F;[/OEQER%F@0
M $YVC:H!"X!QD@GF@:+OCO#16"/_ *MM4M0_IL_>9S[4 B/XC,1IL97[RW<!
M7_>W'&* 0[PV=VMZP[?ZP26J\]0@B;;^! _' H ;I+,OB?4@/NM!;%O]X(H7
M/O@G\* Z"?$3>]E;+&QC<W]OM=>"K?/A@>Q4\CW% (Y[7/#MMH^H:?#I[36P
MOW>"Y9)7W2I\A.YF8G<V3EACKD $## O+:P^$]<6/3PT=O/932R0[V92\66#
M#>Q.X[<9SW/]XT@&:#X8AU_3QJMX\C:C=[Y4N!(X,!WMY8C ;:%7 R"#W'0#
M %[&_P##MRV@6I/4F<G\;B6@&9&L:1'K7BA()V80KIH:1%8KYJBY<"-BI#;-
MQ5FP>J@=Z Z%C2;<>'->;2K0L+*ZM3<+"S%EBD5]IV;LD*P'(SR2,\*M %[X
MC'_BG[K_ +8_^E$5 ([;=181Y?I.E6_C"XO=0U+?*(KJ2VMD\QD$*1!<,H1A
MM=MV23GD9YSD@]BWX @:T?4H7<RLE_("[?><X^\W^TW5O<F@&>B[J+"#=18
MW46 L^$/OZE_U_K_ .F^PKGQ'V/\'_M\SJH[2_Q?^VQ.RKB.D* /!?&/'CS3
MO^O!OY7U>YA_]VG_ (__ ) \RO\ Q8_X?_DCN-U9V(#=18 W46 -U%@#=18
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M)I9?W)_^^4_^.4_[2H_RS^Z/_P D+^S*W\U/[Y?_ "([_A,[/^Y-_P!\I_\
M'*/[1I?RS^Z/_P D+^S*W\U/[Y?_ "(O_"8V?]R;_OE/_CE/^T:7\L_NC_\
M)"_LVM_-#[Y?_(B_\)A9_P!R;_OE/_CE']H4OY9_='_Y(/[-K?S0^^7_ ,B+
M_P )?9_W)O\ OE/_ (Y3_M"E_+/[H_\ R0O[-J_S0^^7_P B'_"7VG]R;_OE
M/_CE']H4OY9_='_Y(/[.J_S0^^7_ ,B'_"7VG]R;_OE/_CE']H4OY9_='_Y(
M/[.J_P T/OE_\B'_  E]G_<F_P"^4_\ CE']H4OY9_='_P"2#^S:O\T/OE_\
MB)_PF%G_ ')O^^4_^.4?VA2_EG]T?_DA_P!FU?YH??+_ .1#_A,;,?P3?]\I
M_P#'*7]HTOY9_='_ .2#^S:W\T/OE_\ (C?^$RLQ_!-_WRG_ ,<I?VC2_EG]
MT?\ Y(?]F5OYH??+_P"1$_X3.R'\$W_?*?\ QRC^T:7\L_NC_P#)!_9E;^:G
M]\O_ )$3_A-;(?P3_P#?*?\ QRE_:5'^6?W1_P#DA_V76_FI_?+_ .1&_P#"
M;V0_@G_[Y3_XY2_M.C_+/[H__)#_ ++K?S4_OE_\@-/CFQ'_ "SG_P"^8_\
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M_P"U:'\M3[H__)A_9%?^:G]\O_D!I^*NE#_EE=_]\1?_ !^C^U:'\M3[H_\
MR8O[(K_S4_OE_P#(#3\6-*'_ "RN_P#OB+_X_3_M2C_+4^Z/_P F']DU_P":
MG]\O_D!A^+6DC_EE=_\ ?$/_ ,?H_M2C_+4^Z/\ \D']DU_YJ?WR_P#D!I^+
MND#_ )8WG_?$/_Q^C^U*/\M3[H__ "0O[)K_ ,U/[Y?_ " T_&#2!_RQO/\
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MLW?X'WBOS/7:]\^=.4\:_P#(,_[>]/\ _3A:UU8?^(O\,_\ TB1A6^!^L?\
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MX[T[_KP;_P!OJ]S#?[M/_'_\@>97_B+_  _YG9[JDR#=0 ;J #=0 ;J #=0
M;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #
M=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J /%_B\<FQ_[>/\ VA772^"I_A_2
M1#^*/K^J/&ZX#K"@#V'1?&6JZIIKV:ZJMG?).'WW<OEJ]N(]H2.4JRHR299E
M(4N&7#'85KG<$G?ENK=.YLI-JU[/S.8\<ZLVI26L4UTNH7-K;^7/<1DF)G,K
MN!&2JAMD916D"@.P/4@L;@K7LK)O1$R=[:W.%K4S"@#Z*^ /74_^W/\ ]NJQ
MK_!#_%/\H&U+XI>D?SD?1=>>=1X]\;?^0+!_U_1_^B+BO%S+^#'_ !K_ -)D
M>[E?\:7_ %[?_I43Y@6ODC[$G6D,F6D,F6D,F6D,G6D,F6D,F6D,F6D,F6D,
MF44ADRBD,F44ADRBD,F44ADRBD,E44#)E%6B"915(S9*!5HADRBM$02@5:(9
M*HJB"0"J() *JQ)(!56)N. JK$W';:=A"[:=@%VT6$)MHL,:5I6&-(J;#N,(
MJ;%$9%241D5):(B*DI$1%0RT1$5#+1$PJ&:(A(J"T0L*AEHA85)1$PIB(6%,
M1"PIB(6%,1"U,1"PIB(6IB(6IB(6IB(6IB(6IDD#50B%J8B%J8B!J8CIO __
M "';'_KYB_\ 0UK>C_%I?]?*?_I:.>O_  :O_7JI_P"D,^UZ_0#\Y.3\;?\
M(,_[>]/_ /3A:UU8?^(O\,__ $B1A6^!^L?_ $I&'NKT#S@W4 &Z@ W4 &Z@
M W4 &Z@ W4 &Z@ W4 &Z@#EY_!NCW$IGDME+LVYL-(JENN3&KA#SSRM*Q5V=
M,@6-0B *J@  #  '   X  X '2@0[=3$&Z@ W4 &Z@ W4 &Z@ W4 &Z@ W4
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MW_Y!9_Z^]/\ _3A:UUX?^(O2?_I$CGK? _E_Z4CGMU>B>:&Z@ W4 &Z@ W4
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M_P '5W%AL+'%T)XJO*3JOFM+F?N\JTLMO^!9*QFZM91:1XBM?LH$:RO"Q4<
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MS\Q_SK>E_%I_]?*?_I<3"M_"J_\ 7NI_Z1(^V*_03\X.2\;_ /(+/_7WI_\
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M##?\_/\ R6?_ ,B2CX9^(A_RZ?\ D>V_^/4?4,3_ "?^30_^2'_:&&_Y^?\
MDL__ )$E'PU\0C_ET_\ (]O_ /'J7U#$_P#/O_R:'_R0_P"T,-_S\_\ )9__
M ")(/AOX@'_+I_Y&M_\ X[2^H8G_ )]_^30_^2#^T<+_ ,_/_)9__(DH^'.O
MC_EU_P#(UO\ _':7]GXG_GW_ .30_P#DA_VCA?\ GY_Y+/\ ^1)1\.]>'_+K
M_P"1K?\ ^.TO[/Q/_/O_ ,FA_P#)#_M'"_\ /S_R6?\ \B2K\/M>'_+K_P"1
MK?\ ^.TO[/Q/_/O_ ,FA_P#)#_M'"_\ /S_R2?\ \B2CX?ZZ/^7;_P C0?\
MQVC^S\3_ ,^__)H?_)#_ +1PO_/S_P DG_\ (DH\!:X/^7;_ ,C0?_':7]GX
MG_GW_P"30_\ DA_VEA?^?G_DD_\ Y$D'@36Q_P NW_D6#_X[2_L[%?\ /O\
M\FA_\D']I87_ )^?^23_ /D24>!M:'_+O_Y%@_\ CE+^SL5_S[_\FA_\D/\
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M#?\ /S_R6?\ \B1'PCJO_/#_ ,B1?_%U']GXG_GW_P"30_\ DBUF.%_Y^?\
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MOU'_ *!EY_W]T_\ ^3J.:'_/R/W3_P#D Y)_RO[X_P"8;]1_Z!EY_P!_=/\
M_DZCFA_S\C]T_P#Y .2?\K^^/^8;]1_Z!EY_W]T__P"3J.:'_/R/W3_^0#DG
M_*_OC_F&_4?^@9>?]_=/_P#DZCFA_P _(_=/_P"0#DG_ "O[X_YFWX3M+FW%
MY+=PO:FYNQ*D<C1,^P6EK#N/DR2H,O$^!OS@ D#-<M>49.*@[VC9M76O-)]4
MGLUT.FE%Q3YE:[OT[)=+]CK*Y3<* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#*U'_7V?_7RW_I)=5R5OCH?]?'_ .F:IV4?@K_]>E_Z>HFK76<8
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!E:U_P >I]I(?_1T=<F)_AO_ !0_]+B=F%_BK_#4_P#3<C5K
MK.,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H RM1_U]G_ -?+?^DE
MU7)6^.A_U\?_ *9JG91^"O\ ]>E_Z>HFK76<84 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'C7B#QKXBBU^;0M"M;6Z,,22@2[E?:4C9B6:YA3AG
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MI--:-6!.^Q3@\1:7<SBUAO+62X)*B))XFD++G< @<MD8.1C(P<]*?*UK9V]
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M@ H * "@ H * "@ H * ,K6O^/1O]Z+_ -&I7)B?X3]8_P#I<3LPO\5>D_\
MTB1JUUG&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 96H_P"OL_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M76<84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MI>5FM5W#5)73T9T.J7-QXUFM+*WL[RVMH+J*ZN9KN%K<;(#N6*-7^=WD; )
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M;T_,[KQEI$NO:-=6%N0)IH_W>3@%T99%7)X&XJ%R>!G)K*#Y9)LN2NFD<4D
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % %#5-,AUBUDLKD$Q3+AMK%6&"&5E8
M<AE8!E/8@<$<4T^5W0FKZ&/I_A6*RNDOI[BZOIX5=(6NI$<1!P ^Q8XXUW,
M SL&<CC=5.5U9))>0E&VNIT]04% !0 4 % !0 4 % !0 4 % !0 4 9.LZ-#
MK< @F:2,QR++')"^R2.1/NNC8(R 2/F5@02"*I/EV$U?0I:9X9@TZ:2ZDEN+
MRYFC$+37$@9Q$"6\M/+2)$7<2QV*"6P2<TW*^FB7D)*QMVEI%80I;6ZB.*%0
MB*.BJHP!SR>.Y))ZDDU+UU96VB+%( H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
@@ H * "@ H * "@ H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>sava-20230331x10qg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sava-20230331x10qg003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #_!7(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/[F?JK17Y5?\/\?B%_T)?@S\[G_XY1_P_P ?B%_T)?@S\[G_ ..4?\0ZSO\
MD7_@2#_6K+OYG]S/U5HK\JO^'^/Q"_Z$OP9^=S_\<H_X?X_$+_H2_!GYW/\
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M*/\ A_C\0O\ H2_!GYW/_P <H_XAUG?\B_\  D'^M67?S/[F?JK17Y5?\/\
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MYSF=L]O2A^'&=)?#'_P)!_K9E_=_<?K!17Y5?\/\?B%_T)?@S\[G_P".4?\
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M/SN?_CE'_$.L[_D7_@2#_6K+OYG]S/U5HK\JO^'^/Q"_Z$OP9^=S_P#'*/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_0W7XMXK_P ;#>DOS1^@\%?PZOJOU"BBBOR0^W"BBB@ HHHH **** "BBB@
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M4U[U^CVM<^S/VGM?@E_X)]?LZ:CK\CWEFFLZ7+?M-F0RPK;S;]V?O?(#5_\
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M)494R>3M YKG?C+\?O&/[0>OQ:GXQUZ\UR[MT,<)E"I' IY(2- J)GC.U1G
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M9_X6EXF_Z&+7?_ ^7_XJC_A:7B;_ *&+7?\ P/E_^*H_XA14_P"@E?\ @/\
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M_P#BJ/\ B%%3_H)7_@/_ -L'^NL/^?3^_P#X!_1-17\[/_"TO$W_ $,6N_\
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M_MC+_76'_/I_?_P#^B:BOYV?^%I>)O\ H8M=_P# ^7_XJC_A:7B;_H8M=_\
M ^7_ .*H_P"(45/^@E?^ _\ VP?ZZP_Y]/[_ /@']$U%?SL_\+2\3?\ 0Q:[
M_P"!\O\ \51_PM+Q-_T,6N_^!\O_ ,51_P 0HJ?]!*_\!_\ M@_UUA_SZ?W_
M / /Z)J*_G9_X6EXF_Z&+7?_  /E_P#BJ/\ A:7B;_H8M=_\#Y?_ (JC_B%%
M3_H)7_@/_P!L'^NL/^?3^_\ X!_1-17\[/\ PM+Q-_T,6N_^!\O_ ,51_P +
M2\3?]#%KO_@?+_\ %4?\0HJ?]!*_\!_^V#_76'_/I_?_ , _HFHK^=G_ (6E
MXF_Z&+7?_ ^7_P"*H_X6EXF_Z&+7?_ ^7_XJC_B%%3_H)7_@/_VP?ZZP_P"?
M3^__ (!_1-17\[/_  M+Q-_T,6N_^!\O_P 51_PM+Q-_T,6N_P#@?+_\51_Q
M"BI_T$K_ ,!_^V#_ %UA_P ^G]__  #^B:BOYV?^%I>)O^ABUW_P/E_^*H_X
M6EXF_P"ABUW_ ,#Y?_BJ/^(45/\ H)7_ (#_ /;!_KK#_GT_O_X!_1-17\[/
M_"TO$W_0Q:[_ .!\O_Q5'_"TO$W_ $,6N_\ @?+_ /%4?\0HJ?\ 02O_  '_
M .V#_76'_/I_?_P#^B:BOYV?^%I>)O\ H8M=_P# ^7_XJOU&_P""%/B'4/$?
M[/'B^74+Z\OY$\1E%>XF:5E'V:$X!8GBO#XAX"GE6">,E64K-*W+;=^K/1RO
MB6.-Q"H*G:]];]OD?<%%%%?GQ].>5?ME_LQ)^UY\#;OP5)K+Z"MU=07/VM;7
M[25\I]V-F].OUKX[_P"(?>S_ .BJW/\ X3J__)->Y_\ !8W6;S0?V']6N+&Z
MN;.X&IV0$L$K1N 9>1D$&OQ__P"%I>)O^ABUW_P/E_\ BJ_6^!\NS:OESG@<
M7[*',].12ULM;L^(XBQ6!IXI1Q%'GE9:\S7?L?H;_P 0^]G_ -%5N?\ PG5_
M^2:/^(?>S_Z*K<_^$ZO_ ,DU^>7_  M+Q-_T,6N_^!\O_P 51_PM+Q-_T,6N
M_P#@?+_\57V/]B\1?]#'_P I1/!_M#*O^@7_ ,G9^AO_ !#[V?\ T56Y_P#"
M=7_Y)H_XA][/_HJMS_X3J_\ R37YY?\ "TO$W_0Q:[_X'R__ !5'_"TO$W_0
MQ:[_ .!\O_Q5']B\1?\ 0Q_\I1#^T,J_Z!?_ "=GZ&_\0^]G_P!%5N?_  G5
M_P#DFC_B'WL_^BJW/_A.K_\ )-?GE_PM+Q-_T,6N_P#@?+_\51_PM+Q-_P!#
M%KO_ ('R_P#Q5']B\1?]#'_RE$/[0RK_ *!?_)V?H;_Q#[V?_15;G_PG5_\
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M_P#@?+_\51_8O$7_ $,?_*40_M#*O^@7_P G9^AO_$/O9_\ 15;G_P )U?\
MY)JY%_P;^Z&-"FC?XEZJVIF9&BN%T>,0)$ VY6B\TLS$[2&$@  (VG.1^<W_
M  M+Q-_T,6N_^!\O_P 57L_A'XAZ^_[ ?C:Y.N:P;F/QII$:2F\DWJIM+XE0
MV<@$@<>PKEQ66<0THQ;S"]Y17\./5I&U'&97-M+"]&_B?1'U-_Q#[V?_ $56
MY_\ "=7_ .2:/^(?>S_Z*K<_^$ZO_P DU^>7_"TO$W_0Q:[_ .!\O_Q5'_"T
MO$W_ $,6N_\ @?+_ /%5U?V+Q%_T,?\ RE$Q_M#*O^@7_P G9^AO_$/O9_\
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M  M+Q-_T,6N_^!\O_P 51_8O$7_0Q_\ *40_M#*O^@7_ ,G9^AO_ !#[V?\
MT56Y_P#"=7_Y)H_XA][/_HJMS_X3J_\ R37YY?\ "TO$W_0Q:[_X'R__ !5'
M_"TO$W_0Q:[_ .!\O_Q5']B\1?\ 0Q_\I1#^T,J_Z!?_ "=GZ&_\0^]G_P!%
M5N?_  G5_P#DFC_B'WL_^BJW/_A.K_\ )-?GE_PM+Q-_T,6N_P#@?+_\51_P
MM+Q-_P!#%KO_ ('R_P#Q5']B\1?]#'_RE$/[0RK_ *!?_)V?H;_Q#[V?_15;
MG_PG5_\ DFC_ (A][/\ Z*K<_P#A.K_\DU^>7_"TO$W_ $,6N_\ @?+_ /%4
M?\+2\3?]#%KO_@?+_P#%4?V+Q%_T,?\ RE$/[0RK_H%_\G9^AO\ Q#[V?_15
M;G_PG5_^2:/^(?>S_P"BJW/_ (3J_P#R37YY?\+2\3?]#%KO_@?+_P#%4?\
M"TO$W_0Q:[_X'R__ !5']B\1?]#'_P I1#^T,J_Z!?\ R=GZ&_\ $/O9_P#1
M5;G_ ,)U?_DFC_B'WL_^BJW/_A.K_P#)-?GE_P +2\3?]#%KO_@?+_\ %4?\
M+2\3?]#%KO\ X'R__%4?V+Q%_P!#'_RE$/[0RK_H%_\ )V?H;_Q#[V?_ $56
MY_\ "=7_ .2:^UOV4_@&G[+_ , ?#_@6/5&UI-!6=1>M;_9S/YD\DWW-S8QY
MF/O'IFOP<_X6EXF_Z&+7?_ ^7_XJOVB_X)6ZI<ZS^P/X N;RXGNKB2.]WRS2
M%W?%_<@9)Y/  _"OB>.\OS7#X&$\=BO:QYU9<BC9VEK=>5_O/H.&\5@JF)E'
M#4>1\N_,WI=::GT)1117Y2?:GSW^WS^P7#^W/I'AJUE\3R>&?^$<FN)0R:>+
MO[1YHC&,&1-N-GOG-?-7_$/O9_\ 15;G_P )U?\ Y)K7_P""]/B?4O#?A+X:
MG3M0OK RW=^'-M.T6_"08SM(SU-?FW_PM+Q-_P!#%KO_ ('R_P#Q5?L_"&69
MS6RJG4PF,]G#WK1Y(NWO.^K[O4^ SS&8"GC91KT.:6FO,UT70_0W_B'WL_\
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M=_\  ^7_ .*H_L7B+_H8_P#E*(?VAE7_ $"_^3L_0W_B'WL_^BJW/_A.K_\
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M=_\  ^7_ .*H_L7B+_H8_P#E*(?VAE7_ $"_^3L_0W_B'WL_^BJW/_A.K_\
M)-'_ !#[V?\ T56Y_P#"=7_Y)K\\O^%I>)O^ABUW_P #Y?\ XJC_ (6EXF_Z
M&+7?_ ^7_P"*H_L7B+_H8_\ E*(?VAE7_0+_ .3L_2'P3_P0;M/!OC/2-7'Q
M/N;@Z5>PW@B.@*OF^6ZOMS]H.,XQG%?H+7\__P %/B9XDN/C)X21_$&MNCZU
M9JRM?2D,#.F01NK^@"OS3C[!YAAZE%8_$>U;4K>ZHVVOMO<^NX9KX6K"H\-2
MY-KZMWW[A1117Y\?3A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#3A<U^(U?MS_P2;_Y1]?#S_KG??^G"YK\T\4O^173_ .OB_P#29'UW!O\
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MWBO_ !L-Z2_-'Z#P5_#J^J_4****_)#[<**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \#_ ."H7_)A7Q'_ .O&'_TIAK\-Z_<C_@J%_P F
M%?$?_KQA_P#2F&OPWK]W\+/^1;5_QO\ ])B?F_&?^]P_P_JS?^%/CC_A6/Q1
M\-^)/LOVW_A'M5M=3^S>9Y?VCR9EDV;L';G;C.#C/0U]!_$G]L[X+?%OQYJG
MB77OV>KF\UC6;AKF[G'C^[B$DAZG:L 4?0"OEVBOO,5E>'Q%15JG,I)6O&4H
MZ;V]UH^9HXRK2@X1M9ZZQ3_-,]PT7]JCPI\/O%GCJZ\&_#J3P[I'C7P7=>$S
MIS^();TV<EP\;-=^;)%N?'E@>5A1_M"N3^'7QZ_X0']G_P"(_@7^ROM?_"P9
M-+?[=]I\O[!]BGDE_P!7L/F;_,Q]Y=N,\YQ7G=>H_ W]B_XD_M(^&;K6/!GA
M^'5M.LKHV<TKZK9VA24(KE=LTJ,?E=3D#'/7@UE6PV!PU)SQ#Y8WBVY2>\6G
M&[D^C2ZZ];FE.MB:L^6DKNST26SWT2\_D:?[3W[8%[^T#\<= \=:;IC^%=1\
M.V%C:VH2\%VR2VK%DF#&- #N(.TJ<8ZFO0&_X*$^$9?B(GQ$D^"F@/\ %-,7
M7]L_VU<#33?!<"[-@%V[]WS8\S[WS9W?-7->(O\ @EU\<O">DWE]J'@N"VMK
M"![F=FU_324C52S-M%P2> 3@#)[5X!7)A\%E.+I1IX:2E&"Y?<F]G]EN,KM.
MVSNC>KB,=0FY54TY._O16ZZJZT?FCV/4?VO[[Q!^S1XL\!ZGIAOM2\7^+3XM
MN];-V%/G,JAT\D1X.Y@6W;QC=C;Q74^./V_?^$S_ &@/BWXZ_P"$3^S?\+3\
M)2>%OL/]J;_[,WP6D7G^9Y(\W'V7.S:GW\;N,GYSHKL_L7!7<N3>_5]>5OK_
M '(_=YN_/_:&(M;F[=NE[?\ I3^\]3T3]I;^QOV/M9^%']B^9_:_B./7_P"U
M/MF/*V1)'Y7D[.<[,[MXZ]*Z:Z_;QUK3-'^"W_"/:7'H^L?!N&YBM[R6Y^TQ
MZGY[(6#Q;%V*55D(#,2'."IKP:BKEE.$DVY0O=N77>4>5Z7ZQTML3'&UXJT9
M=$ODG=?CJ?3T/[?OA+P5KNN^*/ OP=TSPGX_UZVG@;6GUZ:^M[%I_P#726]H
MT82-CDX^8A<D8VDJ?)?B+\>O^$^_9_\ AQX%_LK[)_PKZ35'^W?:?,^W_;9X
MY?\ 5[!Y>SR\?>;=G/&,5RWC/X=:W\/$T@ZUIT^G?V]IL6KV EQFYM)2PCF
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MVT-1\-?#CXS:/J^F'7=4^,8MWN]2-V+?[%+%+/(S^4(R'#&;A04"A>..!F?
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MGZH?*'_!:/\ Y,4U?_L*6/\ Z-K\:J_97_@M'_R8IJ__ &%+'_T;7XU5^_\
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M:=IUI>*(]+UJ5$DFLK9^ 'P%9=I 3#@;0,#YV^!O[//Q@L_A'XELKB[_ .$
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M9Y=2P\+TVVT[===-_A2^YRWW/(*]M\'_ /*/;QS_ -COHW_I)?UXE7MO@_\
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MZ5_0W7XMXK_QL-Z2_-'Z#P5_#J^J_4****_)#[<**** "BBB@ HHHH ****
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MB'PU:^%O$VF6,X1X_P#1T),$G3S(2Q49(&2X.",CP3QK\5?@GX)^#/B'P_\
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M)%%(K*DFW<QP>/*)P#7%?'ZP\?\ Q%^'/P7\"_$#P[\,OA;X9\9>++=[30]
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M&'![5YRS3%RA]=56U25*CTC:\JCBW9KY[]?2W4\'0C+ZNX7BIU.]](IK6_\
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M'_!_]G?P1XKC^$.C_$2]\5>+])FT&75?%<UK%'I=G-CS?)BMB0\C;5P7(VD
M@\%6K67[2/PN^-7P0\&>&/BSIOCFVU;X?P/I^FZKX7%H[7MD2"L,R3LH4I@
M,,^N.37G*EC6^:I&;I\^K24*DER-+FY&FTI66EFUTLM>ISPZ5HN/-RZ)^]!/
MFZ<U]U?NO.YN_#?X)_!CQQ\>/&4OA*R\8?$W1K/2X=0\.>$K&TO(;B[N96"R
MP7%TL8,<-L3DR$KN#* SL"'W/VOOV.=*\'_LCKX^/PRG^$/B33?$$>FS:3_;
M\FKQ:A:2Q;EF.]F:)P_ 7(X#$YRN*OA3]O;X<6TWQ$\.)X0U_P"'W@GQ99:=
M9:==^#/L\&MVRV3,0UPS%4E:;<WF'=G!*DOG?7-?$K]J'X7#]CO7OA=X,TSQ
MW'<7VOP:ZNJ:XUO-)J4H 65IO+<"'Y0H4('SMRQR2:QC#,_K5.251)2AN[^[
M9<U^62AO>_NRE?6Z5K:.6#]A->[=J6RMK=VM=.7IJE;2USZ%^+_[)-A^TO\
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MGT:6.A*'MJ<E)*GRJF^6"M\2:OR^MT]+*#OJ=52>&:E[.2:O*[DKR?9IVO\
M<UK\1]$?#3]B#P)XN^(>F>']/^ GBK5? ER(K=O'VK:]>:3>3;HQFY6RE\L8
M\S(">7\PY&017GNG_#=O!O\ P3R^._A"P:2^?2OB9!H]LS85K@QSPPJ3T +8
M'MS4FN?MV_!K5/VF]-^+<]E\8]9UVUOXKQ-%O[NT&EZ82%20P$.SL$7<R)A
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M/_Y+5X0_[#=E_P"CTK^ANOQ;Q7_C8;TE^:/T'@K^'5]5^H4445^2'VX4444
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M'4/P*_Z%S7?_  >R_P"%'_$1\K_EG]R_^2#_ %2QO>/WO_(_)&BOUN_X=0_
MK_H7-=_\'LO^%'_#J'X%?]"YKO\ X/9?\*/^(CY7_+/[E_\ )!_JEC>\?O?^
M1^2-=?X0_:"\>_#[0/[)T'QOXOT32\L?L>GZQ<6UO\Q)/[M'"\DG/'>OT_\
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M35&BVB)IPS$2E-B;2^=NQ<8P*S(/'6MVW@^;P]'K&J1Z!<W(O)M,6[D%G+.
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M%'_#J'X%?]"YKO\ X/9?\*:\1,H4G)0G=[^['7_R83X4QS23E&R\W_D?E?\
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M2:'3XSC*0HQ(C4[5X4 ?*/2OU7_X=0_ K_H7-=_\'LO^%'_#J'X%?]"YKO\
MX/9?\*E^(N4MIN$[K^['_P"2&N%,<E92C][_ ,C\IYO'NNW'@N+PW)K6K/X>
M@NOML6EM=R&RCGP5\Y8<[!)AF&X#.&//-/\ !'Q$\0?#/5SJ'AS7-8\/WY3R
MS<Z;>R6DQ7(.W?&0<9 XSVK]5?\ AU#\"O\ H7-=_P#![+_A1_PZA^!7_0N:
M[_X/9?\ "I?B%D[BXNG.SW]V.O\ Y,5_JKC[WYHW7F_\C\K/'/Q*\1_$_4TO
M?$NOZUXAO(T\M+C4[Z6[E5<YVAI&) SVK7_X:)^(!\(_\(__ ,)UXQ_L'R?L
M_P#9O]M7/V3RL8V>5OV;<<8QC%?IY_PZA^!7_0N:[_X/9?\ "C_AU#\"O^A<
MUW_P>R_X5+X_R5Q472E9;>['3T]X?^J^8)MJ:N_-_P"1^6&L?%7Q1XB\0Z=J
M^H>)->OM6T>..&PO;C4)9;BR2,EHUBD9BR*A)*A2 "3BM+5OVA_'^OW&HRWW
MCGQA>RZQ9C3K]Y]9N9&OK8;L02DN=\8WO\C97YVXY-?I[_PZA^!7_0N:[_X/
M9?\ "C_AU#\"O^A<UW_P>R_X4?Z_9*[7I2T_NQ_^2#_5C,/YU][_ ,C\H],\
M9:QHGA[4](L]5U*TTG6_*_M&RAN7CM[_ ,IB\7G1@[9-C$LNX':3D8-2VGQ
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M .2#_5+&]X_>_P#(_)&BOUN_X=0_ K_H7-=_\'LO^%'_  ZA^!7_ $+FN_\
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MO_@]E_PH_P"(CY7_ "S^Y?\ R0?ZI8WO'[W_ )'Y(T5^MW_#J'X%?]"YKO\
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MN7_R0?ZI8WO'[W_D?DC17ZW?\.H?@5_T+FN_^#V7_"C_ (=0_ K_ *%S7?\
MP>R_X4?\1'RO^6?W+_Y(/]4L;WC][_R/RZ^!_P#R6KPA_P!ANR_]'I7]#=?'
M'A;_ ()<_!+P[XGT[4+3P]K:75C=17$+-K<K!71PRDC'/('%?8]?G/'?$.&S
M6I1EADURIWNDM[=FSZOAS*JV"A-5FM;;?\,%%%%? GTH4444 %%%% !1110
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M;PJN,C[Q%=UX _:/^)$?QY\%>"O&F@^'M(N?$-C=7E[';!GDB\L7!CV.L[H
M1$N<Y/)Z=N?#\98*K5]C[.I%\T8^]3DDI2:23;V;NG;MJ=.(X)QU&C[;VE*2
MY927+4C)N,4VVDMTN5JZZZ'T117E/B;XYZMHW[7GAWP!%;Z<VCZOHLFI33/&
M_P!I613. %;?MV_NUZJ3R>:\JNOVY/%D'[*&H>.AI_AW^U[3Q&VCI"8)OLQA
M"@[BOF[M_/7=CVKIQ7%. P[FJC?N<]]/Y%%R_"2L<F$X3S#$JFZ27O\ );7_
M )^.2C^,'?L?5=%?.'CW]M^ZB_9?\+^//#5MI<M]JVJP:5J%K>([I:2F.0RJ
M KJ<AD!4D\JP)'/'3W_[4,GA?]IOQ3X8UR32-.\)^'/#@UI[YT<7"OO@7!.X
MA@?-("JFXG:!D\&EQ1ES:2GH^37I[ZE*+OVM%W["?">9*+;AJN?3K[CC&2MW
MO)6[GM%%>/?LU?&CQE\?=4U/7Y])TW1? +2/'HPF@D_M*_4' E9O,V!>#G"G
MD[03M+'UN_OX=+L)KFXD6&WMXVEED8X"*HR2?8 5ZF S"EBZ"Q-*_(]FU:Z[
MZ]'T?5:GE9AEU7!8AX6M;G5KI.]GV=NJV:6ST)J*^<OV5_VU]3^.'Q7O]"US
M2K/2K/4K:34?#<D4<B/=V\<TD;!RS$.V%/S*%&8I..@'9?\ "^M8_P"&Q_\
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MAG_@K9IQOW6V7Q)\+CI^FO(<"ZN(-4>:2%?5A&X?'H#71:.C2Z&%Y:IOJ/\
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M ,$V?@/XHTC0]+LO$K:CX8U9]62V07TES<(DLTC38WL6=B3DGH/08]:_9Q\
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M?P/OM3LO@+\-[U/%%O:6$GA634OMVM69&+FQ")9A&C:(_>E*HK;<LN\YY_\
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M%^,$FC:3\"/[:\)K>Q0)XC_X36QMM\#;=\_V5D\P;,M\F<G;QUKP%_B=X_\
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MBY;_ / O_0C7#5W/@_\ Y%RW_P"!?^A&N?$?"7#<TZ***XS4YOXA_P"HM?\
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M?1;U9% ^X")F8#H0<?\ +/CNOBI\ =/_ &C?^"@VOZ'JE[>6=A;>'8KZ46V
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MN?!__(N6_P#P+_T(UPU=SX/_ .1<M_\ @7_H1KGQ'PEPW-.BBBN,U.;^(?\
MJ+7_ 'F_I7+UU'Q#_P!1:_[S?TKEZ[J'P&,MPHHHK8D**** "O!/C9\'X?B+
MXZ\07NK?"R7Q!]MT7_A']4OK;Q'):OJVBF<SK;6T:R(!.)6=G#^6"J[1*PD
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M  H_X6IX@_Z"4G_?"?X5?U2IY?U\B?:Q.XHKA_\ A:GB#_H)2?\ ?"?X4?\
M"U/$'_02D_[X3_"CZI4\OZ^0>UB=Q17#_P#"U/$'_02D_P"^$_PH_P"%J>(/
M^@E)_P!\)_A1]4J>7]?(/:Q.XHKA_P#A:GB#_H)2?]\)_A1_PM3Q!_T$I/\
MOA/\*/JE3R_KY![6)W%%</\ \+4\0?\ 02D_[X3_  H_X6IX@_Z"4G_?"?X4
M?5*GE_7R#VL3N**X?_A:GB#_ *"4G_?"?X4?\+4\0?\ 02D_[X3_  H^J5/+
M^OD'M8G<45P__"U/$'_02D_[X3_"C_A:GB#_ *"4G_?"?X4?5*GE_7R#VL3N
M**X?_A:GB#_H)2?]\)_A1_PM3Q!_T$I/^^$_PH^J5/+^OD'M8G<45P__  M3
MQ!_T$I/^^$_PH_X6IX@_Z"4G_?"?X4?5*GE_7R#VL3N**X?_ (6IX@_Z"4G_
M 'PG^%'_  M3Q!_T$I/^^$_PH^J5/+^OD'M8G<45P_\ PM3Q!_T$I/\ OA/\
M*/\ A:GB#_H)2?\ ?"?X4?5*GE_7R#VL3N**X?\ X6IX@_Z"4G_?"?X4?\+4
M\0?]!*3_ +X3_"CZI4\OZ^0>UB=Q17#_ /"U/$'_ $$I/^^$_P */^%J>(/^
M@E)_WPG^%'U2IY?U\@]K$[BBN'_X6IX@_P"@E)_WPG^%'_"U/$'_ $$I/^^$
M_P */JE3R_KY![6)WMC_ ,?L/^^O\Z]'KP31OB=KMQK%I&^H2%'F16&Q>06&
M>U>]UP8VE*#7,;TI)K0****X34**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH YSXM_\DZU3_KFO_H:U\_5] _%O_DG6J?\ 7-?_ $-:^?J]
MW*_X;]3CQ'Q!1117IG.%%<C\:?#WB_Q3X,^P^"O$-EX6U>:XC#ZG<6*WOV:#
MG>4B;Y6?I@-@=>:\>7X=?M0:+)-IUO\ $3X;ZU8SG8-8U#19+?4;5<_?2"%?
M(+8[.2/?O3);MT/H^O'?BA^VCX:^'_QQ\)_#ZS,6N>(O$6I)97<4%Q@:.C D
M/*0K#>2.(^"1DDC S[%7S!^TU\,/#_PX^,GP=ET/2;/39M>^(C:EJ,L2?O+R
MXDBE=Y'8\L<L<#.!G  '%""3:6A]/UXGXQ_:KU^Z^*'B#PO\/OA_-XZG\(I'
M_;5R^LQ:9!;S2+O2"(NC^;)M!R/E"G@FO;*\ _8@DAB\;?'.V8;=23XAWLTH
M8?-Y#PP^2?IQ)B@'?8V)_P!MWPQ'^S/#\2$M-2DCN9AIT6CA +YM1,GE?8R.
M@?>#DG^$;O04G@;]J/7E^+&C^$/B!X"E\"W_ (F@EET:X36(M3MKUXE#20,Z
M(FR4+SMY![$U\U:+<P_\(KI^I;H_["D_:8>[M9 NR*.V)D5&/  7S._;CICC
MW3]M?=<?&OX V]L5^W-XS$RC;EC"D),V.#QM(S]1]:=B.9M7-/Q%^UUXCU7Q
MEXIT_P  ?#:\\<:?X)N6L=7OAK$5CFZ10TD%O&R,TSH#R/EYX'49]0^#GQ7T
MKXY?#'1_%FB-(VF:U!YT0D7$D9#%71AR RNK*>>JFO(O^"=6(/AYX\MG&R^M
M?'NLI>(WWTD\U3\WOM*U%_P3"25OV7S<9!L;W7]4GL"%PI@-RX!' XW!_P#/
M%)E1;/HBBBBD6%;_ (U_Y!OA_P#[!J_^C9*P*W_&O_(-\/\ _8-7_P!&R5E/
MXX_UT*6S,"BBBM23D/C9\<_#?[/W@>XU[Q-J,5E;1*1#%G,][(!Q%$G5W)P,
M#UR<#FL?X6_M':?X[_9GLOB;J=M_86ES:9+JES"TWG_98H]^[YMJ[CA/0<G%
M:/QF^&'A_P 7Z=_;NJ:39W^K>&]/O3I=Q.F\V1EC&]D!X#'RT^;&1C@C)S\T
MVEO+<_\ !%@K"KLX\+NY"]=JW!+'Z!0<^V:9#;3/0],_;EUNQTOP_P")O$WP
MTU#PW\//$US#!::Z^KPW$UNL_%O-<6JJ&BC?*\AVVAAGD@'K?BQ^TQJ?AKXL
M0^!?!?A"3QMXI73_ .U;Z%M3CTZUTZV+;$,DS*_SLW1 N<<]*X']M^_L[C_@
MF9J)@:,PWVCZ2EDJC/FLTUMY80=ST(QZ9[5I?L_;K#]NKXPV^J,DFLS:)X>D
M20#B5$MY$F9.!\OF%>PY[4_,5W>QZ/\ L\?'Z#X\>']4:32KKP]K_AV_?2]9
MT>YD6273[A.<!UX=&!!5QPPSZ5Z#7S[^S%(+S]LO]HFYM61M.-]HD";$V@7$
M=@RS]ASNQGW!/?)ROV[_  C#X^^,OP-T6YGO+>TU+7KRWN3:S-#))"UJ?,CW
MJ0P#IN1L$':YI=1\WNW/I>BOB[PO^RYX-D_;P\3_  ]73[F'P$OABVUZ3P]%
M?3+87%[YODB5TW_-A7;C.,D$C@5QL/BO4OAW\$_'_P /=$U:^T30$^+47A*W
MNUN9&FT?3+AE\Q(W)+*H"$>O[Q^YIV%S]S] Z*^./VAOV4O!/P!^)/P2O_"%
MO)H;7/CW3[2ZL$O)9(]0^61A<.KN<R1[2N_&<3G)Y%?1G[3_ (\U'X8?L[>-
M?$.D#_B9Z1HUS<VK%=PCD6,X<CN%^]^%(J^]SNZ*^,?%?[)_A'PO^Q+)\1[*
M\U.#XAVGAM/$R>+/[3G^W7%YY G^]NP4=CL"$8PP[\U!!X"T[]K']M3P.WC6
MT:[M-0^#ECKM]I_F-%#<SM>,-L@1AE5:<L!G&Y5]*+"YV?:M%5-!T.U\,:'9
MZ;8Q>19:? EM;Q;BWEQHH55R22<  9)S5ND66-'_ .0M:_\ 79/YBKWC[_D>
M-7_Z_)?_ $,U1T?_ )"UK_UV3^8J]X^_Y'C5_P#K\E_]#-9?\O%Z?Y%?9,FB
MBBM20HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O8?V<_\ D5K[
M_KZ_]D6O'J]A_9S_ .16OO\ KZ_]D6N',?X#-J'QGH=%%%?.G<<;\=O^2>3?
M]=H_YUX;7N7QV_Y)Y-_UVC_G7AM>_EG\'YG%B/B"BBBO1, HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K>LO^2:ZA_P!A"#_T"2L&MZR_
MY)KJ'_80@_\ 0)*RJ[+U7YE1,&BBBM20HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O?/@S_P DUTSZ2?\ HQZ\#KWSX,_\DUTSZ2?^C'KS,T_A
M+U_S.C#_ !'44445X1V'F7[27_'EI/\ OR_R6O**]7_:2_X\M)_WY?Y+7E%?
M1Y?_  %\_P S@K?&PHHHKM,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "M[X8?\C[IW_70_P#H)K!K>^&'_(^Z=_UT/_H)K*M_#EZ,J'Q(P:**
M*U)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"WX?_P"0]9?]?$?_ *$*^F:^9O#_ /R'K+_KXC_]"%?3->+F
MN\?F=>&V84445Y)TA17P+^WE_P (K_PV3_Q67_"0_P!B?V+!N_L7R?M6_P"?
M;CS?EV^O>NA_8;T)K?XE^)+[P1#XQ@^&=QHDHDDUY$7[3=C &PQ#RV9?FY7D
M+N!/(!^ I\<.>:RRU44[3<+J=Y:?:<>72/=\VA^BU. E#*8YFZ[7-!3LX6CK
M]E3YM9=ERZ^1]LT5^47PO_X5'_PB_P#Q6G_"Q_[:\UL_V)]B^R^7QM_UOS;N
MN>W2O:/VQM$\)^'_ (9? .#=XB;P:]G=7.<PG4_LLHM)<=!%YN'_ -W/KUKS
ML+XCNM@JN-]C&T%%V]K=^].,?>]SW;7O?7:QZ6*\,E1QU+ ^WG>;DK^RLO=A
M*7N_O/>O:UM-[]+'WK17Q!^S%KOPX^'7A?XC>,OAT/'3ZMX>T!U=/$!M/)/F
M-N0J(1DD/$,Y.,9]>-7X4?L$6G[0WPNL_''BCQCXFN/%WB2 WL5VDB-';$KB
M$,K*7?9@<*Z#&%7;C->OAN+L5BH4U@\,JE22E*RJ+E44^6_,XZMO2UO5GCXK
M@W"X2=1XW$NG3BXQNZ3YG)QYK<BEHE'6_-UT1]E45\3?\-+^-?\ AB+R/[6E
M_P"$D_X2S_A#O[8\UOM/E^7YWF[_ +V_'[O?]['/WOFKL;;_ ()NS_#?6M"U
MSP)XXU?3_$=I=1OJ%W?X>&>/(,I6.-5)R03Y;N58':6'WJUI<65L5RO+L,ZB
MY8RE[RBX\U[))_$U9WU2\]3"KP?1PG,LRQ2I/FE&'NN2ER6NVU\*=U;1ORT/
MJBBOG'P,I'_!3KQEQU\(QD>_SV=4O"<5]+_P4$^+8TQDCU$^%X5M'<91)C#:
M["<\8W8KL_UD^']UO6E2W_E4GS;=>7;SW.+_ %8UE^]VH1K;?S.*Y=^G-\7E
ML?3=%?F;I?AKPOH6M"+XB:O\3O 7Q--R]TVMSPBYLXR'+)/M4+<L6VE R,PW
M8;=MR!^@$'QC\+^$?#FBKKWC?PT+J\T^&Y2[N;V"S&I*5'^D(A?A'()&,@9Q
MGBN?A_BV&8JHZT%2Y;;S3:OTDFHRB_DUV>AT\1\'SRQTU0G*KSWVIM)VZQDG
M*,D_5-=8I,[*BOD#_@H7XIL_BG\0=!^'W]NZ=I%G9:?=:Y=W-U=)% \_D/\
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M"UKHWP%^(_Q)TCXB?%#XF?#G4;OQ+>:Q8G2Y%CLM?MIV#)/&3;2EYNS+OR.
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MJFD_VMKVFQ)?Z3>O:S/;S,<[9$(.&4@^G2H_'7[&?B7PCX7O-5\#_%WXM?\
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M7..]'[47_!/[PS\/_#-KXY^&'@_1(_$?@Z3[?+I,]O\ :[36[9>9(C%+N7S
MH)1E ;(P#G;CK?&?[9)U3X3> O'N@>'8_$GPRULRV_BV&*T:[O\ 2%*!4 C5
M@NU)0ZR95@0%QC<#0+:_0SO!GPDU(:MHFO?"'XY:OXU%K>1/JVG>)/$PUBQO
M+,\2 &-&:&7!^4XQGTQS]/U\#?&+4_@]\5]6T>7]G[3W7XLMJ=J]C<^'=,N=
M.M[*,2+YSWBE$B$7E[MV1NSC/&X'[YI,N 4444BPHHHH *WOAA_R/NG?]=#_
M .@FL&M[X8?\C[IW_70_^@FLJW\.7HRH?$C!HHHK4D**** "BBB@ HHHH **
M** "OCC]O/XH?$3P!^U?X)D\"WVI3C2M!N=:O-"2ZD6UUB*&0F9&B!VN_E;L
M$@L"!MYQ7V/7SA\3/^4G?PT_[%/4?_0FIHB>QF_M>?M#_P#";?LB>$?&O@?7
M-1L+;7=?TP+/97+V\RH\A66!RA!R""K+G&5/6JGCWPCJGQM_X*#:[X3G\<_$
M'PYH>G>$+;4XK;P_KTU@AF,X0L57*\AN>,\#FO'OVZ/A9JW[-.OPZ/HUN7^&
MGC_Q/8ZM!"OW-#U2.4>;&@Z+'*A+ >J8&-O/I_C?X"^$?V@O^"F'B+2_&&C1
M:W86?@BUNH8I)9(PDOVD+NRC*>C,.N.:HB[;U-#R=8_9E_;#^'7A31/B#XQ\
M::?XS2\CUC1_$.I_VG-8)%$'CN4<C=$,YX/!"GUX[']D+QEJ_B7XY?'2TU'5
M=2U"UTCQ/';V,-S<O+'91^6QV1*Q(1<]EP*[KX/_ +*/P[^ >HRWGA'PGIFC
MWLR&-[E TL^T]5#R%F /< XXKR/]E*_U#3/B_P#M(W&DZ?'JNI1>)E:VLY+D
M6R7,GDMM0R%6V GJVTX]#2*2L?3]%>'_  =\8?$KXE_"/QQ#+J7A^#QM8>)+
MK2+>X6$FPTY$,(?RQMW2^6K2%#(OSL%W@ D#7^!?BO7+GXO>./#TWB*\\:>'
M_#ZVB1ZO=V]K%-:7["0W%B6MHHXI-B""0_(&0S;6SD8DNYZS1110,**** "B
MBB@ HHHH **** +?A_\ Y#UE_P!?$?\ Z$*^F:^9O#__ "'K+_KXC_\ 0A7T
MS7BYKO'YG7AMF%%%%>2=)X]=?L^:O=?MCI\06GTMM"&C'37MV=S<LY!'W=FS
M;S_>_"LSX<?LQZ[\%?C/XCG\,76CP_#WQ3 SW&E2R2+-8W.QMK0J$*;-QQC<
M/D;&#Y:U[I17A_ZNX/VGM4FI*;J7OK>2M)?X6M&CW_\ 67&^S]BVG%TU3M;2
MT7>+_P 47JGNCX_^%_[*O[0WP9\+_P!C>&O'/@O3=-$K3^3L\[YVQD[I+-F[
M#O7HGB']G;QYX[USX/ZOK^LZ%?ZOX&O;FZUN=6:,78>6)D\E5A520D>#D)SC
MKUKWRBN##<'X.A2]@IU'#W;1<Y.*Y91DK)Z+6*VZ774[\5QIC:];ZPZ=-5/>
MO*-.*D^:,HN[6KNI/?K9]#/\5^&+/QKX8U#2-0C\ZQU.WDM9T_O(ZE3CWP:^
M8-/_ &2_CA\--*N?#'@SXEZ7#X.8NMO]J0QWD"2#YPI$+M&02V#'*O/S#82<
M?5]%>CFF0X;'SC4JN49QNN:$G%V>Z;3U3['FY3Q!BLOA*E2490DT^6<5-76T
MDFM&NZ/#5_84\/K^R_\ \*X%].)1/_: U<0_O!??\]_+W8QM^39N^YQNW?-7
M#Q_LE?&?XA:SH5CXZ^)-G/X9T.[BND.F.Z7[-$1L;>(8SYG'$C.Q4G=\QZ_5
M5%<=?A'+:O(E%Q44HVC*45*,=E))^];SUUW.[#\99I2YVY*<I2<KRC&3C*6D
MG!M>ZWY::;'@'Q]_9?\ &FK?&&U\>?#3Q19^']?-B-.O4O\ +131#H<^7(&Z
M+E74C**P.14GP!_92\2^$]0\8^(/&WBMM1\7>,;1K"6\TQC']CC*X#QOM0AQ
MA-NU5";!C/;WNBM%PO@5BWC/>O=RY>9\G,U9R4;VNU?4R?%F8/!K!7C:RCS<
ML>?E3NHN5K\J:6GD?)WB+]E/X\^(?#UQX2O/B9H>J^$+EO(EDOH3+>S0;]VY
MBT+.7'4#S^P&\"O4I/V'/A[KGA/P[INO:1)KDOAS3DTV"YDO+B!G126)*Q2*
M.79CWQG&>*]?HJ,-PGEM)R=2+JW27[QNHE%.Z24KV29>*XPS.K&,:4E2LV_W
M25-N35G)N%KMH^=/#?[!VF^-/B%XO\0_$NST_7)=8O5.DP6FHW073[5 51&8
M>46;9Y:G.1^[&,9-5-)_8KUWP+IGQ2\.^';W1H?"'C.R"Z3;3W,YEL;C &'R
MC?)@N-P9F(5,CKCZ6HJ?]4,K23C3M*\FY+23YU)2YI;M/F>CVTML5_KIFS;4
MJEX6BE%ZPCR.+CRQO9-<JU6^M]SY1\$_L_\ [27@#PYI^C:9X_\ !=MI6FQK
M!! (0_EQCMN:R+'\35#QA^R#\:]9^/\ ?^/[#Q1X*M]5>5UL9)3)+]C@P41%
M1[9T4A.,C)R6.222?KVBN67!.#E2C1E5JN,6G&]27NN.UNUK]#KCQWCH595H
M4:*E)-2M2C[RE9OF[WMU/.OV=O#?Q(\-Z-J*?$CQ!I'B"]DG5K.2PC5%BCV_
M,&Q#%SGV/UKT6BBOJ,'A5AJ,:*E*5NLFY-^K>K/E,;BWB:\J\HQBWTBE&*]$
MM$<Y\6_^2=:I_P!<U_\ 0UKY^KZ!^+?_ "3K5/\ KFO_ *&M?/U?397_  WZ
MGDXCX@HHHKTSG/EOP;\,OB'\)KOQ%J_P2\2?#WQMX*\1ZQ<ZL^EZE(VZTNI'
MQ-'!=0,5;!4#$A&W!&,C)S/$_P"T"=;_ &>OCD%\)M\+_BGX;TX3ZXME+&MQ
M.[1DP727405I1@-ANJY'/()[2+]C#Q/\-_$6K3?"_P"*=_X&T;6KN2^GT:YT
M2#5[2":0Y=H!(RF($_PC(_3'1> /V.]*T#P3XUL?$6LZKXOUKXC0&W\0ZS>!
M(I[I/*:)$B11MB6-6.P#.T_0 496>QYM^U3\0_$'A[_@G3X2UO3]<UBQUJYM
M]!:;4+>]DBNI3)Y/F%I%(8[LG=D\Y.:S=1^$5W\7/^"DOCZW7Q1XA\-:=:>&
M].>[_L2\^QW=X2,(GG ;U0?,3MQDA>:V_%O_  3_ /%GQ ^$UCX*UKXO7EYH
M&A_9O[*@3P_#$8Q Z[!<,LNZ?$8*CE.2&.XK@]9XW_9&\0:A^T/K/Q(\+_$*
M;POK&JV-OIXMSHZ7ML(HP0XE5I%\S<=A7&PH5ZMDT:!9O<\7^*WQ-\9_"[X%
M?M$>"V\7:[J%W\.GTFYT77GO&35$MKYD<123)M8L@1ANX+!SVP!=^,OQTUCQ
M?\?=)\$S7WQ1M_#FA>%[34K]?!%I//J>I7<Z@J998@7CA52._P S$^O!^V!\
M,]'_ &>OV2/'&CZEXBN?$OQ(^+%U%(]W+;;+G7KB*X@Q%##&"J)&C *@/&X\
M] /9/&'[*FI:UXF\.^,/"_BJ?P+XVTS1HM&O+A;&/4+74+=0&\J:%F4,5?.&
M# CCT&#05G>QXSX=_:5\<_!/X8_%R?\ L[XBWV@>'M-AU#PQJGC729[>\CFE
M987@D>11YX1W5U).=H;/'3T/PC^S7\0-%\.^$?%&B?%#Q1JOBMI;6\UFWU[5
M))=%U""10;B)+94(B(!^0J!C')YR.F\$?L96$&C^./\ A-=<O/&^M_$2%;76
M-0E@6S40(FV.*")21$J]1R3D*3TK M?V(_$6L:-H/AKQ1\4-1\1^ _#US;W$
M&D'1XK:YNUMV#0Q7%TKEI$4@9PJDX'.0#0.SZGG_ .SM\(]4\/\ Q@_:%NO"
M^O>)KKQ+H=PUMH\6H:O)-;7MU)8$Q/=*YVRLLFW#/]T<=*YOX2?%6WT'QEX0
MMO%/Q#^,_P /_'@O+<:I:^,DENM%UIS@2V\29$42.3\DGR[5]3@U] ']C^1_
MB=X_U!_%#OX1^)41&L:$VG+YWF_9_)$D5V'W)C[P&P\@<UST_P"PWXD\5>&-
M$\*>*OBC=^(? N@W%M-#I?\ 84%O=W"6Y'E1370<E@, $A%)QR<\T70N5K8^
MC:***DV"M_QK_P @WP__ -@U?_1LE8%;_C7_ )!OA_\ [!J_^C9*RG\<?ZZ%
M+9F!1116I(4444 >3?MH_!C7OC]\%?\ A&M U'2=,FN=4LI[F342_D/#%,LF
MW" EF+K'A3@$C&1UKAO$?CGXD?LR?&?P!9^(_&<'C_PWX^U3^PY8YM'@TZXT
MRX<9CDB:$89,]5?) '4DY'JW[1/P%LOVAO MOI5QJ%_HU]I=_#J^E:G9$>?I
MU[#GRIE!X.-S @]03R#@CC_#/[*6NZO\4="\4_$3Q]-XYF\*EY=&LHM(CTNT
MM9V&W[0Z([^9*!G!) !Z"GT(:=]#(_X)TA9OAYX\NG^:^N_'NLR7DC??>3S5
M'S=\[0M1?\$PII#^R^8.!8VFOZI#8!6RH@%RY 7D\;B_^>:T?$7[(GB32O&O
MBK4? /Q*O? ^G^-IS>ZM8?V1%?XNF&V2>WD9U,+N.IPW//88]1^#GPHTKX&_
M#'1_">B)(NF:+!Y,1D;=)(2Q9W8\ LSLS'CJQH813/!_%WA[7_C!^WIXC\*-
MXW\7Z!X6L?"UGJ,EGH^I26CRS&61!M<?ZL?,2VS!;:F3@5POPJ\%^+?BE\*O
MBQ-JOQ4^(J?\*NUW6- T-[+53;32BS!E6:Z=1NN&;>JX<XVICOD?3&B_ O\
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M_P"3$7_Q5'_"E?$O_0-_\F(O_BJ][HK?^U*O9?U\R/J\3P3_ (4KXE_Z!O\
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M4KXE_P"@;_Y,1?\ Q5'_  I7Q+_T#?\ R8B_^*KWNBC^U*O9?U\P^KQ/!/\
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M_%4?\*5\2_\ 0-_\F(O_ (JO>Z*/[4J]E_7S#ZO$\$_X4KXE_P"@;_Y,1?\
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M_%5[W16O]J5>R_KYD_5XG@G_  I7Q+_T#?\ R8B_^*H_X4KXE_Z!O_DQ%_\
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M^*KWNBC^U*O9?U\P^KQ/!/\ A2OB7_H&_P#DQ%_\51_PI7Q+_P! W_R8B_\
MBJ][HH_M2KV7]?,/J\3P3_A2OB7_ *!O_DQ%_P#%4?\ "E?$O_0-_P#)B+_X
MJO>Z*/[4J]E_7S#ZO$\$_P"%*^)?^@;_ .3$7_Q5'_"E?$O_ $#?_)B+_P"*
MKWNBC^U*O9?U\P^KQ/!/^%*^)?\ H&_^3$7_ ,51_P *5\2_] W_ ,F(O_BJ
M][HH_M2KV7]?,/J\3P3_ (4KXE_Z!O\ Y,1?_%4?\*5\2_\ 0-_\F(O_ (JO
M>Z*/[4J]E_7S#ZO$\$_X4KXE_P"@;_Y,1?\ Q5'_  I7Q+_T#?\ R8B_^*KW
MNBC^U*O9?U\P^KQ/!/\ A2OB7_H&_P#DQ%_\51_PI7Q+_P! W_R8B_\ BJ][
MHH_M2KV7]?,/J\3P3_A2OB7_ *!O_DQ%_P#%4?\ "E?$O_0-_P#)B+_XJO>Z
M*/[4J]E_7S#ZO$\-T?X.^([75K65]/PD<R,Q^T1< $$_Q5[E117+B,3.LTY=
,#2$%'8****YRS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sava-20230331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/1/2023 8:19:42 AM-->
<!--Modified on: 5/1/2023 8:19:42 AM-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" targetNamespace="http://www.cassavasciences.com/20230331" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sava="http://www.cassavasciences.com/20230331" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022">
  <annotation>
    <appinfo><link:roleType roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets"><link:definition>00100 - Statement - Condensed Consolidated Balance Sheets</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations"><link:definition>00200 - Statement - Condensed Consolidated Statements Of Operations</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows"><link:definition>00500 - Statement - Condensed Consolidated Statements Of Cash Flows</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"><link:definition>40301 - Disclosure - Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails" id="DisclosureRealPropertyComponentsOfOtherIncomeNetDetails"><link:definition>40403 - Disclosure - Real Property (Components Of Other Income, Net) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"><link:definition>40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" id="DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"><link:definition>40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" id="DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"><link:definition>40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation"><link:definition>00090 - Document - Document And Entity Information</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical"><link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfStockholdersEquity"><link:definition>00400 - Statement - Condensed Consolidated Statements Of Stockholders&apos; Equity</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity" id="DisclosureGeneralAndLiquidity"><link:definition>10101 - Disclosure - General And Liquidity</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies"><link:definition>10201 - Disclosure - Significant Accounting Policies</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets"><link:definition>10301 - Disclosure - Prepaid Expenses And Other Current Assets</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureRealProperty" id="DisclosureRealProperty"><link:definition>10401 - Disclosure - Real Property</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment"><link:definition>10501 - Disclosure - Property And Equipment</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets"><link:definition>10601 - Disclosure - Intangible Assets</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpense" id="DisclosureStockholdersEquityAndStockBasedCompensationExpense"><link:definition>10701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes"><link:definition>10801 - Disclosure - Income Taxes</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureCommitments" id="DisclosureCommitments"><link:definition>10901 - Disclosure - Commitments</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan" id="Disclosure2020CashIncentiveBonusPlan"><link:definition>11001 - Disclosure - 2020 Cash Incentive Bonus Plan</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureContingencies" id="DisclosureContingencies"><link:definition>11101 - Disclosure - Contingencies</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy" id="DisclosureSignificantAccountingPoliciesPolicy"><link:definition>20202 - Disclosure - Significant Accounting Policies (Policy)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables"><link:definition>30203 - Disclosure - Significant Accounting Policies (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"><link:definition>30303 - Disclosure - Prepaid Expenses And Other Current Assets (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyTables" id="DisclosureRealPropertyTables"><link:definition>30403 - Disclosure - Real Property (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables"><link:definition>30503 - Disclosure - Property And Equipment (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables"><link:definition>30603 - Disclosure - Intangible Assets (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables" id="DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables"><link:definition>30703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Tables)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails" id="DisclosureGeneralAndLiquidityNarrativeDetails"><link:definition>40101 - Disclosure - General And Liquidity (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSignificantAccountingPoliciesNarrativeDetails"><link:definition>40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"><link:definition>40202 - Disclosure - Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails" id="DisclosureRealPropertyNarrativeDetails"><link:definition>40401 - Disclosure - Real Property (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" id="DisclosurePropertyAndEquipmentNarrativeDetails"><link:definition>40501 - Disclosure - Property And Equipment (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails" id="DisclosureIntangibleAssetsNarrativeDetails"><link:definition>40601 - Disclosure - Intangible Assets (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"><link:definition>40701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"><link:definition>40703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Stock Options And Unvested Performance Award Outstanding Activity) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails" id="DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"><link:definition>40706 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Stock-Based Compensation Expenses) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails"><link:definition>40801 - Disclosure - Income Taxes (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails" id="DisclosureCommitmentsNarrativeDetails"><link:definition>40901 - Disclosure - Commitments (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" id="Disclosure2020CashIncentiveBonusPlanNarrativeDetails"><link:definition>41001 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:roleType roleURI="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails" id="DisclosureContingenciesNarrativeDetails"><link:definition>41101 - Disclosure - Contingencies (Narrative) (Details)</link:definition><link:usedOn>link:presentationLink</link:usedOn><link:usedOn>link:calculationLink</link:usedOn><link:usedOn>link:definitionLink</link:usedOn></link:roleType><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="sava-20230331_cal.xml" xlink:title="Calculation Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="sava-20230331_def.xml" xlink:title="Definition Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="sava-20230331_lab.xml" xlink:title="Label Links, all"></link:linkbaseRef><link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="sava-20230331_pre.xml" xlink:title="Presentation Links, all"></link:linkbaseRef></appinfo></annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"></import>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"></import>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"></import>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"></import>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"></import>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"></import>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"></import>
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"></import>
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"></import>
  <element name="AustinMember" id="sava_AustinMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"></element>
  <element id="sava_StockOptionAndPerformanceAwardActivity" name="StockOptionAndPerformanceAwardActivity" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_AtMarketEquityProgramMember" name="AtMarketEquityProgramMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ReductionToResearchAndDevelopmentExpense" name="ReductionToResearchAndDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="sava_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" name="ResearchAndDevelopmentExpenseNetOfGrantReimbursement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="sava_ProceedsFromGrantsPolicyPolicyTextBlock" name="ProceedsFromGrantsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" name="ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_CashIncentiveBonusPlanTextBlock" name="CashIncentiveBonusPlanTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_CashIncentiveBonusPlanAbstract" name="CashIncentiveBonusPlanAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_PerformancePlanValuationAmount" name="PerformancePlanValuationAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="sava_CashIncentiveBonusAward" name="CashIncentiveBonusAward" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"></element>
  <element id="sava_CashIncentiveBonusPlanTable" name="CashIncentiveBonusPlanTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_CashIncentiveBonusPlanLineItems" name="CashIncentiveBonusPlanLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"></element>
  <element id="sava_CashIncentiveBonusPlanMember" name="CashIncentiveBonusPlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_StockOptionAndPerformanceAwardActivity2020PlanMember" name="StockOptionAndPerformanceAwardActivity2020PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_Exceeds5BillionMarketCapitalizationMember" name="Exceeds5BillionMarketCapitalizationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" name="PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_FirstValuationMilestoneMember" name="FirstValuationMilestoneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PaymentsForCashIncentiveBonus" name="PaymentsForCashIncentiveBonus" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit"></element>
  <element id="sava_SecondThroughEighthValuationMilestonesMember" name="SecondThroughEighthValuationMilestonesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" name="StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice" name="ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element>
  <element id="sava_OperatingLeasesMember" name="OperatingLeasesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PrepaidAndOtherAssetsDisclosureTextBlock" name="PrepaidAndOtherAssetsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_LeasingCommissionsAndOtherMember" name="LeasingCommissionsAndOtherMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PercentageOfCurrentlyLeased" name="PercentageOfCurrentlyLeased" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_PercentageOfOccupancy" name="PercentageOfOccupancy" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" name="ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_NumberOfValuationMilestonesAchieved" name="NumberOfValuationMilestonesAchieved" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense" name="MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" name="MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ViolationsOfFederalSecuritiesLawsMember" name="ViolationsOfFederalSecuritiesLawsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_NumberOfClassActionsConvertedToCase" name="NumberOfClassActionsConvertedToCase" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_ShareholderDerivativeActionsMember" name="ShareholderDerivativeActionsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_TwoBuildingOfficeComplexAssetMember" name="TwoBuildingOfficeComplexAssetMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_RegisteredDirectOffering2022Member" name="RegisteredDirectOffering2022Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_IndependentDirectorsMember" name="IndependentDirectorsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"></element>
  <element id="sava_IncreaseDecreaseInDevelopmentExpense" name="IncreaseDecreaseInDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"></element></schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sava-20230331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/1/2023 8:19:42 AM-->
<!--Modified on: 5/1/2023 8:19:42 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureRealPropertyComponentsOfOtherIncomeNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"></roleRef>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638185259808939699"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638185259808939699" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638185259808949683"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638185259808939699" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638185259808949683" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638185259808949683"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638185259808939699" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638185259808949683" order="2" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638185259808949683"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638185259808949683" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638185259808949683"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638185259808949683" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638185259808949683"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638185259808949683" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638185259808999822"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638185259808999822" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638185259808999822"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638185259808999822" xlink:to="us-gaap_LiabilitiesCurrent_638185259808999822" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638185259808999822"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638185259808999822" xlink:to="us-gaap_AccountsPayableCurrent_638185259808999822" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638185259808999822"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638185259808999822" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638185259808999822" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638185259808999822"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638185259808999822" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638185259808999822" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638185259808999822"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638185259808999822" xlink:to="us-gaap_OtherLiabilitiesCurrent_638185259808999822" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638185259808999822" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638185259809009804" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638185259808999822" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638185259809009804" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638185259808999822" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638185259809009804" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638185259809009804" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638185259809009804" xlink:to="us-gaap_PreferredStockValue_638185259809009804" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638185259809009804" xlink:to="us-gaap_CommonStockValue_638185259809009804" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638185259809009804" xlink:to="us-gaap_AdditionalPaidInCapital_638185259809009804" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638185259809009804" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638185259809009804" order="4" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements Of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638185259809009804" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome_638185259809009804" order="2" use="optional" weight="1" priority="9"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638185259809009804" order="3" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638185259809009804" xlink:to="us-gaap_OperatingExpenses_638185259809009804" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638185259809009804" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638185259809009804" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638185259809009804" xlink:to="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_638185259809009804" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Condensed Consolidated Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" order="1" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense_638185259809009804" order="1" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="us-gaap_NetIncomeLoss_638185259809009804" order="2" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="us-gaap_ShareBasedCompensation_638185259809009804" order="3" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638185259809009804" order="4" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="us-gaap_Depreciation_638185259809009804" order="5" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638185259809009804" order="6" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638185259809009804" order="7" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638185259809009804" order="8" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_638185259809009804" order="9" use="optional" weight="-1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809009804" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638185259809009804" order="10" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638185259809009804" order="2" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638185259809009804"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638185259809009804" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638185259809009804" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638185259809019809" order="3" use="optional" weight="1" priority="1"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638185259809019809" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638185259809019809" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638185259809019809" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638185259809019809" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638185259809019809" order="1" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_638185259809019809" order="2" use="optional" weight="1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositContractsAssets_638185259809019809" order="3" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Real Property (Components Of Other Income, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense_638185259809019809" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome_638185259809019809" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638185259809019809" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638185259809019809" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638185259809019809" order="1" use="optional" weight="-1" priority="2"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638185259809019809" order="2" use="optional" weight="1" priority="2"></calculationArc></calculationLink>
  <calculationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638185259809019809" order="1" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638185259809019809" order="2" use="optional" weight="1" priority="3"></calculationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_638185259809019809"></loc>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_638185259809019809" order="3" use="optional" weight="1" priority="3"></calculationArc></calculationLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sava-20230331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/1/2023 8:19:42 AM-->
<!--Modified on: 5/1/2023 8:19:42 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureRealPropertyNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureRealPropertyComponentsOfOtherIncomeNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureCommitmentsNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#Disclosure2020CashIncentiveBonusPlanNarrativeDetails" roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureContingenciesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"></roleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"></arcroleRef>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"></arcroleRef>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements Of Stockholders&apos; Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638185259809318689"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_638185259809318689" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_SignificantAccountingPoliciesTable" xlink:label="sava_SignificantAccountingPoliciesTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="sava_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809339003"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809339003" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="sava_SignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809339003"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809339003" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="sava_SignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638185259809339003"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638185259809339003" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_SignificantAccountingPoliciesLineItems" xlink:label="sava_SignificantAccountingPoliciesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="sava_SignificantAccountingPoliciesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ReductionToResearchAndDevelopmentExpense" xlink:label="sava_ReductionToResearchAndDevelopmentExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="sava_ReductionToResearchAndDevelopmentExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638185259809348603"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638185259809348603" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Real Property (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638185259809388493"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_638185259809388493" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AustinMember" xlink:label="sava_AustinMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638185259809388493"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_638185259809388493" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_TwoBuildingOfficeComplexAssetMember" xlink:label="sava_TwoBuildingOfficeComplexAssetMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="sava_TwoBuildingOfficeComplexAssetMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sava_PercentageOfOccupancy" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PercentageOfCurrentlyLeased" xlink:label="sava_PercentageOfCurrentlyLeased"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="sava_PercentageOfCurrentlyLeased" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Real Property (Components Of Other Income, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AustinMember" xlink:label="sava_AustinMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sava_LeasingCommissionsAndOtherMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638185259809418418"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638185259809418418" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638185259809418418"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_638185259809418418" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_RegisteredDirectOffering2022Member" xlink:label="sava_RegisteredDirectOffering2022Member"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_RegisteredDirectOffering2022Member" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AtMarketEquityProgramMember" xlink:label="sava_AtMarketEquityProgramMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_AtMarketEquityProgramMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_StockOptionAndPerformanceAwardActivity2020PlanMember" xlink:label="sava_StockOptionAndPerformanceAwardActivity2020PlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_StockOptionAndPerformanceAwardActivity2020PlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_TwoThousandEighteenEquityIncentivePlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638185259809428385"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638185259809428385" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Stock Options And Unvested Performance Award Outstanding Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Stock-Based Compensation Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638185259809458602"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_638185259809458602" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AustinMember" xlink:label="sava_AustinMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="sava_AustinMember" priority="2" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638185259809468568"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_638185259809468568" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_OperatingLeasesMember" xlink:label="sava_OperatingLeasesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sava_OperatingLeasesMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanTable" xlink:label="sava_CashIncentiveBonusPlanTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="us-gaap_PlanNameAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="srt_RangeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="srt_StatementScenarioAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638185259809478567"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_638185259809478567" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_Exceeds5BillionMarketCapitalizationMember" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_Exceeds5BillionMarketCapitalizationMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_FirstValuationMilestoneMember" xlink:label="sava_FirstValuationMilestoneMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_FirstValuationMilestoneMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_SecondThroughEighthValuationMilestonesMember" xlink:label="sava_SecondThroughEighthValuationMilestonesMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="sava_SecondThroughEighthValuationMilestonesMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638185259809488242"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_638185259809488242" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="srt_TitleOfIndividualAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638185259809488242"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638185259809488242" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_IndependentDirectorsMember" xlink:label="sava_IndependentDirectorsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sava_IndependentDirectorsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanLineItems" xlink:label="sava_CashIncentiveBonusPlanLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_CashIncentiveBonusPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense" xlink:label="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_NumberOfValuationMilestonesAchieved" xlink:label="sava_NumberOfValuationMilestonesAchieved"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_NumberOfValuationMilestonesAchieved" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PerformancePlanValuationAmount" xlink:label="sava_PerformancePlanValuationAmount"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_PerformancePlanValuationAmount" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_CashIncentiveBonusAward" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus" priority="1" use="optional"></definitionArc></definitionLink>
  <definitionLink xlink:role="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_LitigationCaseAxis" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638185259809498517"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain_638185259809498517" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"></definitionArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" priority="1" use="optional"></definitionArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_NumberOfClassActionsConvertedToCase" xlink:label="sava_NumberOfClassActionsConvertedToCase"></loc>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="sava_NumberOfClassActionsConvertedToCase" priority="1" use="optional"></definitionArc></definitionLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sava-20230331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/1/2023 8:19:42 AM-->
<!--Modified on: 5/1/2023 8:19:42 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"></roleRef>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"></roleRef>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"></roleRef>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Development Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee Related Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Notes 10, 11 and 12)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&apos; equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 120,000,000 shares authorized; 41,749,435 and 41,735,557 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&apos; equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&apos; equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Par value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements Of Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:to="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" xml:lang="en-US">Research and Development Expense, Net Of Grant Reimbursement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" xml:lang="en-US">Research and Development Expense, Net Of Grant Reimbursement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_lbl" xml:lang="en-US">Research and development, net of grant reimbursement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest And Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Weighted-average shares used in computing net income (loss) per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Shares used in computing net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements Of Stockholders&apos; Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balance, Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Stock options for employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock options for non-employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements Of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense for intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_lbl" xml:lang="en-US">Operating lease right-of-use assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInDevelopmentExpense" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense_lbl" xml:lang="en-US">Increase (Decrease) in development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense_lbl" xml:lang="en-US">Increase (Decrease) in development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense_lbl" xml:lang="en-US">Accrued development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase Decrease In Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Increase Decrease In Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from common stock offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General And Liquidity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">General And Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="sava_PrepaidAndOtherAssetsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid And Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid And Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Real Property [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Real Property</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property And Equipment [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property And Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity And Stock-Based Compensation Expense [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Shareholders&apos; Equity and Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity And Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanAbstract" xlink:label="sava_CashIncentiveBonusPlanAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanAbstract" xlink:to="sava_CashIncentiveBonusPlanAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanAbstract_lbl" xml:lang="en-US">2020 Cash Incentive Bonus Plan [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanAbstract_lbl" xml:lang="en-US">2020 Cash Incentive Bonus Plan [Abstract]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTextBlock" xlink:to="sava_CashIncentiveBonusPlanTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanTextBlock_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanTextBlock_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CashIncentiveBonusPlanTextBlock_lbl" xml:lang="en-US">2020 Cash Incentive Bonus Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingencyAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAbstract_lbl" xml:lang="en-US">Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xml:lang="en-US">Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDisclosures_lbl" xml:lang="en-US">Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use Of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash And Cash Equivalents And Concentration Of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Business Segments</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:to="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Proceeds From Grants Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Proceeds From Grants Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Proceeds From Grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value Of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:to="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Research Contract Costs And Accruals Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Research Contract Costs And Accruals Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Research Contract Costs And Accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Incentive Bonus Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property And Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Components Of Other Income, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Components Of Property And Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Components Of Intangible Assets, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Amortization Expense For Finite-Lived Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_StockOptionAndPerformanceAwardActivity" xlink:label="sava_StockOptionAndPerformanceAwardActivity"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockOptionAndPerformanceAwardActivity" xlink:to="sava_StockOptionAndPerformanceAwardActivity_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_StockOptionAndPerformanceAwardActivity_lbl" xml:lang="en-US">Tabular disclosure of the change in stock options and perfromance award activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_StockOptionAndPerformanceAwardActivity_lbl" xml:lang="en-US">Stock Option And Performance Award Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_StockOptionAndPerformanceAwardActivity_lbl" xml:lang="en-US">Stock Options And Unvested Performance Award Outstanding Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_SignificantAccountingPoliciesTable" xlink:label="sava_SignificantAccountingPoliciesTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SignificantAccountingPoliciesTable" xlink:to="sava_SignificantAccountingPoliciesTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_SignificantAccountingPoliciesLineItems" xlink:label="sava_SignificantAccountingPoliciesLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SignificantAccountingPoliciesLineItems" xlink:to="sava_SignificantAccountingPoliciesLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ReductionToResearchAndDevelopmentExpense" xlink:label="sava_ReductionToResearchAndDevelopmentExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ReductionToResearchAndDevelopmentExpense" xlink:to="sava_ReductionToResearchAndDevelopmentExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Reduction To Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Reduction To Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Reimbursement from National Institutes of Health research grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of business segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible assets, Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Dilutive common stock options excluded from net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income Loss [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted Average Number Of Shares Outstanding Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsAssets" xlink:to="us-gaap_DepositContractsAssets_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsAssets_lbl" xml:lang="en-US">Deposit Contracts, Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositContractsAssets_lbl" xml:lang="en-US">Contract research organization and other deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Asset Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfOccupancy" xlink:to="sava_PercentageOfOccupancy_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PercentageOfOccupancy_lbl" xml:lang="en-US">Percentage Of Occupancy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PercentageOfOccupancy_lbl" xml:lang="en-US">Percentage Of Occupancy</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PercentageOfCurrentlyLeased" xlink:label="sava_PercentageOfCurrentlyLeased"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfCurrentlyLeased" xlink:to="sava_PercentageOfCurrentlyLeased_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PercentageOfCurrentlyLeased_lbl" xml:lang="en-US">Percentage Of Currently Leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PercentageOfCurrentlyLeased_lbl" xml:lang="en-US">Percentage Of Currently Leased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Net Rentable Area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Office space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Buildings [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Lease revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Property operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Gross property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Award [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AtMarketEquityProgramMember" xlink:label="sava_AtMarketEquityProgramMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AtMarketEquityProgramMember" xlink:to="sava_AtMarketEquityProgramMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_AtMarketEquityProgramMember_lbl" xml:lang="en-US">At-The-Market Equity Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_AtMarketEquityProgramMember_lbl" xml:lang="en-US">At Market Equity Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_AtMarketEquityProgramMember_lbl" xml:lang="en-US">ATM [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_StockOptionAndPerformanceAwardActivity2020PlanMember" xlink:label="sava_StockOptionAndPerformanceAwardActivity2020PlanMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockOptionAndPerformanceAwardActivity2020PlanMember" xlink:to="sava_StockOptionAndPerformanceAwardActivity2020PlanMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_StockOptionAndPerformanceAwardActivity2020PlanMember_lbl" xml:lang="en-US">Stock Option And Performance Award Activity 2020 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_StockOptionAndPerformanceAwardActivity2020PlanMember_lbl" xml:lang="en-US">Stock Option And Performance Award Activity2020 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_StockOptionAndPerformanceAwardActivity2020PlanMember_lbl" xml:lang="en-US">Stock Option And Performance Award [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2018 Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl" xml:lang="en-US">Stock Options Exercised Net Settled Satisfaction Of Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl" xml:lang="en-US">Stock Options Exercised Net Settled Satisfaction Of Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl" xml:lang="en-US">Stock options exercised, net settled in satisfaction of the exercise price</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:to="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl" xml:lang="en-US">Proceeds From Stock Options Exercised Net Settled Satisfaction Of Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl" xml:lang="en-US">Proceeds From Stock Options Exercised Net Settled Satisfaction Of Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice_lbl" xml:lang="en-US">Proceeds from stock options exercised net settled in satisfaction of the exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price or options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding as of, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding as of, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options forfeited/canceled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding as of, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding as of, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Options forfeited/cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xml:lang="en-US">Schedule Of Operating Leased Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AustinMember" xlink:label="sava_AustinMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AustinMember" xlink:to="sava_AustinMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_AustinMember_lbl" xml:lang="en-US">Austin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_AustinMember_lbl" xml:lang="en-US">Austin [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_AustinMember_lbl" xml:lang="en-US">Austin, Texas [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US">Operating Leased Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US">Operating Leased Assets [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Rent expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanTable" xlink:label="sava_CashIncentiveBonusPlanTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTable" xlink:to="sava_CashIncentiveBonusPlanTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanTable_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanTable_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanLineItems" xlink:label="sava_CashIncentiveBonusPlanLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanLineItems" xlink:to="sava_CashIncentiveBonusPlanLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanLineItems_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanLineItems_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Line Items]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:to="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained_lbl" xml:lang="en-US">Minimum Number of Days Valuation Milestone must be achieved and maintained</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained_lbl" xml:lang="en-US">Minimum Number of Days Valuation Milestone must be achieved and maintained</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense" xlink:label="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense" xlink:to="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense_lbl" xml:lang="en-US">Minimum number of valuation milestones to recognize compensation expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense_lbl" xml:lang="en-US">Minimum number of valuation milestones to recognize compensation expense</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_NumberOfValuationMilestonesAchieved" xlink:label="sava_NumberOfValuationMilestonesAchieved"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NumberOfValuationMilestonesAchieved" xlink:to="sava_NumberOfValuationMilestonesAchieved_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_NumberOfValuationMilestonesAchieved_lbl" xml:lang="en-US">Number of Valuation Milestones Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_NumberOfValuationMilestonesAchieved_lbl" xml:lang="en-US">Number of Valuation Milestones Achieved</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PerformancePlanValuationAmount" xlink:label="sava_PerformancePlanValuationAmount"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanValuationAmount" xlink:to="sava_PerformancePlanValuationAmount_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PerformancePlanValuationAmount_lbl" xml:lang="en-US">Performance Plan Valuation Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PerformancePlanValuationAmount_lbl" xml:lang="en-US">Performance Plan Valuation Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PerformancePlanValuationAmount_lbl" xml:lang="en-US">Valuation milestone amount in market capitalization</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_lbl" xml:lang="en-US">Percentage of each cash bonus award associated with Valuation Milestone subject to adjustment and approval</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAward" xlink:to="sava_CashIncentiveBonusAward_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusAward_lbl" xml:lang="en-US">Cash Incentive Bonus Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusAward_lbl" xml:lang="en-US">Cash Incentive Bonus Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CashIncentiveBonusAward_lbl" xml:lang="en-US">Cash bonus award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xml:lang="en-US">Compensation expense</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PaymentsForCashIncentiveBonus" xlink:to="sava_PaymentsForCashIncentiveBonus_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_PaymentsForCashIncentiveBonus_lbl" xml:lang="en-US">Payments For Cash Incentive Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_PaymentsForCashIncentiveBonus_lbl" xml:lang="en-US">Payments For Cash Incentive Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_PaymentsForCashIncentiveBonus_lbl" xml:lang="en-US">Payments authorized or made to participants under the Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xml:lang="en-US">Putative class action lawsuits</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_NumberOfClassActionsConvertedToCase" xlink:label="sava_NumberOfClassActionsConvertedToCase"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NumberOfClassActionsConvertedToCase" xlink:to="sava_NumberOfClassActionsConvertedToCase_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_NumberOfClassActionsConvertedToCase_lbl" xml:lang="en-US">Number of class actions converted to case</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_NumberOfClassActionsConvertedToCase_lbl" xml:lang="en-US">Number of class actions converted to case</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Building And Building Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Site Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Tenant Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAcquiredInPlaceMember" xlink:to="us-gaap_LeasesAcquiredInPlaceMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAcquiredInPlaceMember_lbl" xml:lang="en-US">Leases Acquired In Place [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesAcquiredInPlaceMember_lbl" xml:lang="en-US">Lease-In-Place Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_TwoBuildingOfficeComplexAssetMember" xlink:label="sava_TwoBuildingOfficeComplexAssetMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_TwoBuildingOfficeComplexAssetMember" xlink:to="sava_TwoBuildingOfficeComplexAssetMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_TwoBuildingOfficeComplexAssetMember_lbl" xml:lang="en-US">Two-building office complex</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_TwoBuildingOfficeComplexAssetMember_lbl" xml:lang="en-US">Two Building Office Complex Asset [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_TwoBuildingOfficeComplexAssetMember_lbl" xml:lang="en-US">Two-building office complex [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture And Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction In Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction In Progress [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasingCommissionsAndOtherMember" xlink:to="sava_LeasingCommissionsAndOtherMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_LeasingCommissionsAndOtherMember_lbl" xml:lang="en-US">Leasing Commissions And Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_LeasingCommissionsAndOtherMember_lbl" xml:lang="en-US">Leasing Commissions And Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_LeasingCommissionsAndOtherMember_lbl" xml:lang="en-US">Leasing Commissions And Other [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_RegisteredDirectOffering2022Member" xlink:label="sava_RegisteredDirectOffering2022Member"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RegisteredDirectOffering2022Member" xlink:to="sava_RegisteredDirectOffering2022Member_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_RegisteredDirectOffering2022Member_lbl" xml:lang="en-US">Registered Direct Offering 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_RegisteredDirectOffering2022Member_lbl" xml:lang="en-US">Registered Direct Offering2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_RegisteredDirectOffering2022Member_lbl" xml:lang="en-US">Registered Direct Offering 2022 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_OperatingLeasesMember" xlink:label="sava_OperatingLeasesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_OperatingLeasesMember" xlink:to="sava_OperatingLeasesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_OperatingLeasesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_OperatingLeasesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_OperatingLeasesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanMember" xlink:to="sava_CashIncentiveBonusPlanMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_CashIncentiveBonusPlanMember_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_CashIncentiveBonusPlanMember_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_CashIncentiveBonusPlanMember_lbl" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" xlink:to="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_lbl" xml:lang="en-US">Exceeding Performance Milestones Minimum 20 Consecutive Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_lbl" xml:lang="en-US">Exceeding Performance Milestones Minimum20 Consecutive Days [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_lbl" xml:lang="en-US">Exceeding Performance Milestones Minimum 20 Consecutive Days [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_Exceeds5BillionMarketCapitalizationMember" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_Exceeds5BillionMarketCapitalizationMember" xlink:to="sava_Exceeds5BillionMarketCapitalizationMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_lbl" xml:lang="en-US">Exceeds 5 Billion Market Capitalization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_lbl" xml:lang="en-US">Exceeds5 Billion Market Capitalization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_lbl" xml:lang="en-US">Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_FirstValuationMilestoneMember" xlink:label="sava_FirstValuationMilestoneMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_FirstValuationMilestoneMember" xlink:to="sava_FirstValuationMilestoneMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_FirstValuationMilestoneMember_lbl" xml:lang="en-US">First Valuation Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_FirstValuationMilestoneMember_lbl" xml:lang="en-US">First Valuation Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_FirstValuationMilestoneMember_lbl" xml:lang="en-US">First Valuation Milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_SecondThroughEighthValuationMilestonesMember" xlink:label="sava_SecondThroughEighthValuationMilestonesMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_SecondThroughEighthValuationMilestonesMember" xlink:to="sava_SecondThroughEighthValuationMilestonesMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_lbl" xml:lang="en-US">Second Through Eighth Valuation Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_lbl" xml:lang="en-US">Second Through Eighth Valuation Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_lbl" xml:lang="en-US">Second Through Eighth Valuation Milestones [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_IndependentDirectorsMember" xlink:label="sava_IndependentDirectorsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IndependentDirectorsMember" xlink:to="sava_IndependentDirectorsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_IndependentDirectorsMember_lbl" xml:lang="en-US">Independent Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_IndependentDirectorsMember_lbl" xml:lang="en-US">Independent Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_IndependentDirectorsMember_lbl" xml:lang="en-US">Independent Directors [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember_lbl" xml:lang="en-US">violations of the federal securities laws</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember_lbl" xml:lang="en-US">Violations Of Federal Securities Laws [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember_lbl" xml:lang="en-US">Violations of the federal securities laws [Member]</label>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember"></loc>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsMember" xlink:to="sava_ShareholderDerivativeActionsMember_lbl"></labelArc>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="sava_ShareholderDerivativeActionsMember_lbl" xml:lang="en-US">Shareholder derivative actions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sava_ShareholderDerivativeActionsMember_lbl" xml:lang="en-US">Shareholder Derivative Actions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sava_ShareholderDerivativeActionsMember_lbl" xml:lang="en-US">Shareholder derivative actions [Member]</label></labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sava-20230331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created by Certent Disclosure Management 22.4.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/1/2023 8:19:42 AM-->
<!--Modified on: 5/1/2023 8:19:42 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureGeneralAndLiquidity" roleURI="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPolicies"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureRealProperty" roleURI="http://www.cassavasciences.com/role/DisclosureRealProperty"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIntangibleAssets" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssets"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureStockholdersEquityAndStockBasedCompensationExpense" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpense"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIncomeTaxes" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxes"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureCommitments" roleURI="http://www.cassavasciences.com/role/DisclosureCommitments"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#Disclosure2020CashIncentiveBonusPlan" roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureContingencies" roleURI="http://www.cassavasciences.com/role/DisclosureContingencies"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureSignificantAccountingPoliciesPolicy" roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureRealPropertyTables" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIntangibleAssetsTables" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureGeneralAndLiquidityNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureRealPropertyNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureRealPropertyComponentsOfOtherIncomeNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePropertyAndEquipmentNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails" roleURI="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureCommitmentsNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#Disclosure2020CashIncentiveBonusPlanNarrativeDetails" roleURI="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"></roleRef>
  <roleRef xlink:type="simple" xlink:href="sava-20230331.xsd#DisclosureContingenciesNarrativeDetails" roleURI="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"></roleRef>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638185259809677720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638185259809677720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638185259809697665"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638185259809697665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638185259809697665"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638185259809697665" order="3" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638185259809697665"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638185259809697665" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638185259809697665"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638185259809697665" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638185259809697665"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638185259809697665" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638185259809697665"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638185259809697665" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638185259809697665"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638185259809697665" order="8" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638185259809697665"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638185259809697665" order="9" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638185259809697665"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638185259809697665" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638185259809707638" order="11" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638185259809707638" order="12" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638185259809707638" order="13" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638185259809707638" order="14" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638185259809707638" order="15" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638185259809707638" order="16" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638185259809707638" order="17" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638185259809707638" order="18" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638185259809707638" order="19" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638185259809707638" order="20" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638185259809707638" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638185259809707638" order="22" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638185259809707638" order="23" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638185259809707638" order="24" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638185259809707638" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638185259809707638" order="26" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638185259809707638" order="27" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638185259809707638" order="28" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638185259809707638"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638185259809707638" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638185259809717611" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_638185259809717611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638185259809717611" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638185259809717611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638185259809717611" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638185259809717611" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638185259809717611" xlink:to="us-gaap_AssetsCurrent_638185259809717611" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638185259809717611" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638185259809717611" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638185259809717611" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets_638185259809717611" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638185259809717611" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638185259809717611" xlink:to="us-gaap_AccountsPayableCurrent_638185259809717611" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638185259809717611" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638185259809717611" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638185259809717611" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638185259809717611" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638185259809717611" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638185259809717611" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638185259809717611" xlink:to="us-gaap_OtherLiabilitiesCurrent_638185259809717611" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638185259809717611" xlink:to="us-gaap_LiabilitiesCurrent_638185259809717611" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638185259809717611" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638185259809717611" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638185259809717611" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638185259809717611" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities_638185259809717611" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies_638185259809717611" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638185259809717611"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_638185259809717611" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638185259809717611" xlink:to="us-gaap_PreferredStockValue_638185259809727585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638185259809717611" xlink:to="us-gaap_CommonStockValue_638185259809727585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638185259809717611" xlink:to="us-gaap_AdditionalPaidInCapital_638185259809727585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638185259809717611" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638185259809727585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638185259809717611" xlink:to="us-gaap_StockholdersEquity_638185259809727585" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638185259809727585" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638185259809727585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638185259809727585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638185259809727585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638185259809727585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638185259809727585" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638185259809727585" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638185259809727585" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638185259809727585"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638185259809727585" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements Of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638185259809747535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement" xlink:label="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638185259809747535" xlink:to="sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement_638185259809747535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638185259809747535" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638185259809747535" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638185259809747535" xlink:to="us-gaap_OperatingExpenses_638185259809747535" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638185259809747535" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome_638185259809747535" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638185259809747535" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638185259809747535" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638185259809747535" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638185259809747535" xlink:to="us-gaap_EarningsPerShareDiluted_638185259809747535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_638185259809747535" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638185259809747535" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638185259809747535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="5"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements Of Stockholders&apos; Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638185259809747535"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638185259809747535" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638185259809747535" xlink:to="us-gaap_StatementEquityComponentsAxis_638185259809757517" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638185259809757517" xlink:to="us-gaap_CommonStockMember_638185259809757517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638185259809757517" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638185259809757517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638185259809757517" xlink:to="us-gaap_RetainedEarningsMember_638185259809757517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638185259809757517" xlink:to="us-gaap_EquityComponentDomain_638185259809757517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638185259809747535" xlink:to="us-gaap_StatementLineItems_638185259809757517" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638185259809757517" xlink:to="us-gaap_StockholdersEquity_638185259809757517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638185259809757517" xlink:to="us-gaap_SharesIssued_638185259809757517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638185259809757517" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_638185259809757517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638185259809757517" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638185259809757517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638185259809757517" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638185259809757517" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638185259809757517" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638185259809757517" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638185259809757517" xlink:to="us-gaap_NetIncomeLoss_638185259809757517" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6381852598097575171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638185259809757517" xlink:to="us-gaap_StockholdersEquity_6381852598097575171" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_6381852598097575171"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638185259809757517" xlink:to="us-gaap_SharesIssued_6381852598097575171" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Condensed Consolidated Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_NetIncomeLoss_638185259809757517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_ShareBasedCompensation_638185259809757517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_Depreciation_638185259809757517" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638185259809757517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638185259809757517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638185259809757517" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638185259809757517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638185259809757517" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet_638185259809757517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638185259809757517" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638185259809757517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638185259809757517" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense_638185259809757517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638185259809757517" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638185259809757517" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638185259809757517" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_638185259809757517" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638185259809757517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638185259809757517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638185259809757517" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638185259809757517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638185259809757517" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638185259809757517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638185259809757517"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638185259809757517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638185259809767814" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638185259809757517" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638185259809767814" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638185259809767814" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638185259809767814" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381852598097678141"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381852598097678141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity" xlink:type="extended" xlink:title="10101 - Disclosure - General And Liquidity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10301 - Disclosure - Prepaid Expenses And Other Current Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="sava_PrepaidAndOtherAssetsDisclosureTextBlock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="sava_PrepaidAndOtherAssetsDisclosureTextBlock_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealProperty" xlink:type="extended" xlink:title="10401 - Disclosure - Real Property">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10501 - Disclosure - Property And Equipment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssets" xlink:type="extended" xlink:title="10601 - Disclosure - Intangible Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpense" xlink:type="extended" xlink:title="10701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="10901 - Disclosure - Commitments">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_638185259809767814"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_638185259809767814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan" xlink:type="extended" xlink:title="11001 - Disclosure - 2020 Cash Incentive Bonus Plan">
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanAbstract" xlink:label="sava_CashIncentiveBonusPlanAbstract"></loc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock_638185259809777749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureContingencies" xlink:type="extended" xlink:title="11101 - Disclosure - Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingencyDisclosures_638185259809777749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy" xlink:type="extended" xlink:title="20202 - Disclosure - Significant Accounting Policies (Policy)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638185259809777749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638185259809777749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638185259809777749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638185259809777749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ProceedsFromGrantsPolicyPolicyTextBlock" xlink:label="sava_ProceedsFromGrantsPolicyPolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_ProceedsFromGrantsPolicyPolicyTextBlock_638185259809777749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638185259809777749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638185259809777749" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638185259809777749" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock_638185259809777749" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638185259809777749" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638185259809777749" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638185259809777749" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_638185259809777749" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638185259809777749" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638185259809777749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Prepaid Expenses And Other Current Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390404728571071"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390404728571071" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_638185259809777749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyTables" xlink:type="extended" xlink:title="30403 - Disclosure - Real Property (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_637709203959354913"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_637709203959354913" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_638185259809777749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30503 - Disclosure - Property And Equipment (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637708885067040668"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638185259809777749"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637708885067040668" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638185259809777749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Intangible Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709277228814078"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709277228814078" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709277228814078" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638185259809787720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_StockOptionAndPerformanceAwardActivity" xlink:label="sava_StockOptionAndPerformanceAwardActivity_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="sava_StockOptionAndPerformanceAwardActivity_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638185259809787720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - General And Liquidity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"></loc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_SignificantAccountingPoliciesTable" xlink:label="sava_SignificantAccountingPoliciesTable_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sava_SignificantAccountingPoliciesTable_638185259809787720" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesTable_638185259809787720" xlink:to="us-gaap_AwardTypeAxis_638185259809787720" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638185259809787720" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809787720" xlink:to="us-gaap_EmployeeStockOptionMember_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809787720" xlink:to="us-gaap_RestrictedStockMember_638185259809787720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesTable_638185259809787720" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809787720" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809787720" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809787720" xlink:to="us-gaap_BuildingMember_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809787720" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638185259809787720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809787720" xlink:to="us-gaap_LeaseholdImprovementsMember_638185259809787720" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesTable_638185259809787720" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638185259809787720" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638185259809787720" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638185259809787720" xlink:to="us-gaap_LeasesAcquiredInPlaceMember_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_SignificantAccountingPoliciesLineItems" xlink:label="sava_SignificantAccountingPoliciesLineItems_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesTable_638185259809787720" xlink:to="sava_SignificantAccountingPoliciesLineItems_638185259809787720" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ReductionToResearchAndDevelopmentExpense" xlink:label="sava_ReductionToResearchAndDevelopmentExpense_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638185259809787720" xlink:to="sava_ReductionToResearchAndDevelopmentExpense_638185259809787720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638185259809787720" xlink:to="us-gaap_NumberOfOperatingSegments_638185259809787720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638185259809787720" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638185259809787720" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638185259809787720" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638185259809787720" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638185259809787720" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638185259809787720" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638185259809787720"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_SignificantAccountingPoliciesLineItems_638185259809787720" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638185259809787720" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_635240128367044116"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_635240128367044116" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638185259809797719" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638185259809797719" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638185259809797719" order="1" use="optional" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638185259809797719" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638185259809797719" xlink:to="us-gaap_EmployeeStockOptionMember_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638185259809797719" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638185259809797719" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638185259809797719" xlink:to="us-gaap_NetIncomeLossAbstract_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638185259809797719" xlink:to="us-gaap_NetIncomeLoss_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638185259809797719" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_638185259809797719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_638185259809797719" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638185259809797719" xlink:to="us-gaap_EarningsPerShareDiluted_638185259809797719" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638185259809797719" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638185259809797719" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622" xlink:to="us-gaap_PrepaidInsurance_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622" xlink:to="us-gaap_DepositContractsAssets_638185259809797719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638185259809797719" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_637390406778822622" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638185259809797719" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Real Property (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_637709232385376924"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_637709232385376924" xlink:to="us-gaap_AssetAcquisitionTable_638185259809797719" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638185259809797719" xlink:to="srt_StatementGeographicalAxis_638185259809797719" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638185259809797719" xlink:to="srt_SegmentGeographicalDomain_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AustinMember" xlink:label="sava_AustinMember_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638185259809797719" xlink:to="sava_AustinMember_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638185259809797719" xlink:to="us-gaap_AssetAcquisitionAxis_638185259809797719" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638185259809797719" xlink:to="us-gaap_AssetAcquisitionDomain_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_TwoBuildingOfficeComplexAssetMember" xlink:label="sava_TwoBuildingOfficeComplexAssetMember_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638185259809797719" xlink:to="sava_TwoBuildingOfficeComplexAssetMember_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638185259809797719" xlink:to="us-gaap_AssetAcquisitionLineItems_638185259809797719" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638185259809797719" xlink:to="sava_PercentageOfOccupancy_638185259809797719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PercentageOfCurrentlyLeased" xlink:label="sava_PercentageOfCurrentlyLeased_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638185259809797719" xlink:to="sava_PercentageOfCurrentlyLeased_638185259809797719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638185259809797719" xlink:to="us-gaap_NetRentableArea_638185259809797719" order="3" use="optional" priority="2"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Real Property (Components Of Other Income, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_637709261558608168"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638185259809797719"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_637709261558608168" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638185259809797719" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638185259809797719" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809807668" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809807668" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668" xlink:to="us-gaap_BuildingMember_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638185259809797719" xlink:to="srt_StatementGeographicalAxis_638185259809807668" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638185259809807668" xlink:to="srt_SegmentGeographicalDomain_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AustinMember" xlink:label="sava_AustinMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638185259809807668" xlink:to="sava_AustinMember_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638185259809797719" xlink:to="us-gaap_BusinessAcquisitionLineItems_638185259809807668" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638185259809807668" xlink:to="us-gaap_OtherNonoperatingIncome_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638185259809807668" xlink:to="us-gaap_OtherNonoperatingExpense_638185259809807668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="8"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638185259809807668" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638185259809807668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property And Equipment (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637708886452535935"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637708886452535935" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638185259809807668" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638185259809807668" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809807668" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809807668" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668" xlink:to="us-gaap_LandMember_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668" xlink:to="us-gaap_BuildingMember_638185259809807668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638185259809807668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668" xlink:to="us-gaap_LeaseholdImprovementsMember_638185259809807668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668" xlink:to="us-gaap_FurnitureAndFixturesMember_638185259809807668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809807668" xlink:to="us-gaap_ConstructionInProgressMember_638185259809807668" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638185259809807668" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638185259809807668" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638185259809807668" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638185259809807668" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638185259809807668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638185259809807668" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638185259809807668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Intangible Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709278730154570"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637709278730154570" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638185259809807668" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638185259809807668" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638185259809807668" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638185259809807668" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638185259809807668" xlink:to="us-gaap_LeasesAcquiredInPlaceMember_638185259809807668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember_638185259809807668"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638185259809807668" xlink:to="sava_LeasingCommissionsAndOtherMember_638185259809807668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638185259809807668" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638185259809817660" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638185259809817660" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638185259809817660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638185259809817660" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638185259809817660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638185259809817660" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638185259809817660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_638185259809817660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638185259809817660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638185259809817660" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637720627070870562" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638185259809817660" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809817660" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809817660" xlink:to="us-gaap_StatementClassOfStockAxis_638185259809817660" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638185259809817660" xlink:to="us-gaap_ClassOfStockDomain_638185259809817660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638185259809817660" xlink:to="us-gaap_CommonStockMember_638185259809817660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809817660" xlink:to="us-gaap_AwardTypeAxis_638185259809817660" order="2" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638185259809817660" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809817660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809817660" xlink:to="us-gaap_EmployeeStockOptionMember_638185259809817660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809817660" xlink:to="us-gaap_PerformanceSharesMember_638185259809817660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638185259809817660"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809817660" xlink:to="us-gaap_PlanNameAxis_638185259809817660" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638185259809817660" xlink:to="us-gaap_PlanNameDomain_638185259809827329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_RegisteredDirectOffering2022Member" xlink:label="sava_RegisteredDirectOffering2022Member_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638185259809827329" xlink:to="sava_RegisteredDirectOffering2022Member_638185259809827329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AtMarketEquityProgramMember" xlink:label="sava_AtMarketEquityProgramMember_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638185259809827329" xlink:to="sava_AtMarketEquityProgramMember_638185259809827329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_StockOptionAndPerformanceAwardActivity2020PlanMember" xlink:label="sava_StockOptionAndPerformanceAwardActivity2020PlanMember_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638185259809827329" xlink:to="sava_StockOptionAndPerformanceAwardActivity2020PlanMember_638185259809827329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="sava_TwoThousandEighteenEquityIncentivePlanMember_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638185259809827329" xlink:to="sava_TwoThousandEighteenEquityIncentivePlanMember_638185259809827329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809817660" xlink:to="srt_RangeAxis_638185259809827329" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638185259809827329" xlink:to="srt_RangeMember_638185259809827329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638185259809827329" xlink:to="srt_MaximumMember_638185259809827329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809817660" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" order="5" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638185259809827329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638185259809827329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_638185259809827329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638185259809827329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_SaleOfStockPricePerShare_638185259809827329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638185259809827329" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice_638185259809827329" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice_638185259809827329" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638185259809827329" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638185259809827329" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638185259809827329" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638185259809827329" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638185259809827329" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638185259809827329"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809827329" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638185259809827329" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Stock Options And Unvested Performance Award Outstanding Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638185259809837503" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638185259809837503" xlink:to="us-gaap_AwardTypeAxis_638185259809837503" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809837503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809837503" xlink:to="us-gaap_EmployeeStockOptionMember_638185259809837503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638185259809837503" xlink:to="us-gaap_PerformanceSharesMember_638185259809837503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" order="2" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638185259809837503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638185259809837503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638185259809837503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638185259809837503" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381852598098375031"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381852598098375031" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638185259809837503" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638185259809837503" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638185259809837503" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638185259809837503" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381852598098375031"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638185259809837503" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381852598098375031" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Stockholders&apos; Equity And Stock-Based Compensation Expense (Stock-Based Compensation Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809837503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809837503" xlink:to="us-gaap_IncomeStatementLocationAxis_638185259809837503" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638185259809837503" xlink:to="us-gaap_IncomeStatementLocationDomain_638185259809837503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638185259809837503" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638185259809837503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638185259809837503" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638185259809837503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638185259809837503" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809837503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638185259809837503" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638185259809837503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638185259809837503"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638185259809837503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable_638185259809847269" xlink:to="srt_StatementGeographicalAxis_638185259809847269" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638185259809847269" xlink:to="srt_SegmentGeographicalDomain_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_AustinMember" xlink:label="sava_AustinMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638185259809847269" xlink:to="sava_AustinMember_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable_638185259809847269" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809847269" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638185259809847269" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638185259809847269" xlink:to="us-gaap_BuildingMember_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable_638185259809847269" xlink:to="us-gaap_LeaseContractualTermAxis_638185259809847269" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638185259809847269" xlink:to="us-gaap_LeaseContractualTermDomain_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_OperatingLeasesMember" xlink:label="sava_OperatingLeasesMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638185259809847269" xlink:to="sava_OperatingLeasesMember_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable_638185259809847269" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_638185259809847269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems_638185259809847269" xlink:to="us-gaap_NetRentableArea_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems_638185259809847269" xlink:to="us-gaap_LeaseExpirationDate1_638185259809847269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems_638185259809847269" xlink:to="us-gaap_OperatingLeaseExpense_638185259809847269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems_638185259809847269" xlink:to="us-gaap_OperatingLeasePayments_638185259809847269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanAbstract" xlink:label="sava_CashIncentiveBonusPlanAbstract_637399223356820786"></loc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanTable" xlink:label="sava_CashIncentiveBonusPlanTable_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanAbstract_637399223356820786" xlink:to="sava_CashIncentiveBonusPlanTable_638185259809847269" order="1" use="optional" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638185259809847269" xlink:to="srt_RangeAxis_638185259809847269" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638185259809847269" xlink:to="srt_RangeMember_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638185259809847269" xlink:to="srt_MinimumMember_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638185259809847269" xlink:to="srt_MaximumMember_638185259809847269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638185259809847269" xlink:to="us-gaap_PlanNameAxis_638185259809847269" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638185259809847269" xlink:to="us-gaap_PlanNameDomain_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638185259809847269" xlink:to="sava_CashIncentiveBonusPlanMember_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638185259809847269" xlink:to="srt_StatementScenarioAxis_638185259809847269" order="3" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638185259809847269" xlink:to="srt_ScenarioUnspecifiedDomain_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember" xlink:label="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638185259809847269" xlink:to="sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_638185259809847269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_Exceeds5BillionMarketCapitalizationMember" xlink:label="sava_Exceeds5BillionMarketCapitalizationMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638185259809847269" xlink:to="sava_Exceeds5BillionMarketCapitalizationMember_638185259809847269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_FirstValuationMilestoneMember" xlink:label="sava_FirstValuationMilestoneMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638185259809847269" xlink:to="sava_FirstValuationMilestoneMember_638185259809847269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_SecondThroughEighthValuationMilestonesMember" xlink:label="sava_SecondThroughEighthValuationMilestonesMember_638185259809847269"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638185259809847269" xlink:to="sava_SecondThroughEighthValuationMilestonesMember_638185259809847269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638185259809847269" xlink:to="us-gaap_SubsequentEventTypeAxis_638185259809857249" order="4" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638185259809857249" xlink:to="us-gaap_SubsequentEventTypeDomain_638185259809857249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638185259809857249" xlink:to="us-gaap_SubsequentEventMember_638185259809857249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638185259809847269" xlink:to="srt_TitleOfIndividualAxis_638185259809857249" order="5" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638185259809857249" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638185259809857249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_IndependentDirectorsMember" xlink:label="sava_IndependentDirectorsMember_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638185259809857249" xlink:to="sava_IndependentDirectorsMember_638185259809857249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusPlanLineItems" xlink:label="sava_CashIncentiveBonusPlanLineItems_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanTable_638185259809847269" xlink:to="sava_CashIncentiveBonusPlanLineItems_638185259809857249" order="6" use="optional"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638185259809857249" xlink:to="sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained_638185259809857249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense" xlink:label="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638185259809857249" xlink:to="sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense_638185259809857249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_NumberOfValuationMilestonesAchieved" xlink:label="sava_NumberOfValuationMilestonesAchieved_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638185259809857249" xlink:to="sava_NumberOfValuationMilestonesAchieved_638185259809857249" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PerformancePlanValuationAmount" xlink:label="sava_PerformancePlanValuationAmount_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638185259809857249" xlink:to="sava_PerformancePlanValuationAmount_638185259809857249" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638185259809857249" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment_638185259809857249" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638185259809857249" xlink:to="sava_CashIncentiveBonusAward_638185259809857249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638185259809857249" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_638185259809857249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_CashIncentiveBonusPlanLineItems_638185259809857249" xlink:to="sava_PaymentsForCashIncentiveBonus_638185259809857249" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"></presentationArc></presentationLink>
  <presentationLink xlink:role="http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAbstract" xlink:label="us-gaap_LossContingencyAbstract"></loc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyAbstract" xlink:to="us-gaap_LossContingenciesTable_638185259809857249" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638185259809857249" xlink:to="srt_LitigationCaseAxis_638185259809857249" order="1" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638185259809857249" xlink:to="srt_LitigationCaseTypeDomain_638185259809857249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638185259809857249" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember_638185259809857249" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638185259809857249" xlink:to="sava_ShareholderDerivativeActionsMember_638185259809857249" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638185259809857249"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638185259809857249" xlink:to="us-gaap_LossContingenciesLineItems_638185259809857249" order="2" use="optional" priority="2"></presentationArc>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_638185259809867455"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638185259809857249" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_638185259809867455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"></presentationArc>
    <loc xlink:type="locator" xlink:href="sava-20230331.xsd#sava_NumberOfClassActionsConvertedToCase" xlink:label="sava_NumberOfClassActionsConvertedToCase_638185259809867455"></loc>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638185259809857249" xlink:to="sava_NumberOfClassActionsConvertedToCase_638185259809867455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2"></presentationArc></presentationLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843506948160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-29959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cassava Sciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1911336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6801 N. Capital of Texas Highway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 1; Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-2444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,749,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001069530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843502390640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 187,467<span></span>
</td>
<td class="nump">$ 201,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,532<span></span>
</td>
<td class="nump">10,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">194,999<span></span>
</td>
<td class="nump">211,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,609<span></span>
</td>
<td class="nump">22,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">218,111<span></span>
</td>
<td class="nump">234,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">8,242<span></span>
</td>
<td class="nump">4,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued development expense</a></td>
<td class="nump">5,276<span></span>
</td>
<td class="nump">2,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,909<span></span>
</td>
<td class="nump">7,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,106<span></span>
</td>
<td class="nump">7,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 10, 11 and 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 120,000,000 shares authorized; 41,749,435 and 41,735,557 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">511,786<span></span>
</td>
<td class="nump">511,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(307,823)<span></span>
</td>
<td class="num">(283,552)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">204,005<span></span>
</td>
<td class="nump">227,539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 218,111<span></span>
</td>
<td class="nump">$ 234,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843507407536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">41,749,435<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">41,749,435<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843504954368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement', window );">Research and development, net of grant reimbursement</a></td>
<td class="nump">$ 22,120<span></span>
</td>
<td class="nump">$ 14,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,392<span></span>
</td>
<td class="nump">2,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">26,512<span></span>
</td>
<td class="nump">17,821<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(26,512)<span></span>
</td>
<td class="num">(17,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">2,051<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,271)<span></span>
</td>
<td class="num">$ (17,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, Diluted</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Weighted-average shares used in computing net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share, diluted</a></td>
<td class="nump">41,739<span></span>
</td>
<td class="nump">39,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Net Of Grant Reimbursement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843502341008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 461,181,000<span></span>
</td>
<td class="num">$ (207,306,000)<span></span>
</td>
<td class="nump">$ 253,915,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">40,016,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Stock options for employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock options for non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options, shares</a></td>
<td class="nump">14,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,527,000)<span></span>
</td>
<td class="num">(17,527,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">461,887,000<span></span>
</td>
<td class="num">(224,833,000)<span></span>
</td>
<td class="nump">237,094,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2022</a></td>
<td class="nump">40,031,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">511,049,000<span></span>
</td>
<td class="num">(283,552,000)<span></span>
</td>
<td class="nump">227,539,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="nump">41,735,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Stock options for employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock options for non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="nump">$ 13,878<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,271,000)<span></span>
</td>
<td class="num">(24,271,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">$ 511,786,000<span></span>
</td>
<td class="num">$ (307,823,000)<span></span>
</td>
<td class="nump">$ 204,005,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2023</a></td>
<td class="nump">41,749,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843502188432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,271,000)<span></span>
</td>
<td class="num">$ (17,527,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">673,000<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">272,000<span></span>
</td>
<td class="nump">178,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">119,000<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">2,679,000<span></span>
</td>
<td class="num">(1,063,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="num">(17,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">4,565,000<span></span>
</td>
<td class="num">(3,794,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInDevelopmentExpense', window );">Accrued development expense</a></td>
<td class="nump">2,996,000<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="num">(1,705,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(313,000)<span></span>
</td>
<td class="num">(370,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,255,000)<span></span>
</td>
<td class="num">(23,530,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(357,000)<span></span>
</td>
<td class="num">(425,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(357,000)<span></span>
</td>
<td class="num">(425,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(13,548,000)<span></span>
</td>
<td class="num">(23,744,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">201,015,000<span></span>
</td>
<td class="nump">233,437,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 187,467,000<span></span>
</td>
<td class="nump">$ 209,693,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in development expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509492384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General And Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">General And Liquidity</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 1.  General and Liquidity</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discover and develop proprietary pharmaceutical product candidates that may offer significant improvements to patients and healthcare professionals. The Company generally focuses its discovery and product development efforts on disorders of the nervous system. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions to the Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All intercompany transactions and balances have been eliminated in consolidation.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for any other interim period or for the year 2023</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Liquidity</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">307.8</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million at March 31, 2023. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company may seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are no assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next 12 months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843504948272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 2.&#160;&#160;Significant Accounting Policies</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and assumptions.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cash and Cash Equivalents and Concentration of Credit Risk</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at one financial institution. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value Measurements </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 1 includes quoted prices in active markets.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company does not have any financial instruments where the fair value is based on Level 2 inputs.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any financial instruments where the fair value is based on Level 3 inputs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at March 31, 2023 and December 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Business Segments</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">one</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> business segment: the development of novel drugs and diagnostics.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Proceeds from Grants</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended March 31, 2023,&#160;there were </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three months ended March 31, 2022</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, the Company received reimbursements totaling $</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.1</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million pursuant to NIH research grants. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records the proceeds from these grants as reductions to its research and development expenses.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </span><span id="_cp_text_1_372" style="text-decoration: none;"/><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Net Loss per Share </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">method. Potential dilutive common shares consist of outstanding common stock options.&#160;&#160;There is no difference between the Company&#8217;s net loss and comprehensive loss. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerator:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,271</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,527</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denominator:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41,739</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,962</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.58</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.44</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Dilutive common stock options excluded from net loss per share, diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,034</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,086</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">dilutive. The Company also excluded </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">57,143</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted stock awards from the calculation of net loss per share, diluted, until their expiration in June 2022 because the effect of including restricted stock awards would have been anti</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">dilutive.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160; &#160; </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Research Contract Costs and Accruals </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have not been materially different from actual costs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Incentive Bonus Plan</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#8220;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note 10 for further discussion of the Plan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Leases</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Property and equipment</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years and approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.1</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Intangible assets</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years at March 31, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to be impaired, an impairment loss is recognized.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Income Taxes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">condensed</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843502324352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses And Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 3.  Prepaid Expenses and </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Other Current Assets</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid expenses and other current assets at March 31, 2023 and December 31, 2022 consisted of the following (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid insurance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">439</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">874</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contract research organization and other deposits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,816</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,177</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">277</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">160</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total prepaid expenses and other current assets</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,532</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,211</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">       Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid And Other Assets Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843520236304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Real Property<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Real Property [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Real Property</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 4. Real Property</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company owns a two-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#8217;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are being outsourced to professional real-estate managers. The office complex measures approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">90,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> rentable square feet. At March 31, 2023, the property was over </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">60</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% leased. The Company also occupies approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">25</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the property.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records the net income from building operations and leases as other income, net, as leasing is not core to the Company&#8217;s operations. Building depreciation and amortization for space not occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">557</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">573</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property operating expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">367</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">310</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Other income, net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">263</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843511626832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property And Equipment</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 5.  Property and equipment</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of property and equipment, net, as of March 31, 2023&#160;and&#160;December 31, 2022&#160;were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Land</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Buildings</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Site improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">470</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">470</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tenant improvements</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,016</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,016</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">868</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">851</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Construction in progress</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,081</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,064</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated depreciation</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,472</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,200</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Property and equipment, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22,609</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22,864</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Depreciation expense for property and equipment was&#160;$</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">272,000</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;and&#160;$</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">178,000</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;for the three months ended&#160;March 31, 2023&#160;and 2022, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509702512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 6.  Intangible assets</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The components of intangible assets, net, as of March 31, 2023&#160;and&#160;December 31, 2022&#160;were as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease-in-place agreements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasing commissions and other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">290</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">290</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,343</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,343</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated amortization</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">840</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">721</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Intangible assets, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">503</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">622</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization expense for intangible assets was&#160;$</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">119,000</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">135,000</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> for the three months ended&#160;March 31, 2023 and 2022, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Amortization expense for finite-lived intangible assets as of March 31, 2023 is expected to be as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">For the year ending December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">332</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">167</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total amortization</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">503</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843508884176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders&#8217; Equity And Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stockholders' Equity And Stock-Based Compensation Expense</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;">Note 7.  Stockholders&#8217; Equity and Stock-Based Compensation Expense</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2022 Registered Direct Offering</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November&#160;22, 2022, the Company completed a common stock offering pursuant to which certain investors purchased </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,666,667</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock at a price of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">30.00</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share. Net proceeds of the offering were approximately $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">47.3</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million after deducting offering expenses.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">At-the-Market Common Stock Offering </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In March 2020, the Company established an at-the-market offering program (&#8220;2020 Program&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">in transactions pursuant to a shelf registration statement that was declared effective by the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> on May 5, 2020</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company gave notice of termination for the 2020 Program on April 26, 2023, which is effective May 1, 2023. There were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> common stock sales under the 2020 Program through its termination. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock Option and Performance Award Activity in 2023</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023, stock options and unvested Performance Awards outstanding under the Company&#8217;s stock option plans changed as follows:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock Options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Performance Awards</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,529,448</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,142</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-dd238c04-f83e-48b9-bb8b-2c297a0680b7;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-05eb815c-fd10-48c9-8d79-99d6ee0a77d4;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,017</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a22d958c-bef2-4f73-8328-e8bfeb74d56d;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-4c45888e-635f-47a9-8d16-d034a6483bd4;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-b786222f-0c6a-455c-9a63-3cd0d3ae33f5;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of March 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,510,431</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,142</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The weighted average exercise price of options outstanding at </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023 was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">12.15</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. As outstanding options vest over the current remaining vesting period of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2.3</span><span style="white-space:pre-wrap; color: #FF0000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">years, the Company expects to recognize stock-based </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">compensation expense of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million. If and when outstanding Performance Awards vest, the Company will recognize stock-based compensation expense of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.1</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million over the implicit service period.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023, there were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,017</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options exercised. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Of the stock options exercised, </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,139</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options were net settled in satisfaction of the exercise price, with </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> cash proceeds received. Cash proceeds</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to the Company </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">for options not net settled</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> totaled $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">64,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> during the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended March 31, 2022, there were </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,609</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options exercised. Of the stock options exercised, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,121</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> stock options were net settled in satisfaction of the exercise price, with </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> cash proceeds received. Cash proceeds to the Company for options not net settled totaled $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">211,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> during the three months ended March 31, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock-based Compensation Expense in 2023</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.21in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three and nine months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023 and 2022, the Company&#8217;s stock-based compensation expense was as follows (in thousands):</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">389</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">422</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">284</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">673</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">495</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">2018 Equity Incentive Plan </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or a designated committee of the Board is responsible for administration of the Company&#8217;s 2018 Omnibus Incentive Plan, as amended (the &#8220;2018 Plan&#8221;) and determines the terms and conditions of each option granted, consistent with the terms of the 2018 Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the 2018 Plan, including grants of stock options and Performance Awards. Share-based awards generally expire </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years from the date of grant. The 2018 Plan, as amended on May 5, 2022, provides for issuance of up to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5,000,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> shares of common stock, par value $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.001</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per share, subject to adjustment as provided in the 2018 Plan. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279; </span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses&#160;its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509676576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 8.  Income Taxes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company did </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t provide for income taxes during the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, because it has projected a net loss for the full year 2023 </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">for which any benefit will be offset by an increase in the valuation allowance</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. There was also </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> provision for income taxes for the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">,</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 2022.</span></p><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509509152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 9.  </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Commitments</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Right-of-use Asset and Liability</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company had an operating lease for approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> square feet of office space in Austin, Texas with an expiration of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">April 30, 2024</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The Company and the landlord consented to early terminate this lease on February 22, 2023 with no continuing obligations.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Rent expense for the </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three months ended&#160;</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023&#160;and 2022&#160;totaled $</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,000</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41,000</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash paid for operating lease liabilities during the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023 and 2022 totaled $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41,000</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Other Commitments</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.</span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509514640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2020 Cash Incentive Bonus Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanAbstract', window );"><strong>2020 Cash Incentive Bonus Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanTextBlock', window );">2020 Cash Incentive Bonus Plan</a></td>
<td class="text"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note&#160;10.&#160; 2020 Cash Incentive Bonus Plan</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In August 2020, the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has not occurred&#160;as of </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March 31</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of December 31, 2022, the Company&#8217;s independent directors were participants in the Plan. However, effective March 16, 2023, the Board of Directors amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the Plan were completely forfeited to the Company and will not be allocated to any other participant under the Plan. The Company&#8217;s independent directors have </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">t received, and as a result of such amendment will never receive, any payments under the Plan.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company&#8217;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (1) the closing price&#160;of one share&#160;of the Company&#8217;s common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (2) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;This constitutes a market condition under applicable accounting guidance.&#160; &#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">200</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million and&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for no less than </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">67</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;not awarded by the Compensation Committee&#160;are&#160;no longer available for distribution.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If the Company were to exceed a $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">111.4</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">289.7</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(1)&#160;the Company completes a Merger Transaction, or&#160;(2)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which may ever occur. Accordingly, there can be no assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">14</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In October 2020, the Company&#160;achieved&#160;the first&#160;Valuation&#160;Milestone.&#160;Subsequently, the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.5</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million&#160;in total&#160;for&#160;all Plan participants (after the March 2023 Plan amendment), subject to future satisfaction of a Performance Condition.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the year ended December&#160;31, 2021, the Company achieved </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">74.9</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million up to a hypothetical maximum of $</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">202.3</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million (after the March 2023 Plan amendment), to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;compensation expense was recorded&#160;since no&#160;grant date has occurred and no&#160;Performance Conditions are considered probable of being met.&#160;There is no continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No Valuation Milestones were achieved during 2022 or the three months ended </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">March</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> 31, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> actual cash payments were authorized or made to participants under the Plan through May 1, 2023.</span></p><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>2020 Cash Incentive Bonus Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Incentive Bonus Plan [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509576816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Note 11. Contingencies</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">From time to time, the Company may become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">and Citizen Petitions submitted to FDA, and may receive inquiries from government authorities relating to matters arising from the ordinary course of business</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to the Company. No information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, no accrual for these matters has been recorded within the condensed consolidated financial statements.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Government Investigations</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 15, 2021, the Company disclosed that certain government agencies had asked it to provide them with corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and will continue to cooperate with government authorities. No government agency has informed the Company that it has found evidence of research misconduct. No government agency has informed the Company that any wrongdoing has occurred by any party. No government agency has filed any charges against the Company, or anyone associated with it. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency may pursue an enforcement action against the Company or others.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Securities Class Actions and Shareholder Derivative Actions</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Between August 27, 2021 and October 26, 2021, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On June 30, 2022, a federal judge consolidated the </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> class action lawsuits into </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">one</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of the Company&#8217;s securities between September 14, 2020 and July 26, 2022. Briefing on defendants&#8217; motion to dismiss was completed on January 23, 2023</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and an argument on defendants&#8217; motion was held </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">on April 26, 2023</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> The Company believes the claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s board of directors. This complaint relies on the allegations made in Citizen Petitions that were submitted to </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(and subsequently denied by) </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since November 4, 2021, </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, and one in Texas state court (Travis County District Court). </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All four actions have</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> been stayed pending the resolution of the motions to dismiss in the securities class actions. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July 5, 2022, the three federal court actions were consolidated into a single action.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s board of directors. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the 2020 Cash Incentive Bonus Plan in August 2020. The complaints seek unspecified compensatory damages and other relief. On </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">January 6, 2023, the plaintiffs filed an amended complaint. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Defendants filed a partial answer to the amended complaint on March 10, 2023, and moved to partially dismiss the amended complaint on March 14, 2023. Defendants&#8217; motion to dismiss remains pending. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Although the plaintiffs in this derivative case do</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2127163<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2127197<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843435303840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policy)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use Of Estimates</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> and assumptions.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash And Cash Equivalents And Concentration Of Credit Risk</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Cash and Cash Equivalents and Concentration of Credit Risk</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at one financial institution. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value Measurements </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 1 includes quoted prices in active markets.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company does not have any financial instruments where the fair value is based on Level 2 inputs.</span></p><p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"><span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;">&#61623;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any financial instruments where the fair value is based on Level 3 inputs.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at March 31, 2023 and December 31, 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Business Segments</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Business Segments</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">one</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> business segment: the development of novel drugs and diagnostics.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ProceedsFromGrantsPolicyPolicyTextBlock', window );">Proceeds From Grants</a></td>
<td class="text"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Proceeds from Grants</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the three months ended March 31, 2023,&#160;there were </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. </span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">During the </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">three months ended March 31, 2022</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, the Company received reimbursements totaling $</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.1</span><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;million pursuant to NIH research grants. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company records the proceeds from these grants as reductions to its research and development expenses.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each </span><span id="_cp_text_1_372" style="text-decoration: none;"/><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">four years</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">.</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Net Loss per Share </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#65279;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">method. Potential dilutive common shares consist of outstanding common stock options.&#160;&#160;There is no difference between the Company&#8217;s net loss and comprehensive loss. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerator:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,271</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,527</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denominator:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41,739</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,962</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.58</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.44</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Dilutive common stock options excluded from net loss per share, diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,034</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,086</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">dilutive. The Company also excluded </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">57,143</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> restricted stock awards from the calculation of net loss per share, diluted, until their expiration in June 2022 because the effect of including restricted stock awards would have been anti</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">-</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">dilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Of Financial Instruments</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Fair Value of Financial Instruments</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160; &#160; </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock', window );">Research Contract Costs And Accruals</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Research Contract Costs and Accruals </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have not been materially different from actual costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Incentive Bonus Plan</a></td>
<td class="text"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Incentive Bonus Plan</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#8220;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Stock-based Compensation</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note 10 for further discussion of the Plan.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Leases</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property And Equipment</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Property and equipment</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years and approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.1</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Intangible assets</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years at March 31, 2023.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> to be impaired, an impairment loss is recognized.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Income Taxes</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">&#160;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company accounts for uncertain tax positions in accordance with ASC 740, &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">condensed</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ProceedsFromGrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Grants Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ProceedsFromGrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Contract Costs And Accruals Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509541504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Numerator:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,271</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">17,527</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Denominator:</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Shares used in computing net loss per share, basic and diluted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">41,739</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,962</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Net loss per share, basic and diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.58</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">0.44</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> Dilutive common stock options excluded from net loss per share, diluted</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,034</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,086</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509570960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses And Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule Of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Prepaid insurance</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">439</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">874</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Contract research organization and other deposits</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6,816</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">9,177</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Other</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">277</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">160</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Total prepaid expenses and other current assets</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,532</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10,211</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843506142416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Real Property (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Real Property [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Components Of Other Income, Net</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease revenue</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">557</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">573</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Property operating expenses</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">367</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">310</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Other income, net</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">190</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">263</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509715760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components Of Property And Equipment, Net</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Land</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,734</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Buildings</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15,980</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Site improvements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">470</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">470</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Tenant improvements</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,016</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,016</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Furniture and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">868</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">851</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Construction in progress</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross property and equipment</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,081</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">24,064</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated depreciation</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,472</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,200</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Property and equipment, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22,609</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">22,864</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843508659088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Components Of Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">December 31,</span><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"><br/>&#8206;</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Lease-in-place agreements</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,053</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Leasing commissions and other</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">290</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">290</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Gross intangible assets</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,343</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1,343</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Accumulated amortization</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">840</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">721</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">  Intangible assets, net</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">503</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">622</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Amortization Expense For Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;">For the year ending December 31,</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">332</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">167</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2025</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total amortization</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">503</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"><p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509532272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders&#8217; Equity And Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockOptionAndPerformanceAwardActivity', window );">Stock Options And Unvested Performance Award Outstanding Activity</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Stock Options</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Performance Awards</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of December 31, 2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,529,448</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,142</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options granted</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-dd238c04-f83e-48b9-bb8b-2c297a0680b7;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-05eb815c-fd10-48c9-8d79-99d6ee0a77d4;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options exercised</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">19,017</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a22d958c-bef2-4f73-8328-e8bfeb74d56d;">&#8212;</span></span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Options forfeited/canceled</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-4c45888e-635f-47a9-8d16-d034a6483bd4;">&#8212;</span></span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"><span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-b786222f-0c6a-455c-9a63-3cd0d3ae33f5;">&#8212;</span></span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Outstanding as of March 31, 2023</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2,510,431</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,142</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Three months ended</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">March 31,</span></p></td></tr><tr><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2023</span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">2022</span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Research and development</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">389</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">422</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">General and administrative</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">284</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">73</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total stock-based compensation expense</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">673</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">495</span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">&#160;</span></p></td></tr><tr><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"><p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockOptionAndPerformanceAwardActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options and perfromance award activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockOptionAndPerformanceAwardActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509553824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General And Liquidity (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General And Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 307,823<span></span>
</td>
<td class="nump">$ 283,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843507131328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ReductionToResearchAndDevelopmentExpense', window );">Reimbursement from National Institutes of Health research grants | $</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Lease-In-Place Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, Estimated useful lives</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, Estimated useful lives</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Site Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Tenant Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, Estimated useful lives</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_SignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common stock options excluded from net loss per share, diluted | shares</a></td>
<td class="nump">57,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ReductionToResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction To Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ReductionToResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843507122368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,271)<span></span>
</td>
<td class="num">$ (17,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share, diluted</a></td>
<td class="nump">41,739<span></span>
</td>
<td class="nump">39,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, Diluted</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive common stock options excluded from net loss per share, diluted</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">2,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843505923184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 439<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsAssets', window );">Contract research organization and other deposits</a></td>
<td class="nump">6,816<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 7,532<span></span>
</td>
<td class="nump">$ 10,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99397363&amp;loc=d3e9420-108338<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99383045&amp;loc=d3e9351-108337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843507883904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Real Property (Narrative) (Details) - Austin, Texas [Member] - Two-building office complex [Member] - ft&#178;<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Aug. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfOccupancy', window );">Percentage Of Occupancy</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfCurrentlyLeased', window );">Percentage Of Currently Leased</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfCurrentlyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Currently Leased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfCurrentlyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfOccupancy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Occupancy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfOccupancy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sava_AustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sava_AustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sava_TwoBuildingOfficeComplexAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sava_TwoBuildingOfficeComplexAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843435890000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Real Property (Components Of Other Income, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member] | Austin, Texas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Lease revenue</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Property operating expenses</a></td>
<td class="num">(367)<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sava_AustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sava_AustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509509808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property And Equipment (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 272,000<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843507037552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property And Equipment (Components Of Property And Equipment, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 24,081<span></span>
</td>
<td class="nump">$ 24,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,472)<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,609<span></span>
</td>
<td class="nump">22,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,734<span></span>
</td>
<td class="nump">3,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">15,980<span></span>
</td>
<td class="nump">15,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Site Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Tenant Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,016<span></span>
</td>
<td class="nump">3,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture And Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction In Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843509690000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843505430032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Components Of Intangible Assets, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(840)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Lease-In-Place Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember', window );">Leasing Commissions And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843505831984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843505032416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation Expense (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 673,000<span></span>
</td>
<td class="nump">$ 495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember', window );">ATM [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,017<span></span>
</td>
<td class="nump">19,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice', window );">Stock options exercised, net settled in satisfaction of the exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,139<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice', window );">Proceeds from stock options exercised net settled in satisfaction of the exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member] | Stock Option And Performance Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price or options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Registered Direct Offering 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised Net Settled Satisfaction Of Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options Exercised Net Settled Satisfaction Of Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_AtMarketEquityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_StockOptionAndPerformanceAwardActivity2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_StockOptionAndPerformanceAwardActivity2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_RegisteredDirectOffering2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_RegisteredDirectOffering2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843507027984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation Expense (Stock Options And Unvested Performance Award Outstanding Activity) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of, Beginning</a></td>
<td class="nump">2,529,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(19,017)<span></span>
</td>
<td class="num">(19,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited/canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of, Ending</a></td>
<td class="nump">2,510,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of, Beginning</a></td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Options forfeited/cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding as of, Ending</a></td>
<td class="nump">7,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843506118928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity And Stock-Based Compensation Expense (Stock-Based Compensation Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843508659088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843507049232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sava_AustinMember', window );">Austin, Texas [Member] | Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Office space | ft&#178;</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Apr. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sava_AustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sava_AustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sava_OperatingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sava_OperatingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843436059264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2020 Cash Incentive Bonus Plan (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense', window );">Minimum number of valuation milestones to recognize compensation expense | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_NumberOfValuationMilestonesAchieved', window );">Number of Valuation Milestones Achieved | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=sava_IndependentDirectorsMember', window );">Independent Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Cash Incentive Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained', window );">Minimum Number of Days Valuation Milestone must be achieved and maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment', window );">Percentage of each cash bonus award associated with Valuation Milestone subject to adjustment and approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Cash Incentive Bonus Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PaymentsForCashIncentiveBonus', window );">Payments authorized or made to participants under the Plan</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Cash Incentive Bonus Plan [Member] | Exceeding Performance Milestones Minimum 20 Consecutive Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationAmount', window );">Valuation milestone amount in market capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Cash Incentive Bonus Plan [Member] | First Valuation Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Cash Incentive Bonus Plan [Member] | Second Through Eighth Valuation Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Cash Incentive Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationAmount', window );">Valuation milestone amount in market capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Cash Incentive Bonus Plan [Member] | Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Cash Incentive Bonus Plan [Member] | Second Through Eighth Valuation Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cash Incentive Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationAmount', window );">Valuation milestone amount in market capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cash Incentive Bonus Plan [Member] | Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cash Incentive Bonus Plan [Member] | Second Through Eighth Valuation Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanLineItems', window );"><strong>Cash Incentive Bonus Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash bonus award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Incentive Bonus Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Incentive Bonus Plan [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Number of Days Valuation Milestone must be achieved and maintained</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum number of valuation milestones to recognize compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_NumberOfValuationMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Valuation Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_NumberOfValuationMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PaymentsForCashIncentiveBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Cash Incentive Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PaymentsForCashIncentiveBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanValuationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance Plan Valuation Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanValuationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sava_IndependentDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sava_IndependentDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_FirstValuationMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_FirstValuationMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_SecondThroughEighthValuationMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_SecondThroughEighthValuationMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sava_Exceeds5BillionMarketCapitalizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sava_Exceeds5BillionMarketCapitalizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139843435888240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Narrative) (Details) - item<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 04, 2021</div></th>
<th class="th"><div>Oct. 26, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember', window );">Violations of the federal securities laws [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Putative class action lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_NumberOfClassActionsConvertedToCase', window );">Number of class actions converted to case</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember', window );">Shareholder derivative actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Putative class action lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_NumberOfClassActionsConvertedToCase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of class actions converted to case</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_NumberOfClassActionsConvertedToCase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>sava-20230331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sava="http://www.cassavasciences.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sava-20230331.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_5_2022_To_5_5_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:StockOptionAndPerformanceAwardActivity2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="Duration_4_30_2023_To_4_30_2023_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:AtMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:RegisteredDirectOffering2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_OperatingLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:OperatingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sava:TwoBuildingOfficeComplexAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_4_2021_To_11_4_2021_srt_LitigationCaseAxis_sava_ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="Duration_8_28_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-28</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_OperatingLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:OperatingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_5_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:StockOptionAndPerformanceAwardActivity2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sava:AustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sava:TwoBuildingOfficeComplexAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_1_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2022_To_6_30_2022_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:Exceeds5BillionMarketCapitalizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_TitleOfIndividualAxis_sava_IndependentDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sava:IndependentDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:SecondThroughEighthValuationMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sava:FirstValuationMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="As_Of_4_27_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-04-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="Unit17">
        <measure>sava:segment</measure>
    </unit>
    <unit id="Unit16">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit15">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit14">
        <measure>pure</measure>
    </unit>
    <unit id="Unit13">
        <measure>sava:item</measure>
    </unit>
    <unit id="Unit12">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit1">
        <measure>shares</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-ba1ff8d6-a35f-4bf9-9151-555a3dd11e7f">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-23e35512-eeb5-449f-a1c2-4f98e71b33ea">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-180d411d-6d07-43b7-9c3e-f51316c20bf4">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-0bbbc5fb-8925-4c27-a029-2ee86f047dcf">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-13a290a7-15eb-4798-83c2-21753cdb54a3">0001069530</dei:EntityCentralIndexKey>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-2ee72825-f424-4cad-989d-4fdf3594c244">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-5a52fcd1-2225-4e77-80d9-13ca85140cc1">Yes</dei:EntityInteractiveDataCurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022"
      id="ct-nonFraction-cbc88618-b081-4619-b685-3e0fad376ad5"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2023"
      id="ct-nonFraction-dc8da0e0-df89-4507-a6dd-b30ddbfcd92f"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022"
      id="ct-nonFraction-cf2a5b87-8893-455d-a0c1-91fb0a2ee367"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_3_31_2023"
      id="ct-nonFraction-e8e3c658-e35d-4eea-99f7-fdbacb758fa7"
      unitRef="Unit12"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="ct-nonFraction-b786222f-0c6a-455c-9a63-3cd0d3ae33f5"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="ct-nonFraction-05eb815c-fd10-48c9-8d79-99d6ee0a77d4"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="ct-nonFraction-a22d958c-bef2-4f73-8328-e8bfeb74d56d"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="ct-nonFraction-4c45888e-635f-47a9-8d16-d034a6483bd4"
      unitRef="Unit1"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="ct-nonFraction-dd238c04-f83e-48b9-bb8b-2c297a0680b7"
      unitRef="Unit1"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-db49bb90-90c1-4054-b075-883e7fe336f6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-1658005c-f64d-4906-992b-5fd6ef864ec3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-e4c724dc-6981-4f37-bed5-3c9d05c148d5">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-fe7fe05a-bb50-4472-a93c-e16248ef9c7c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-6a7c56e7-384f-4484-b81a-e1cbc253b3d0">000-29959</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-357e6b00-3a5f-4492-b430-7ef8bccfd707">Cassava Sciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-4114d034-ebf5-48a0-b11d-02ae9f3d039d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-eea3cce6-72a0-43d7-83bd-b02220492110">91-1911336</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-9c223c3f-d3f3-41ed-9f76-d0cce480ba27">6801 N. Capital of Texas Highway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-a89c59e1-95c7-4be4-8bb7-c0c1e7faae99">Building 1; Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-b60e1356-2b66-4049-9acf-9cd7a3cfb0c9">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-a164ed87-c135-4254-af64-1a53c58610d2">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-fecb4b23-92f7-42da-98f7-96108b55fa99">78731</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-fdc8ed95-f5e2-4d70-b800-056098db3db4">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-42e2f4d9-7f90-49d5-8c65-c08980296962">501-2444</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-ca4e16c7-6570-4b11-8b6e-e81d0ffb0172">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-07b676e3-21b0-46ae-a5a3-707cbc0e419c">SAVA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-5e01c39d-0ecb-4708-846e-95405e4e1452">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-44f1e2a9-0ee5-4184-a9de-3bc703541586">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-9220927f-348e-4445-a0d7-57cec8e1174d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-49fb2261-58da-42af-acbe-922e0c58f308">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-94125644-9401-407b-a10e-e9d83f19de3c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_4_27_2023"
      decimals="INF"
      id="ct-nonFraction-7b2cad65-3bcd-4bcf-b49c-1fd7ba4c1abc"
      unitRef="Unit1">41749435</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-284d8c79-d3b3-43b8-8949-62c992b4c363"
      unitRef="Unit12">187467000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-daf94512-cdde-4bbb-8d57-f6415c02b8b2"
      unitRef="Unit12">201015000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-8b4d1fbc-f112-41fa-a600-4d730e039641"
      unitRef="Unit12">7532000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-46d8bb3b-6a32-4913-bc67-977275ccde7a"
      unitRef="Unit12">10211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-0de1f0dd-c983-4494-a6b1-1658e0c06b33"
      unitRef="Unit12">194999000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a66db293-d1b1-4c20-9aba-3d73b94fae1e"
      unitRef="Unit12">211226000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-50cc5f27-b929-45b3-b2eb-bf5142e2ecd2"
      unitRef="Unit12">122000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-35933e12-12d6-48d8-8f21-5e9c25e44e81"
      unitRef="Unit12">22609000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-9c14825f-5aca-46d1-ad8d-5918de7210b4"
      unitRef="Unit12">22864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-608d3135-cb50-4ba9-87e7-f9964f4965cf"
      unitRef="Unit12">503000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-bd687735-5cad-4ece-820a-24d6963b995e"
      unitRef="Unit12">622000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-3b63652f-bdd3-496d-b7d6-f64841a0711d"
      unitRef="Unit12">218111000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-2830550d-a0e2-4fd9-80f0-2ff99575746e"
      unitRef="Unit12">234834000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-a29293d9-835c-4560-af26-7e57a7295731"
      unitRef="Unit12">8242000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a30e50db-bc46-46ba-97b4-3172c8b70909"
      unitRef="Unit12">4017000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-3f998460-8fe6-4d64-af7b-f5741286cc9d"
      unitRef="Unit12">5276000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-4dfcf56f-5a41-428c-b898-ca7534f06165"
      unitRef="Unit12">2280000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-d1b6d2fb-2760-474f-b449-c47da3bdad8a"
      unitRef="Unit12">212000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-066181d2-9415-4342-9fbe-d9201c2b6f14"
      unitRef="Unit12">170000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-215601da-ad4f-4774-b217-d94dea41aed0"
      unitRef="Unit12">104000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-2e59def4-be2c-43fb-a559-961acf45bb6d"
      unitRef="Unit12">179000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-6ec0d1e2-2d19-48a8-a82b-0d099e7a903f"
      unitRef="Unit12">492000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-82061396-0a17-4de5-a924-1f5a99f33650"
      unitRef="Unit12">13909000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-15491824-5da1-4eda-832f-9cda25b392e1"
      unitRef="Unit12">7063000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-6f7735c2-698d-4946-98cb-11be73cc6a95"
      unitRef="Unit12">35000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-a827be24-87ef-429d-bcda-27d586dcd399"
      unitRef="Unit12">197000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-168c6178-2d1e-423c-8684-0be3c6a475f6"
      unitRef="Unit12">197000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-eb37df70-d629-46b4-aaba-dbf3f16ebfb0"
      unitRef="Unit12">14106000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b74fb81a-e4e5-4e9b-b2b9-6e7ecbd5c638"
      unitRef="Unit12">7295000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-21ad2be7-8289-4f2c-adb8-3af2d4c95694"
      unitRef="Unit15">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-2ed3a297-0251-4ecf-a811-ba62e3a76d84"
      unitRef="Unit15">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-1d236f44-14a5-4ac2-aa51-9cf5ddf2713f"
      unitRef="Unit1">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-11b2a8b7-2da2-47ff-8e5e-97ed2df22833"
      unitRef="Unit1">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-37211f3c-60f7-400e-815a-0c00ed267645"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-aa88cb0e-73cc-484d-a3de-e9082462f6d3"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-e01cccfb-416e-4b27-a0fc-be84d009db0e"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-3a4d3b14-3897-4b39-be90-9ba8d5b66028"
      unitRef="Unit1">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-8f8bca4e-210c-4502-8d65-27f81a791343"
      unitRef="Unit15">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-67c603b6-cb4b-457c-a7bf-a97731ffeae2"
      unitRef="Unit15">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-1b033372-0544-4067-b8cd-4458c4045dad"
      unitRef="Unit1">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-121bc351-05e8-461e-8c76-097c0f094acb"
      unitRef="Unit1">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-f07c1b8d-ffc3-457f-b116-719f58187a3a"
      unitRef="Unit1">41749435</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-32c75f56-f63e-4bd8-a2f2-f63146fbfe00"
      unitRef="Unit1">41749435</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-a31f77dd-d01c-483b-8f76-968b94a91262"
      unitRef="Unit1">41735557</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022"
      decimals="INF"
      id="ct-nonFraction-31e5dd03-7ff0-416b-ac64-adc3a6ca30ca"
      unitRef="Unit1">41735557</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-9f5c87f6-3f60-416c-9204-0cdaf47eb6f8"
      unitRef="Unit12">42000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-b59ca39c-5af6-4ed0-9689-5c061c2f6cf9"
      unitRef="Unit12">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-7700dbb6-1588-4f31-ac1a-90dd73e8596e"
      unitRef="Unit12">511786000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-0095a48b-21a7-4183-a5a0-9ebdfb84c32f"
      unitRef="Unit12">511049000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-93179a7c-a6bf-42c6-b620-02386e92537e"
      unitRef="Unit12">-307823000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-42b0d102-a88a-4b6f-95ab-65c5b5b70f91"
      unitRef="Unit12">-283552000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-549496ec-61be-454e-80d6-35d6af091d04"
      unitRef="Unit12">204005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-4052fe62-8e0f-40c6-a226-b3904ad7348a"
      unitRef="Unit12">227539000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-08cb176e-4d77-41f7-92be-2555ef0c5db2"
      unitRef="Unit12">218111000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-2c9fe665-26f1-4f33-aeb9-208bfeb9c844"
      unitRef="Unit12">234834000</us-gaap:LiabilitiesAndStockholdersEquity>
    <sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-39d101f4-1c7c-49d3-ba04-eaa37d145a37"
      unitRef="Unit12">22120000</sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement>
    <sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-ee1c01ee-bd83-4778-b807-d4b7b3659605"
      unitRef="Unit12">14906000</sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-b30e9751-2e51-4298-8bce-c4a4e2adc9d7"
      unitRef="Unit12">4392000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-0422f7f5-1153-4a5a-912b-edffda8a6443"
      unitRef="Unit12">2915000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-224cca01-d471-47bd-977e-cc021e03b008"
      unitRef="Unit12">26512000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-1e058e37-aa6b-4f06-8a5e-51690d1f114c"
      unitRef="Unit12">17821000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-d3180f6d-8a9b-466c-835b-7ba6e4cd35e8"
      unitRef="Unit12">-26512000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-01eb3002-fc93-4f3a-8568-d6d7cbe2b958"
      unitRef="Unit12">-17821000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-3167b6a5-faba-49b4-9e72-dbbc4ca626cf"
      unitRef="Unit12">2051000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-20c513d6-4e23-4a4c-a593-756f4c6b358f"
      unitRef="Unit12">31000</us-gaap:InterestAndOtherIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-84859641-80e9-4d6d-97eb-f99ab4b4388a"
      unitRef="Unit12">190000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-bb8f2718-092c-420d-b591-1bd97c19abb2"
      unitRef="Unit12">263000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-2cc2d1df-c515-4c12-8383-c22fc48860e5"
      unitRef="Unit12">-24271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-14254f39-1161-44fc-a1e9-b5cb54d6e6ff"
      unitRef="Unit12">-17527000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="2"
      id="ct-nonFraction-b1464ff1-c5a1-49a9-95eb-9485e483303e"
      unitRef="Unit15">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="2"
      id="ct-nonFraction-906a1442-84cb-48dc-82eb-f38280589574"
      unitRef="Unit15">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-faccc685-51e1-4fa7-a1b6-8bb239465fb0"
      unitRef="Unit1">41739000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-afcf1627-4d83-4fbd-84c2-ed880c2eab57"
      unitRef="Unit1">39962000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-ff7a2c18-f1d9-4b39-b3e0-507ef131baec"
      unitRef="Unit1">40016792</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-a5d6e7c9-0884-4583-a537-b2e03cc8d93e"
      unitRef="Unit12">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-f0504b58-7fac-46e9-b7ac-ad5a86359a3a"
      unitRef="Unit12">461181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-d2acae48-3e55-4e48-961d-11d182167e69"
      unitRef="Unit12">-207306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-4a9e2eb2-53c4-4caf-9326-89501d20b6c1"
      unitRef="Unit12">253915000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-d40afa37-53e3-4ddc-8c5f-254ac3b51586"
      unitRef="Unit12">471000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-32b6fa1b-9471-4bf4-b9a4-92c6382d5bb8"
      unitRef="Unit12">471000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-1415f7d0-26a4-45c5-9403-76e5e5c8aaf3"
      unitRef="Unit12">24000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-3043b68e-d149-4091-b232-1bb72c5737a1"
      unitRef="Unit12">24000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-d4591aeb-4d02-48bc-b090-04ed8271434a"
      unitRef="Unit1">14488</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-13fd85ac-bb77-4f8f-bcf1-0b4ba8f977b7"
      unitRef="Unit12">211000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-064694e0-231c-4a99-9b5f-d4a68b4fb222"
      unitRef="Unit12">211000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-0c26c1a6-f53e-41c6-a9c8-2257e3388079"
      unitRef="Unit12">-17527000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-1e903e94-fa2c-4167-9433-7e6dee877999"
      unitRef="Unit12">-17527000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-76b7dac3-ed20-499f-9595-b8e045e7d13b"
      unitRef="Unit1">40031280</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-b05b99aa-3b52-4759-a779-5ffdd5dfee3d"
      unitRef="Unit12">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-2ab5eef9-ab28-49fb-9586-e43138dd20d0"
      unitRef="Unit12">461887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-e6bb3f6d-5ddc-496c-9374-8ec04a310d9e"
      unitRef="Unit12">-224833000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-1b0c409e-7b6d-4e04-af30-6a80c52a6f26"
      unitRef="Unit12">237094000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-5eb2e7cf-714b-4c1e-913a-a2fe14938751"
      unitRef="Unit1">41735557</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-c3aecad7-1d61-4b92-be3e-cca6fcf0cb30"
      unitRef="Unit12">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-bc05f4c1-1e5c-4c61-a6f7-2bce643f067d"
      unitRef="Unit12">511049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-1fec2147-d3f4-414b-8404-a3cc3fe75f07"
      unitRef="Unit12">-283552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-a9765cab-f677-441f-86a0-61eb82d32876"
      unitRef="Unit12">227539000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-127819f2-75af-4e46-a3c7-afbf0311beb0"
      unitRef="Unit12">650000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-688cb02d-b4cb-4355-93da-11af192b85ed"
      unitRef="Unit12">650000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-f05745d4-fa48-44c8-8913-434f685b226e"
      unitRef="Unit12">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-e4986608-40e0-44cb-9312-eb02aca1b6df"
      unitRef="Unit12">23000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-0c131113-522a-499b-8625-c1318231039f"
      unitRef="Unit12">13878</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-33b39368-0be3-4b60-bb14-54d0779d8a80"
      unitRef="Unit12">64000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-8669b04d-3afe-4da5-aea2-1fcab0c79d93"
      unitRef="Unit12">64000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-9d007b72-8d17-42d2-bcf6-ec778fee9663"
      unitRef="Unit12">-24271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-a19f8224-112f-462a-9e65-2a9238ffed1b"
      unitRef="Unit12">-24271000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-42b2dc13-785a-4d6f-93ac-b4ca4f91d134"
      unitRef="Unit1">41749435</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="ct-nonFraction-a828bd37-e6bd-4f38-9883-500428bb25df"
      unitRef="Unit12">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="ct-nonFraction-130b7549-c963-4bcc-a00c-7a33f81d9fc4"
      unitRef="Unit12">511786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="ct-nonFraction-7e19bef6-87c5-43b3-bf41-5f93a9d7bb64"
      unitRef="Unit12">-307823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-7260df80-5e60-4196-b43e-ccaa579e2765"
      unitRef="Unit12">204005000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-94b372ab-5779-47ac-a6cc-1e38a6ad3eaf"
      unitRef="Unit12">-24271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-2e691f4f-6e5e-40f2-87b5-e89ba37d5d3d"
      unitRef="Unit12">-17527000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-92594fa4-0c05-40e1-9f8b-2e1bd8111a8b"
      unitRef="Unit12">673000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-336f8214-77a4-486d-9f3e-e8119fa06550"
      unitRef="Unit12">495000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-0a3b6fd3-cdf4-4d97-b678-3c7551cf8646"
      unitRef="Unit12">272000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-bbadb172-7a8b-4531-94c7-c2b6a1b84514"
      unitRef="Unit12">178000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-c3d729c2-3340-40b1-bdcf-bfea14f1c9f2"
      unitRef="Unit12">119000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-256c35b7-d5fb-416e-9377-5e4edb95873b"
      unitRef="Unit12">135000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-9030b596-5c1f-4cf2-b3d6-b1c6813b100e"
      unitRef="Unit12">-2679000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-a01ee60b-91ac-4f89-86be-47c0c9a2a5e5"
      unitRef="Unit12">1063000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-7ef4cafd-8b43-43e8-958b-b6dfeebd8281"
      unitRef="Unit12">17000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-1f2535f9-86e5-4eea-9158-cc4174995a3c"
      unitRef="Unit12">1000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-b7bffbd4-02a7-4b77-8d31-2772b40093f9"
      unitRef="Unit12">4565000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-5d3a28ac-f79b-479e-88ff-6b3090cdec33"
      unitRef="Unit12">-3794000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-2ed4bcd4-f5b0-4e30-a758-016f542e6932"
      unitRef="Unit12">2996000</sava:IncreaseDecreaseInDevelopmentExpense>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-59cae46e-8697-4d6a-8dfd-f0819b22e032"
      unitRef="Unit12">122000</sava:IncreaseDecreaseInDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-d50561df-85e8-42e9-b8a8-22d769c1f63d"
      unitRef="Unit12">42000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-d6b8342e-b98f-40a5-b77e-e1f245d0ba13"
      unitRef="Unit12">-1705000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-c67dcfac-ea60-4f3e-93f7-d56c0fdad65b"
      unitRef="Unit12">-313000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-6deb50e1-c884-4951-9924-25bfcdecede4"
      unitRef="Unit12">-370000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-1c9c1b72-89a7-44c2-a3d6-d23b601c6796"
      unitRef="Unit12">-13255000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-3c293e28-cbdc-44d1-b6b4-613273440577"
      unitRef="Unit12">-23530000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-6501dcf3-db4f-4bac-959d-60f1f4535f0b"
      unitRef="Unit12">357000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-2314d03e-07dc-4a56-ad8d-c301f1348056"
      unitRef="Unit12">425000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-80158669-b365-4c38-af07-db8427a43556"
      unitRef="Unit12">-357000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-ab820bf3-f6b1-4b18-baaf-3f40c77ed83c"
      unitRef="Unit12">-425000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-0efb16e0-7d5b-4142-86fc-91044c142401"
      unitRef="Unit12">64000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-9b5c3ed1-ed5e-4522-b44d-a5c6c26d0d13"
      unitRef="Unit12">211000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-3960c6d6-1408-4287-b465-39c78649f112"
      unitRef="Unit12">64000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-9cdfb84c-4f78-44e7-bcc6-5ec03608c074"
      unitRef="Unit12">211000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-30867167-ee4d-4d36-9d6d-10ef1feca90f"
      unitRef="Unit12">-13548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-c49c2a85-f802-4e53-9a68-3cb34518dd39"
      unitRef="Unit12">-23744000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-9159d760-5420-439e-87c4-bf9d80ca852d"
      unitRef="Unit12">201015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021"
      decimals="-3"
      id="ct-nonFraction-1b02e340-b302-4849-9d73-c183c23a0893"
      unitRef="Unit12">233437000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-13e2630c-6d3e-4d8b-8612-65fa39af9cb9"
      unitRef="Unit12">187467000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-3c818366-c70a-4520-9a1f-2e5a27cd79fc"
      unitRef="Unit12">209693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-7a4f0676-bfd9-4063-87e5-244ef394eecd">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Note 1.  General and Liquidity&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#x201c;Company&#x201d;) discover and develop proprietary pharmaceutical product candidates that may offer significant improvements to patients and healthcare professionals. The Company generally focuses its discovery and product development efforts on disorders of the nervous system. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the instructions to the Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for any other interim period or for the year 2023&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;For further information, refer to the consolidated financial statements and footnotes thereto included in the Company&#x2019;s Annual Report on Form&#160;10-K for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;307.8&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million at March 31, 2023. The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#x2019;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company may seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are no assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital needs for at least the next 12 months.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2023"
      decimals="-5"
      id="ct-nonFraction-4449fd82-cf2c-493e-a07f-f1d5823deed5"
      unitRef="Unit12">-307800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-abdf142f-328c-4633-a4ad-c76908182082">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Note 2.&#160;&#160;Significant Accounting Policies&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and assumptions.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at one financial institution. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 1 includes quoted prices in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company does not have any financial instruments where the fair value is based on Level 2 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any financial instruments where the fair value is based on Level 3 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Business Segments&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;one&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; business segment: the development of novel drugs and diagnostics.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Proceeds from Grants&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the three months ended March 31, 2023,&#160;there were &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; reimbursements received pursuant to National Institutes of Health (&#x201c;NIH&#x201d;) research grants. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three months ended March 31, 2022&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, the Company received reimbursements totaling $&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million pursuant to NIH research grants. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#x201c;Black-Scholes&#x201d;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each &lt;/span&gt;&lt;span id="_cp_text_1_372" style="text-decoration: none;"/&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four years&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Net Loss per Share &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;method. Potential dilutive common shares consist of outstanding common stock options.&#160;&#160;There is no difference between the Company&#x2019;s net loss and comprehensive loss. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Three months ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,271&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,527&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;41,739&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,962&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.58&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.44&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; Dilutive common stock options excluded from net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,034&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,086&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;-&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;dilutive. The Company also excluded &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;57,143&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; restricted stock awards from the calculation of net loss per share, diluted, until their expiration in June 2022 because the effect of including restricted stock awards would have been anti&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;-&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160; &#160; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Research Contract Costs and Accruals &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have not been materially different from actual costs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Incentive Bonus Plan&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#x201c;Plan&#x201d;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#x201c;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x201d;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note 10 for further discussion of the Plan.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years and approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years at March 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; to be impaired, an impairment loss is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Income Taxes&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740, &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;condensed&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-4693fe08-5099-4611-bc5b-c00c02904eef">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to manufacturing agreements and research collaborations. Actual results could differ from these estimates&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and assumptions.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-35f92385-ba87-4ea2-9673-25aedb475563">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit, and U.S. Treasury securities.&#160;The Company maintains&#160;its cash and cash equivalents at one financial institution. &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-6a5583ba-8455-4d0e-86eb-97d81deecd13">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value Measurements &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 1 includes quoted prices in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 2 includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from third-party providers. It uses the bid price to establish fair value where a bid price is available. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company does not have any financial instruments where the fair value is based on Level 2 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: Symbol;font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.50in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: -0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;display: inline-block;font-family: Symbol;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;text-indent: 0;width: 0.250in;"&gt;&#xf0b7;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Level 3 includes unobservable inputs that are supported by little or no market activity. The Company does not have any financial instruments where the fair value is based on Level 3 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 inputs at March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-41b2c1bd-10eb-4f17-9a02-870909487f59">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Business Segments&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;one&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; business segment: the development of novel drugs and diagnostics.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-38b16210-3dbb-419c-8d23-c0eac0498bca"
      unitRef="Unit17">1</us-gaap:NumberOfOperatingSegments>
    <sava:ProceedsFromGrantsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-f5de3718-0c78-4be0-aac6-988b0f795712">&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Proceeds from Grants&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the three months ended March 31, 2023,&#160;there were &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; reimbursements received pursuant to National Institutes of Health (&#x201c;NIH&#x201d;) research grants. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three months ended March 31, 2022&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, the Company received reimbursements totaling $&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million pursuant to NIH research grants. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;</sava:ProceedsFromGrantsPolicyPolicyTextBlock>
    <sava:ReductionToResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-6"
      id="ct-nonFraction-4e3f95cc-c8ec-4518-a52b-d421a69f2ed1"
      unitRef="Unit12">0</sava:ReductionToResearchAndDevelopmentExpense>
    <sava:ReductionToResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-5"
      id="ct-nonFraction-e7b73f4c-11a9-4746-bebd-796e11dbd364"
      unitRef="Unit12">100000</sava:ReductionToResearchAndDevelopmentExpense>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-20d2f389-e805-40d1-9f87-75f5cb7e7b43">&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The&#160;Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#x201c;Black-Scholes&#x201d;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each &lt;/span&gt;&lt;span id="_cp_text_1_372" style="text-decoration: none;"/&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four years&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0.25in;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-e06138a8-277d-4a4a-9bcf-5ce5d0e4cbeb">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-2b872ce6-131d-41f5-94a1-8d960de65332">&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Net Loss per Share &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Tahoma', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&#xfeff;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;method. Potential dilutive common shares consist of outstanding common stock options.&#160;&#160;There is no difference between the Company&#x2019;s net loss and comprehensive loss. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Three months ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,271&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,527&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;41,739&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,962&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.58&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.44&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; Dilutive common stock options excluded from net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,034&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,086&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company excluded common stock options outstanding from the calculation of net loss per share, diluted, because the effect of including outstanding options would have been anti&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;-&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;dilutive. The Company also excluded &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;57,143&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; restricted stock awards from the calculation of net loss per share, diluted, until their expiration in June 2022 because the effect of including restricted stock awards would have been anti&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;-&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-5df35553-4478-4ea9-bf01-cfc4efa5ee98">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Three months ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,271&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;17,527&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;41,739&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39,962&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.58&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.44&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; Dilutive common stock options excluded from net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,034&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,086&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 68.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 12.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-04e54472-2d97-450e-ae8e-c38bf291dbee"
      unitRef="Unit12">-24271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-aeef729d-55ae-40cb-9042-627d1390528b"
      unitRef="Unit12">-17527000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-a82913c9-bba2-4bda-bb60-bb1b61429f8c"
      unitRef="Unit1">41739000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-e286c69c-bdb2-4f11-a9d1-eb79b3faddcf"
      unitRef="Unit1">39962000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="2"
      id="ct-nonFraction-15cb17e5-e0c2-4fab-aff4-7559ee746ac5"
      unitRef="Unit15">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="2"
      id="ct-nonFraction-81fc2270-5243-4cbd-8aec-2efdd3f97069"
      unitRef="Unit15">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="ct-nonFraction-cdf20db9-94a4-4d2f-a21e-9dff7af571ad"
      unitRef="Unit1">2034000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="ct-nonFraction-1b4a5934-7840-4bab-a6f5-9032f9d2ed1a"
      unitRef="Unit1">2086000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="ct-nonFraction-21f87bed-e4f3-44a7-8e13-d985ebac7c90"
      unitRef="Unit1">57143</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-4396299f-e30e-4961-b139-348d45815afc">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160; &#160; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 6pt;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Financial instruments include accounts payable and accrued liabilities. The estimated fair value of certain financial instruments may be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <sava:ResearchContractCostsAndAccrualsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-61e4eb64-6671-4759-aa00-610a1d638a23">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Research Contract Costs and Accruals &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company has entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have not been materially different from actual costs.&lt;/span&gt;&lt;/p&gt;</sava:ResearchContractCostsAndAccrualsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-a5f4cfba-a4b6-46c0-8e92-52058c395fe9">&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Incentive Bonus Plan&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In 2020, the Company established the 2020 Cash Incentive Bonus Plan (the &#x201c;Plan&#x201d;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718 &#x201c;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#x201d;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note 10 for further discussion of the Plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-968df001-b19d-4701-86de-5ea32edb4d8e">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Leases&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;condensed consolidated balance sheets.&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not recognize right-of-use assets or lease liabilities. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As the Company`s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-6d9ccbd7-3a68-44c2-be3c-38987bc4cfcb">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Property and equipment&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;39&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years and approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      id="ct-nonNumeric-991c40a2-c81b-456a-b3b0-b972926f2875">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      id="ct-nonNumeric-d4302cee-7837-4910-bf38-146df965ccbb">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      id="ct-nonNumeric-ac54698e-4a1f-41ea-a40c-cd3a1c5b1c19">P1Y1M6D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-781f6395-158f-4499-a062-858a3ff6d5dd">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Intangible assets&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years at March 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; to be impaired, an impairment loss is recognized.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"
      id="ct-nonNumeric-4d391b39-8a3b-4aa1-a146-2e6b6d42c571">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-55947cd2-c0fa-4609-9bb1-f2f5809df4a9">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;Income Taxes&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for income taxes under the asset and liability method. &#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740, &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;condensed&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <sava:PrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-40a3b4f1-4965-4952-98ae-0d94cf20e464">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;"&gt;Note 3.  Prepaid Expenses and &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Other Current Assets&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Prepaid expenses and other current assets at March 31, 2023 and December 31, 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;439&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;874&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Contract research organization and other deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,816&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,177&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;277&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;160&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,532&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,211&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;       Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.&lt;/span&gt;</sava:PrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-0371b82f-48e2-4264-a1e0-bec78c32ad49">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 47.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 22.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;439&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;874&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Contract research organization and other deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,816&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;9,177&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;277&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;160&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,532&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10,211&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-33965396-3e1d-4f77-98a2-04f700b8ba02"
      unitRef="Unit12">439000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-3b0f4606-9abc-4c71-b7ba-87fad14f1ef2"
      unitRef="Unit12">874000</us-gaap:PrepaidInsurance>
    <us-gaap:DepositContractsAssets
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-c1367525-abb8-4183-9750-3791ab330edd"
      unitRef="Unit12">6816000</us-gaap:DepositContractsAssets>
    <us-gaap:DepositContractsAssets
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-8d898ad5-316f-4115-8209-317775b1378e"
      unitRef="Unit12">9177000</us-gaap:DepositContractsAssets>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-16dd4b76-bee6-46f0-bf67-f0d7bfbf8089"
      unitRef="Unit12">277000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-3160f5ec-fb18-4ebe-97c4-ce107bb968ac"
      unitRef="Unit12">160000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-72a30f92-e9e8-4935-96ea-49df6da3b3dd"
      unitRef="Unit12">7532000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-711abfcb-5327-4e70-9f79-82512462e80e"
      unitRef="Unit12">10211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-ae6301ad-7712-42b8-a60f-2f3183ee647f">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;"&gt;Note 4. Real Property&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company owns a two-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#x2019;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are being outsourced to professional real-estate managers. The office complex measures approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;90,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; rentable square feet. At March 31, 2023, the property was over &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;60&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% leased. The Company also occupies approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;25&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of the property.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company records the net income from building operations and leases as other income, net, as leasing is not core to the Company&#x2019;s operations. Building depreciation and amortization for space not occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Three months ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;557&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;573&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;367&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;310&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;263&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:NetRentableArea
      contextRef="As_Of_8_4_2021_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember"
      decimals="0"
      id="ct-nonFraction-c18e2753-83fd-48e9-98f4-53b2d63ca5dd"
      unitRef="Unit16">90000</us-gaap:NetRentableArea>
    <sava:PercentageOfCurrentlyLeased
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember"
      decimals="2"
      id="ct-nonFraction-327cf1dd-6af9-4bfa-bca3-1fdd8e42eaff"
      unitRef="Unit14">0.60</sava:PercentageOfCurrentlyLeased>
    <sava:PercentageOfOccupancy
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember"
      decimals="2"
      id="ct-nonFraction-fa5f1ae9-2d1e-42a3-949d-b3c9a1172f10"
      unitRef="Unit14">0.25</sava:PercentageOfOccupancy>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-e750b05b-d06b-4768-8351-160168ec8758">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Three months ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;557&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;573&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Property operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;367&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;310&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.25in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;190&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;263&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-4863db93-f0a0-4dd5-a92e-2f8ac9db09ad"
      unitRef="Unit12">557000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-d23653a0-c4ab-4831-8ff9-8022ef92fdab"
      unitRef="Unit12">573000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-c4d081d8-5669-4c08-8cdf-3107731cf263"
      unitRef="Unit12">367000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-69da07ed-4266-46cc-adb4-a17b6e507f89"
      unitRef="Unit12">310000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-8871c8f2-1c4f-4e62-ab54-e55dbdda6e89"
      unitRef="Unit12">190000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-16ffc434-4d21-4e6d-9d9d-3ad13a5ce44a"
      unitRef="Unit12">263000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-e3c2e436-f19a-4f9e-a332-7bf567ac33be">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;"&gt;Note 5.  Property and equipment&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The components of property and equipment, net, as of March 31, 2023&#160;and&#160;December 31, 2022&#160;were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Land&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Site improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;470&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;470&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tenant improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,016&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,016&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;868&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;851&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Gross property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,081&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,064&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,472&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,200&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22,609&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22,864&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Depreciation expense for property and equipment was&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;272,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;and&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;178,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;for the three months ended&#160;March 31, 2023&#160;and 2022, respectively.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-79e47a16-9746-448b-b33a-9c1c55c64b81">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Land&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,734&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Buildings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;15,980&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Site improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;470&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;470&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Tenant improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,016&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;3,016&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;868&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;851&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;13&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Gross property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,081&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,064&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,472&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,200&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22,609&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;22,864&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"
      decimals="-3"
      id="ct-nonFraction-9d66f3fb-1d38-438d-89bf-c47692370907"
      unitRef="Unit12">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"
      decimals="-3"
      id="ct-nonFraction-694d03a3-5ec5-4878-aeb2-ca361f54caa7"
      unitRef="Unit12">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-819dcec5-4800-4e9a-b59b-cc45f21ff537"
      unitRef="Unit12">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-2a83f01c-25fd-4b87-8abf-4a682843f756"
      unitRef="Unit12">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-3e59d6d3-cf69-4655-b8ae-56fc1cc2e936"
      unitRef="Unit12">470000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-313c7cfd-a69b-428f-94fc-16598e7ac439"
      unitRef="Unit12">470000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-37ea943d-ee17-4415-9673-2a01865f47ba"
      unitRef="Unit12">3016000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="ct-nonFraction-aa4fd562-ddad-418a-8ad8-703235c62c9f"
      unitRef="Unit12">3016000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="ct-nonFraction-df07f382-abde-42e6-bcf9-8e06ce44c0e2"
      unitRef="Unit12">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="ct-nonFraction-7659169d-93ba-460c-9f92-6d46b43045e7"
      unitRef="Unit12">851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="ct-nonFraction-af1a6d25-ceca-4265-a7ef-e3fa9309a648"
      unitRef="Unit12">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="ct-nonFraction-4bb5e26d-a5d9-4bbc-8dc1-116c7a6ef3d0"
      unitRef="Unit12">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-a68a04ab-907f-4ddb-b40c-1be0da224edb"
      unitRef="Unit12">24081000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-365397c9-6901-4f12-9945-335d6efaeebf"
      unitRef="Unit12">24064000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-577a5622-45dd-431d-bc5d-4faaa82dc340"
      unitRef="Unit12">1472000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-e02201d7-d6b6-47e8-991e-37a8e8ed87b5"
      unitRef="Unit12">1200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-6adba2e6-aaba-459e-9fe0-3dcf09a6efd5"
      unitRef="Unit12">22609000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c4bed00a-bc06-4143-bc1b-5fbdebab4236"
      unitRef="Unit12">22864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="0"
      id="ct-nonFraction-449f68c2-f3cf-4342-946a-45d2c8030e23"
      unitRef="Unit12">272000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="0"
      id="ct-nonFraction-e4ff8499-faa5-4125-875c-510e617ebb87"
      unitRef="Unit12">178000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-5fbae18e-5077-4f1f-9f74-abd7c21661ab">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;"&gt;Note 6.  Intangible assets&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;letter-spacing: 0;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The components of intangible assets, net, as of March 31, 2023&#160;and&#160;December 31, 2022&#160;were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease-in-place agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Leasing commissions and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;290&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;290&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Gross intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,343&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,343&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;840&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;721&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;503&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;622&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Amortization expense for intangible assets was&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;119,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;135,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; for the three months ended&#160;March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Amortization expense for finite-lived intangible assets as of March 31, 2023 is expected to be as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;"&gt;For the year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;332&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;167&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;503&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-99d12ba2-2072-4cdb-b86e-eb493d1baeae">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;December 31,&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;&lt;br/&gt;&#x200e;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Lease-in-place agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,053&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Leasing commissions and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;290&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;290&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Gross intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,343&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,343&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;840&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;721&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;  Intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;503&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;622&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 52.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 3.3%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 19.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="ct-nonFraction-3a0ef5ed-57cd-44de-a2f6-e8653f7d6fab"
      unitRef="Unit12">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="ct-nonFraction-5d9b6969-4219-4919-bf56-f71dd669d9f0"
      unitRef="Unit12">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-a7e639f2-785b-4d70-b739-8cb97d68d4cf"
      unitRef="Unit12">290000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_sava_LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="ct-nonFraction-0a5c1643-b3d8-4ec6-aafe-646a53a8564c"
      unitRef="Unit12">290000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-4417d074-a5a2-480f-95f9-d3db1357b56b"
      unitRef="Unit12">1343000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-c8581035-b048-4ccb-93ca-2a4a8e7684ac"
      unitRef="Unit12">1343000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-8a203ce5-202a-40b4-b586-373ca7fa3ffb"
      unitRef="Unit12">840000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-788829df-5d02-4be8-966c-5e518c96b21d"
      unitRef="Unit12">721000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-f6012e3e-694f-4c4c-ae29-d549db808773"
      unitRef="Unit12">503000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022"
      decimals="-3"
      id="ct-nonFraction-48743a24-a76a-425f-bfba-acbbf70a583c"
      unitRef="Unit12">622000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="0"
      id="ct-nonFraction-067c17a5-6695-45db-bfe3-f5e914cf504c"
      unitRef="Unit12">119000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="0"
      id="ct-nonFraction-4c4ed742-a6f7-407d-828a-b4798b1aeceb"
      unitRef="Unit12">135000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-2f566bb9-a436-45f9-a8f2-3539c8a6b71c">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;text-decoration: underline;"&gt;For the year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;332&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;167&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;4&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.33in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;503&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 85.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 9.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: Calibri;font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-70b33d0b-f0ee-4fcd-ba29-a2798c29209a"
      unitRef="Unit12">332000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-e809fed7-43d1-4e1c-bc5b-9220f138c81c"
      unitRef="Unit12">167000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-4a050361-51e8-4d10-9d3a-98884049f955"
      unitRef="Unit12">4000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-384a035e-be17-430b-945d-46f690e50627"
      unitRef="Unit12">503000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-67b6e6d7-c5df-4197-89b8-4e1dac2d3739">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;letter-spacing: 0;margin: 0;padding: 0;"&gt;Note 7.  Stockholders&#x2019; Equity and Stock-Based Compensation Expense&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;2022 Registered Direct Offering&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On November&#160;22, 2022, the Company completed a common stock offering pursuant to which certain investors purchased &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;1,666,667&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock at a price of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;30.00&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; per share. Net proceeds of the offering were approximately $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;47.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million after deducting offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;At-the-Market Common Stock Offering &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In March 2020, the Company established an at-the-market offering program (&#x201c;2020 Program&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;100&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;in transactions pursuant to a shelf registration statement that was declared effective by the &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;)&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; on May 5, 2020&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The Company gave notice of termination for the 2020 Program on April 26, 2023, which is effective May 1, 2023. There were &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; common stock sales under the 2020 Program through its termination. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Stock Option and Performance Award Activity in 2023&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the three months ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, 2023, stock options and unvested Performance Awards outstanding under the Company&#x2019;s stock option plans changed as follows:&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Performance Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,529,448&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,142&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-dd238c04-f83e-48b9-bb8b-2c297a0680b7;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-05eb815c-fd10-48c9-8d79-99d6ee0a77d4;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,017&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a22d958c-bef2-4f73-8328-e8bfeb74d56d;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-4c45888e-635f-47a9-8d16-d034a6483bd4;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-b786222f-0c6a-455c-9a63-3cd0d3ae33f5;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,510,431&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,142&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The weighted average exercise price of options outstanding at &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, 2023 was $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;12.15&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. As outstanding options vest over the current remaining vesting period of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #FF0000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;years, the Company expects to recognize stock-based &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;compensation expense of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7.0&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million. If and when outstanding Performance Awards vest, the Company will recognize stock-based compensation expense of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.1&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; million over the implicit service period.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the three months ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, 2023, there were &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,017&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; stock options exercised. &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Of the stock options exercised, &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,139&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; stock options were net settled in satisfaction of the exercise price, with &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; cash proceeds received. Cash proceeds&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; to the Company &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;for options not net settled&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; totaled $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;64,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; during the three months ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the three months ended March 31, 2022, there were &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,609&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; stock options exercised. Of the stock options exercised, &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,121&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; stock options were net settled in satisfaction of the exercise price, with &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; cash proceeds received. Cash proceeds to the Company for options not net settled totaled $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;211,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; during the three months ended March 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Stock-based Compensation Expense in 2023&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.21in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the three and nine months ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, 2023 and 2022, the Company&#x2019;s stock-based compensation expense was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Three months ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;389&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;422&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;284&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;73&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;673&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;495&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0.03in;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt;2018 Equity Incentive Plan &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) or a designated committee of the Board is responsible for administration of the Company&#x2019;s 2018 Omnibus Incentive Plan, as amended (the &#x201c;2018 Plan&#x201d;) and determines the terms and conditions of each option granted, consistent with the terms of the 2018 Plan. The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the 2018 Plan, including grants of stock options and Performance Awards. Share-based awards generally expire &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;10&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; years from the date of grant. The 2018 Plan, as amended on May 5, 2022, provides for issuance of up to &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5,000,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;0.001&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; per share, subject to adjustment as provided in the 2018 Plan. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#xfeff; &lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses&#160;its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.&lt;/span&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="ct-nonFraction-c3337d22-2397-441a-aad3-3bccfcefc39c"
      unitRef="Unit1">1666667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="2"
      id="ct-nonFraction-d30cd964-f152-4d1c-b2d4-06079df223d0"
      unitRef="Unit15">30.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_11_22_2022_To_11_22_2022_us-gaap_PlanNameAxis_sava_RegisteredDirectOffering2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="ct-nonFraction-e7fedaec-accc-43ac-9fed-aa6b329d3184"
      unitRef="Unit12">47300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="Duration_3_1_2020_To_3_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"
      decimals="-6"
      id="ct-nonFraction-28fc557d-4f5e-4ea8-93cb-18a5cd4545d4"
      unitRef="Unit12">100000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_4_30_2023_To_4_30_2023_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember"
      decimals="INF"
      id="ct-nonFraction-b371a7ba-614b-4c35-a377-30a3481e0361"
      unitRef="Unit1">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sava:StockOptionAndPerformanceAwardActivity
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-888a7289-24a2-4a0b-918d-abd4591138a4">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Performance Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,529,448&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,142&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-dd238c04-f83e-48b9-bb8b-2c297a0680b7;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-05eb815c-fd10-48c9-8d79-99d6ee0a77d4;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; (&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;19,017&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-a22d958c-bef2-4f73-8328-e8bfeb74d56d;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Options forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-4c45888e-635f-47a9-8d16-d034a6483bd4;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&lt;span style="white-space:pre-wrap; -sec-ix-hidden:ct-nonFraction-b786222f-0c6a-455c-9a63-3cd0d3ae33f5;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;2,510,431&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;7,142&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 62.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 1.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 15.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sava:StockOptionAndPerformanceAwardActivity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-e8a794d0-8f01-4fd0-a3cc-4dd6acf940d3"
      unitRef="Unit1">2529448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-35f1c435-63ec-44a0-898b-75583ae4d20b"
      unitRef="Unit1">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-27841093-0c84-4cc7-b5ed-3e99f06b4aa7"
      unitRef="Unit1">19017</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-6af35ecf-d3a4-448f-9e8c-de5154d8bcfd"
      unitRef="Unit1">2510431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="ct-nonFraction-71cb1c72-2bf2-4af7-ab0f-f2f5ce757f34"
      unitRef="Unit1">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember"
      decimals="2"
      id="ct-nonFraction-95585ba3-491e-4236-b786-841550f3c9a5"
      unitRef="Unit15">12.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember"
      id="ct-nonNumeric-b492c77d-d562-4f75-a26c-263eb8b481db">P2Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_sava_StockOptionAndPerformanceAwardActivity2020PlanMember"
      decimals="-5"
      id="ct-nonFraction-ab343e3e-360f-4d4b-9b1a-a75332309002"
      unitRef="Unit12">7000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="ct-nonFraction-0d914c20-2371-451a-803c-913174ea0be8"
      unitRef="Unit12">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-3094861b-7268-49f6-8f96-4836af9ded6e"
      unitRef="Unit1">19017</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-37984c12-b252-4610-9e4f-fae1f34f858c"
      unitRef="Unit1">5139</sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice>
    <sava:ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-be6e2690-f366-4b6a-ae4c-6149214b3a3d"
      unitRef="Unit12">0</sava:ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-081d10b9-4b9b-430b-9053-1441fbda8cea"
      unitRef="Unit12">64000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-dc91ec4c-3245-4a78-baa7-aacd9f43627c"
      unitRef="Unit1">19609</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-67de9249-4f95-4a61-bd80-708468b82d06"
      unitRef="Unit1">5121</sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice>
    <sava:ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-8c5a3a4e-d791-45f7-ad6e-66ef2212f00f"
      unitRef="Unit12">0</sava:ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="ct-nonFraction-9fd2b9e7-47f1-43dc-bbc9-b7b276b2d4d1"
      unitRef="Unit12">211000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-7447cfe3-7ab6-41b6-882d-f383f5a28d78">&lt;div style="text-align:left"&gt;&lt;table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Three months ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 8pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 0.0%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: center;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;389&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;422&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;284&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;73&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.17in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;673&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 9pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;495&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.4%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.5%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.1%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0.08in;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 13.7%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.7%;"&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: right;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 2.9%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 11.6%;"&gt;&lt;p dir="ltr" style="text-align:left; font-family: 'Arial', 'sans-serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-2f4e8efa-e0c9-4f20-8e1f-58ac9de5c2f2"
      unitRef="Unit12">389000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="ct-nonFraction-e376d1fe-9f43-4292-bedb-c2f34ff9a3ac"
      unitRef="Unit12">422000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="ct-nonFraction-c74ed195-037f-4974-92e3-4a4235c723e2"
      unitRef="Unit12">284000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="ct-nonFraction-a32db236-729b-4408-9020-4cb4664f9cd1"
      unitRef="Unit12">73000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-3ee311bd-bad9-4f19-bb1d-bd0915e260cb"
      unitRef="Unit12">673000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-518323b1-1005-4806-a9aa-dba9e1082812"
      unitRef="Unit12">495000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"
      id="ct-nonNumeric-00a1b241-90d9-4a60-8845-d3e9386715f2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_5_5_2022_To_5_5_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="0"
      id="ct-nonFraction-c61c2421-c89b-4251-b861-80f65df8de6a"
      unitRef="Unit1">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_5_5_2022_us-gaap_PlanNameAxis_sava_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="ct-nonFraction-96d13e1d-4f84-4616-b3f2-fe7010ebb5b5"
      unitRef="Unit15">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-cf069b86-66c1-4463-962a-6c0702242feb">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Note 8.  Income Taxes&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company did &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;t provide for income taxes during the three months ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, 2023&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, because it has projected a net loss for the full year 2023 &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;for which any benefit will be offset by an increase in the valuation allowance&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. There was also &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; provision for income taxes for the three months ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;,&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; 2022.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-0e844b72-b580-4f55-ad45-80ce7c2d5a9b"
      unitRef="Unit12">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="INF"
      id="ct-nonFraction-82171521-daff-47cf-be37-5fe9f850cfb7"
      unitRef="Unit12">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-950acc6a-cbba-4964-9ffe-91a438e03c89">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Note 9.  &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Commitments&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Right-of-use Asset and Liability&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 1.00in;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company had an operating lease for approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; square feet of office space in Austin, Texas with an expiration of &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;April 30, 2024&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The Company and the landlord consented to early terminate this lease on February 22, 2023 with no continuing obligations.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Rent expense for the &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three months ended&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, 2023&#160;and 2022&#160;totaled $&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;41,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Cash paid for operating lease liabilities during the three months ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, 2023 and 2022 totaled $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;24,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;41,000&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Other Commitments&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company&#x2019;s obligations under these contracts are largely based on services performed.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:NetRentableArea
      contextRef="As_Of_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_OperatingLeasesMember"
      decimals="0"
      id="ct-nonFraction-8ef8ccad-cdf8-48ca-ac97-b14f60a14633"
      unitRef="Unit16">6000</us-gaap:NetRentableArea>
    <us-gaap:LeaseExpirationDate1
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_LeaseContractualTermAxis_sava_OperatingLeasesMember"
      id="ct-nonNumeric-ba012256-84ed-48b2-8f49-b2046e88763d">2024-04-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-3"
      id="ct-nonFraction-32c983b9-86df-461a-8160-4154aefd868a"
      unitRef="Unit12">24000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="0"
      id="ct-nonFraction-29ac622b-7c2a-4d83-91dc-d8fc5068cef5"
      unitRef="Unit12">41000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="-3"
      id="ct-nonFraction-1a6b38db-29b5-417b-81bf-c95fa272a485"
      unitRef="Unit12">24000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_3_31_2022"
      decimals="-3"
      id="ct-nonFraction-63315068-9ff8-4c51-a618-e76feccf921f"
      unitRef="Unit12">41000</us-gaap:OperatingLeasePayments>
    <sava:CashIncentiveBonusPlanTextBlock
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-30d43a08-7dcb-43e4-86c0-48bb7c09f9c1">&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Note&#160;10.&#160; 2020 Cash Incentive Bonus Plan&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In August 2020, the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#x201c;at-risk&#x201d; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s market capitalization. The Plan is considered &#x201c;at-risk&#x201d; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#x2019;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has not occurred&#160;as of &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March 31&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;As of December 31, 2022, the Company&#x2019;s independent directors were participants in the Plan. However, effective March 16, 2023, the Board of Directors amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#x2019; share of potential benefits under the Plan were completely forfeited to the Company and will not be allocated to any other participant under the Plan. The Company&#x2019;s independent directors have &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;t received, and as a result of such amendment will never receive, any payments under the Plan.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company&#x2019;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (1) the closing price&#160;of one share&#160;of the Company&#x2019;s common stock on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (2) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction.&#160;This constitutes a market condition under applicable accounting guidance.&#160; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#x2019;s market capitalization increases significantly, up to a maximum&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;200&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million and&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;billion&#160;(each increment,&#160;a &#x201c;Valuation Milestone&#x201d;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for no less than &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;20&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;67&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;not awarded by the Compensation Committee&#160;are&#160;no longer available for distribution.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;If the Company were to exceed a $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;111.4&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;289.7&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(1)&#160;the Company completes a Merger Transaction, or&#160;(2)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#x201c;Performance Condition&#x201d;),&#160;neither&#160;of which may ever occur. Accordingly, there can be no assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#x2019;s market capitalization increases&#160;significantly.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;14&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;In October 2020, the Company&#160;achieved&#160;the first&#160;Valuation&#160;Milestone.&#160;Subsequently, the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;6.5&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million&#160;in total&#160;for&#160;all Plan participants (after the March 2023 Plan amendment), subject to future satisfaction of a Performance Condition.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;During the year ended December&#160;31, 2021, the Company achieved &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;11&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;74.9&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million up to a hypothetical maximum of $&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;202.3&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;million (after the March 2023 Plan amendment), to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;no&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;compensation expense was recorded&#160;since no&#160;grant date has occurred and no&#160;Performance Conditions are considered probable of being met.&#160;There is no continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;No Valuation Milestones were achieved during 2022 or the three months ended &lt;/span&gt;&lt;span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;March&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;No&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; actual cash payments were authorized or made to participants under the Plan through May 1, 2023.&lt;/span&gt;&lt;/p&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;&#160;&lt;/span&gt;</sava:CashIncentiveBonusPlanTextBlock>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_3_31_2023_srt_TitleOfIndividualAxis_sava_IndependentDirectorsMember"
      decimals="INF"
      id="ct-nonFraction-4399b6ec-ef12-47cd-aaf7-0ac3de515ec9"
      unitRef="Unit12">0</sava:CashIncentiveBonusAward>
    <sava:PerformancePlanValuationAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-9"
      id="ct-nonFraction-0b4f3888-fd57-4aae-9959-8db74f4d7953"
      unitRef="Unit12">5000000000</sava:PerformancePlanValuationAmount>
    <sava:PerformancePlanValuationAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-6"
      id="ct-nonFraction-8111b617-e837-43d6-8725-81b02f08e5a1"
      unitRef="Unit12">200000000</sava:PerformancePlanValuationAmount>
    <sava:PerformancePlanValuationAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-9"
      id="ct-nonFraction-5596c97a-dd7a-4a79-a247-db001783c06b"
      unitRef="Unit12">5000000000</sava:PerformancePlanValuationAmount>
    <sava:MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      id="ct-nonNumeric-7638dfab-b210-4caa-b346-b5e18267faa1">P20D</sava:MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained>
    <sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="2"
      id="ct-nonFraction-cc7b4332-a0b9-450b-96e9-172e03d7a2e3"
      unitRef="Unit14">0.67</sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment>
    <sava:PerformancePlanValuationAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementScenarioAxis_sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-9"
      id="ct-nonFraction-0cbe67e3-b122-47ed-96fb-fa8c4c0af60b"
      unitRef="Unit12">5000000000</sava:PerformancePlanValuationAmount>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_3_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-26dd58e7-6865-4fe0-99f9-f706f382cc68"
      unitRef="Unit12">111400000</sava:CashIncentiveBonusAward>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_3_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_Exceeds5BillionMarketCapitalizationMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-f9a3faac-c087-41f6-ad04-82880b354154"
      unitRef="Unit12">289700000</sava:CashIncentiveBonusAward>
    <sava:MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023"
      decimals="INF"
      id="ct-nonFraction-9834886b-cc83-4fc2-937b-22af0386dc29"
      unitRef="Unit13">14</sava:MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_10_31_2020_srt_StatementScenarioAxis_sava_FirstValuationMilestoneMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-be6942cc-7c5e-40d3-b2e5-64bd69f23e49"
      unitRef="Unit12">6500000</sava:CashIncentiveBonusAward>
    <sava:NumberOfValuationMilestonesAchieved
      contextRef="Duration_1_1_2021_To_12_31_2021"
      decimals="INF"
      id="ct-nonFraction-a9ffc803-1f7b-458a-9dfe-69feb8df7971"
      unitRef="Unit13">11</sava:NumberOfValuationMilestonesAchieved>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-0a670dee-6297-4fe2-8e5a-9f25d4dbab39"
      unitRef="Unit12">74900000</sava:CashIncentiveBonusAward>
    <sava:CashIncentiveBonusAward
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-3e994f94-5e8b-4a09-a8bf-674d6efab850"
      unitRef="Unit12">202300000</sava:CashIncentiveBonusAward>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_StatementScenarioAxis_sava_SecondThroughEighthValuationMilestonesMember_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember"
      decimals="-5"
      id="ct-nonFraction-b4e9c259-91d8-4b44-ac0f-29afd336a875"
      unitRef="Unit12">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <sava:PaymentsForCashIncentiveBonus
      contextRef="Duration_5_1_2023_To_5_1_2023_us-gaap_PlanNameAxis_sava_CashIncentiveBonusPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="ct-nonFraction-16780f2d-0dfe-41e3-b95d-6d8efc8cbaba"
      unitRef="Unit12">0</sava:PaymentsForCashIncentiveBonus>
    <us-gaap:LossContingencyDisclosures
      contextRef="Duration_1_1_2023_To_3_31_2023"
      id="ct-nonNumeric-a33425ed-3770-4a8c-a52b-f3ecd441d748">&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;"&gt;Note 11. Contingencies&lt;/span&gt;&lt;p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;From time to time, the Company may become involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;and Citizen Petitions submitted to FDA, and may receive inquiries from government authorities relating to matters arising from the ordinary course of business&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to the Company. No information is available to indicate that it is probable that a loss has been incurred or can be reasonably estimated as of the date of the condensed consolidated financial statements and, as such, no accrual for these matters has been recorded within the condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Government Investigations&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On November 15, 2021, the Company disclosed that certain government agencies had asked it to provide them with corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and will continue to cooperate with government authorities. No government agency has informed the Company that it has found evidence of research misconduct. No government agency has informed the Company that any wrongdoing has occurred by any party. No government agency has filed any charges against the Company, or anyone associated with it. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency may pursue an enforcement action against the Company or others.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;"&gt;Securities Class Actions and Shareholder Derivative Actions&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 120.0%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Between August 27, 2021 and October 26, 2021, &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On June 30, 2022, a federal judge consolidated the &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;four&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; class action lawsuits into &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;one&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of the Company&#x2019;s securities between September 14, 2020 and July 26, 2022. Briefing on defendants&#x2019; motion to dismiss was completed on January 23, 2023&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; and an argument on defendants&#x2019; motion was held &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;on April 26, 2023&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;.&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; The Company believes the claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s board of directors. This complaint relies on the allegations made in Citizen Petitions that were submitted to &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;(and subsequently denied by) &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#x2019;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Since November 4, 2021, &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;three&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, and one in Texas state court (Travis County District Court). &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;All four actions have&lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; been stayed pending the resolution of the motions to dismiss in the securities class actions. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On July 5, 2022, the three federal court actions were consolidated into a single action.&lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#x2019;s board of directors. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the 2020 Cash Incentive Bonus Plan in August 2020. The complaints seek unspecified compensatory damages and other relief. On &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;January 6, 2023, the plaintiffs filed an amended complaint. &lt;/span&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Defendants filed a partial answer to the amended complaint on March 10, 2023, and moved to partially dismiss the amended complaint on March 14, 2023. Defendants&#x2019; motion to dismiss remains pending. &lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;Although the plaintiffs in this derivative case do&lt;/span&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; color: #000000;font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.25in;"&gt;&lt;span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"&gt;The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.&lt;/span&gt;&lt;/p&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="Duration_8_28_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="ct-nonFraction-b24d63be-de73-417f-ba4e-12cc1e01ea33"
      unitRef="Unit13">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="Duration_8_28_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="ct-nonFraction-a75cc3af-d31f-4669-829b-e47e71cc9b28"
      unitRef="Unit13">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <sava:NumberOfClassActionsConvertedToCase
      contextRef="Duration_6_30_2022_To_6_30_2022_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="ct-nonFraction-9715dfa0-f571-4719-8d3a-1c565b6d3519"
      unitRef="Unit13">1</sava:NumberOfClassActionsConvertedToCase>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="Duration_11_4_2021_To_11_4_2021_srt_LitigationCaseAxis_sava_ShareholderDerivativeActionsMember"
      decimals="INF"
      id="ct-nonFraction-69d5669e-9173-4349-ba01-fd631d0b2d87"
      unitRef="Unit13">3</us-gaap:LossContingencyNewClaimsFiledNumber>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M9P#;"L#O2PFDN5W8B]OFHG[^/U!+ P04    "  D2Z%6P'W[VM,"  #Q"0
M&    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*V676_3,!2&_XH5$ )I--]-
M.]I(6R<T+I"J3< %XL)-3AMK3AQLMQW\>HZ3+#1;UH]!+UH[.>_KYS@G/9YL
MA;Q3&8 F]SDOU-3*M"[/;5LE&>14#40)!=Y9"IE3C5.YLE4I@::5*.>VYSA#
M.Z>LL.))=6TNXXE8:\X*F$NBUGE.Y:]+X&([M5SKX<(-6V7:7+#C24E7< OZ
M2SF7.+-;EY3E4"@F"B)A.;4NW/.9ZQA!%?&5P5;MC(E)92'$G9E\2J>68XB
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MPK<-D\8 _M\(H0\3LT'[M;3X'U!+ P04    "  D2Z%6(8,.P\X$  !%&@
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M=GI[SEB2H)L:Q,7Q8Z@H$HN=MQ4,3,KF M\Z,%N2+AD=<36*HG&M1)_$8:+
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M.]@!'LT5:VL$E%:DP-;JO%WB;@5AD9S88MA*("RUEO#IO*I,""32N1DAX>T
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MT5L.UT^R(LPV>X$D_D\JN.-L+)4YNH3[Z8*5%&%GU(Q;Q7!F@\:SVE%3 +.
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M1D]\0^&LDY\TU(N:.GJ".H9+*4RFX5RDF/[N[Y/,5FNTU[J(CA)>,M6%..Q
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MT3EN ZZ[+W2+8.LXHQ<V8.+'3^F=[$0 _Y<6O;Q?B('MI6W^#U!+ P04
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M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6R-56U/VS 0_BNG;)I
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M8CH?35#V1>$5; DJ(#E9 RG#CFXK!<[L2%RX]S#Z'I7Q%;ZN CK/]9:YCY7
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M"W!_J;7;_& 'W5O2\[\ 4$L#!!0    ( "1+H586B/,LE0(  .H%   9
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MFYR_& D7/UG$BV!K_DRPM"'8DG_F&LHX6H#G*XN<3!=T0/?=Z.I_4$L#!!0
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M I@ QM9[( @69=O1KH*S$-D+@B#94I(O*:VB)/WY<^' 9 AO29^",[KDS16
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ME54NVUNUB;FWG?%!)^S%VQ88R66[G(EK3(8581-&'#";]8K&<<P0*'1" !(
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MG$KW9/IE0=JPHW E$CDZL+[CJ_OBI#N8D^:VJ3]F/6;?5\F7]"0*.AU:]?C
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M +8RC5C)>^3,]I 3)YAX?JK\CHJ6'"VUDS&2M2?\LT[X;;4G\DY,KJU]#K-
M3]\T\ PPOS*=PP8E@T3N_TK&623CID _, "+!9*B7\@2'_!Y"#Y2(C 7,KK$
M2-DD(ZB-AC<IY#5J"7;[!Y)/&+4UX(1/0X$+LF:(") .YG-UWYY *W;H W/)
MVE)R3/FE?P_3TX/1:2/W.#,+),/!/U%N%HHF O%>96J] 'WW5^?3D1AV$6/8
MQ6CH>=<Z=-1.W*GEP>CUC2!VXA;J'+"1;P*)W)' Q"G2OP*D-=YKE(5$IDRS
M862X@819ALR9WJ<85E &L CGMY5NV$WYP_I>Y/OO7LQG%Z]=@$9E".<U!7D)
MD"XF#!&>A_**ZP<4D:F)!CBX,BBQW+;+$##ELC*07V1N3"POHEA>C/+TUII,
M*0AO']!S_<W* Y(9A3*<V4;010<:/<JS^<7+U^)]5Z[T\D>%O8 =K21; P9N
M\ ]X$:OT>M%:Y_,(R%@4Q"SPDW"M]>;SB1@/UG[CDS%. S\J64)X?X(RFI^^
M_G3SD3[-7C_M"I4EH3K]%A3G@OU!DD0Q2CNH-J:1)0+]BSB=S@0$HQ+ULX?X
MS<=]5'83-)NSOM8]'G/!Q.]@Z(4,NLU8_P"P)E9YP*1*B::%>G(T7WT9E>KE
MJ%+=-2;[<OR.C ZQ!L@DC2'%>@RDQ1ZD3H\.I*Z5J8[9%3)A%/V;/;>)WM[A
M&6"KWE!CM'<K,%I_MMQ(8/E KH @WY42D+S+5J9$)2- @MT*?EJ;'"PX:%SO
MX:A[()[@X/<B&Z#90W$BT&^P7N*'4AW[,PE+(6O0"NEEC/TI;#L>(V?!WS=6
M+UI&2T&^GOM\FG&T&#=LFFW2X>WB-\598;^=$SH#R.(,HSVCR=G*O<%@!<$?
M(F5\H-0%9VZAJ,]1+H4"^[1LGXH01SI"*IN>296A(ZR2OD4!-1\""-D%=EVT
M9Q5GTNA]=;6B@ X^OZVP.H2,;1*Z+E8!'E Z</9"]/K&AER2Z?[5B=_:G-ST
M5'P 74+-"3I#%J?R"8:61 >Y%8/=C9UZ TPSJ"5*;4=(U'D1X/998;% [EHY
MD4< N/922;5C(I:J@JB#H:TPK15;L'<GIL,&LY(1^0%UY\P$S^<4!H[5X#)"
M9/(\[$7*#))JP%-&=;]-;EX1U*#S.[4V<JDNM6=;U5(" J?L \"D<M]$N*&X
M!A<=^%'UVG%$YM?L+-4^2-?3UI/0ZQK;OHW \(8:[@6"CH4YLYLV1&;@(SN*
M/>2S'J4O02T.H0/)<85Z"$;@4W5.RR.&%#:&L 2E \>QX/("J&> 6*>5B.8]
MCCO(7MHZ9Z8X]C5@\,C.G6YB<0A%!L+X.;*?J%MC^$V'5(&4D\$EH@=*-'B-
MD'KOZ.W! T8BW^RTFY:<CD:L3^" ?C20U &VX@YM:G P\D@@=0 R;+] =4V9
M#?J,3%3P6AE>(WL.5N!]"A._H4&4RH^AS++@WQ)K"VS$=^%YJ!$:X"ZIHX^?
M^[WE][ILT8$,G*Y=0#'_WV%2@]J(VC381(#\+L?CT0T>?J.+EXWO^1VSHH08
M>/LU:$G@20'W'4YH2_]"R:K&)"36D:!G"]5LE*K2/#%6"I%W7I<ABU[A8/->
MT65V&< <K">,]96 JLP:BEJZH!EN4B4BKJP67#8<%!)EU1);,R44J$X\(5BF
M=9(:J>HA4W4S]")V59Z^ M2^DKYS@OPI8/]*? JP_B*>B/GY9'XQ$T_IR^QB
M EH.7]YWQ+UB"^@:7ZQ2R/]]I"8#-)_/)A=G+\79R\G+Y_/N\-%W$)G3Z;,7
M'J_3Z?DY8K6K';W4$3B%'M=W@89P"]#GD].S<_S[XGE_-!,@#,+OF://]W<E
M/G(JD*DRV3H.?(KG8M2%"(E<>D X=$-C&>K(+%![(8IJ<1SMI!_,N-<9B'AV
M,9F=GV%(@ZPS21!]=O&G2, 1;(EO07"$F*C]9 2TXN\MY$ZD:5\C\Q!"7R-U
M+#XDT_398UOP/Q?B0VQ*W70-KL& ,0IUN !/CC('CDJN]EO\/&6)@Y5:;F/7
M%2[:5NUUY56:U/=[4SY1'.[FK>46VV:Y@B"\IO8(N^O8Z^QZK5U#)W:(TP0D
M*;G(KYO2+ FYCV8#\=].XF2)P(9\'CVUKWS(O5!S"+A('B9M($/RZ$OFG>HC
M4OLZK26:56]X2:T+]*.9<DY:7>+0#M,K<B@^((;)-.5L/!%=8,R5)?43@>Q-
MN%A+FI]!^4 #8*##XPKVMY+5TIMF9P#,UJZQ&7JQZ;"\RD\P5V6L]S@99(44
M692C;U,."MZ3PEADTMHM2349O3]2N8AUQ [7Q((.Q?[@69L<FK<J(.56D*>$
M2>66&8P3[$3W1IL=LWEGTO-1D_X<FBK7IJ)U$/C@_ 3Y"ND!MSAHTW\.K$S
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M?=;&S8".J?LL];MG*4,I^[]R*:S_N'!<;@BDW]#HM7AQE82Z^;P?P!41K_>
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M/_KM'N??3D/^L,0?,I6J@%=/IQ=0=UG^.3)_:4Q-/P%>F*8Q:_JX4A+"%SX
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M>]3.@?:W2MF#X0[H_A_SWU!+ P04    "  D2Z%6C]$U-H<"  #+!0  &0
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MI&7.'5X9^5,4OIRP<P8%+OA*^GNSN<96SR#@Y4:Z>H1-$YLF#/*5\T:UR<1
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M- L;E(P+E(8K"1KGHV#2/9KVG;]W^,%Q:39L<)G,E+ISD_-L%$2.$):86H?
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M%A@,+\<8J;8#6\/(RA?Q1AK;$GY;V*$%RCG8^ZV4YF"XONC'8/H;4$L#!!0
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M+@UV8C=<XET)R@;@\U1*LYO8#>K;-_H+4$L#!!0    ( "1+H58!!%-Q! ,
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M+0AQ3-)8W?/Y=RST- Q>P&.9/6%>^#H6!*E4/"F"-8.$LOQ-%L4^K 1HG.H
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M*4@3@-\W0NCCQB1H[3G^!5!+ P04    "  D2Z%60\1#90\$  "L%@  &0
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M6%,+A&2-LUA^9/N_25G06.,%+!;Y)]B7L8X%@DQ(EI3)BD$2T>(;_RB%:"3
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M-/@0L +6?"OQ2N^_0JOGU/'E6EK_R_9-[&D4L'QK45<MF"JHA&J^_*[MPQ&
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M4+\OLBQ__5)DL'T9Q?3_4$L#!!0    ( "1+H59A%"J=Q@,  #01   9
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MJH$VXB5:QZ#I"+^._([?#\.;@;MN<K+N>B:G;LVI:^=4192%<K;<O]$E#2M
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M!Z$-\'O,N=H,] +5OX'@+U!+ P04    "  D2Z%6^5.T9+$'  #&1@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6S%G.]OVC@<QO\5BYM.FW0J).%'
MNVN1UL;355IWU;KM7DSWP@07LB4Q<T)II_OCSPX08QH,V3WH^H)"B#_^\82O
M_7TP.5\(^2V?<EZ0QS3)\HO6M"AFK]OM/)KRE.4G8L8S]<Z]D"DKU$LY:><S
MR=FX+)0F;;_3Z;=3%F>MX7EY[%8.S\6\2.*,WTJ2S].4R:=+GHC%1<MKK0]\
MB"?30A]H#\]G;,+O>/%I=BO5JW9%&<<IS_)89$3R^XO6&^\U[?JZ0'G&YY@O
M\HWG1'=E),0W_>)Z?-'JZ!;QA$>%1C#U[X%?\231)-6.[RMHJZI3%]Q\OJ:_
M+3NO.C-B.;\2R5_QN)A>M$Y;9,SOV3PI/HC%'WS5H9[F12+)RT>R6)W;:9%H
MGA<B7156+4CC;/F?/:X&8J. [^THX*\*^-L%!CL*!*L"P:$%NJL"W>T"_HX"
MO56!LNOM9=_+@0M9P8;G4BR(U&<KFGY2CGY96HU7G.D+Y:Z0ZMU8E2N&?L?O
MD"N63\EU%O%,JT8N13;/R6W",O+R/9.2Z:.OR,N0%RQ.\E?G[4+5K,NWHU4M
M5\M:_!VU!.1&9,4T)S0;\W%-^=!=WO,=@+;J<M5O?]WO2]])O&%/I./]1E3_
M _+I+B0O7]3V:Q]%GI!@"T/B@J=U?72S0AY5+&\?B[I9?T9%Q>K4=\\:M:"Z
M6H*2&^S@[KY0OKQ3IY)KU=K\[YKV7BZYW7JNCH:O\QF+^$5+A;N<RP?>&O[Z
MB]?O_%XG"A(6(F$4!+/$Z5;B=%WTX4V<Q>D\)=D\'7%)Q#UY8,F<E?$XC1.N
M8DG&<U((%> C,<GB'YQ$(E533KX\B3_JYYS\L^NJNW0VH*F*2UBOA.GY[&'H
M=<_;#YO:(.NC()BE3:_2IN?4YGVER>=*DQNCR9MH&O,'/G8,O9/?=.B1L+#W
M7$?/UI&"ZK.&OE\-?=\Y]-=JQE#7]5C%+!+&ZM(OA,S)EQNN%:F-54Y>TZ%&
MPD(DC()@EBB#2I3!D2:2 5(<)"Q$PB@(9HES6HESZOS$E.*,2DG8@LFZ]=JE
MD]!4AB6LOQ%!.EL3 ;(Z"H)98WM6C>W9_K&MO_ =$<G);#K:2%B(A%$0S!+&
MZYA,J'.DF+0"@_2!TD(HC:)HMD0;R:IWT!+7+*="]I37K:E(JG)G,N*$K9=6
M+!L3[9RH'#:KS4$OW94WEM'=%967C57;:R5#MH.B:+9DOI',=_;SEDO]B6(3
MKN7B2@X2;<TOA.6YB&)6*)46<3&MU3.?C[ZJM9M.7]CXJQ(WU0LZ+2J;S:10
MJ4ZMI,[&-99T2=,? C-3G?0'6Y,5M%**HMGZF8S?<^:L!TQ8*FFYFX]R_GVN
M%:$/^M$UF;DK;*P)U R TBB*9DMG_ "O>ZP)#9KH0VDAE$91-%LB8PMX;E_@
MECWI.*8"X;R8"AG_4"%02#5/C;F.=#,FBSB*9TR?,E<YK"3%E)<:ULK6V[>0
MOG*WI[$62!I%T6PMC$_@N8V"@R(=?8PX'\?9A*B)K?R>1A78M'+62Q1MJXLL
MY]&\I)7K%&=4A+H.4%H(I5$4S9;9. _>L:P'#^H]0&DAE$91-%LBXS]X;@/B
M\W/?FK!4S-7"(E;'F/S&"[6*G,4%2^(?Y9FU>D%-"N^Y2]'KK/^V5X!0OP)%
ML]4PCH7W7RT+%1??QE+E6W4+=V?0@QH;4%H(I5$4S?ZRTW@;_K&\#1_J;4!I
M(91&431;(N-M^&Y#X!#7U8UH+ :2%D)I=$7;C+;]GAUJ[7$VAH3O-B0.2VAY
M)+(Q^3B58CZ9$JJWF]3Z$NY%G;LIC?5"TD(HC:)HMJC&I?"/M3'!A[H14%H(
MI5$4S9;(N!&^>WO"5<U6@UI!H-Z#_WR7P?9B#5HA1='L43:&@N\V%-;IYT8L
M^[FOG-SU-)8!:CM :11%LQ4SMH/?/U;H@EH&4%H(I5$4S9;(6 :^,]]%Y:/N
M6AKK-7@6V?P=Z2BT8HJBV6(8<\!WFP,_%>$JYRXG+WKD,DZ2<A6W5.[*4HZ\
M%9*\%^0=SW.U %20+2OOHV2E ;C7TG-WI+'>2%H(I5$4S;XDC$/AGQTKA$(-
M""@MA-(HBF;O&S8&1.#,G@_*;MV(QIN$.S7[$KUN77R$5DQ1-'NDC8\0'+9'
MHFE\!*6\[M8U%A%J44!I%$6S=38^1N ?*>@%4%<"2@NA-(JBV1)M_%KB@+T3
M^X(>]I<1V)]&!,],N$'WK":"4E2]]D ;;R%P>PLW[!&3];KK::P&=.,#E$91
M-%LQXU,$O6-%+Z@Q :6%4!I%T6R)C#$1N/=#@+)>=RV-]>H_6]7M_!866C-%
MT6PUC <1N#V(GPIQ_TO:Z^Y(8\&AVR2@-(JBV9>$<4*"TV/%4*@S :6%4!I%
MT6R)C#,1'+!W8M\*$.I!K&B;:S;_]&Q0&Q^A!@.*9O_VU1@,7;?!\+/Q$93V
MNEO75$0H+832*(IFZVSLC:YWI*#7A3H34%H(I5$4S9;(.!/= W98[ EZ;D1C
M,: >Q(IFA=".']3EO:B*ER/=WKB/1\KEI+R!2DXBO>9>WM*C.EK=I.5->6N2
MMCE]>8<7M<:;Q%E.$GZOBG9.!FK%+)<W35F^*,2LO"O(2!2%2,NG4\[&7.H3
MU/OW0A3K%[J"ZM8UPW\!4$L#!!0    ( "1+H59[PTR5'0,  /0,   9
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M:K:!<1\<87O+A$#-O?U\J^:@&[6312O(P"9(FV:1);,&R&$-<MBY21>%-/4
MQ10KI+BLUGI7%D2*-HZ=?J=RM&D6E69#8Z9?A]LPF+K;%CBC&LZH$\Y]H1]+
M_?0>TA$H9OD6N(0$289B]59JXS1Z%4V_CJ9,OG/Q4Y.W9-;@=%%SNNCD])AB
M#BFCJKJI=S(GVW)+[7%UE;=.XU-WDTVSR))9 ^BX!CJV7=[&-D':-(LLF35
M3FJ0$\OEK=/O5(Z35S5@T*P!D:7E2CCNP3DQ [XVYVU=KHI<ED?&>K0^TE^9
MDZS[=WKY/7"'^9JH9Y?"2DF]WH5*@I=G[+(CV<:<.I=,JC.L::;JLP2XGJ"N
MKQB3^XY>H/[0"?\ 4$L#!!0    ( "1+H58#U[=Q)P,  &82   -    >&PO
M<W1Y;&5S+GAM;-U8;6_:,!#^*U&Z3JTT-4!&2E9 VI J3=JF2NV'?:L,<8(E
MQ\X<T\%^_7QV""_U(=8/6UD0C7V/[[G'=Y<Z8ECK%:?W<TIUL"RYJ$?A7.OJ
M0Q35LSDM27TE*RH,DDM5$FVFJHCJ2E&2U>!4\JC7Z21129@(QT.Q*&]+70<S
MN1!Z%/9;4^!NG[-1V$W>AX&CF\B,CL+'B[<_%E+?O G<_>S=V5GG\?)FWWYA
M@<LP\I+VCR"]ZG1P8@ Q\N0X\D/<&/7U4=0'F#'BP2ZQ77UN>)S?N76+FH*-
MA[D4F[K%H3,87E+2X(GP43@AG$T5 Z^<E(ROG+D'AIGD4@7:-(P)U 5+_<O!
M73>#7FIX2B:DLK%=!/=WVBS? ]8S$,@X;P7V0F<8#RNB-57BUDSL8FM\!@7-
M^&%5&86%(JMNKQ]N'.S-!)E*E5'5ANF&:]-XR&D.<A0KYG#7LHH U%J69I Q
M4DA!K(:U1S,PM#/*^3T\:-_S'>YEOE6Q#M1+M$,CJ!DZ&C<!_FTVQ[U-^S+>
MH&)/4G]:F.T(.X<6HW>*YFQIY\N\%8"Q=W%V4E5\]9&S0I34;?[H@.,A6?L%
M<ZG8+Q,-6F5F#%2%P1-5FLVV+3\5J1[H4J_;:9GCFGLGJ/GOYKF@@BK"MT6;
MWG_-67ZQXOCZ7TFV_U7V!7LU-J?G:Q?9/P61R2F(/(F>'+Q*D5%S-FX=P#O'
M;VL-X#5G%'Z#UR6^"1I,%XQK)IK9G&49%<].84.OR=2\1._PF_49S<F"ZX<6
M'(6;\5>:L469MJON(!'-JLWX"VROF[3O6"86$QE=TFS23%4QM</ #$S4Y@*'
M?>367GX$\W&8'P$,BX,IP'R<%Q;G?]K/ -V/PS!M R\R0'T&J(_S\B$3^\'B
M^'U2<_EWFJ9QG"181B<3KX()EK<D@:^?#=,&'E@<B/1GN<:KC7?(X3[ :GJH
M0["=XIV([13/-2#^O(%'FOJKC<4!#ZP*6.] ?'\<Z"F_3QQ#53%MV!.,(VF*
M(="+_AY-$B0["7S\]<&>DCA.4S\"F%]!'&,(/(TX@BD #1@2Q_8<W#N/HO4Y
M%6U^61K_!E!+ P04    "  D2Z%6EXJ[',     3 @  "P   %]R96QS+RYR
M96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY
M/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL
M/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%
MY4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.
MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( "1+H5;Z@U5WN0,  ' <   /
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ME8?=!'JQ-N8,RR[L5Z?JS8;99K/O_6]02P,$%     @ )$NA5K[+,T&9 0
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MSE'O_)UZAWBM?'CV/-9X_W=2'6_7^N?M[\O'9N^YW'%V\)=E]0M02P,$%
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M@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M (:M (:M
M(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:S)?Y+U7>O5
M7_]+:->X5F5S]&?=#YOY)U!+ 0(4 Q0    ( "1+H58'04UB@0   +$    0
M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M)$NA5C 7CWOO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ )$NA5IE<G",0!@  G"<  !,
M ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  D2Z%6KA\6
M)OL%  #Z'P  &               @($."   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ )$NA5@&@LFJH!0  M!<  !@
M ("!/PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "1+
MH5; ??O:TP(  /$)   8              " @1T4  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  D2Z%6(%1%M,D#   Y#0  &
M        @($F%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ )$NA5B&##L/.!   11H  !@              ("!)1L  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "1+H59%%I1B6@4  $T6   8
M              " @2D@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  D2Z%6P;_<2#L&  !G#@  &               @(&Y)0  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ )$NA5KEM>61K$@
MUS8  !@              ("!*BP  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( "1+H59XE8D*RP(  ,@&   8              " @<L^
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  D2Z%6_+K<
M($4$  # "0  &0              @(',00  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( "1+H59M>I=?$0,  !('   9
M  " @4A&  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M)$NA5H"S.F07 P  ;0<  !D              ("!D$D  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  D2Z%6"F98@.$'   Q%0  &0
M            @('>3   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( "1+H586B/,LE0(  .H%   9              " @?94  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ )$NA5EZI+12\ P
MC @  !D              ("!PE<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  D2Z%6N%QRZ4X)  !#&@  &0              @(&U
M6P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "1+H580
M\ B!L@D  %(;   9              " @3IE  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ )$NA5E\W0C![$P  (#X  !D
M     ("!(V\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "1+H58\Q,43TP(  +H&   9              "
M@1J.  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ )$NA
M5I_=M/L* P  <P<  !D              ("!))$  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  D2Z%6Q94["S "   2!0  &0
M        @(%EE   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( "1+H5:P5EL;E00  "@7   9              " @<R6  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ )$NA5M<VXJ5N P  ( L
M !D              ("!F)L  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  D2Z%65>44,+<"  !I!P  &0              @($]GP
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( "1+H588^E[&
MQ0(  (D'   9              " @2NB  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ )$NA5@$$4W$$ P  GPD  !D
M ("!)Z4  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  D
M2Z%6G[\$]%,"  "J!0  &0              @(%BJ   >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "1+H59#Q$-E#P0  *P6   9
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M970S-BYX;6Q02P$"% ,4    "  D2Z%6810JG<8#   T$0  &0
M    @('DP   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M "1+H59)2#P/0P,  !0,   9              " @>'$  !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ )$NA5L7WQ%Q# @  D@4  !D
M             ("!6\@  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  D2Z%6\@W*0C4#   9#   &0              @('5R@  >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "1+H5;Y4[1DL0<
M ,9&   9              " @4'.  !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ )$NA5GO#3)4= P  ] P  !D              ("!
M*=8  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  D2Z%6
M ]>W<2<#  !F$@  #0              @ %]V0  >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( "1+H5:7BKL<P    !,"   +              "  <_<  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( "1+H5;Z@U5WN0,  ' <   /
M      "  ;C=  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  D2Z%6OLLS
M09D!  !U&0  &@              @ &>X0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  D2Z%6(]5N#:@!  "X&0  $P
M    @ %OXP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ,@ R )4-  !(
%Y0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>91</ContextCount>
  <ElementCount>177</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements Of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements Of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Consolidated Statements Of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements Of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00500 - Statement - Condensed Consolidated Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - General And Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity</Role>
      <ShortName>General And Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Prepaid Expenses And Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses And Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Real Property</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureRealProperty</Role>
      <ShortName>Real Property</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Property And Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property And Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpense</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureCommitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - 2020 Cash Incentive Bonus Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan</Role>
      <ShortName>2020 Cash Incentive Bonus Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureContingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Significant Accounting Policies (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy</Role>
      <ShortName>Significant Accounting Policies (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Prepaid Expenses And Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses And Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Real Property (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureRealPropertyTables</Role>
      <ShortName>Real Property (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureRealProperty</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Property And Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property And Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpense</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40101 - Disclosure - General And Liquidity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails</Role>
      <ShortName>General And Liquidity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Real Property (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails</Role>
      <ShortName>Real Property (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureRealPropertyTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Real Property (Components Of Other Income, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails</Role>
      <ShortName>Real Property (Components Of Other Income, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureRealPropertyTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Property And Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property And Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property And Equipment (Components Of Property And Equipment, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets (Components Of Intangible Assets, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation Expense (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense (Stock Options And Unvested Performance Award Outstanding Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation Expense (Stock Options And Unvested Performance Award Outstanding Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40706 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense (Stock-Based Compensation Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails</Role>
      <ShortName>Stockholders' Equity And Stock-Based Compensation Expense (Stock-Based Compensation Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Commitments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails</Role>
      <ShortName>Commitments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureCommitments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>41001 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails</Role>
      <ShortName>2020 Cash Incentive Bonus Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sava-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails</Role>
      <ShortName>Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/role/DisclosureContingencies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sava-20230331x10q.htm">sava-20230331x10q.htm</File>
    <File>sava-20230331.xsd</File>
    <File>sava-20230331_cal.xml</File>
    <File>sava-20230331_def.xml</File>
    <File>sava-20230331_lab.xml</File>
    <File>sava-20230331_pre.xml</File>
    <File>sava-20230331xex31_1.htm</File>
    <File>sava-20230331xex31_2.htm</File>
    <File>sava-20230331xex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sava-20230331x10qg001.jpg</File>
    <File>sava-20230331x10qg002.jpg</File>
    <File>sava-20230331x10qg003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="284">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>61
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sava-20230331x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 284,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 91,
   "dts": {
    "calculationLink": {
     "local": [
      "sava-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sava-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sava-20230331x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sava-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sava-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sava-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 296,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://xbrl.sec.gov/dei/2022": 7,
    "total": 16
   },
   "keyCustom": 21,
   "keyStandard": 156,
   "memberCustom": 16,
   "memberStandard": 18,
   "nsprefix": "sava",
   "nsuri": "http://www.cassavasciences.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Real Property",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cassavasciences.com/role/DisclosureRealProperty",
     "shortName": "Real Property",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Property And Equipment",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment",
     "shortName": "Property And Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpense",
     "shortName": "Stockholders' Equity And Stock-Based Compensation Expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cassavasciences.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Commitments",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cassavasciences.com/role/DisclosureCommitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - 2020 Cash Incentive Bonus Plan",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan",
     "shortName": "2020 Cash Incentive Bonus Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cassavasciences.com/role/DisclosureContingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDisclosures",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Significant Accounting Policies (Policy)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy",
     "shortName": "Significant Accounting Policies (Policy)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Prepaid Expenses And Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses And Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Real Property (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.cassavasciences.com/role/DisclosureRealPropertyTables",
     "shortName": "Real Property (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Property And Equipment (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property And Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:StockOptionAndPerformanceAwardActivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables",
     "shortName": "Stockholders' Equity And Stock-Based Compensation Expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:StockOptionAndPerformanceAwardActivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - General And Liquidity (Narrative) (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails",
     "shortName": "General And Liquidity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "sava:ReductionToResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "sava:ReductionToResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "sava:PercentageOfOccupancy",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit14",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Real Property (Narrative) (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails",
     "shortName": "Real Property (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_AssetAcquisitionAxis_sava_TwoBuildingOfficeComplexAssetMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "sava:PercentageOfOccupancy",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit14",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit15",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Real Property (Components Of Other Income, Net) (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails",
     "shortName": "Real Property (Components Of Other Income, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_srt_StatementGeographicalAxis_sava_AustinMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherNonoperatingIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Property And Equipment (Narrative) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
     "shortName": "Property And Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Property And Equipment (Components Of Property And Equipment, Net) (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
     "shortName": "Property And Equipment (Components Of Property And Equipment, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Intangible Assets (Narrative) (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Intangible Assets (Components Of Intangible Assets, Net) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails",
     "shortName": "Intangible Assets (Components Of Intangible Assets, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails",
     "shortName": "Intangible Assets (Amortization Expense For Finite-Lived Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense (Narrative) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
     "shortName": "Stockholders' Equity And Stock-Based Compensation Expense (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_4_30_2023_To_4_30_2023_us-gaap_PlanNameAxis_sava_AtMarketEquityProgramMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "sava:StockOptionAndPerformanceAwardActivity",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense (Stock Options And Unvested Performance Award Outstanding Activity) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails",
     "shortName": "Stockholders' Equity And Stock-Based Compensation Expense (Stock Options And Unvested Performance Award Outstanding Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "sava:StockOptionAndPerformanceAwardActivity",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit1",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40706 - Disclosure - Stockholders' Equity And Stock-Based Compensation Expense (Stock-Based Compensation Expenses) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails",
     "shortName": "Stockholders' Equity And Stock-Based Compensation Expense (Stock-Based Compensation Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Condensed Consolidated Statements Of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements Of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sava:ResearchAndDevelopmentExpenseNetOfGrantReimbursement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Commitments (Narrative) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails",
     "shortName": "Commitments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sava:MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - 2020 Cash Incentive Bonus Plan (Narrative) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
     "shortName": "2020 Cash Incentive Bonus Plan (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sava:MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_8_28_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Contingencies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails",
     "shortName": "Contingencies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_8_28_2021_To_10_26_2021_srt_LitigationCaseAxis_sava_ViolationsOfFederalSecuritiesLawsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit13",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Condensed Consolidated Statements Of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements Of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit12",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Condensed Consolidated Statements Of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements Of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit12",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - General And Liquidity",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity",
     "shortName": "General And Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:PrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Prepaid Expenses And Other Current Assets",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses And Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sava-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sava:PrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 36,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sava_AtMarketEquityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Equity Program [Member]",
        "label": "At Market Equity Program [Member]",
        "terseLabel": "ATM [Member]"
       }
      }
     },
     "localname": "AtMarketEquityProgramMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_AustinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Austin [Member]",
        "label": "Austin [Member]",
        "terseLabel": "Austin, Texas [Member]"
       }
      }
     },
     "localname": "AustinMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_CashIncentiveBonusAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Award",
        "label": "Cash Incentive Bonus Award",
        "terseLabel": "Cash bonus award"
       }
      }
     },
     "localname": "CashIncentiveBonusAward",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_CashIncentiveBonusPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Cash Incentive Bonus Plan [Abstract]",
        "label": "2020 Cash Incentive Bonus Plan [Abstract]"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanAbstract",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "xbrltype": "stringItemType"
    },
    "sava_CashIncentiveBonusPlanLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Plan [Line Items]",
        "label": "Cash Incentive Bonus Plan [Line Items]"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanLineItems",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_CashIncentiveBonusPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Plan [Member]",
        "label": "Cash Incentive Bonus Plan [Member]",
        "terseLabel": "Cash Incentive Bonus Plan [Member]"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_CashIncentiveBonusPlanTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Plan [Table]",
        "label": "Cash Incentive Bonus Plan [Table]"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanTable",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_CashIncentiveBonusPlanTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Incentive Bonus Plan [Text Block]",
        "label": "Cash Incentive Bonus Plan [Text Block]",
        "terseLabel": "2020 Cash Incentive Bonus Plan"
       }
      }
     },
     "localname": "CashIncentiveBonusPlanTextBlock",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exceeding Performance Milestones Minimum 20 Consecutive Days",
        "label": "Exceeding Performance Milestones Minimum20 Consecutive Days [Member]",
        "terseLabel": "Exceeding Performance Milestones Minimum 20 Consecutive Days [Member]"
       }
      }
     },
     "localname": "ExceedingPerformanceMilestonesMinimum20ConsecutiveDaysMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_Exceeds5BillionMarketCapitalizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exceeds 5 Billion Market Capitalization [Member]",
        "label": "Exceeds5 Billion Market Capitalization [Member]",
        "terseLabel": "Exceeds $5 Billion Market Capitalization For No Less Than 20 Consecutive Trading Days [Member]"
       }
      }
     },
     "localname": "Exceeds5BillionMarketCapitalizationMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_FirstValuationMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Valuation Milestone [Member]",
        "label": "First Valuation Milestone [Member]",
        "terseLabel": "First Valuation Milestone [Member]"
       }
      }
     },
     "localname": "FirstValuationMilestoneMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_IncreaseDecreaseInDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in development expense",
        "label": "Increase (Decrease) in development expense",
        "terseLabel": "Accrued development expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInDevelopmentExpense",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets and Liabilities, Net",
        "negatedLabel": "Operating lease right-of-use assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_IndependentDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Independent Directors",
        "label": "Independent Directors [Member]",
        "terseLabel": "Independent Directors [Member]"
       }
      }
     },
     "localname": "IndependentDirectorsMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_LeasingCommissionsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasing Commissions And Other [Member]",
        "label": "Leasing Commissions And Other [Member]",
        "terseLabel": "Leasing Commissions And Other [Member]"
       }
      }
     },
     "localname": "LeasingCommissionsAndOtherMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Number of Days Valuation Milestone must be achieved and maintained",
        "label": "Minimum Number of Days Valuation Milestone must be achieved and maintained"
       }
      }
     },
     "localname": "MinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sava_MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum number of valuation milestones to recognize compensation expense.",
        "label": "Minimum number of valuation milestones to recognize compensation expense"
       }
      }
     },
     "localname": "MinimumNumberOfValuationMilestonesToRecognizeCompensationExpense",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sava_NumberOfClassActionsConvertedToCase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of class actions converted to case",
        "label": "Number of class actions converted to case"
       }
      }
     },
     "localname": "NumberOfClassActionsConvertedToCase",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sava_NumberOfValuationMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Valuation Milestones Achieved",
        "label": "Number of Valuation Milestones Achieved"
       }
      }
     },
     "localname": "NumberOfValuationMilestonesAchieved",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sava_OperatingLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases [Member]",
        "label": "Operating Leases [Member]",
        "terseLabel": "Operating Leases [Member]"
       }
      }
     },
     "localname": "OperatingLeasesMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_PaymentsForCashIncentiveBonus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Cash Incentive Bonus",
        "label": "Payments For Cash Incentive Bonus",
        "terseLabel": "Payments authorized or made to participants under the Plan"
       }
      }
     },
     "localname": "PaymentsForCashIncentiveBonus",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_PercentageOfCurrentlyLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Currently Leased",
        "label": "Percentage Of Currently Leased"
       }
      }
     },
     "localname": "PercentageOfCurrentlyLeased",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sava_PercentageOfOccupancy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Occupancy",
        "label": "Percentage Of Occupancy"
       }
      }
     },
     "localname": "PercentageOfOccupancy",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment",
        "label": "Percentage Valuation Milestone Cash Bonus Award Subject To Approval And Adjustment",
        "terseLabel": "Percentage of each cash bonus award associated with Valuation Milestone subject to adjustment and approval"
       }
      }
     },
     "localname": "PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sava_PerformancePlanValuationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Plan Valuation Amount",
        "label": "Performance Plan Valuation Amount",
        "terseLabel": "Valuation milestone amount in market capitalization"
       }
      }
     },
     "localname": "PerformancePlanValuationAmount",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_PrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid And Other Assets Disclosure [Text Block]",
        "label": "Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_ProceedsFromGrantsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Grants Policy [Policy Text Block]",
        "label": "Proceeds From Grants Policy [Policy Text Block]",
        "terseLabel": "Proceeds From Grants"
       }
      }
     },
     "localname": "ProceedsFromGrantsPolicyPolicyTextBlock",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised Net Settled Satisfaction Of Exercise Price",
        "label": "Proceeds From Stock Options Exercised Net Settled Satisfaction Of Exercise Price",
        "terseLabel": "Proceeds from stock options exercised net settled in satisfaction of the exercise price"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedNetSettledSatisfactionOfExercisePrice",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_ReductionToResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction To Research And Development Expense",
        "label": "Reduction To Research And Development Expense",
        "verboseLabel": "Reimbursement from National Institutes of Health research grants"
       }
      }
     },
     "localname": "ReductionToResearchAndDevelopmentExpense",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_RegisteredDirectOffering2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered Direct Offering 2022 [Member]",
        "label": "Registered Direct Offering2022 [Member]",
        "terseLabel": "Registered Direct Offering 2022 [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOffering2022Member",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_ResearchAndDevelopmentExpenseNetOfGrantReimbursement": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Expense, Net Of Grant Reimbursement",
        "label": "Research and Development Expense, Net Of Grant Reimbursement",
        "terseLabel": "Research and development, net of grant reimbursement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseNetOfGrantReimbursement",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sava_ResearchContractCostsAndAccrualsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Contract Costs And Accruals Policy [Policy Text Block]",
        "label": "Research Contract Costs And Accruals Policy [Policy Text Block]",
        "terseLabel": "Research Contract Costs And Accruals"
       }
      }
     },
     "localname": "ResearchContractCostsAndAccrualsPolicyPolicyTextBlock",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_SecondThroughEighthValuationMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Through Eighth Valuation Milestones [Member]",
        "label": "Second Through Eighth Valuation Milestones [Member]",
        "terseLabel": "Second Through Eighth Valuation Milestones [Member]"
       }
      }
     },
     "localname": "SecondThroughEighthValuationMilestonesMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_ShareholderDerivativeActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder derivative actions",
        "label": "Shareholder Derivative Actions [Member]",
        "terseLabel": "Shareholder derivative actions [Member]"
       }
      }
     },
     "localname": "ShareholderDerivativeActionsMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Line Items]",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table]",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sava_StockOptionAndPerformanceAwardActivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options and perfromance award activity",
        "label": "Stock Option And Performance Award Activity",
        "terseLabel": "Stock Options And Unvested Performance Award Outstanding Activity"
       }
      }
     },
     "localname": "StockOptionAndPerformanceAwardActivity",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sava_StockOptionAndPerformanceAwardActivity2020PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option And Performance Award Activity 2020 Plan [Member]",
        "label": "Stock Option And Performance Award Activity2020 Plan [Member]",
        "terseLabel": "Stock Option And Performance Award [Member]"
       }
      }
     },
     "localname": "StockOptionAndPerformanceAwardActivity2020PlanMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options Exercised Net Settled Satisfaction Of Exercise Price",
        "label": "Stock Options Exercised Net Settled Satisfaction Of Exercise Price",
        "terseLabel": "Stock options exercised, net settled in satisfaction of the exercise price"
       }
      }
     },
     "localname": "StockOptionsExercisedNetSettledSatisfactionOfExercisePrice",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sava_TwoBuildingOfficeComplexAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-building office complex",
        "label": "Two Building Office Complex Asset [Member]",
        "terseLabel": "Two-building office complex [Member]"
       }
      }
     },
     "localname": "TwoBuildingOfficeComplexAssetMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sava_ViolationsOfFederalSecuritiesLawsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "violations of the federal securities laws",
        "label": "Violations Of Federal Securities Laws [Member]",
        "terseLabel": "Violations of the federal securities laws [Member]"
       }
      }
     },
     "localname": "ViolationsOfFederalSecuritiesLawsMember",
     "nsuri": "http://www.cassavasciences.com/20230331",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case Type [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r163",
      "r165",
      "r166",
      "r167",
      "r187",
      "r269",
      "r280",
      "r299",
      "r300",
      "r309",
      "r311",
      "r316",
      "r346",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r163",
      "r165",
      "r166",
      "r167",
      "r187",
      "r269",
      "r280",
      "r299",
      "r300",
      "r309",
      "r311",
      "r316",
      "r346",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r163",
      "r165",
      "r166",
      "r167",
      "r186",
      "r187",
      "r216",
      "r217",
      "r218",
      "r268",
      "r269",
      "r280",
      "r299",
      "r300",
      "r309",
      "r311",
      "r316",
      "r341",
      "r346",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r163",
      "r165",
      "r166",
      "r167",
      "r186",
      "r187",
      "r216",
      "r217",
      "r218",
      "r268",
      "r269",
      "r280",
      "r299",
      "r300",
      "r309",
      "r311",
      "r316",
      "r341",
      "r346",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r118",
      "r188",
      "r324",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r310",
      "r315",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r286",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r310",
      "r315",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r118",
      "r188",
      "r324",
      "r325",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r338",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r314"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Development Expense Current",
        "terseLabel": "Accrued development expense"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r46",
      "r85"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r314"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r331",
      "r332",
      "r333",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition",
        "verboseLabel": "Stock options for non-employees"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r24",
      "r37",
      "r42"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense for intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "verboseLabel": "Dilutive common stock options excluded from net loss per share, diluted"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r69",
      "r73",
      "r87",
      "r102",
      "r136",
      "r144",
      "r146",
      "r150",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r246",
      "r248",
      "r253",
      "r314",
      "r344",
      "r345",
      "r381"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r81",
      "r91",
      "r102",
      "r150",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r246",
      "r248",
      "r253",
      "r314",
      "r344",
      "r345",
      "r381"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building And Building Improvements [Member]",
        "terseLabel": "Site Improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Real Property"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealProperty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Property [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26",
      "r83",
      "r302"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "verboseLabel": "Cash And Cash Equivalents And Concentration Of Credit Risk"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r21",
      "r26",
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r21",
      "r68"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r102",
      "r120",
      "r121",
      "r123",
      "r125",
      "r129",
      "r130",
      "r150",
      "r171",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r253",
      "r301",
      "r323",
      "r329",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r71",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Notes 10, 11 and 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r331",
      "r332",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r314"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value; 120,000,000 shares authorized; 41,749,435 and 41,735,557 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction In Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Current Assets [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositContractsAssets": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.",
        "label": "Deposit Contracts, Assets",
        "terseLabel": "Contract research organization and other deposits"
       }
      }
     },
     "localname": "DepositContractsAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r24",
      "r44"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity And Stock-Based Compensation Expense [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average shares used in computing net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r98",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r120",
      "r123",
      "r124",
      "r125",
      "r127",
      "r251",
      "r252",
      "r276",
      "r278",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r52",
      "r79",
      "r95",
      "r96",
      "r97",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r128",
      "r151",
      "r185",
      "r221",
      "r222",
      "r223",
      "r235",
      "r236",
      "r250",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r266",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Intangible assets, Estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r86",
      "r156"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r41",
      "r275"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r38",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r41",
      "r274"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsAmortizationExpenseForFiniteLivedIntangibleAssetsDetails",
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture And Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements Of Operations [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r229",
      "r230",
      "r233",
      "r237",
      "r239",
      "r241",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r116",
      "r117",
      "r135",
      "r228",
      "r238",
      "r240",
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase Decrease In Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase Decrease In Other Accrued Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r40",
      "r270",
      "r271",
      "r272",
      "r274",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r36",
      "r39"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest And Other Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Tenant Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAcquiredInPlaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired.",
        "label": "Leases Acquired In Place [Member]",
        "terseLabel": "Lease-In-Place Agreements [Member]"
       }
      }
     },
     "localname": "LeasesAcquiredInPlaceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r102",
      "r150",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r247",
      "r248",
      "r249",
      "r253",
      "r306",
      "r344",
      "r381",
      "r382"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r70",
      "r75",
      "r314",
      "r330",
      "r339",
      "r377"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r82",
      "r102",
      "r150",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r247",
      "r248",
      "r249",
      "r253",
      "r314",
      "r344",
      "r381",
      "r382"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r50",
      "r51",
      "r161",
      "r163",
      "r165",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies [Abstract]"
       }
      }
     },
     "localname": "LossContingencyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDisclosures": {
     "auth_ref": [
      "r161",
      "r162",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.",
        "label": "Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "LossContingencyDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Putative class action lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r21",
      "r22",
      "r25"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r15",
      "r25",
      "r72",
      "r78",
      "r80",
      "r92",
      "r93",
      "r97",
      "r102",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r122",
      "r136",
      "r143",
      "r145",
      "r147",
      "r150",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r252",
      "r253",
      "r307",
      "r344"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Office space"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r136",
      "r143",
      "r145",
      "r147",
      "r307"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r263",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Liquidity [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]",
        "terseLabel": "General And Liquidity"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r314"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedTerseLabel": "Property operating expenses"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Lease revenue"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "totalLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r326",
      "r340"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Award [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r314"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "verboseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r303",
      "r308",
      "r340"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "netLabel": "Proceeds from offering",
        "verboseLabel": "Proceeds from common stock offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r58"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r48",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r45",
      "r84"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Gross property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r47",
      "r76",
      "r277",
      "r314"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components Of Property And Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails",
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails",
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Property and equipment, Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r53",
      "r74",
      "r284",
      "r285",
      "r314"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureGeneralAndLiquidityNarrativeDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r79",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r151",
      "r221",
      "r222",
      "r223",
      "r235",
      "r236",
      "r250",
      "r281",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r62",
      "r63",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyComponentsOfOtherIncomeNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r56",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r38",
      "r40",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r38",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Components Of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule Of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureCommitmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Components Of Other Income, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureRealPropertyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosurePropertyAndEquipmentComponentsOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Amortization Expense For Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Business Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period 1",
        "terseLabel": "Vesting period of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Options forfeited/cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding as of, Ending",
        "periodStartLabel": "Outstanding as of, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding as of, Ending",
        "periodStartLabel": "Outstanding as of, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price or options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r194",
      "r213",
      "r214",
      "r215",
      "r216",
      "r219",
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Incentive Bonus Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r54",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Stockholders' Equity And Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r29",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r102",
      "r120",
      "r121",
      "r123",
      "r125",
      "r129",
      "r130",
      "r150",
      "r171",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r253",
      "r301",
      "r323",
      "r329",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r52",
      "r79",
      "r95",
      "r96",
      "r97",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r128",
      "r151",
      "r185",
      "r221",
      "r222",
      "r223",
      "r235",
      "r236",
      "r250",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r266",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements Of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r128",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r52",
      "r53",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options, shares",
        "verboseLabel": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseNarrativeDetails",
      "http://www.cassavasciences.com/role/DisclosureStockholdersEquityAndStockBasedCompensationExpenseStockOptionsAndUnvestedPerformanceAwardOutstandingActivityDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r1",
      "r2",
      "r52",
      "r53",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan",
        "verboseLabel": "Stock options for employees"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r52",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r35",
      "r314",
      "r330",
      "r339",
      "r377"
     ],
     "calculation": {
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/Disclosure2020CashIncentiveBonusPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r131",
      "r132",
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use Of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r119",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "netLabel": "Shares used in computing net loss per share, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cassavasciences.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding Basic [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cassavasciences.com/role/DisclosureSignificantAccountingPoliciesNumeratorsAndDenominatorsInCalculationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=99383045&loc=d3e9351-108337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=99397363&loc=d3e9420-108338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/subtopic&trid=2127163",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/subtopic&trid=2127197",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r317": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r318": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r319": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r321": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r322": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001069530-23-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001069530-23-000017-xbrl.zip
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MO0F8*D\ZWS!YQ:JAM"!ZO403KCM_/OH6!*^ 3#>.E_@-5CA?]&O?S(::0!]
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M#+*]#5^&^OIB+0@+*9IDR/IFR>9S+A5IF[(F/.F%I](^_A=02P,$%     @
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M3"$*\>'X#@(.MN1CMA6%)99\G#)3=L46CHC'.T/@7OCS@@7Y\A=02P,$%
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M,!U;=QQHIE:#A6Y#O1>%56IOWO!5-'6+J>#(J]FP,1W"J?=H;?\9QY'MB/P
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MW5BTGSJB7@)CF,\8+X2E+&XB'97W7/RJ@S!?!$BP2E?T!0]@@55(4YC6%5^
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MU!)(RR#E@E&4^ 5I_4F8L$5B#1]%#>/IVY6@48FA?50H[?8(K>L*98UQE#X
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M93?>3C:52<E OW0YY.87WZ2!_/(E2)0*<*!%C'CY26QRR+/I[57DQPEUB_P
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M:NC-TZ8C$9(A-'(B)C('0^!!D#;Z@=9+]E2<9#O^BB4*SN.(32@X\M5ZJN.
M?$YE%J3QB$I-#OATR@!*]DRUXA#OINH\0$^D1@G!WT?5>=#7-W%&_SE]OT*G
MI_SSTP^=ZTH+O?^._5^W<1C0(6 W_[(WXZMO)0/H6V^3&,T7WBIJR'?=6DR2
MO)LU!B0XP.]=C!+B7[Q]G/Z1WR?-WF!N7]S19C -K@*.2_<45T8)^T!0!;SU
M(+!-!OH 4 I&^BY.4!;Y;.9[+&MQUV(([%1DK?GG]]^\?W^*]EZ"7AC?']D,
M\/X]_P^E(J6-EV?;."&_X8 O>#$B:<J.U?A;N0G3W0P-K(KL/=IGZFTRX!!*
M!KD=-]5I8(.E#A)Y<%$E=X)\.=X+KMH(/FBLX(_H]Z>K?_W]]ZO??_L=-P+V
MZ[??K;[[[E]+8KF%("]#GZBF;-&WIRM$=?E;3G&!?<RJ(I1__;!"M(T]YFEE
M0Y@D/.L@X/E;O/#.(\%5=.[M"5U(J>ZU**@A[SSI!6C<>)*3 MYWT@"2W'*H
MJ!$C1U<1*AB +CD-1<]>8I^0"/ER](OH_3W./!+AX-)+(FJQZ=KW\UW.KYU<
MX WQB6H18L$(: WV8M4-P\P%9R.6V+H*5S*BDA/56%'!.ZWE?"_$B? SO[XT
MAU1U&8(Y9+"U_CDE -I^L%Y9NK7=8+?-X-+V@OVVPBRZO<<)B8/+2&NAUJB+
M''8S(GW(O"1S'JMQ#]\:I=C*3U7[,] '3NLHL/8=1C8WCJ:T(BG.JZ0\3AQB
MJ9'IK_FP'?^E?%"?$Z\^\G2.P?C*TRU;:FYCW7G);<)3BP9\)7^'$YYBV6H/
M3,GLS(:H23SU'JF*TY5M4RT^XT[JBBYB$U896+0@]I(0;4,DV ;+GS:%@,5V
M4[7/Y("5B:SEZVIORVH .DS.6)5*'+4UM3E<L2(I+@OK*=+0'QA=L)C>PA26
MTMEZ=<9BKO@&;P_A"P;'+*4IALE*!+5;%E+#9&\=@LD=R[ 4HFD51"H$F$6H
M"[38<CEF&XH2+98L;EF)N::)RE3 *K1,)4[3:!PZK^ZYP+'A=.-4N\_2QH+-
MB;/OGC%_LS20@RN:T:*9UC*3B&%Q]V6X('<E=+2GWT4J^RZ6=@F6JS$=AQLN
MP&8=IB%WPN0M%RW2*F#0RZ_!8CBU\.I(H5UUJ:A=L@CU>DM!ZI E:!<I,BM8
M@:ZS!N%W9H75H_ZE%8M+1F!86+E5^=(:E:U-@"^HADOBUE+J*O+C':Z*SQD>
MB:BH01,I:P5HYDZ6DD*F2U8#LB[S5[&GZ':#BH?6E "ZX%_UY+M(&I<:=$M-
M[T). I40TEP$;6('<A!((>G>Z9<,X&^/AHM0YKP<].8H]5X\IM3?OO_VVU.N
MV.PO?[O'*6:7S]=14$N,6$"[P=GMYL?$B[)[3'9/.95LU\TB,+P= $,8+30S
MD,&-S&LX0>SGK!?N+Z?ZDI079D53Q5N%3DI-D>V>.G#>(FHT.8O=R;S&%R^T
MTMG,*GDM\2A/_(_B#7KF$B<ZB1>9I7_$$767(15Y'>Q(1)AK92]F"JD5/MG$
M!3AC6PI4G[<-+'"SMPVPKNX57/S&79.OM#N8B7R<-#R9=8//C:C6-FIQ*HJU
MBEX=BEJMHU68ZZ2V>,7]T;@3H,)JLEB%7L>I49=KE"YH<Q>X5)\/9 YH= N,
M3J<%*6*TP&K= W0H0;M4K3!,1R$KR]<*S,J-%RDQ;#TP#?Q6!3 ))6C-+Q4>
M:24L3LR#$Y'Y3-##A"3#L!,IXN52%=[$4=PT37VT;F""3EEH%*>3ME#) 9RZ
M4(]+E?JOSE4Z_:\+1J!:=R.D$<8!6/=R'NR+6/<-SHS!6),&T':E8.NFVB"
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MM5D^@XYV-2A>,2A-YXGBI/3!,)D#Q(D3G4ZDHZ0OC6K)#)EKH)=XC20$5IR
MV0GL\4F.+$IF]1GN+"56;;>!1PG'XZ;";_EUD?",(EGXH5%"/;+DU")FZR':
M<J'8D]F_/K7]*Y68B/,V<;RM\]^3M \=3DTY2)V :8K&@4.BR428)>@Y]%1<
MQP!,&S'C2-7$W$O%='M]USPN-#N6R?J =BY3#]8D*S)9!T>X[E**,8NCZ1S+
M@[N;)<8,]J!^NC6BN'\P_UJTZ.<8W8YIT&;:#!*='*'[T8JRX :/Z'46/R1"
MC<M(6[UJJ0&LT2&/Y7BDP1__;4;1'S(OR1P5_@P_DRB2R'\4OOE'2IBEY12D
M*W\Y1T]'[)\U S>EAY9T<[P^6B7,O%Y:]'H(%4$+@2XWA.7A[C/C.-+(\6.<
M;##)<A8KS[1<U?1TQ-Y),W!3>B=)-\?KG53"S.N=:KW.M9JUKX"ZW!"6WFDC
M.'#PSF=)6L)C<U1E,HDT2_B]I_0VV^+D<>M%A80W<?2"4RK@/$O?WOT?HU,;
M.LB3N+J^G1^A QPDXCS'"&6:E0H*XEA01L$<G&:%YXB7W1,-^I>U')]O4(YT
MF6X<D.:"8/'OH]7]%SF[R(=XF<FEV?>7.+=()(2<6MJ[!4>V33#-<!_UWH%Q
M"'[F$PB8RVQU_T6Z3/D0+^,RFWU_B2Y3(B&DRQ1PCGCW8IH!%T1?F*_\6.[/
M@+G++H(OTF,J!WH9I]GI_DOTFW(A(5UGA>A+]IZVPZ[:$X;:%+Z*_'B'JV*N
MUT7V,4V1(AT'H->R$*3N933D<%[!!*JK3H(#52RHY($L>*000UO_2,_CGEZI
MJR-I&9S3+6TY(HUV@=926D:616SE'J>8:N-V'047^ 6'\9Z!*YX":4LCVG "
MVDT/P>K68\$&9T.VX"2)L M.7K"CQEN^L@,NK#B!8*Q$0E 3##39\H\XPHD7
M4G'6P8Y$A(9M'JMH8&-7=KR EM5+N+IM63'"69<]O*X:%KS<O)K<CEC8%,(Q
M$_.:PH%:V>V>9TN-GJ_C-#WWDN2-KFK8:BE]])Y"U9MQ$Q>@95D*5+<I PN<
M-=D DRU/"R[$V%"##_W".5W3M6M#2GP;3B=UKB.8G=Y=PZ>CMP775_^N@=.>
MBS7$H_=:>.TSZI@W)-.N4KK4X(M9I0#=96R'%'H!*P>D7.Y1\BH ^+K@^!U4
M_H=^$MPE\0M)V0*5&@ B0I[,>\4P>6(>_"T.<I:']F#=F&V3KM,49]H9WXH5
M\L"CAVB-DPH+/L C!EMTDK.!@I5EQ*MY9,Z-!+LJ&%CHZL@$LL6]99NM7E6U
M*?4C9@6(]UOBTZ6"O *>FA:HCI41?%G32DD(4]]*#T>V"CN0+5U([P$_MY%*
M=]/UM% *8@)?*8B*$$A!M' DGD70HZ:B@&R4#X%O!7M$)N5UGE)7JZX0W/@<
M*JNQ#&25F[C^(7"&X0X428HW3@)4?-<1?/I<N]8@5^@1OWJI*[MMM4C'?O-#
MRN3$OH=.'/F6AXS#A=T.)2[M1D<S]-3L<2P36R\FSB)6P^$<,II=T)CO5"&X
ME!300G30ZW8AHX.S!B6:KM)PTGI6/48,H_2]4>,#ZD""&F!&T&?JE=,ZX_\U
M>7BEA*YX>WW.UI977,'FU.V#_)XM9"!SRC;!%E<Q[:*<BM@9[6[#5ZMW2>F*
M?C?P6"AX2>^"AANPGWOI%NT]$O#]];B2).3^/23>$PE)1H9MMRO6P*S/*ZH\
M$3N\/XNC/+VCF&1[YT9RJ!6RA0C5@EE#"[Q^-B%3J$O%@C@/8DRS[H0K%]@+
M"#"YGJL6JU8L;NF[=*%J0^^DWIM6=QK5F7NYVM, YI%DA"5\(A'9Y;NRENV%
M]Y;^[(4Y_X(^D1"G61SA3WF:G>&UOR7XA:ZXH^"31^B72 &UGZ)-TR:4+4TU
M&)6QC6T0V!HG@=]5\J+96IUGUC*JFD95VVA'&T=/&'E%\_R.X:[J8%F3/KKA
MF,XO=.5,'^-[[,?/$?D-FPOR3-.F(WYA\&"H_$+O!MWR"\/@JPTAJ@SAI;*!
M7=4TRF*4E(U+B\Q\ ^H67!N-"9V"1L32X<D&R(8-RK1[B%19KP4/L(':(NQJ
MW6$2DLP_*2JYE[6PQ<494Y 9)YLXV;%'TRQNK[I=[^(\:E_%M>$ *Z!L)<BA
M,+*6'+K@L1F<Y(+K@4DLP0XJ)/B6-8(CDL%00GB((#]WYS[D<0:6M6'G);_B
M#/G>GF1>2'[CE-,:-5N2>\^XZX+8DIVOTT51F?SI[]C/'N/U?I_$+\6+JK_3
MN)TIJ&(XIFD;T%%,.CAUES))P_#.9SHQI"9>-"]=,O(=);&/Q/M 12?H,49E
M-\6SQ+*CQ?W:?PV/V64N-$8T4L*>OZ6NE([+$Q\7CX^+EZ:Q3WA)UL\DVTH'
M,RW&CJY)O*I/\2RT0#/K'CX? +N]6$'JSIY] [IFKY[3.;='?T!EN:/-&:#W
MXQU"K;?^ =!KE@MR/<*NE/ -SFXWC]ZKXKB\9R/.5_%NB]N_FG?9@NM5O1LX
M];G=JIQMAR1GU3VD%?(VU#38*TF8"QN32'L^[Z9<>8WD8YQT'84TF- R@*TB
M;,0X+ UTU-#QOA&;) (K>%@R0B2;?!:.R8]&!$/</$8.+\^V<4)^HTZ*2K3S
M LP"V[V79,0G>YZA/(\"GDY2;*[ 7"!G*0SBB%T-PY%/L/:ELX(8\A*Y%G[C
M&KF4$O BN1J/Y%(VSQ91IP;-5M+!?FUXIZ-A<$EY.F)H%>@:_FV. 9.=(EU#
MOV%I"/%V@S^?AQ[9I1]):"BY9</IC'YI!5,KFI3-%8U3@S.JWML*468DN!%G
MG[42E/F-S&#)[O),I"OS0X_*Z/D\5 ^]SVE.NG?%)SA /V?]K'DW#/(+3N@:
MXS&F,8KTXHP-&_0!NH5(G0-T#8\C!^@FA+H3Y[HRI<@ON5D0Z7LS/;(Q'J$O
M*-!2^6FSA/ALB9[%_J^FC+026M@<M&KPK:RS74+0/+,*.-($K 4MXL3PF62G
MA[Z(II_E)&3%]-914/YXM6.G*GS/+-5JOATOH"7T$JYN&5:,<)9B#Z^K?B4#
M/WZL?JFS ]O2&.$>2(;M9%GN&?XV#@-KD])Q0#_*UPO2>9LO)P=^HJ\!I7CS
MSCA<,H_^8CSBR(LRA\SB(XFHG5[3I5%P1:/EZ)D\A5BDSCA[^^3]/4Y$/*FN
MQM*G!4"S&2!HW8QZL,.955^07?T4+9SP)M"AC3*9RM,;XLT@W@YDA1>-J =!
M;[P=UM9\Z=N*F_JK$]A2AV5-.*G'2J J748J7:XK,FL+N*+,E#*K['=E+_1R
M,5FZ]O^1DX37+0L]7U\:0\<!'9/I!>G$9')RX)A, TH1D[$G%H*%ZAOB3"Y$
M9?T%.;F*3@3\]7."78C-N-%R.5)B*(DG)86\+J6!WK@4):$#O/JD0B-)R\A(
M48T6,AAJX];&/ IBAY1%'<'(*=U1&.W<+%$9T(AC)O C#L\>/\?E-M/M9D-\
M_I8VQ*^\<W7>7ALVJ,.S'B)5AV<6/,"'9[8()1L@G^.3IW*G,^:\_$TS95[V
MN&R4"(?-6L&+"F819T-F%)[EFP'>N?6B0+\H.!! K@$Z,!LA?_4I8(3?Q"")
M@]E#'N#@?13&9;:>\H0NLO,$KZ/@(WEE/^D/$C0,D!M*1C$:>T=*:L!M(CTF
MR>Y(R< /W$H68(T?*06K"^] O=/SF%>FYS='Z)([B>D:.M6;A98%T#!L1*F;
MAHX>SCB,J&3/6 XL?#.G8 (VD"4D&;%H89M'-&2B<=:.I*Q:6DK-\C;;XD2]
M8C'R0"U7;(6IUBHF!N"%BA4\^88@"X-K?-S9<DZ@@B;')XI^I;*H/"/L^QX_
MDY2*@H,+DF _H\LJG% $; I46[@%%Y2-VPM46;F9!=C.+0'*;@"6C$APHI(5
M,5X@6Y]!G/FET9O[XM_0<B>8[$E"XOE9[H6/.-EICFF4Y-!GEQH1.@>7$EK@
M4TL5(E7IE!H]8@R09S<R ;3G-QH&Q[1(?8ZCIG9+D[1'(BI= CW4F5N*$8%4
MLS:&?&] 0P@5+FEA5Q&2E HX*%)C,M91F7G-KPQ\W(6LCVYFP3UY^0NUR6GI
MW4FBU17"4/7""3LT0NM5)0+$+H]'A+Z)MF:08[8BW$7"<+D9=SX'*K8M!5D6
MV&Y\"%-4NPM!G9D=2%,G0CE?,?BR</T#M0HO(;%DR:NF@RH"KP-=%8"7$0$5
M?U="D;RU*T@F7\B:%*'H]Z<HW6.?; @.I&M7/2V40IC 5TJA(@12#"T<C7+4
M&(!6J6/@KZSPCXB9+U]]C-GMIUKZ\D,E@<+9?GC/SA:QG[-@@%7Q4<?4H]J#
MBKFG&(0J)A_3&'#,/AIZ5Y&K)E$]9W^M5D4YGW]XCVKM\EI1RT;[@,)+9(=<
M+SBF!G-L%0@\Z7=G) Q9UG%>:.&\46?!Y.-LF&$=6@_Q6M[+@M,)5V6+4Z60
M*?H.%2T@T01JM@&T\S"1=*#"V?B8\=_?/YMD9&E;;V)TS2Y"/6Z]J.UA'A./
M^Z6Y/,U'DJ29I)ZBTKOH&: \BI48E1?14@-[#C,VV0MCRB.M#0'C'XY(!KT;
M6$:0$>;[@*EE!(_;),Z?MY?D>9MM)>7:U-;<BQ_*N(<(6=EZ'V9@T^\-5;(P
MYTV@H@TD&I%7X8-Q#5^0C'K7X8:@BUR7><B?4OR/G*KVY0O]WR/M2G/?2D4-
M>%'&($#]EHR"%.Z*C Z01*4J:L3)$:.'O&HE@:^]::6F=TM_U/>LE,1.Z9!^
M^U>N1:"7K.:5 <(6M ^UY+3NV(#Z:9:4T!G=UT_(;9V!?80U"_39SB4?21;B
MV\U5%) 7$N1>J#B@EM,!G4=J09=GD5(BF'-(-11)<@%&RS*,'ZB7/JONP/TK
MR;;W..3Q;;HE^\?X,LI(]J8\P>[;@BMZ9">H4L/T[([HG@5(E5;>-K22-83J
M+;$ZL:(MP$/S*>5M6>'T!^FT=;S']']1)E[LQ(EF6TA##;4)9!:@VO)1DP)O
M\!B =96CQH JCF4W;*;!#+D3,[,$LTV.UR0CSUR76)T01;0D(0*:XM1PRUFL
M2P$S42EP2-[A5(2LM.+T^R2]%$"Y-:(E=4(9Y!LB.CH7%,.XA=!6#\!=D G0
MSQ!T_$SB(AJZW7S$ 4Z\\ '[>4)[QNFU]UD3@=BR0H4C/46K8A-+/N! I0_*
MKF:]5-PLKF5U6C>B#916C? Z;\M&,N.$.G"SQ4G!CPX-(-8"9)@SF7CZ[VR6
M4VQ6YYO5[,#)!4[("R\+6)1+TYQ=F[G 3JRM!3J<4QM9H$^G[0 JZLX+1A14
MG&5%NX6/GZ<0XL")"E;0@^9YOI>.2,6_U[1_]C/]YXF&#7_Y?U!+ P04
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MR)RPD_ ,T51YA8S;=5/EX1*#[=AQG63T@\SP!WC\@PP!@X2"0XH]=5+L58]
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M( "E@/,(^X8"6,'=TA5X!8ZW07S9;GZH3MP<-?L$(B'/[(JTZPZF[\ %ON%
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MU4N)309R'?YX@</[Q_\'4$L#!!0    ( "1+H59+A9E%/6<! $^C&@ 5
M<V%V82TR,#(S,#,S,7@Q,'$N:'1M[+UI<]M(EB[\?2+F/^"J^M9413#ES$1B
MDY<;*EGN4HPMN255S\S[19$;+'11  L ;6M^_9L)DA(E430E<4F Q]5M<P&!
M7)X\YSE+GGSS_[Y?];VONJRR(G^[0W;QCJ=S6:@L__)V9UBG*-[Y?^_^_=_>
M_!^$CO)^EFOOOW\[_>BI0@ZO=%Y[LM2\ULH3U]Z!+FO[T?NLDOVB&I;:^\1S
M_D4W%YI;V_\0&M_M8/S#(M_S</ *DU<44]\C_A[%>SCT/G\:77I9FP::1N;5
MVYW+NA[LO7KU[=NWW6_^;E%^>462)'GUW5ZS,[IH+_M^Y[KOHNPW5U),_%=9
MTP7;@\GEYOV?C_T ^Z_LUX)7>G+Y]P?7WVF(_?:V(?7L&]\VXE5=\KQ*B_**
MUV;\;1L#A"FBX=1-4*7EG1N9][M?BJ\_O$^,?'+3[BJ;U6K31_+JOS]]/).7
M^HJC+*]JGLO;WIHFJ]L?3@]-^&KTY>12I>]=-VFE^<+.+)U<6/&O_$Y3)*_L
M9Y7,#/!TM2N+JP8*V+]M?E7>CF7**]&TPGQXY\[#"GWA?/#PPO$7=R[.JH)1
M$LV9^O$5-W>ORT<O3EZ9;Z<'+9MWW\D@&W1[WIM+S57SRKRNL[JOW]G10),1
M^$[P7V]>C;X87W6E:^[9VR/]US#[^G;GH,CMPD/GUP,S=7+T[NU.K;_7KT9+
MX]6[-Z]N'O1&%.K:-G:OS^TJUSGZXVQG<G>5??6J^KJOW^ZHK!KT^?5>7N2F
MM6^R[WOV'KH<O<R4TGGSTGQ_;*1!F4DOYU?VASK;VS>K7MF5_Z'/O^QXF7J[
M(VMT>RD2G*1IK$+$_2!%3*0)2DA 4! $W%>*$!VEX]Y\KT]U^G;G_;!L\'U!
MS']V@"[.BPO_PA^]V?%&"^#MCEDT>Z(H^IKG*>^;Q?NN^>?-JSMM?;SI!\.R
MM TW<HSW_T?S\C!7[XVPFM4+ZFL_" A%6HL ,9:DB!-)$4N36$=$^+[F3^K%
M.X3,W7RR<&O?CT7QJ+F?S;>%^F ^JV8UE\18,4(4"A6.$/-%A!+I:Y0&Q">A
MI%BD[&G-_<=S6VH']M%V8B&$#%*!XH2:894T0AS3!%&MXS#%+%+R:>!X9_]>
MN*6'N5EQUP>FK27O'^5*?_]/?3US/'U.$\PC1 (M$(N2&,6^F7XC. )?*A$P
M[C^MG=B(9!PF@8^?VMH1:D_UH"AKH[[/:E[/'EPSB!&-S;BFC#(SN%RA)$Z4
MP:Q*_2 QH\V>"(+_T=436WMD;EYR66=?M5E:?-SX6:T->$!3J0BBU$)!1Q$R
M($[,T$L>!X1A*<FR6ONA:5*13S5C\A&20L9Q2&(D<$P0"TF"1!@'R-<XY<J/
M0JZ"G7$_QQIG[Z"XNLIJB_EJ/U=63IN),6HNT]7=)N]7%R?I!:'C1AHU-<RS
MT5=_F!?$ZJTJV\NSOI'KY="*XU=WF[Q(%Y2,%<<:(Y7&"6*!$0$\5 H)'RLE
MS" G-'UA%Z;$\2IZ(%/* Q$;",2);WH0*",7)#&:(Q68&V#[872_!Y]+G6H#
M+W56%_+/?_+^4&]B\'6L?1D&,3(*PZPUK3E*DC1"J1)<BBB(4_[<IJ]XT$44
MAV;QI0C+D-M!ERCAH8^,@,/*Y]KWTP?(/[ODI?[-,&<#F:N!SJMF1>Z7AJB.
M#(+?KF\O^<RO[4?[WWBI#@VGL>*A,NUM4'=27^KR_)+G)P-[B^I#4:8Z,Z;#
M43Y2=D]9_!?C]ETTS[*$:?][5MU\:F[8D A#SYK659_TE=#E_6%=RJABHS%B
M8L8R500C%LL$Q2HR)"A1H=9&IT2*K6]4_VYN45<M'U).J4J"V'!+G5H*%OE&
M&U.SXF*1:A$Q%81J?4/Z3UVU'Z5,LB".8XW"AJ5'W**4A$AAG_&0Q;Y8(DKO
MKO"AZ=D*1N_P:M OKK5N1.KHB2L</Z6H'TO,4!H;FLUB85B#B 6BDB81QV&,
MQ0.I_]+QN[N6_UX65>7H^+VZ:T@VVJ[Q KQ[8UTI>U7CES"W]!K7REYM&O-V
MI\I,$ZR3HOGLLK1/O&,T[WZOE'W<W7N,'C?]C.9M50S+YEUCN.^-QZF9RP7'
MR3+M9EY&(L%.FK&8+6&:'C=+I(J\&;7Q>$T>J1M&/'F7*?L^S73I-4W7,YT_
M!T?_>==6N/_CR>TJ_<4V;?16F8=]'_0SF=6C-G@J,]^.G'\W\)O7G9UWT\3P
M3G_>O)KYB'>3MMVTY-6L;@\:L-ZTNN9E;6WNQFY#F)C_W=SGYKN;\5-3E_J-
M\7SWF\G[R4->W9GK1::>3D\]A:E?T]33Q:>>+FOJ[W'J)\[UJ:YYEFMUR,O<
M6$I5)R9\=J>6.>LCKV@]8PU/OEGW1.XKE5D)P/N?>69HW $?9#7O=V(^Y_:M
M'=-Z:Z[# EWS J43#_6&9Q)6J-/S^ERV! OTY1.Y$@T*ZW/3ZW,U&I3  EWS
M B4KTJ!/G4E8H4[/*[B:UN!O<-!$@?EK-8&%Z6LWOX'YV[#VNW&^!^:_B?/]
MYG55UA>G-A363)I]]XE_SZZ&5Z->W(9)^SP_YE?CR_A7?G'^K3B_+(85S]5A
M]N6RUCJ?1'&E[>-7;7_CYIR;?N[=]'KGG7U[I]N/SNG":)H>KYTF"W7O*0.V
MRAA 8/ZW8 Q@^M+EQP">&!*=@\6I:_=S-172;QZQ;S/CS/"8AV-W,7E#M:='
MY5;N/#HL*\'J<P:T'3SRY9'YKN/&J>F:0?MAOIRD^0OF=W2+2+BN[C>1[?$T
M.?M8_IVC$_W(JGVD%QV3L3!7&W>C$#-1].Y</92HI_I+5M6ZU.I]5FI9GZ2I
M>4S^Q?[L'I>^L7H/^KRJ3M)&[;33@)\A@W\\$"]GSX^.X$9<=G9GSQ)U.;OP
M\8TROWWS./3VZT^\_%./G2B?R^)+R:]:AYLYO5BEJF;HMF<_4-73ERXA,=,?
M<38\S=GP"YQ#+8+!1GQ!FP 8MJQA,2Z(5Y7Y^YA14!;FGF8@S$C5^WFS'60P
M2LY_0$(^:E[IRZ*OCJX&9?&U$;V.$Y$%NG>K+.;TKU-FP@J@\=LPZ]MB&^:R
MR<N.@F2AGG8*+H]9E2 ZUBXZUNF<?=+T\EQU:39ONK,-D_=A6.;--D5SW8?L
M>[-AL4.3^7CWMF%R#XIF9V^S4?$H;^BNKKHTO?,ZN T3/"$A'9K2NUW:IDD$
M^MRB*9_AO =*O$E*O/H-7<")MV7V@!1W>7:!%7=]AH$6=VD6@1>W8LYO PNW
MN1+G!61.0.;$_,3X.[D3\Q/C[URZLA"8#;C?C-'?M8T1#RXSR?M3<?9A56</
M\N,[HZ%L,/[1$9B$TJ>&8 FQ>C=TX<;#;3\HV070!&ANJJ38"A,'W(2:RP!P
M4#8! +HN >X'.YZKC1KGL*W";FNH#GG_7)=7MS\Y,0WBMD![<YFC9M[ZU=!C
M@S9^V,Q1:T<H);Y@HQWNS\73?E7I>E^:55DUU5+N['&:K$=C2652V^WE??V]
M^04@:[Q?8\;PW6ZF^M'XK0ACQ)[]A-DRW1)+J'\,5:,Z35T !.L"P68-&#+1
M."/_Y)3Z^6@DX)?FJ@.C1J<J'=@=:S:>K<OWYH%?N=U(NM]$6!R=?ZM''O9F
M4F?@A]U9V<P3Z\6[%>SS9O[>I4N8^?B"QK<SCR]H^..I_V=6])N/JY/T@S8C
MQOMG6@Y+<[FN/O)O;9S_!?NT0A 8[4[C!4& $0V=]?J",=-"8\8Y0O((*_V0
MY5FM/QKAK(YR0X"_9**O&_)=_7;]B?^K*)L8SL/4LJKA\V5S=$^?2^TF\&X2
M4A;OYKT4L]G][!14'DLQ!6QL'!OKS"A^RG0WJL>.@1&AS=F'E1U3>_9A<[Y7
MAR:\41<_ZFD[IGQ&M@PL<9>6^.JSHV"-N[;&ESSG-_4_H2S7FLIRW2W-.UU8
M<VF5E5<]"T_NY6H*$+O5S>77Z7W..9*GNJK+3-;CPXW=7I6/U.6:V8=.65"+
M3K'I@\KZ0RN,;KUAA]]E?ZBT^E 65]9Y/JR;>YVD$T_Y9UV.3C*]GGV#EI?+
M7-V@K+GXIG,P?"0(!3#<'A@ZF,=WQP]^9K@9-S>>"H1I<R]U?ED6PR^7#9.[
M_"?O#YL[?LKZ1I<4^<1C.X?E'O#J\H;Y_5;DP\I=5GO'/3X](I-@VA.&Y.6N
M\QG<>MY@=EJ"+N?,;RAPOST%[ML"8;.<BRM](W4^%I+?9+9-&1^:E_+2#.1[
M_57WBR8G]?#[P,R#XQZ_.=V[8YC\J'_;" VH$;T5T[R(!/B[SFWJAED@^^HJ
MRS-CR#>9/-V1 0OUL-/P>,1*! 6Q607A@N7V FB Y.@^/%Z4Z0ZGZFZ1,@%(
M; 82#FSB<RNJM[*4&K>ZN>[#O^#HMJT1Y3#5[1?1"T1H[AT/8_CM(L?#M"WJ
M<O]\F.EN0B1EO1!;\ 2BMD-LY4<0 <06BC,??I=:VWWG4R[AJ6#J2!)0;$M=
M:ME$]=_SZ^V*.[]DB #:ZX(VU+&8,0@=KV/A#D"#*8#>O'Z>>+SU%@U%I?\:
M6I_*5_/7 V/CWO=NPG/98FSA!SXR>K<VSLSA6R4Z@\71.7WI\L3G:#>^2XGF
M]S>K+[J [V6E+V&(PO'AKXVY?_L&"A:LMV"!L>W#!4^)O7?IZ@LNMIKD IW\
MD6O/-7'H0-#BARZPA8S+*O@MZ_>M"[$Y$W@<\LG^ER^4&MJF1;8Z7]IB-NH"
M(]UJ@W0==0!^Y)(#R*_)MP>07R?DS[.ZKT_2HUQE7S,UG/:AF,_TP.@4T\S1
M80E%Z3"UG=F1\:0]WI-V3-FM[?92S;REVXLVHYRW9N/2*O:-+X+\IRAH0/X:
M=30@_^7(QV/DXQ\A^T-65O7#X>T<E.<!;NX8= 5AV);J7!["V 6-W,Q19(A&
M+^_E?/^> YW>B&-LF&>CX?G#O"#1S3!<:5X-2ST"]QB@DUM,OIN\M_>8?;_P
MP?V&=;E7_94^XU[!S;T:2J^GKSH>7MD2ID5Y_W%953!*HKT_SM[/>^*#W]L/
MW^N\N,KR6;<=3TJS9V[>?>_<XM7=UO^PP^S!X(TGU+Q\^O#YLZ<V,S+TZ3>C
M#VZVX$#/OMTC'?WQ^)HWV?<]<U$Q+*6N1F\O-5?-DC,C_>[?_\TS?]Z8EYZT
M-<[,^FV^MM5P;05VJ]KN7?CNS< (_?+M3K\N=[RJONZ;59^:ZU'*K[+^]9[W
M'^=&)U3>L?[FG197//^/GO<?E5EFZ7^\;JZKLO_5>QYA@_IUWSP#76K+><PG
M./Z_KZ]X^27+D2CJNKC:\W:-V##7C3_MZ]1<AW<IR?+)9^7HQWCROBX&]IU=
MQ8CWLR_YGF?UCBY?F[Y4 YY/VOSMTLPN,I](O3<H-?I6\L%K[[D]&;VW=][S
M<IO_TA]]]&W<.5'TU;B)MGD#KFS\W[[<>??'\='YX7OO['S__/#LS2O;2#/L
M P=&ND.#?'9X\,?IT?G1X9FW?_S>._SO@]_WC_]^Z!V<?/IT='9V='*\@I''
M71AY_,*1_R]#_LP;0S%[WOO=@UV/XH ERQ_MI .#G2PPUN//'AGMBUE_MF6P
MES6(W@ID0>CDB#VC$R^1!1_,]3>#:]A(7N0-N\RDEW-K/RB=[;TOY/!JG(ZT
MT_ @6:/;*Y$2+!$BP2C!DB!FI D2. I0'/LZ2K7OAVFXXXVI_*E.%[!NW!PM
M8\'^XP:)=T:K^TO9.;EI2?*XV5,=&_7+=*OFHJ\?SH<H2L.G[<-S_7KT!LFB
MW^>#RC1S\FJ1T>;#NK@WX,U'WS)57]I)P__7#F]=3AX]F4Z\BRU?MM^IN\T:
M/^]VT&[;:)\YZ_/FR;.^,'-^Y^/QX-YTZ6:X;\ S>7^#GLD'8_A\U65M<W0G
M$#(?3SJ;[-*FLS,6P-3<V <];^&N:D4\59.1Y6JR5[7J$ BB9!<#"K8=!83L
MQH""9Z+@55U:C?$H'!X"808$'DS^#Z?]10+>58;S+[M_)+W>M+4R;W5O;#KG
MB>I-SJ>_2_&M*]%-VCK/0/C%)G1Y)[G^U7D(S)/3L*1!5#MMC(*D;HD'_$<N
MI7\,>6DN[5^?ZD%1UK.\2R0,8HP#B=*0*<02'*(DH0(%J0IU&H=,2_])WB6O
MV0]=O]W)OM=[HBCZFN=U.=1/5RK_9>;0SF/U9/_\?%@^M1T__S4LZM<WK1F]
MW7GW\T\T8*]O(#[;;[6Y&,7\,?CY)Q+BU]-_3WK@I.;_QQ_[I^>'IQ__QSL]
M_'QR>NY]_N/T[(_]XW/O_,0[.SPX/SHY]HCOG9QZ)/A%=8@?/+X(7-4;2T G
M\(%MX7FN3:>KIIOCP89YLOOD@W?^^Z$WE9%PDXVP?W#NF:])XC/GD=%&B\XA
MYM\(\%=-V&B<9+6D@0P<'LC Q="\F\A;KTSZ4)1>?:F]&P/)^]QDQGJ'N=)J
MX9#]Z$>'HR3;6=:59C*B3$D4)C%!+/4C)+0*D"\398PNPF(5/-^Z4C;IW?SV
M4O'K:\U+G;LZWI]LK7C/)SW/]@*"_.L8\Z+<CGA^1ZC_RB)ORZ#^:XS)=H7Z
MPWQVB[!OW7R"RV7C]@-X7%H?@CDO>3ZJB?EX#":U>;PXX$B( "/&(HIXXAOK
M@824Q3I-9"1?'(-)>;_J8A"&A#$$8=9B4)R?[A^?'36AEFV+PCBD2ESRW@-%
MZ.:\NC:=$)5Q("K3Y;%W>">=FP.V[OU*$X?]+9V>>.S3LKCRIC8Q&;GA/;*G
MR4G9!AS$T<!B[,I6B-A%L>1H"M*:-_L?%%=7664+0GD?LK[VC,DI;+SD1P'$
MPZ;TC_W)Z!>SO (ACV00Z@CY,4L18S%#(B8<:2*%I($O?(6=V/?[TD'$&".:
M)$&R^KC@]J#V2=M_ER\>W-S^?]NV-<K3,\-8FF4Y/3Z4NN&F' FB4_VE.:0[
MKVTENUG"R \B'0JS4'T>6&&44"28CU&DTUA(F:H(1TL71K+H%T:8_D0^L"1Z
M_WK!47V1/.>5K83EG<E,YU)7/>\HE[NKETOKAL-*Y-*+1]];J?OS/HUJBH++
MIRS[7PZ_<UDWJ\<K4J^\634>K[QJH*6M[Z>\+#?WKCQYV>06_;I\X>J[S/']
MY4K7[N:MM&_S.:50@@!*$- (2A  "FBPFP *MAX%;-<'%'0M>CI/S[OJDG8C
MY.-DA&&>PG9_.N=[+HQY7I2#8N1J:$X!."B&>5U>'Q1JIB.#$<(4]AG2(@T0
MBSE&@A"%,.4Z27WS5:*>G6N%*BUM>?9:#\KBJVVKNULRWNL^_\9M]? U)DV]
MM-$M6&QS>%';%]LY_WXT/L9 -DOB\>"%UMR74H<HHF:%,5]%*/:%0@)32C%+
M*"%.!"]>"LB$()(0XOLAK*/EKJ,YS-+]=;1Q#@+<LIOSZMQT+I=;=B(^>W_>
MGQ%H:)CL2J,A2TM?7VO*^M.'\G87+ SC2X:QOM0PDLL8R7\-RZQ2F;1<%P9T
M&=!,W=>2RS4*04N.M.31[NGNV:[KB\AKQ2HZO!KTBVM=NK^6P# $PQ#FU?EE
M"H;A"J1T-AWN<%WQM4+O@7VXI&'\PO/L?QM<NK_O&_CX*C!P-S8$RVH)0SH*
ML+5@00$I?S$I7\4>1MB&XS;RYL?;]Y4J=56-__EHFD5FQ=H32:DO_10I/_41
M(UJA)(U"I+"4FL58<+K\O3DK"EK/G_ PQL0[WO4.^,#*4KL)XUQ_YY7WN_GU
M-W[M7 Q^?G=Z"^X3?8@#.@L'/$YDD&B"DD!&B G-4"Q$A"261$<IYSI)NH&#
MWX99W[[SR&OO;&B:Y?D8=WOR#\S+D_*\^);/FGH18DW\($14A"%BF"4HX3(U
MHD%%W)>IP+(C4[]OMR7EW9[K)OI[4GXNBZ_&X)^9QLA)R+2*S>(VTXX8#1CB
M:<@0X8$O@S@D6-%N3/CY?[=LLI\VUY^+RFBR_R\;/):PFFHIF* ^2FAJI#I5
M'"6Q>968.8Y%$*2\*U(]BB.?0&WP-:'TEQ_!U&J<_5+S1X&I9*Q5$J TT!0Q
M%6$D8HP1#D*<Q$KX2K!N #,@M&4RZ-<?"J&/A;'D/U\:P__Q)%Y&-4V92E"4
M)ABQ1 4HEF%@"&6<Q)@F81)V1,D$F"#*&%N]]%E95:$U2I\E[*0?:[^>9PA.
M?]AP^?_-!@9+2O?N[JW_^:>8DNAUY0U*<VTV,&:?_J[EL,Z^VEWX:29-@WFN
MEN\+@*FR4U7KOAY8.>'EC:"8GC)NU$,S9RLH<K 6U]6DR$'S699;![:Y9'1,
M,OBSUCN*ZY;Y9T:(E%F=F6>-I(TNM?(&P[(:VI(>=>&9*YI*@X3^(GZU4LE6
M(-R7]=Z/"U3805Q'>8K[T[1=M2E&=YKTUX\[7Y[BZ0U^V1K!SX\\.0T5TGFD
M0/&"A7 0+#7I;"'.@M=(%M?%3&#1+"L]S^WE F(3Q*;! 9LC-@$(+\[ KHI^
MIKR?<//'+CK3BC7E]"S.J%?E4%FG>GR9+^7)Y^=D=;\I'*FYO/1DGU>5FXE=
M"PO]53DDW,7 2PLOW,TZ_/&T.R,*ELR4MUT4E-R^V9#/NKOC>G9]9;[^I7(T
M8W:5@G7+9[ZU@G4>EP88/!4&Q^/:W W%TM_E)<^_F ]RS[30?'+KZ%_;QLA9
M0'M)JOV2.?GZ^-ACF0CC.,PUH:)AR+,R$21GFH0R0F$08<0$(2@6H48Z)@JG
MJ< DZD@F@CU1QL#UK"[DGSWO;]A:N=Z E]Y7WA^Z5ZROE=M4P;Y9X9P_51%O
M4*JNU,+9O& =&QDC3CQ+JN)(A%&H?42),%(UY!KQ@/LHPI$4$FM&DJ>=.^TL
M*,_V_[D/LA-D)\C.U<C.)1LQFY>=$U)Z.#8A'CL7*]"82#]1"&LI$(MPC&)F
MB&D2,!QH0UI9\#1B^J"<M#5B-E])^@?;E'FE^%]M$["3782?>/FGKM>X*[>K
MX:VM2UE<B:Y?XRB&FQ_"=:_ZHUS9 A7:$]>>O-3R3\]<^*?W[5+;"I=-AN?4
MN6Z_D%^]2UYY:=;7RN/]OOER4)2U31G]:YC9A-&Z\(0>7V#N>9,SZGM%:6R*
M7]1-YNA4PNE$K=AL4ONU/6O=4^;;_$MSJ1DDJ4<[7*EW97IW67F_F/L9Y>!5
M0WGI59>%/5S.&^CF$.SZDM?WV_Z-WVVE;>+HQ^,^_-JS>?/>+W341V%4C/E>
M_,OTP%[?7&I^9%LQOL^5F>.J:4332%[57H(]Q:^K7>]_=/6BDAK_99YC>UPM
M=[Z?VHR?_QH6]>N;QHS>+G0;JZU1]AU=9LJLA;V[/(%J'=&8!BAEE"$FN4))
M;&@#2U7J!PF3E+&& -* W1+ ._\XNJ!&DSXN<GA<=!@#MFOQ@\D!B>V4Q+:2
MS BQJZRNC=C3?2/,RB*WEDO_VM/&BKGVCBSYY[+90/2>UWQT=/<]@7Y[C^D=
M :=#<Z5A]E9FG^HOPWY#Y;TS=.[]8N$1O:8^W1U?4%]FS2F@ WL*Z*JE^ZB]
M-T);5[_N>B"3Y\KD@ <TE8H@2HU@9CJ*4(Q5@H@O>1P0AJ4D;9;)TW^#8 ;!
MO%G!;&0A]_KF3MKC4AK!7'(K7:VL*BT1G?FI=5ZAF5]4IF'FY9C+6EDJBRLS
M3M<]R[O-[0Q9M:W^XGTIBV_UY>3K74/#]1,.FAZ?02[Z7/[Y>K7#W-=&WY1-
M"\9C_,C VY%U7 (IG69Y9I5C956AW<1+\>O'IK_YFKR>7/;X!>V>MW'WQM!U
M? 9GK*P.C+[!D+5YQS/QB(P87^GZ!&7YB(\2*A"=.!FF/0N[T[IP:I_J_<T
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M7MP:-MM@XTV&P+-#X(V&8,JV SNN\TH6[#C0O,#906D")D#%@!WG*$JV0)M
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M='SP<"ORX\9Y!,:YXWLJG)-PW<;*JMW# )7N0&75_F+ 2G>PTNG]X@ 5T$
M%=! [<;*XZ8[!=,=3/=EF^XGQ^\/C\\.WWOFU=G)QZ/W^^?FS6_['_>-)>^=
M_7YX>'ZV.$9)#!AU?T_/FC'ZTATZO_R1\Z$RC5,][RCWZLMB6/%<53U/?Y=Z
M4'O5)2^U9S[R!KSTOO+^4'N*U_Q7 "X =]-JVP_ N?ER#KC9G6F/8VG)&]46
MK-0R S5[7E7T,S5IH['?+,K=A<]5IE1?KT88K64O\7J5Z"(XFZ=#/_%27GH^
MZ2V^S?5EH)_7F#>B]%Z]^_FGF.+P]<L:M-Y1I)@^K/C?;<$^QV4(- %D.\CV
MS4NE]UKJ*Z%+*]Z?4,8 Y/LL^4Z?8#,"LP=F[W8<8+;FV&#L"#@#H.89822
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MD@3<4!N=L;<_EX4!?GW=;*VPU28&5SJO>UZNZXX'B("1M,K]#^P#V(<#[5V
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M<$0'@/@'<@#DP%5T #D <O!<<H##D,1$490P$B#F,_,J%1JIA&(BJ0A3\N!
MR&>1@V7[*DBT9$]%)_V7X+U8TU([&>B2U^:MU]>\TM-U 7J>'"V+[?.> V^!
M> MP&2<%EO?S3[&QL%]O'\3 R@9Y!!H,$ ,:K.4:K'O6."5!B(GBB"N6(A9%
M# E*(F.-,Z4Y(UPK?-\:O[$\/EK#8V*,7Z_3%,=++L;?>B$ 9O>ZS.[Z4I<3
M^WK:Z%[\O)=9I[.T!6= 3]84&&@Y3("3 "=Y-B?10:)T:IB(IA(Q/Q6(!T&"
MDI!PF;) B/#!QHA&+&\D:8!$"20-N*$"0/J[@A @"0 3( G.*-T.DH102ZR(
MIH@JDB 6\QCQF J$%4X2'?$$^^D+2,+2"S\D"Z060O* PUZ,51X?N/8%=E[4
MO/]4+\;ZCNJ!,Y'7!KUN!5[@Z&,@,BZU=P$B$U,<$C\)$>8D0DSI /&$,D32
M@"=)ZOMA\" "LQE'A]]+\--\'9TD*>#_ !T!] *@ _0"Z(7[](($+"&QX1.!
MX@0QK3B*?9JB1"I. ^$G5#\HJ[T9%TG4PZ$/:1UM<8ATQA<R=R.%F66TP&:*
MU@,-Z,F:0C;M1 <P$(<V2;0?3F!!@YP!+03H "WDJ!;JGAT<IE'D!Y*B,(D5
M8@D+41)+@0@1.O*E#'GRH#3B(QL=CHM<KL\L]@-('  [V8%%-MKY,&40+RMO
MH.59;,!9-N?8;SET@-  H7DNH>$QC82F#,613A&CB4)"*HYHI((X5%+YR8.#
MK^XG0,YG,LO.'T@6./FJZT0%7!^@*(!C '2 8P#'<)]CD#"6(8EBN\E"&X[A
M2Q2',4-8:%^&G$5!&KZ,8RR],L0B) -2"+9 >6QH3X4+%2$@P[%S)*6+> %F
M LSDN<Q$"S]2:821"FEBC_UFB'/!D1*IGY)0BU3,VS6Q#G<'ZQ'\M/,R6\\U
MP+L!TA_8 N %V *P!9?8@HA8*F+"D68Z0$PG @DJ$A3J2$NA AGZ\1/9PO)W
M/] $,CU:[<[HC"?CH+BZRNHKG==5<QZF1;_Y4N?2+ ;OE^.B-O\0W/,(:;XG
M]%<7 GE 9+K$>3N.FCET9M/\=UDUTC9$!W[<,%1IB;+OZ#)32N=[]T^OE+'B
M6&.DTCA!+, 1XJ%22/A8*9%*E=#4/.?GGTB(;_=I;![(8.F#U'-=ZH&N!-2
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M)NK&OSJLT!?.!WMC96[LG_T[JGQL JW?F\IZ?D*?9.IT4A" @Q6T!CA= 2Q
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ME_R+/AY>"5V>I&,K;:3^3X9U51NU;MKR$G_XL_:^,M*+_ 0J"8+& (T!] +
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M5VOH,C)^<#A05R#2[;#KQA+>.XB4;D=A 2E 50$HP%P!*"X"I=,A6P *J!X
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M :@ 5$ ! 51  0%4-I*. U !J( " JB  @*H;"0Q!Z "9U5 D!GD"P29 2O
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MJ[SUZJ,!-Q*\TC8Y_6J@\XHWB\> =&^>:FD]Q-S-XVP[E6T]-,#( 62 00/
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M0H%2TG"<4*+$CQB*M<2,^P2K1*^7XZPEKY52UHM]OWMI'\#*W-"AP,H<U9;
MRH"5K0-G#B?4@N/)<5)&!)8,)QI%PC SIC%#//4Q"GF,94!YF-+PA:1L277F
M_*B'DV>>#=IZ+K+JS-/8.55RVZXU;:IH)2[FY8,"+K87%RO. @18M!,6S[=(
M]LN,]QLP\+Q"K3!&UK\OKY68F).(!Z)B>V$!&@1@ 1H$-,C+$I] 5&PO+$"#
M "Q @X &>5E>"8B*[84%:!" !6@0T" OBX&#J'@:+*"<#X!FE>E=K<0*!%H!
M*T!; 2I 95VGLIW$"01I 2J@?0 JH'U ^T" %T2*LU ![0-0 >T#V@>"PR!2
M0/L 5)R%"F@?P D$EC<>6&X]/N!,F/6>"?->RZ9*ST+'PK0>77#>"]1VF-W>
M!6H[!%I0'<D4180)Q"31*"$^1YRFFK#$CZ. //6\%T*=./"%]"(_Z 7!TXJ'
MMEX<P.$NJV&NK0<&E)K:;*FIU@,(CF,!GO%<GB%]KB57$2(J)(B)A"*A?8VD
MY&$J4RR%_\SBY:MC&\^L6$Z!;S@A%58G$(!P .%P0_)VFW# :2E .)Y+.(3$
M0<HD040'$C%I6(=A&A&B0NJ0^2D.HV>>__9LPK&O5GY<2D!(#[,$&(@38@(8
M"# 08"!M!A <9@*'F3R;@I!42TI8A)2?,L1L@"5FMGBV+Z6?ZBA(<;1F"K*>
MTTQBOQ<$C[M!6C+#<T\S:;UD ]($I E($Y F.&NDQ:2I91IU <[$DR@,)!<H
M#:,(,492%(<<HY!H$5/ETSAZYEDCMYQI28>-T*@7^ NX6J!6SN8UQRZ.;U=^
MZ]5' W@D>*65:=#50.<5;Q:4 >[>UF5?NYO_V'8JVTFX@.$#: %C","R30ER
M(%H<1 LH(D +*"( RS8E3H%H<1 MH(@ +:"( "S;E#\#HL5!M( B K2 (@*P
M;%-.0BM%"U3I67/XFD1="U][Q<"&K"L;L_;TU:!?7&M==3HORMU =><2HW[^
M*::$ONXTG( M0P8O,&, 1A<"U*" 6H@F4$ @9T ! 3"Z$)CNG +JWM800J.8
M)"E%4<!3Q#0+[4[:"/%4I-@G1&@QNX38J%+I^V%IGO;9-+Y0_^3]H3X<.QV:
M:TZ^Y;JL+K/!YS[/[VX?,3]LLNLOR$6S?\2_."\N_/%F$M^]&B!A@*'^AQ-"
M!7@(\!#@(2X"P]F\A,[Q$#"$W9$JH(!  8$"<@(8SN8C=$X!=<\0#N-8"DP5
M$DP*Q/P@0(FO."*$IR2A(@[T[-*6*S6$UVB\0D6%S>N/KJ>DF/E%"Z6E=!)X
MD*KBDH'428B!T03YNV!( 5@@S0645^L0!LH+Y!$H+P +I,BT6'EUSS.8XB!B
M@6*F<2Q&C,D8Q0GQ$?-9&L:!H#34]SV#^^I?PZJVB2O5>?%(>DISXN]OMM[D
MP52YR9&_<.0S.=5_#;/*C-V9+K]F4H_<BZ=:%E_RYH[MSJFA_I-2:CHIF(#S
M@!H#S@-@@72<%G,>,-@=0Q@H+P?1 LH+P *I/,XIK^X9[)HE<1AB8ZMCC:W!
M+E#B$XJTP)1+3D2HTA88[.LSLJ'RS)K3?#IU<(I-@..YU%Z1VH-3K@K;:)OY
M,QB6]IO:JPM/?]>ES*KFHFHZ+ZC3":F0\0-J[-EJ#$OB$T)\%%#*$4L2@>*0
M!LA^'%.?8#]YH,;F9:1.*ZK#\7)4*_0@'S2RH'GJ E[CH^,/\S3:.^+WXBB&
M/9B.:+!5)JK";H>6V]. CLVC ]*U'/+^MAY-H(E UK11$P$P(.UJ*Y10]\Q?
MWQ=^XH<QPD+[B(D0(R$(0P%3.(H2%?/X296)UFW^KB&!*F1@#[] G)!UQ)NE
M 88N7ZQI"&@:H"! 02 +REF5ONUVL%-2I7493ZU'QAP%!-QDNZ$!N4Q@!3_7
M"H[#,!&8*>3S5".F>("XYA215'*!I;&#$W^M5O#Z+%<H2+1YXZ5;F4K'NO;Z
M1?6BRD-[7E7T,S7IB='[MEUM@1HD)+ED#G52FH&)M*$\_Y9+)G#@ 6J>3IU
MG8$Z W4&ZLPUV( Z ]1 O@RHL_^?O3=MCMO6UH6_GZKS'UC.OKN2JH9,D.!D
M9[M*GD[\OHGM&WN?<]]/?D$,$G<HLL-!BO:OOPL@V8/4DEL]DFRX$KL'-@$"
M#]9ZUH"%OB',J#,CF(PZ,Z@Y]=P+>USJ[,?Q1;XB;MM!'#@HY#A Q.$.BIGT
MD6!!$$HA(M^_%_GZ**H/&<NOQ*]Y6>XQM_-W45$ (G]'BPR>J=QA4J=5 @+A
M\F>O'#)Q OQ@G&P@,_V3H5A]D7J&8O49-H9B&=2,*K?(4*R^4RR*(QDZ#D$8
M.Q(1WZ$H$KZ''!HY;BBEX#C>&<4R[&@M=F1J,8U#N1U>0+VFJ2[#1"OK-UJP
M2\O%$TNMO'63:U]8/*_C5,Q4H7/F;:<*5^M6D^0T&J4X,'&[ADXD3NQPAET4
MA!Y%A/L212YEZEA02F2$.7;)O81;51BP;#)NEU7B>?GMD]Q?!:6G%% B>!*0
M:$)<SVP:';?J.?R.G=%HCI.SP0\N@O]V:I@R*6J&C&QLH(=.&',W0,*/.2+2
M#5$4AB[R;)O -['CW:]DK.G"99X"Z,N&71R4DFRV'X@XAI3T0B@,/48P1@UB
M6(EA)2;3T+"2OK 2[-IQX)$(L<A7E;D80]2V&0JHZ\H0\TBR^RZ2O;*2<[[W
M6EL>QI,@] U-Z864,#2E?RK%T!1#4TP&Z5!IR@C3&P*!HUA('X4!\Q!Q8Q?%
MDF#DR<BE$0_BV#\P3SE(WJAK!Y/PD6.?!C+!CR:.&F9EF-7I:$'#K RS.J'$
M4>, ZCNQ<GR;R]!&GO!M1'#DHYBX C%&J1=$P@E\;TMBM:/#+VTRL>TU$EYT
MUN7SBL+"AG]Y<MW#A;&);#T.A/[^ _;MI;W5.QK,XX_EO",[Y##?&QT].(?G
M>T\I#WL<H'T1PJ*,@;%%LUOX%"ZOH.$J5Z*%BZP47+W2^A7L,V[))*,92V@*
M3],:;.79^@)ZH??1]H(V+JSGKU0A MM?+D2@Y,]__H<%?W[6H@C^LEA*RU+A
M IZP> .M*$.RZ*,"WQ&B>H2S;O!9]8N@H,#>ZTGX3"_$LU?>O9G[^;+H?C"%
M2UX7@OXQFYJV 1Q.*TOURP+5JJY"L;KLA545M7AIS3]!5$)3+RR:WM#;$KKR
M? D.E[H_BW!HNG /0GU'R9,E\([-R+Z/S^(J4B>5)_*VSX)YF0'H7BH>.?.2
ME=]R^>T-+2^_O4_SFW+9G 4BES<[B5I;Z=D285/P?XH?:(4EML(&>\#KLSL!
MNPXR[ ,JZ[TPF><S?;7:/P'=TR3[_I V<[$\,6 /I71:0K>Z5YLL)5I7^7QK
MB*VMWH?+2NL1&\$N],#9L]-H+3R#,?]$2=?\XM@P?G@/\5CPX9P1 P\#CT?V
MT!E\&'P\$I+8[X9> X]!P\-Y.+W4P,/  ^\[HCEZ?'SG<)RQ &4+*^:\2&BJ
MX4&S$O42(X]D21B1<C![Q@#EI("RA65CD'):2-G8QC% .2F@;&[M&*"<%%"V
ML'L,4AZQ@*!E]>T_GOG/Q@P?F(Q=YFPZ>X7,+@^:WN#!O@>W.$_Y0V![<_[E
MR_E_GUM?WGQX]_'-NR\3Z\/'-V?&!C]F^OG11-?ARA./!3#[#BT:O(P++_NT
MR U61H:5_=GD!BKC@LH>K7(#E7%!99]V^>EAQ5CFQC+?EV7^Z>/;=Q^_O'MK
MP:LOGW[]\/;\*[SY\A7^^>W=QZ]?K$_O+3#??['>__KI?[X8:.X<FOL59T>$
MYCJ2\#%H_OC/C-8<.L<G5I)9U65>@TK@Y7I'?(P0>(_YC<:-/,/#=N\Y,H@Q
MB'FB[\A QD#F:2XD@QB#F*=YD@QB#&*>Z% RD#$Y[\>,MX=]=DB&^Q$U,U^/
M9WP]/0'*[H7./K!C9(Z1.4;F&)FSK7MY'8P]YEW^>ED(85W!Y9>E)3(N^/R0
M7R.TC-#:N=!RUA5:J\O7#@5#1GH=0GI][Q3R$0JGW7H9AP,L(YV,=!J>='*>
MRJ%^>//FW;OW[T<@J$YU>\>!TT-4L4M+JF*7EBSR*RN?"E7C,KNP5$WRZZ1*
M1/EB31VY5_ =YS@"LV?D, &6$4)G[Z7J#';&IO/V7;W.(&:TTF;?E>T,=$8+
MG;U7O3L][*RRT@:OG7ILD9W9X?QPKJ&898^#ZJ.HK#0ORU$?-WFBYE5_CQ$<
M)(KZFVR]XCCF^UY)??& P#3&,YDC$KN!0V/D!4&$2$ 9HCYC" LWI#[EKJ#R
M[M&!(*$_9"R_$K^"F%X^-?!MW1P4\PU_:P]D_IKO^!#!^<'*#IDX 3;G*O=:
M1!G+?G_FV>#1<:+&NZ%!)Y+<;VA0'SJ\!@URA!]A223RA2<0L:6#PB#VD BC
MF+H!][C+MZ!!SB(-<G9,@W P\9Q@?#3(1/R/KP9'Z%\ZY^J\3GWHI3J8N!"P
M<%F2"BMK'4_J4_6:J0R!6AU9G&3]30\P;JNQL/E1(L8D QC(&)>!08QQ(QC$
M] @Q)O1O0O]#-\UP,#;3[$N5LS]03)7-Q?*KJ<A*[489M?>ROS;5_A%FPB2#
MC_-[(W1P#\QUNDZ8W_$B(BE!-K,]1&R!423#&#D"QSS$&-,PONO?_G))"_%:
M">,W"[+XX/'^5W[@/NC<'N=R-P:P40;&V#7H&%DLW%"%H_=W#:K@NKX,'4Q0
M$ !?(*'/@2JX @F@"9&DMN]Y]BZHPAYBXJ](Y'V?*IBX\O%5Q0B=%V\%=(@E
MWW58C!)JQHEAW/#&L=%W$35"MF)3-_8E=Q'C$M@*CP(4^T&(7!9X'F8R](E_
MEZTL2NK#NS.<P'F2.V.<"]^X.(RJ,&X/@QCC"C'DHK?D(HXICW'@H("&,2*>
MBU%$6("8$_L4QR'Q,-F<7.S# 8*#<#,'R.!7NW%V'#2)_BJ'R?BWQK.52RO)
M*II=)'$J+%J6HC+5&\8*-1.',9Z-_LFC$9(/YO+ B9B#7)?8B-@Q1C%G$L52
M4$PD9I%T[I*/1;'\27Z8">5S+9,/[^O .#*I&_W0#$8I'!\=QH=AT&'\%3U1
MP2.D#([G,]>+ \0]&2."?8$B-PB0)XC@<>2%@7LORW,;RK 7#X9K4CB,5^,X
M2^S-)8 ?6EK>[Z\7@D4S;J4)C9/4[/T_.22:*(PI & @8XQH@YA^(L88U@8Q
MI@" *0!P6@:8XXW- /M<B"E-N#:V\NI2%!:KBT)DE8DJCQMIQD5LHLK]$T<C
M=!%'MFO'7N0CCV&)"),.BEWNHQ@S/\1NC&U;W'41?\A8(6@IWHKFWP]9*Z??
M"BE //-W?ZD]?^(\XY^4T#Y2M'GA8(")'YC <T^4A]$;QT>'L8\-.H89>#;U
M\X_?X35H!;6Q$+X=HPA3AH@,(Q3ZL4 D8#:+J$,]X1V"5NPE(CVQ_8<K$ UD
M#DUY_3YJOQ&Z<#[- N>I6M2-=$:Y1'4I'HBEGYSSV7AZ3,QB9-X?P]..W^$U
M>%H@)&%4<A3&Q$7$%2&*O#!&L<^E$#$/G1!W/*VDUW0%29L)^%_5^]]5QS[)
M?Y9MPB"0M5_GDOVCJ(ZPZ6"$9R&-7K09]Y51AL:E91!CW%R&/O67/F'I>*XG
ME7-+>(@(05&$O1 Q1G! HLBC+CLD?=J+NVM\[,ED)HW-BW#X@A>,@3ZL2FM*
M;ZDN<Y%QBS)6U();HG%4F_2DL<+-!!('[Z RZ4E'[^\Z%;>"6,J8$V0[-$ D
M#@(4<A<C)PB<F-AVY,KH^W'$3EA_;F0UD*KS1E(O<*O#^Z7(Q//7V-LZ*H%@
MW#I&71@7CD&'<=?T73F/T5WC<9<Z(65(!E&,2! )%(92(C]V[<AFH*-=]Q!L
M8@]NFGFRLSL)(G(:/IM1NJ6-'^? ?ASMLN'B6J3Y]$KM+6O=-R<7$#$>'1-'
M,UZ>ODNL$7IY',%)S#A!THMM1(1K(QIX(;*Q+SWB"#]RG>^$T=[.Y7>;)GZ$
MDUPF4>2;LUR,D\=H$./X,8@Y56>0X1Q'[^\ZOJ"(44%\@4(_"A#A/D4AEQQ)
M.\11[#C"WCGGV$MVCK/&Z7$FWV5LYNK1_"1LX3QGG?,2BTS(Q)3B&2W43'C*
M>$'Z)X]&R$BX9WL^YA*%G@@1<42$XI"&R'%XX$<,2]_EWX].O;N:IOFM$+^+
ME%;'SG!YVLFVPY<!QO-A-,0 O1R&1/0$(GUV:Y@<E^-W>!T6X<>A"^0!Q5$H
M$;&IA^(@$$A@Z1"/VS'%:^2X;,HB]IK9@B>!_7#"[$"FT&2VG*8&/'SA'5TO
M>4=E=5Y899XFO'LD8+JJ@T,!GG'?'#O(-&S\]-FW8VC9\3N\SNF]?L"9I P)
MZMN(2%<=Q2?5R7P^LR6GW/?N'<6W8K.XDNEOFA+XQ_3L+&0;XQ&60AP[$3-^
M*J,*1^?$,M#I.72,<\NPJ"U9E,]%[-D"(Q:&!)'(PRB*'((<+Y9J^Y;@@NR)
M1>UWSU9@CX]%F:RC _L27'=L/JR/HK(8+2^MNA3\SC',L$JNO^O7VJOV7'W#
M$W9F[1V AP\CC@0TQH-EN->VM0Y9Q' <."B,5"D>PAQ$U4EAW'%CW\;,#R+_
M+O<"^?T&Q/?G(K].N."O;_\)<GRAYN'Y3(@?T86%W8GCC3"N.";:93Q61M^-
MPTUE2%)O06,<5(8D;4F27.9$KG!"Q&+.@"1QC&(_)LC'KA.XA-A>$.R+).W5
M0^6X$\\]$2?5*&-^/79<#<UG%><I?PAA:B5;,LUO2DL6^9659->BO..P>M&'
M@+-Q7HV.QX\;.H^YL QVAH(=XS4PB!F"M.FO \% I^?0><R-8+"S$79,*L&!
MG91V.+94@L]UP2[5 =2YM*:%RB.H;G4!$_%GG>@:/J,.H/37\-H_ULSF8Y,C
MT#^!-$;WM^_9F#/I(AX3B0@0/11Y$4>^+;$DZJA$^]XNE\_T5DG?\FM^SD 4
M%^)S*YT_IS2KSC/^KA/0AR]@XGKC/CMZ^#++6/A&HQDCWJ##A/O[KHC&R'<<
M%Q-NNP+9@0KW4\]'E(<<,=?&$KLDM+U[.9&[XCO[J"9+G!'F09H0__'UW2GL
M35D5ZN_5;D\3\A]G*N:) ,GXIPQ?VY*OA3;V0M^/4.SZ'B+,#1&5=H!X'!(G
MH,3U[O.U!](S/W32OA=[6,;NJ!HE7S/.*Z,4C8O+8.C8&#*.,$.LMB16- X=
M.Y8NDGZ,$8EQB&)*)7(EL5D0"!ZZ;%_$:J_[7D[&(S9X-M5C[]?0'%]/V> B
MDXQF[ D;7,:3Z-E?S]8(N-=X8&(VK@P-)\8+8-#1-REB#'T#$[/YI"^;3T;I
MC^ZQ!37&#2E%SH3@79V LJS!CM+;4UA^=96K1\C9'U8]A9?B+U&PI-F\TGR<
M3Y4K8JO\@D%BU-A<1_1W#Q(Q?4X;, ?S'KV_:SBW;2%C[ L;!=R+$<'$0:$O
M&8JP30B#M\3&][(\6^G^'H3[%R6Q/S4"^UTKR?GA-[/XY$FG\8Y3&!ACVZ@/
M8W<;Q)QH.-T0CJ/W=PW"$<4><P7'2'!/(.(Y#HH)X8AZS&>.SVU^_PS?+0G'
M/G:3.!A_GW&86/38DMZ/MQ-CVJ:26/'MRKCTB=4S[J^O9"P[+T8(&N,N,>QE
M._;B1K[-?.XC3.P0$2<,@+WX'GS.@M GD<2*3ZR5"_B^$^)'W&3Q5+_)X,F+
M\9$8C6$\) 8OQC]B&$8_&4;$N(Q#PA"1 3 ,(H!A,.8C3S#;]>V0V<&]8V!W
MQ3!ZY2@9I?^TQ\Z3\?E->'LJLBI@H7THJB2J?J'JHEX#0K.J%UDFQH4R.FXS
M;NCTV9%B=E4>O\/K>%+LT ^P'R A"$>$NSZ*N,\1MH7$4C :V?(NSU$D1_W_
M;BZ^?Q=E522L$EQ]<9[QY0\6KOP,#YH#*VITPMM6-[S[BZ6UZCB\N*39A?B=
M5N*=A X<OB3KTK&M'@G'MSES[/3.N)>,2C6>)@,=XW0R;*P_'5Z#C3$2,8>&
M'I*A[2 B/!=%U ^1RV*7>#CDW(WZS,;V?3YL0!X.E T$!:94QJ@5Z<'Q].8A
MCYI%*RL6\)-,92BI(XGT6C]:),CLX1H+C1L/3/KL0#-QPJ/W=YTX(?8B'O@V
M\HAC(^)& H4!(RB6$0]M!ES.X3ME;,L$[+S\]DE^P\Z.@X4VGMCXX:ID)B?)
MJ(Q351G&061@,G!GD&$61^_O&LP"Q[8C7&*CV%6^H)!$")B&BQ@.7>:XU ZC
M>SNT]L<L\(Z8A>M.B/MP(7F3BG0J"J5?CA(!GZ_E(OE^O6Z>UW$J9FK+.?.&
MF$%[H@Z4@Z/R;P9LQ@UCR-+69,D5CN_:#/G<%8CP,$:ACQWD>Y*Z$941BW<;
M.%M%EG:\*0R'P83X:W"EL5,DXYDY8D[&6'3,B?IM#*$QJ4"&T/2LO^OD9;,0
MAZ[O(Q;85-7GL5%$L42.\*@3,!Y$\MYI-WLC-#L+*T43/W)-P9ZG:J#S(J&I
M1B/-2K0"DOW4/?/.'2ADL+O\T95JJ+\^%P.0DP#(%L>\&(28U 4#BZ/#XFB:
M95/CUP#D) "RQ9DN!B&KK)?G%859A']Y<GU@-\"31G')[O]775:)O%UO4/?H
MHSSD<)W9-GXB\I;&C('Q+(HG#-G!O0U?A+ H8_D5].]6[07(\@H:KG)E\7.1
ME8(_P8%RG&> GFH_'JT&T-FV+BQ-H7/0X2OE7CD[%KZ'*0Y^C@OK^:N__Q Z
MMO_RB?.]I[B)$N3_^1\6_/E9RW3XRV(I+4LU>;"BBC=P9PK341S8[WM("=:C
M9=8-/JM^$138TWL]"9_IA7CVRK\W<S]?%MT/IG#)ZT+0/V93TS: PVEEJ7Y9
MK$+J*A2KRUY855&+E];\$T0E-/7"HND-O2VA*\^7X'"I^[,(AZ8+]R#4=Y08
M'C F'O &P$FOJ?6%)2)CHIQ8'S)V-+UT\/$V$.T_1#]VS/3-C)F^661^[V?,
MZLN,62VQ Q5)TS=1&]%G5W^;7[ULU7+!\F8'>VN(/WME)G=?D_OC/S-:<^@/
M_VFH@VP,Y*W&K(G[?JROH"OL3O#Z4W%!L^3?>C'.USR\.<_XYT*4 &_]]I.<
M+>OYJGZ;E"S-R[H07Z'EUVG.@-S-H^IMBRB@1-I^X*-8\@@1VW=1& @/.80(
MZ49$"/;$0_-$R>A421-@B,TODZP6_+S:I&G4_IXV1P(>=2G'><H?D](6/K.L
M_Q) ;T$8JZSZ7Y,_ZP16]^T,ITNSW> 6/EI\Q@VGZ/XX#70]&!GRQ#'3GR6*
M&NA<)D?E,O58XZUFW'JY)%4)QG2>IK<HO\F VI1U7,+ZH<6M]2.#SX4J%BW2
M6ZL04A0%7 &TB (YNA26\HLX]LLWC4M/O\,O?X+Y+%E^+0K= !?PZWRJ#BR:
M%HFHU(VGEQ2ZRT2M(P'J*UXS=;!1QC7!4G>GE75%;ZU<0JNZ]DXBX>*LLI(K
M=?91(V]57Z:P_)KM,] :F+QI=<EH(=1=I2A+6)HT+<^LK]#?MJ/612,OX*%D
MSNH2VE/#T'7[5M^IZU3;?]6<):3,"[@2) 9<K&,EI=JNH\8"[GB=UZ55WI:@
M#,X&#W$C%D8O%M226'+(UQTQ7O#(+WF\5WF4NP70+:Y+>BVL6(@,EI"84B4Q
MDDRW4W!][/M-4EWJ][72GA=P60+WG*;PS/.%"=^+:=7\5MU=I?O!.TVU2NO'
M5O+\U_GYYYG8@;4)5X/QD5PM=#3)FIQ I>;UNJX+=?Q\I42'NG&2E4":= )@
MV7WVOVM:P'V@&[^+*:QXM>#?PUU@T-'_UG<Y5T',%-B'K1[_=W%1ITT37]#_
M.>M]8. \39N1:N?>J@J:E;0=!/5\,4W57)4+LRG2Y I&M9T3MDB-S_K^P-:Y
MAA^\3V\G>HJ? G">JU 5/+6J1@=+!D:OQ?Q=<"D'?!/5*M3&SJ(YGT^A5*-3
M#7<J*O']-L] 0^L6\FF2J;M#@S! ]$)_?6?)3727*%=B2/]ZHAM(RJJMN-4,
M#O2)U46A/KM_+:@RZ$HF8,Y+I:)5=ZDE:5*H93RS>A;PT X'/[,^386R3N"^
M<&6=PHBI7ZL.5I>%$-853-1EJ?:V0A._T8)=6BZ>6,IRL92F5H/;M0RX@#MS
M4/6*=G0/VMUW1@MB88F_IH+I\5-=!1#G<.5< C1;:"WXKNO,K:"%;G1@6=K]
MER?OU2C713O^LR4Q:3AC)U6_O]"6EY"ZG8#?=D#K5,$"W<3!R](ZS\ $2^^(
MZK__@'W[)<CK_W=Y_AL0O@6T7<70M1:'SF#=S[NA'H;"/9WV;KG*D@I:9NL[
M.^[[-08ZPJ>.U!TD0@S0SIA;!Z42Z+7V)"R:]9FHK#0OE3&NU$ F+AH&H*MD
MR#2_ =,Z4>:#^FO:J!=U(=R/MOQ WYQJ6Z.^4H1<*/<#W#_1C.EO?5>C:VS'
M(H1$DH<.8M)AB$2N0-0.))*8>Z'C<B&X=W<[UN]"Q__Y.UJH$JSE^7QXWC:C
ML\4F<F^=/5?^0O5DUP[.MCG*XD@&!+27:I9?W6&PRYZEAI0V_B2-W-8.F'FK
M@+@N.;,:2B/KJBY$<RMZI0QCC>U*65P7=]C^C/<T/UK1S WT%>9HJHO)9/"=
MMD[SUK$%3_@'K+7&P-8&.=Q?]7>%&TYWHN'?>5TP[2A3'K$N/*HL S4:VJ:8
M._O@[43#0EO%Z@W,32UAKNM"OP5#Z JL3Z!_R;^[WY;U5!$X]7:A-W<\=XK[
MET+\8:G)J;1O#\8A4Q.EC(V\OK@$"S\&S:J8_[1(KN$Y%@Y(7QKOB95(:!8F
ML[M% H]\39-4Y<SJ3L'P@3EQ57;#I3YOZ6S;)=T_F(;&D %Q5-9%8SIK8V6Q
MG[->Z D"),S;@G8DO<Z+I@'5XD0]@+I!FIY9O^0W,++%9-$&C,$@AP_;=C3!
M5E(5OKG)BS]4,XQ.%<NPIGFI^S!KMZRE6O>B\8)<"5&M!-C=^V0@71K;#AI,
M!2VKUO/Y5V5AIS7SEICT\SN!EF$REIY53A@86?E.O/7+7!J>SWR"G\%.!'R6
MCT91:<PE)HY$KA."+O1=%U%".6*!']DA#AT[=/8415VGZ4%%49VSQF!N_EZ8
M$VL^*58W*[U7UMN%?C>9W-V"!1^Z8H,)%_5+*/ZS%)_D.[CT2M&P5<*/^)$K
MA1TBSXXB>(<QBID7(V;;S'8BFP@A]R3\UFGZ6,+OJ5X5&&A%?V=#/7+1MMG4
M#6]M&5%T$LZD*_H'M"FZQ=OZ@\KZ:MI$,I,N!MT9E4^)^C5!3F7%)M5M$[16
M@3QM[X'4>+A5J@^H:NUF9=)""XU1KV/E<*EH8QUI0N,DU2>Q-^;S+'U07=BL
MPPMEI3WTFZ85]1"=D^ I3SBW[I=ZJ6Y5@&4)TM\"ZUXE!:DKE6LCT[DRG?N.
M:VM^X18ZFJ_C;G>\(M<TK=58-?12S<1\^'3H%/Z^R-7/8UHF8/LV,9_F[OG2
M:!>B<>PIPW71J6#1BT(L/%CGFE"&&=C8;7IU>0:$MJIU,+0)*0*[3=7(ZSPC
M6>17ZGD66QQ8M/ N'/L?F^^/P\ HGY[QX+98V-W# I4=>ONH;\#U9.2XH8=B
M&@:(".J@R ]<Y'A4\)@$GN>[>Z+'ZS0]%'H\JU6N7[Q;K%6>Z2TQ:K=',VY*
M:[P!K9!4UN])^<=PI,Y&1'JS21[>XC2R["2(=))= ]]I..]#QQ,L4[HN::RT
M+J&Q]!9XJ<I/6$J\5(F5740*V',.8YFH0 C0*J!LFL%JUKJ0(Y875BK*+E)V
MOPN_+#76=+N-K>EH2R$6T]GNG;#0I?!!:^)V(1+6D'.=?E1G7.7$J2HUR@-:
M-9WD0@=1FI#S/\^^P&"H$VKK0H6C6/LTK0]UV4))].[K!>;[X  K.@_]NC.$
M257K%,L>T:0A;N&^/V*FD,* "BD$O2^DL(^X MYQ7,%Y]NKP!1_V;R6\ITGQ
MWS2MQ6]:)&LG0&,CK&$I^-3S0C>F*"2>APBW!0I]$:,HX"'F:IL?WI>EL$[3
M0[$4U!Q8>A*LA5DHMZ39FXW0P-!M$B)/F7H7@N47&=RY?( [K]@\I3RNM*XN
M@5%739;D!=#A)I<K:S9M7.NE>+6X%)<]S$TBS[S)U2YF1?J3<GY[E4Z9J=_.
MVI@H3RF-TZ2\5!YI2Q8@FU7FD+Y_TP'EGEWHU8HG4I[U2>=FAG_*I9[2.*^K
MAYZKL4MF/:1IF=_IDK8P$#Q.L7B/2WBO',2W$T6"V*7*%E,#JJ>BV=PSK6%$
MZK+9>K#J4;I@@+KWS+IX<;(+Z3BRZ,OM%6BF[8?KS+/G1U)L.F;H*8-V)V
MD)^F%)XHR73G8\597J[SK-N,]O*4=X58U6/8^CG^_H./?<=]0O6[7L1!?E6I
MJ!;N%F5I_5GG*FX$JUSGL2H9I$5GXP5X6F%$ SD#N8<@Y\PAMYCIG<?0YK7.
M[VT4RZ1)/:9WD:FW,:NAT;41<E7\ )Z#%@N.)IT;W&UWU$IJYOU::*;Q,67:
MD9871:YCH,V.U(6K6B<8IQ753=]O;=GQI\LEM#]2/>[2MYONW+]QV\$\;C8A
M="'6I.!@D1?5K4KTOM:>Q#/K0]7<7FG?.&E'1/D"9_I\48'?-'G7"U<NIF_W
M?]?DXJCR')I4^V#U_EKUR0..5/W,.H5]@4^5*FPN=+;Z'(-JV(U0,T)M)T+-
MG0NU.KLGRN;BI]W$T4@9,"$JM;>A4!LC9LYV4+I)=;LL5'8,?W<3^/>,B?>=
M=?=LN#8V7'JQR#Y(93FO@'RC#Q=7F:2Z>$>;L:0N217F9V58%LS:>7D3?:MN
M]X\*:EV I?MOM4KUPJFG>;,O*LUO0-4V=]3;PE3#3;O),IUI-T$M+$-@*ZRM
M@M(L[H7O5#;;@V&O&WIO >/ND>]MM].W>'S[_FGD$#V.6WH)S_'881C;^GM!
MFWE.$#VU)OIQL\OZ'L3[WE8I<:$6\N]=KN7:,0Z"8X?AF"-LBQ@1B0,44=M!
M86!'=D3"0'K1OC8+K-'T4&(<K^M2.3]+JYV(<LMD_(V&9@ 8/AG>TH^2&$<.
M7TQU2<2R61)+%;%F2OTROU$;QW5IIDR7=YMEA+=%KKH"4O!"_WYA6WK<K3I5
MAJ!Q?;2-+7LF9MN6V[OI5/PF'TAJSP-0EKYKJW4.Y UC,".QC5P>@]3 $4,A
M=US$;$&93:(P9O1N!0B0.,"6/LE9H:Y.@#U-Z"_7@0@6ZT!\^/A^J1 $4 ZF
MBD'<Y 4O1?;L59Z)X15]F$&O!=R+9KO%0D5075Q-,59>U!==B(U>9#DL;-:G
MO?#'I*7#%_3[RV%1=7E??"YRIFHKO"_RJ_\JZ"S%?0UJ)STNW "'R&9!B$@L
M;$0I\U$4AK$M@\@+\+XVP:_3]";4;@\6^5.97C<AC;>ZF9+>2ZOMV.AFLSFP
M1;@G+]%.K.W'9]?8VSU&QY&'>B!.SK?S[:+?K0L[:?+E=0E0ZT;]-;"'7:>6
MFW!EY#&&6"@8(A[(7NHY,>+$P=2/I",X?K9($WX7O"E4_37_O=W=>I[QMW,Z
M^J[9HKL-JU^N[N8_2NKGY=U>9?D6[+X7$P:6;'(5UT799LL5@HGD6BP7#/](
MVUI>']J=&<WND%_TJ0.SJN0?/_PR*TH^VX9\H4G$4Z+2,65_7!1YG7$8F_?Z
MS\M>#-7"0A[8)']/[C@CF)W)4C7^&8SOP+O*%06!67Q"5<S>/O(:PE8$<>!*
MPA#&-$(D(#Z*1<Q1$/D"8QYSUR=[$+;.HK!U=E)*\Y5]AK<0MKV=Q$;C=W4V
MEZ3NAU^VD:.]>+J[*=^@0?4ZG2Y9FDWIB>815698T8%0[XA,M%IJQV&AW&9S
M-DU;GL/4>QB&4^Q(ZVM0Z!@>%AXM9@'+'Y:HQOGO316;-WFY5CD+Q^:.=,,(
MB=#V$+$Y1I$, Q1XTF-Q ,J-[&N3VCI-#]3+]Z6"X49-E&IQ<GJG6AY/Q!C6
MLM[(.;D9"(<G/@[NB-Q$C1A'9&\=D;T@&D!U&Z&T8HLCK&G4)  V='5V.,]R
MLJ#*<2R5=+;RKJC>;(M!>4GA>1NI36\H$.D5&Q34+5^G8.J@+^PR5T?+-3>R
MFKP#]>HJYR*=^6R6+IYY;X!T=VF-]]*.H9M+79Q8*EK<N$74BU2@MDW=2XM.
M@>O3EKF754'56"(%)XM659'$==,M45VJ^GE]7U]Z7V@SANWA PN[)O7@U/&_
MFL-#[]1D["K[S0[P:H:QV<)QG:L4TC2I;B?S"])$-MM9NJ)\^M O*9)*;P^%
MQH0:V'LGL']CTV]J+0$%<@-G[2/7^SKD&D?=EM/%,6U/>],#,:^K*+L3(MK4
M>U4:,FFAVNQX5>DQ27:ITXA36#F9*GM#D_9D%>U\AW$6DS:U7\]G6WBQ/87@
M[W2:ER]+D%Q<9T@,SBY71Y?I _W:H=2VM^ 3E:^T(+?FA]#=V<L,1GHGRM1*
MO[.P=35+2Y^%J^Z@JA7-:V3.< LWGK8K95&B3!:.P^Q&]='T4"487RNYN$AF
MSPMXHF:R7M_.+_E,;]5'YPI2^J__;OKV67<-KS)"A.UC-Z0A<H* (T()15',
M)/*8\+@M"(M%_#0CY&YL@=?%+&%H* "2>5WHH^4>S 8=R(,,RW%T3$;7$++>
MT#I#^OL'D?Z@XTAGO+5Z= 5;;[83*578[#L"#:C.,>K2*5L*LI0)S(I$'>I*
M9VS]\\*76GO-*/N=XZ*4PIZF2:O!,YT'JUJY?P.U8?$^PV^*AE]=Y5FGFK.E
MDMOZ,;]G)F@EWY*W#]52Y7!UFGVJ#ZA36RH5 6ZY@3YE28_,W;3HV6"H2Q9O
M_4!5F;6H2\=0'NK.S:4Z\5=SR'8;:+/E<]9#'<M8U<M$'^45-UNRX>F;&ZJ]
M[:GJYG4B;AKKKIZV9XZ5C:D$]H :SCO%PN5#76QNTO2OU%1NAJW'^G>V"@H:
MG,WM%J8>GB0!TMWME[N#VP<;&%6XHR\J["2VJ[5%!N]BQM2L[,^$/5:S,CS)
MFI7.CFM6NN.L6=D=Q@K:1QOEZP0!XS!PF/ 1=C'8WUAZ*"(4HY!'OLV%[[GN
MOE+]UVEZH$' CZ*R?LW+4BEO2T_%MK&JC<9J>.CNA=DZ.IT_,!R,QV@%JC_5
M^;S*9\MFQY%KL:"-V,[T:WVZ#>-OVA$<4;"@0#4OF)B=[:!^"]?755G1YI3A
M+N9U_]"DMTE:*ZMY1>M)V761[ZXG4["5K"E0%I!&- 7H0?/ZT/4'?S&/<55M
M 7S46$=]7V5=7.WS]YYV(9BR^.#+7H#V;*7%0U.;8Z 3%>.<%6<!.S 6U8T0
MV<H#EF?3W-J:,$9@9Y>J3^KC(00!-<[4KN*\:+>_BBR_2K+F@_:X[872,&I8
MFQ76[)5]$.]ZTP=5Y?#2-+\IK1_UO?*ZI/J !O&7.H][U0]5);N?7O1]Y 9?
MLV D=1YZ/61FQ(X[8H]&6]FEX'6JSNF]8\J]5N)-[15HA-M7Y?I\U+#SN'0]
MSW,1(6KKK: 1BJ6-$9.,"$D](:)P"\.N<0LLYCXTHZRF!;ZL="&_>]"(\X(K
M]X+.C6C>('V4XK2$@>U>;3+QM*[RKCPBMNW_I6:Y*N!_/FM[88^"GO.N TTS
M\]F==TTUM>ISW>:J+P!U2Q^W*%@@Q]TGW5-T[V?X[3YH 7RMS@P"5=>!N+E3
M]Z1^>$;THZY8AG<F93.=U)N"/CMV@E9\[-!PSK!!AD'&"F3@,]\@PR!C%3*,
MT##0,.K$(,.H$X,,HTZ."HWGVGHU%NR@,?)(X4(C30P#,4 QA,0 Q? 3@Y2>
M(\4 Q0#%Z!X#%*-[^H@48RH;R!CA8NC*GH "#:H/__',>S9FT-AG]D.@V0 C
M8=_V=VV?&QYNN77@Z[TZP4:3[4= [0U\6PJH=1!D--D!-=F) >7IFNR%5>9I
MPKL^@GVK,JZ'@AZCTO:LTG[KZMP;3=8W 75FA]^M)]1/*35BN#RBSL8JD ZC
MT)RC*;35-S2:;>":36UY.;YP.@ZXC)0R4LI(J8%(*>>IU/N'-V_>O7O_?@1L
M:M_D.^HG^7[Z0VPGTSYV>_%?K*D0QX.P/;N?-@?8?@V[[3&SKF&W5Z@<1^GM
M.07$8&:,F#&"9LB@,3K)0*7?\L7H)(,9HY..!II5)OG@%5&/S6\<C,C\;JO1
M/2:)!H\E(VOVH: &#XN3XRV'%BY_&S=\=AO)VAM<%@,0^I+A ,CZ\9!G\VW?
MW[;\XON"LCNEUKN/D$V$1TC@((=' 2*>+1 5H4#,#6/I1)C'0CR[4[@1E/2'
MC.570E5]?UI9Q3I+F@O_"2^P\\SB@B7P!.4_GJ'EX^Q>9/45SZOV>T R !_Z
M !>5 !VX_-DKATR< '=%YKM'>L(AE'V8HY]&+90,U3%4QU =0W4,U3%4Y]A4
MAPHA R?BR/.H0,1F,8ILXB#?"3AV(]MSPG@+JN,L4AUGQU0'!Q//"49'=4SV
MSM$UWJBR=][.C\XP^3N]@=B@N?8HH7)R_-M Q41&#5:,!C)0Z0E4C 8R4#$:
MR.3FC-RX'E-NSI?F=,^Z%%P=2]F<I0K?KCA"<G+_A,I1.Z2-A-IWF&O8M5D,
MVS'X, &MXP:TAA4K62>>%3H1=EF$XI@ZB,2<PBO?AK]P[&/B1#)D=^-9_].>
M<7[>'''^49]P_DFV!ZTV&O[3_,SN;9)[-@EXO2)X$KC1P.-<S6GFAO 8A7:Z
M"LT0'H,/0W@,X=DEX1%.Z#,_8BCF,1 >B3&B$<=(Q$$4NQ+NQN1>"<_C*3X;
M$1XWFD2^,T["8[)[CJ[N1I7=\W%;/^,HP6>H^#$B:2\LGM=Q*F;\RSGSAEBU
M[N2(>J\R\4\&98;NFX3])_-][+$8!\)#PF:*[],842D)"CPO$B(@/F7>7;[_
MCA89M%%^%H4F]RW1W\:1Z2T2>^=Q7M_EZ]MG7CAP4O_HQD3#I'HDM0R3ZH6.
M,TS*,"G#I R3ZB&3"K%DCA/8R'.(BPB+.0JI8,@1DG-71H'M1SMA4H][2#=C
M4H2,CDF9-,SQ>$%-Q0?#K<<$BP>8DJ'/!B#'!8@1(4-!B-$L!A8]$AQ&LQB
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M.A6?I%;LK5YOU/I7%5QYE##:;H#C$,Q/$@H'$0<4*\7"1K%@0<A<AW*R38I
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M&[3_2-LT37.F39]85#="K-,#_=7,A:[><'$MTGRJ+:U9-U4K>:;=Y2"/5LR
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M!'^I^EI(!IASWX]X).^=2;L)H9H7V1XWH^K#M)O:W4:%;NG:@C=JI_A54I:
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MLZS#&M >UN5R6S;;[<W,MV^/J,+NH(:/LT"D@'Q #(KLQ)(-F!AK[A>Y4:3
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MY+@(SORED:YI38N,)?!2 [PDAZ7"PXVKJ%@V;B"773UR:.S:4KY:Q^F&\WR
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M-H,]M:1[+"9[3J&B1]RS?<ZU0,_ZPKZ]CG(_3O,RXU_@+C_'P%.[_&4_'$U
M/$W,R<2W3->=.& LV<R<^*,I6#&N'7+O;NT,//?9&C,;62D-)"!4'IP5]WET
M6U*.CBHI]X5W/Z3@:<Z&AB'VW_B"[/VTAM9=(]+&3=X]<L;W]=Q]3N]QJ<%Z
MM!)E+?6ZOF?W-HP?7HW[N$%SV/O@2:N_G\;!'O&9ZWI3V_3&LQ%XV>.QR0)W
M;,Y&/I^"U3MF\VN]=)6JDH7>/_.$AU'Q:,USV]XQA5W!U+M*P6#ER0\_)>E1
MR[P?X60*Y0>+0*70/<*T#,H,@_R4>%AFG!LKN.T2K&4*>-[^/5O=+F_IGU>=
M>/?W.-37<*RNAS,HINSTC+ &X(OX#-P<,"N,I8BW8" &4S_DW8%I*:+C2&!A
M&<<4>Z=7[9MXP[> Y0$QH7SVA!0RKB)X)P^#_F$.[TM.&G)8QAGNBH@Z8814
M&$@LCM,K]!A[]O+DW(*W>X79D#B_2VZC$^N_A6["E*HUMBTS8&%HNE,_-#WN
M3,UQR.?A;#SR0V_Z*+KI#KU(ST W"=64XZ%<4TY*<&C-=%3-U#>*0K8:ZECS
M WWFGISV5D'B*04]]P7PSJD>"M-<^2U#>//QB/G^A)F^YS'3G4]<<QZ&W)Q;
MS'5F?.3XL_F!0GBW>72O0GCSH=&!ZHY]RVS0Q\,">/<YN\>E!1W .XT G@47
M7:O./FHE]O[-_$PM(FEHHG][EJ-[APFX7R/F17%4;$YXKY\'0>YDXOZ4533#
MQ4L68. A77-4V<G"B"G^0/70:_"POH%#6?!XTP&M]7!'G8<SWV>!Z0?AS'1G
M/C.9/Y^:GN6&DQ&SP+YUMAWU#QQ,FH2:@LXRSG959-6UO%@Y6 T6^CM/%[ ?
M2^S;JFNSSE#&)UMUA;_BGI_#C7&E)8N_\&Q5?^6C.ANZ+-]=MS6Y?37AI*>5
MA+^76#81<E'[D88AUGO0XC!<)C9V8( IRW)1%,\2439>U?/?IGJ<-KFN!'\-
MIVGMLHH]-K)L>SPQ9RX/@)@\VYR%[MST[)$[X;/9=.+<5(.ZNQ#\28FG21Y8
MQ4PADH!M,,B*X:'.DL'9.HMBPQE1U-OM6P%YN]1'U =Q(X8?P"$6O1<<&SRP
MV@=. L2N:!'!.O-B&>52.@,UO^5>!ORP,;"<G*+B1/))JDQHE.6I!X8ET5P^
M[)T^U4;Q*=L@J%05PGD5KCV!V.SUB',[SM3C5[M[V+FSKR)$IC@9E,(8^!6_
M%8C)#P+X#ET)G7W+VV 4V_Y\YGAS<S;!:N*)Q<P9;(/I6F.7\3"836;7VG3:
M)L5#IIU_RM#O*#985U^<)0%V*:Q%H\^7S9JW1G+^7$8QOMJ#9V_^9+L/-( [
M>^!D43P3RK7GS)_8MF=.?9N9;C!SS+D5^&8P"_WQ:#+S>7BMY>8>E'O#$-D#
M4>Y^Q\VU3I5P!]2,S7WL38HW_;-5'ZMR\$ 35Z_GMA#=Y/_^'P/^^4\".H%_
M&7[,\AQW-P6G QU*!ON5]2R&C@UN/+O="73('E:;[Q>_<!;P["T=PB>VX#_\
M9#FMPZ3S6F;J&VNXYN>,LZ_5V<@G6+-U8>#"#)"<>)7IX64_&IAU>V74GY@L
MA&?]:+#XBFUR6,M?6_2PI 4UZ4%BXVS3T"%20M8CIX3L'I#S<_)TC]G3V G-
M=XZ]76L6!>0$;X?A8YDRBG3!;6=/4(;?E!MIW,.#[,1[W,+FMMC$<V:!!\:W
M-P8?<>J!M^B%IC\?A\R>VLR=?<?FEJ@-^1--L'FXK]>)H[FK7]>)1=^"GB:.
M8Z&OAEI[9KK^V#+9Q)J9?#H)N>^'<]L*'X.>'@W$_^$N6">.IB/N5M>4OS:G
M;IMG.0 5W[W,YB.80IFQJUZM+V$#G>(ZG@ XCN2]:S+H^ 5""$98^D5N(!+%
M.DOQ%U0?G*QU@6,(6B2EZ"=>L,C8"G$IP,58P 6(^^1A!EO68$08GTE8+,$&
MXYAY*6KK2][\,BLDD" ?(+P%YK*1VQ&CL(8#DV4>H,TOX4_D)1$R(E5"U&M,
MLP5+HC]8C3[H WEB945]#7R;Y^WL/':EJ9LA ,CU!\.*,!G?NCTMO8;WP+JA
MW0B,C=Q\#:0(MU./%" A,1P05E\)5$2$S^+99>0#%:P%1@H/=,/"0P-"767#
MKG4H/(YUL:OX"DN5?L102(50]G.:E#EF5_:V)CBCP'78:&9. ]\S78>[YFSB
MC[ <RYOZHWDX]ZT#M2;<YM'W:4UX(@?A>YT*@O:LT5#\@*&-D4'!JAKSELZ(
M0-$>UBEPGZU\W*-YZDZ!HT.Y]=^ [)KS^.3:X1W6O"[@58@W!PUL:RK<ON2B
MN+#&@"8P>.S#YCG6,T?Y4A0:PL6KE H,P=Y(<>@$SU9&7OI@9N1;,-C8IXXM
MZA2CAMM)@&M6P+[G7R6\M0 L\T@Z2)M.V$49)S W(5($'C;^M&8XW2):L\JR
MPO=$Q@2SB^[E-_!@L=@7]4%>\+6X&K&^HQ ,NJ2H.NASU4*_;7?!;G[E!=QV
M31ZGL-L:&Q3E EP;+#+8GMWOI[ +Z O-U8OWP=9^\5.2%C5H=F-;Q%_+)(8=
MEG5'MUUJ_8;BBXV7CZFD5'SL\PSS=>(7LIWEYS6V.$: X)LUQF5](FAZKG@A
MA?^%N-!'(.[!K5Y:_.!QRFRH,JM-8P,X&KWX]L8+ZV6+P/"H8UX@2)[X(LCT
M!8+G90;S?R^CG%9O@(T,]" BBT1;>&A%5)3T32-G,>$IIU<)N ;+:+U-Q]@Q
MCC8V=N? (ICQ7CSF2WU?PI)_8=?+JRCP?">FO%CNBYNO?KD-^=YT-?(2"]H)
M-Y"V";ZXA-,D&.F A_"=UCD-C9\%$<H3%NN($@1;@%L$40Y4(I CP.$I$TD/
MQ0;H<0&+!?ZM"$_=)..POYGP< ;7%@@;3 Z9P#24A[K-RH2$+7"Q\3M(_ZGO
MEUFFZB!9WBS$U]FJXV2K=,A7AWQ/Q0ZZIH\J:!U*JX/2PE8*%)\M]2-E*;_D
M CIUEP;H,YMHEGA&8>4STJJOP=(DH&''4H,F=IF5^%IK3N]6#W\QKA"EJ<5&
M+6OCE_0*6"4;&#P,1>+0$!K0F@B5TG1 6J-ZU P,=2\Q2&:5HDD,O+E[-8@(
M=L-:JK:IW=]L]5"!$[,4#V.QL/%W?DENC4!GQM6O4QRM$[%8P74UA]T(/PJW
M2]FJ8'B':1;R2#ZV:3KA:DD@H2WDT3N+H?2$.8^6**6Q&F^[]:C=X>/=+[]D
MEW?IHNEL88#KS.?>A/LF#RT;(;4"D[%P:HZ8[P1\;(VY/_]A?^R0<,._WZ[[
M)2IB_C%\!U[19124S6[+=_465]1\BQKNPT)O'>?(*B\V$$.B$,P-DR=E+&#'
MD<V(SU=B(A62.XH+];4!4?I:%FML$_BSU1-:U?;>^MPEFW?';;"^<UUFZS3G
M552M=IPC&4:I(@1!G?,#O8(J0D5*$+,)PV\T\*!R_].$"_W5"@AL+ZTYA,=(
MA5+]P/* _6Z<B^6*K[^G5Y !&.#R:!U']: #*G%4$Q1HMD!9Y 7\@,M2(P[P
M8SG2 8.,)1@+6-):SV%HK&_0#+6PQ0)C% 6O G%B T%\,#F(#D1JF>&HRV4:
MP]^O12G!7)"AB1U&O?C#EZ6,]-5!(W5N*D0FY11;P\O[]&CF^SAJ@:;;E5&
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M?EZQC4&5:]2V,C3.?#^E;AG,4!<TRM0'"@$=#Y8#N,9@(^)#ZI:8&]O:E/F
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M>'N@>*1V9_\NF_CW6DF\VZGC3VAS>T9YVC*^8?L_)J!L+L6<+VN\J\8T$%$
M.:C3D J]91%)GQ4$.FJ0KV@]%W(4\&44T"C@E>CI SF_3C-4+4W]ALHW2/U2
M2',T,C"G+$9B)6$4R.)"3. "5^6M$5:U%@'#O4P*,+]B-+72-0WZH+G"<F26
M<G!Q:>H"+M:UV[XC1;S]HN*)8OER#IE:BE+'>$&(^2N#X_MC1ALT*5@;G&I9
M5K"CH-U*O[C7 PB-+4N319#BZ[42ZMY&CD;*BLV>FX=13-EWV*@ET 4FLQ=P
MJ'EQ;8H*_!='P6SW9D:P]'\1=@5")P)-@T%2M&P<G(@KK39E)\*2:<52_S?=
M)64EL1T+1K-\#99S228AQWWQA?TFH_\[UEXY;$]D'&CAVYG->7*U?R&F!Z$
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M<B;AM B>3SBX584PK#E:E2%XB:L!K833\(E+%I<4U%;A<BQ_2G&1MP.E0I
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MJDL+#ZW=]FJW+^G:Q"U <PX9JD^[K*FUJ_MXC*C<>W)&JHA<A/Z8+'/?IWQ
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MA?$-/XL$)%XSXX_]7]C2I?A/<>L+/EP,!P9<EFWHF_#.;"#F(N8\YC)K5^4
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MSV*@SH$."4\!-3W80OS;6LQI;N N4]^*.,Q2ZG>:%V+*8D5E:)F+C 4<)SK
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M*/U\WDMEUG_=SRW9A, TQM9F(6S7;0+NBM*?1RG98^O>5[9_4/<1DFR=3IY
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M/!U%;@@Y8)FX'52V]E$E(+3_,P,);K]G6B)B<RU'HC'>6E5M)D3!37F]52P
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M\Q#DRV5Z82"#8X>1I926LK2 0VP#DUAZ8O[8\V"?Y$S#@-QO=UD=F:7QV\O
M3R<XT]Y?<'G2!/[S\W=+[_LXP7K^/QMQRPW O*98E6)H^*I5G],[5WT!6U/Y
MV*Y>*4[)?>)FX?[.-]E]8'?Y C.^/1FZ$SD-?#]4;J:ONH<TTQ587=B3NYW$
MVF#W@76.U&\?,LR3'#)ZW0$C@Y&Q@F8<[G?[# V&Q@IH])F=,#)6(N,ELQ-&
MQDID]+H'C Q&Q@IDO.GV&!F,C)5R!B.#D;$*&0>,#$8&&S08&6P$?1)DO" ;
M.=O)[P>1-W6!R!LF'ANKKX_*5A@9C47&8]O)&1H-@D95%GUD.WG;D>'%(7[X
MRP\'/[0+)0M6CC?=5]?!I$ZHN&O,ZOWKH-X&7VLC[R(OQMKZ5,!T.&\]%;JU
MZ-(&>#&'>AR%A['!6C%KQ4P^6"MF9+!6S-!@K;@>R-A<*_Y94#<^IX&A6QV&
M5E^XL'K\M.KQ%S52B8H\U7I"M%.*\?5M?9AGL9[,>C+KR9L(-MMG4S;]N/64
MYTGCF>H'*F91K''7D?R($^H1,BO7Q-H1:+5:8V<:]"3I7W7"!6M4VX?*FGPP
MA@I#Y98)8FV%RM.*-F<!+,AXQU"U)KFLK:AB O3@V69MA0J;=K9JVFDKK)@"
ML?^AEA3H# O]/8#CHMF^=O9@/"K(/L;=N].M9B-KY]P83XLLTZIZ5\'%K@]&
M%WL_:@RN]<+\;L-K!WTF3RS:P_6["B[VLFS#Q-!LS+"[Y9$)THE,[Q%JW6QP
ML=>%"1*[7VI&D.YEEVJ(/9U=+TR&V =3:S+TJTH4MEK:U WSX_'QZ>G962/)
M4FO\+U),$C7ZY8=)FLY^?O'B\O*RJY77'<<7+XX2;Q)<*/U"^6.9O/!E*E_T
M>X=O#O9[+P!J_?Z;_?[@H'?0/Q@<O!Z\\-75?K\[2:>;P?;@</^XOPT#UE(7
M/ "E2G"=85WVN_T<SO)&FMD>)#>0P=(E&]+*$NB>FK^V!RM-=M\PV5M)]HZF
M"O[RA8Q\\47IE"JO'2,*1H"#5(EX)(JJ;'![=R>IY&ZXEK8&T0U=2^W!5<M]
M2EN!4K^W]^^= Q+[CUB.8\?1%JG.JQ>#-R\&O=[!SJ&)/45,>MA%M$724S9=
M[0J.&FBV8J)30VL]@^4A:H2U&2%UM^_<P[!I?NV_0M@,7K^8I8':&^#?![W7
M5^IJ_UMKS)S[W<%-=LO&8[B!++$)GIS&XV)'O3:[0]P6W#7DTH'_4OSC87PZ
MC3\#.^>_8=+([I=:Y(R]WOM7JR'$CA>F+;OH9*D#;3EX\?H%BG2MQA&[5YC
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M\XS_2/.<'P_IAJQDWL_(:R$ =,?12+18.1#W"(B>U0SZ=13V0!:\RGQAA#5
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M0TY;X;,#?(5;/97?(W3[4;$HJ/81<'T;\7"3B5ZKP?:7:@^S4X^ K4.VV]U
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M;_4B)]7Z5^0 TR>I724Y)3<=I#D-DVUIZV?)L-FTW^LJ$_>@@H"Q17?@_GC
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MPU[V?R;9G\X/$MCS9ADKR&Q&_3[,6SUJR\Z=SJOK_6:]S-G-AE;WDB:\OP
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M%?QZV&DRNBR;37;0\3;!FK GD'\B7BCXO8O?Y?64BIR,/*KN9Y(BZB)??&D
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M&':JA&,I[^B3?QMBD1-!%S3K1GN2]:/=RK!RF'@58NV6UW]W\@WVA97:$](
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MQ01UC\ED\$P\ 0#_,2CCA'1-\; 9#$XZE=(+?9<VB98K$\Y1%OM(AJ-]^^)
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MBV0?YRDJT+,:VTPJ \L)$C#IU9X/Z44#0BU$>Y<C] PIF,[SXS&<D]&R/GZ
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M;G/T4[=OD)#X3Y&V>\S"CP".G_YCEB8+7*XCFGN]:QSV> \:9T#8_N39>36
M& WA!8^:L&:[E-3*7+Z4G?'JB"K(ZF,@]0??_\YGFE_W*N9F_>G'3X#]WYY.
MJU"^11]1?*F[5;@H^]&3H-BCIB'J&\EGIH(@L>W\]FL'?EZ(WD@!FW20F!\,
M0")5%0[>(-'U8G342:[%RDFI!<>%0HFMU2'%,UH4)HX.&.\&L@D$6+1=K5TI
M_]ZJ0(T C3R $$5Q\'_TB8K8?C?F2E1:X.Q*]Q+G< 7#:Z$0-MWYQJBZI]AT
MUX#U4X\#X%ARRU6Z>U2P1Q!C^,K8-< Z=9UQH#![&FBF">Z]'*2]6P>F\%6C
M!!CNJN/PTU3'[D%1I85CFWG*C,O??XZ@>\VP0=1@-Y\(<E0#OADJB(9,$7P(
M?HZ)V(<I'%;C%B8U:]=)R?V.7&S8?OR> V=MY:<I^E'V>#K]4!C48' '\6B9
M(^]^#C_-8/[!.*A7[&QH0.YAN+!L'I/<"T[R"15_7N&/6E-\:?A1>3&()+&#
M>9YOW_>YOR]0:N%^/$$IS!'KFETY&$QG*'=H 8PZXLP"OQ)P1DUZ/?M&UHG7
M?TOUU1,XT7E2B[-(L1BT3 /;PE6<:$1G^H,[B/IF<WJ-I_ZI%(6%V+U?+L0J
MZ@8LV,**J/RHX-;QM<D[NW4M2=VF.U;5:]P*TJT^$95PTU]02A=75U9%J#MD
M[&,HE%T#,"BLS,O.X OLJ,FTG\Y_YB>NJ+SW((G-D"+SO-%6AH*'.,Q^CAZ_
M_8H N5X,BESM28T2"DMXD%:[^^2-@4N%HV9"&@?=.)P<*0*?]5G@S(4)6K4]
M0[H^*'-*+/)AL(=!L0;F!FKUTVYG129Q(E]S<Q>*XV@=&LKG9L0[S>2H#S_G
M8#M=H)G=6R_;-)$>A=H/;X.W-.&_4@5X?9GR*]EXI0%VS5ZOT#6*8!^ZA_:Y
M!?.B]I-FF-SP<N7NYV-D\T$H$</#J.99:7C+F#48[#[)5/.>_+6GHD8",6XY
M[]/<W[].,_E\=L?7 Y\.&2PSCDX(U%UA,N\Q'$RKL)WTUU'!G"/O1)[FK\\Y
MW XZ<..1J&CX5.WWM2#_XD0_O-'DU-9KNQ.[%;K"G6-6<1-LQA.T3Z*R1=0L
MQ1R[&4="HVR6AHZ?EWTH8 7V"F_6L*J^;4/A^:Q(@]%]#9B$*UJ&QDD^2KB*
M<8I-_&#I$OX0XM3J!80+'JU/'7!7B9I]_[A\!Y( M_/>*'02.Y5/WFMX)]]<
M).,)0G*!!W"7QO0L)#^[XFF>)^\>?*/?T^ZX,,*]EF%/D)N_O'HB@N8L^"!?
MN-4L9XUY2K,#E U[A^+H9I&B1I.&L>YIHVX]51KG*K+6\@RU6OFK>\-H7_O>
M45_S]"9N#$83FB CK:]68GSLYY@V;JDU=E7KR?%.R_N)'!HQ9H 9@T1)7A07
M$JFEE^5T6J9CW#VO903ZRZJCA5^'SH"1>K]8R'^A)'$E6CL8@RHY!4E7ESHI
M0HVJA<@*1J)5F9/>';R0X U>3C2SG=0FH*,)SJ>]&=J5,HL;_/98[X",$U(Q
ML?ST29%<,*P0"8FMN)4H(66YZG!C^+YI"G@H^E,J2.J&]^,/'_*ZJF%$2J>>
M& A#-E--WD$OPP<]@IRZ/>9GQ2]0AN*XZGAR-?.@40GQY'(2$4M'F&O;U<&>
M1&O8 4UKMB>*1V%%$#2>?<<+#CX<]E")T8%<6A1O+CBE(KZ[^B=2<)4#9.H%
M;9_IMG9K&@<*AEH]<UH34GEM@PT(53?-R]4XS<6C9:D#O%:HH'P(B]*B3^$:
M#[#T7) TJ6"8^.X^)/:.#@0\1Q<Z5?!:$:#1I(*%;=.A&:ZCS&0;G:LKP:;'
MKJ.M7NC0<H&9.,*:5-*N+_>#'SX@"!'L0H]?-%0?Q27BX+A;GZ/[4+/7>195
M<PJ*$^M,KVT0 J\10'37&!2Y,;A9UC-)J9X( =FC,L15U12U*_N2>FT/ES/X
MT&F=9)@4E=<-'@ 3I/!FSH7L[0,4^/-'&[X20J;BW"QO?/3X*-/N07(XXD-.
MMO;/%OEUM$:IZ]QBN70V@K#\[] 62'>"R=LYVUV)HX9/S*?VQELJF'0_IK=:
MWS64!^@*=1#Q40<I 6$';E2C-DW^K_1&.2")$K+G97>(U.K=:T-B#;4>@(E4
M2BSO!VDR9&:)NRV"'C@_ /*"C!;%'E@K(O2'3+JMHE@$S5EN\BR6U0P;%D>8
MN@^"EB0*ET7#]ZV/Y<A]^MG0_>LDLU?(S");\AV-,$@:@)T#Q;QWD9S[)&#'
MV&+2W"JVU88/$0]RQ]4/0K@V%S7('J6_W9QCOA"^YWR,79P+[,\%U1 :3^GK
MXX&Z'"D)&IMI70@KK-?*H)I(Y\$C=0K.F6*E2>C:?'D*%&.V'[#A 'M6Z-,T
M+/$N:I+(':S4-/KA(T_C[>&KK@%XG<>[7>G2J>N8$1S07I/(!UVA<.\YD=">
M$I".J66FK6:.YT.FR^C,*;X..W"U$22/E-YXR0U*9?)W;H"Z08D>"Q GGIP&
MY;O+_78 WL;<NC>O)Z,-T19%?^F=@?F#0?>JY;V\38-6I=7C7C/]U-ZL+A1^
MM_8N'&9,POGH\PZ?QJMRJ6[HPCH_64G@F31!]7+H''4TJ\/>$<T"/!RQ<FA"
M+D\KQUDK2U.*M&7>Q)=38,$AK33IMG7D5;Z#'F5UQU",_J&)QF4Q5LT=<TAT
MZ41>> "Y'^OEO$ERA^6J1D4B5:)ZX7SU(,.CD8U1K:]BZ[3<#9./8H(QT=R8
M52/E<30E9 3$ZFDM[[ Z7.E&.QQ 62X$T9+D-)</5&M*ZD;M0:CD*B!)!8V4
M3W!:D@SSM<9[0%-%)FZ3=/Z/D ZAE/4(\QA<5;58V]7CHUI-:8=PPU,"'O6G
MNWWHB\H%=;I$!>ET'E^'*N+@>L#6KXB>==#JW?TZ$JH6WL$6ER++VM.KI(K#
MG8?_<DIGUHT #_KBRPP[4 ^%9\8V,#M;W5SN,G?V8-@B[EQ80;JJ\ Z.K\%$
ML".',0$Z\5QHT\3Z8;W!.1F!-6K<E/9$UR*P,?B!JU[D/C&@\68.L^L9*1,P
M.Y3A)BN=47H.$R[T@&JBL6&R$1!_G#/%  Q:!\HQ-%])2P,_:R,[=5;18'D.
MA._;DT=MQBZW?\C.?+,97 .^!AR9K]G(+#Y[K7M/:I: ?&FZ-KO/.CZ6&V5]
M\Y4&W!'31+\)?=6Y0FF-JIY[+^-S3&YO"3SB\@$IA+<7#H6\WLAQNK#:FG)@
MNB=;UP#P:Q8&2JJ^VN<)/?84B59<A4)0U7Z0/:+/J?QF%F4.)XF/QQ[UE,?8
MOL=*6:%H(?<)QS6 +&'YTH/C*DCJ0+/[S<[@=.PUX-/((1+5QW+>G;076)BR
M@#49>K9!;:D:/Z61^X+8#64;'LM;)+=LQ#PDMQ>]G&6Z>?=?N>E_V]BE5_K;
M67%!U-_8C#VV<P1^5$DX0A;X=IP=Z_<J (YSV8XK]]F;]ZS?JSA^N9E]+4-(
M;C>6_:@#F/[18^K/*MG3/WL4_UE%'M;C[PO9LLL15L<SRV/*P"9=<;]O\4&7
M\*-.O&7L^A_]8W>?S,^VQ\P'T4H#/Z27 LU0O/*CA%Z(,=E0P0*?[;H'S=&3
M\<DV;Q"8X44]]TPU)"1&-?,P^W(-Z)\0.!XU<))NBG5\?<$#'P9OD1J0\+KT
MXQ;/^T0KOG7+#1R/[RR), U0!X']8_3+0_&CA+"+RY9K@)O2IR:3W[D;-6Y:
MN^5K3(:_!OQLVK8BYCYC*ZKB;IH"Z$D2&%]*KOMS(34Y?_+]TS')G]+W:0H_
M>/5LE%Z3C7TU$\@M(MZ=IR,O09P)NY>,]N8GGFTD/T20Q?F=O#'IM^L  )8_
MY5*XS#2X!@A8W<BEO/U3KM2_U&7XO]8%<1 B@A:,)T<:>K!F3M;NI?(L:P4P
MHY3U/[U>X.\^L'V?GGITYMZ(J'NS<DOFL]L]*6W)Q0S;K.?)O+BD/!F=-!$9
M+E]G-LL&!LR@$#+,,8DYPV&X0A N:!GO70,&;A:7,\\;+E3TYA5DNME'#A\!
MD7E9J5679.DW(J<FH6P>LPP[VY<(K-L72'*[Z=> U[4M#0>$PPT[U +M)0VS
MZB?B5UXW^<#KZ35@5]FCN7@G[/+.^,T2TN@:,)<]56DHSJ!],7P><QK;L!/C
MY'CE$^MX=9?R9/ :@.CXQF.%*]-C1M$CQ.A/%;.N ;X&LR1G=RNOX&ZT:E-P
MF7QKLSC=*U#M\2'WUZHD?VP6HG9!2W*K%7W#SA/=*YJP$U7^^S>H #V^Z8B;
M_Q7A/^+\2^)8OA'X.^*<VFPO)4TT?!ZY<9C*EJ0#@F&/G<<"[6$GTKQ<UP"A
M^IL4?D?I L1XA1WVVF,%9_KD >,U %O\5_F"(!O>7QWWY;9TE\P]FH&S_6>H
MJPTGF$GSXA>//Q$*[/_6:,DUX*_=,*O>HI/K'P3ZYL$Q5YC;M^0]M_=7-J9=
M _"[_ZS,-0"IHUG@ -GR C'F&A#X\;#VT?_/3/\?<?XCSG_$^3>(@SIGB5RV
MSC5Z4$J3K>)1)EX%.\Z5+?#'\36OX=?:)#MYK\BO 8(5-]GI@\=)#B.P!$VK
M]C3SF''_UX$Y]5_(8Z2+/0VQ'C;7 !:9"Y79;%S0NB:(,:7Z&>>%V?3_9<!3
M* /J&.G".\\^10^)V!*PM1IFDQ/:MF'>3&W:V4G&73QDD\QNT+H&_#5< FY?
MW<FE&>J_ <;9#VL^5B/>LIH^#)F8E,MK>YEDAJ+PJI_:QB%^-WY7>RQFON'T
M;&?["E;N&M!!8[1C$8X6A99@\@ ZWN&,O72_BVZER4_:<+\,:<57A:I*2#3^
M9&VWT#]!_>77GE-WGIL)>2&:QPSK->!"FU@W]&92O]Z2=((J< W U1;%3NFV
MN?KUC^+?NUO^UEW;F((HX!]*1,T7_BX0;59:,AJ)]$B=9?;$FA7%%+&POOV1
M\1/$OOUB7?+E^>WYG7P2Q@Z/_</9_@OXI&M 4+X;A^2;YU4C)H&2>(4%[L.D
MML? %P4(%5BJ(?_8U3\7YI^64+;/W28TA1(=9=X(%P4F=0X&67+2EYG@36N7
M*T!8.\L3B/>?)TR2U?BF. CO UH0L&!\,79'WJ9YK[>\-T*]!A /']\,X,,7
M#40W<^RQ-P([^!Y7##7JJ?=%PKTE1)$0CS('$!@73[:OW.MNYA">PS<CO9WS
MK\#;8\G_"T7L^S4[YDE.Y YE*C71H0VEFY61ENR]M8OM_*^6N?IG=<(U=LV8
MV@JUUM;V\ KHYRL-*1>1?/T%=.,'X 7#.IRN 6&%-['W?S ]%LP_]8[_5I%6
MD-H4YV"9]*:L9!T?#51P_R%DR@IHVL?RJ> 9KST=-6G-SA*1L$='V>6-*/:U
M>6;%(&Z^I0\\-:*.R,\VWBS!^*'13##[ZTMX49#YPIW+([#];T#Y7Q5!M<]V
MFAK7*1J*M41GF1)E36E]H"_B:AO>$+]]22O>O3M]<>ED>PV R;P&S$<5VJ:U
MV!:HK^7M(>;-1;,J'$M$6MC>[DP>P(+Y[/SO /+/11Z%=0@:3I[\E&!DB&GB
MWN%-K F-U%D7K*AJYMDZN5#4^$O<SU]^;#O.LR[>\T>1Y]9-1(;T!PZ ,@R3
MD[,5P6+Y3SCN;P<V"!(V_!(R@W_RN1&%OU\"8@])GW<%N\I]A[*-U5L([D2(
M>&*WX=,U8*@VMK]Z2+]ZC,[^9H4'L9;&IQ*@Q@3W>6R'"SZ\4OLC#H2I?U(A
M$ZOLW^2FOQ5I^*V(3:D=6*[]K,XQ..+$1:!D2MK448AK0GXFJ6&J-E*9->$)
MT2,&"*[CN<I$I5S=@0D7J:L\O,"_';?_J@2X+WNNEUQ^R"_MC Y269EM.@?%
M4QFS,GBKT7F%OY'+HS+T:%2G*</YP8::I#WQ9YON>X#S5^UE=P'T_X8]YO^K
MSZ/T-%:8L'QSQ19]V\LXQQ>5\JA['_;F* @C%&3G.\R3A!HBE0<V&8V1***9
M/F-@L!SPAJ5D%1X@2S?112]\T9$0 O6(JKR;'WGKB&X06YYAMKL:30LFX)F)
M&.*ZFQ"FRCE/,> 5\^-H"PUMD#_XX],)&4*%T$+RN["[;/1"CB9@-QCOK2D"
M?[DG7&^YDQH'X)',N;N=8FF==>4BFF=8Q%&$@CM]'H;'<9(F?L$>4N/+=-*P
MJ[>85_!1:3!**($4&# #X.^$Q3P2UX]7$Q877/N!.:**A:6!?YU"G:*V?T^'
MA2%2?]CJMFJ(*@B9HP[7#P+KD%MNPAPRXP*_'BBG)RJ'ML;!71"".KE ?;<%
MDYAJW$H1C3GQ,%>%=?U>V;@0&-'&*Z G/E'6?)*9]&,@U</;8Q2$?62^"[RO
M%3MV"AQ%(&P\(1*B6<A*J"-BKDIWBJB2YT$+\?$8-LS3@:N$\(IIAO>]:0FD
M=C;PM3?&R+;69M^# TST1! C'#( \^N1;41"&V"T=V7>T3]WN3+7269/K6JZ
MR!F9QJ 8J;CM@>^ES516'^7;\;PCT<S/^M*6!64K:_-FAMODY"4<C2)01I>2
MSN+KN!&M\19N:E3Z1\EHMIMG(_Q4@5#C(E?J8RQO-DLN+)C]4I.'?4X=>VR#
M8P(&LS[ZA9/FV7GF3PEB)A_7!8>0/ ?P:S>BM7 NG(T)_0'0N\:@2MR*FN?#
MZO5U-LD3AE6JAJ*$$2K.O [8F<KV,@+G4@/-E6HX$;#5E)5Z1'(50B3O61,V
MD\<^X+XY1&331AHZTO.6-$ 9AX$5$.X\4TU0&CI8*:O%K@B8>H[93_':PH%/
M?3XXMEKY(D"M(D442_$68X!?]>O=%UI.DZRT!A8[:9;+$H8$K;EEKY$/N'KM
MEDKB6FHT(+,0S+Z'VV1JQ"]$DC]M&!:WR\E!0I/-0W\!DPJD%K%ZQK8X<1_/
M./")Z3R2>BE,8^/"OO(K^NRI-4T-L#3BJY  LG.NU\E\,(J]XU/EEF#?Q;RW
M>!1A+C.\,N7OCDC/1L&44MHT\,*V;"-]XVE5\2%;KB8 ]"'?$;QD;L4A)$W
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M#L9W:8*](9:5G:P0E,?=N.XO7DVFG=5!W^>4I4T#7<8^?#&8*E7&9/-53H3
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M(="7<#CD7=!,#;A)VE>1'ZDX,5(KX)GF"URS(T'1NO8=N!A$*(H?,KPN_.=
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MAP7]=4;P]*+]/,L!'DZJ1S]7+E_!@$0KJ/@A?#TSMO((IGKZLLY^_PJT);H
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MO@U#+]O\?#?=?%M:_*XH7^");++V5,J;\)FUHV7K).GP#[)5>579%S2H5'$
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M[V3U,H['T4Y(OOI]$3%4NF!S>/GJG>EEQ ">G$#G$ VR]=4[<[:0IH$^0&N
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M<<-/7\5%:?G]##ERU<^9CV> SU9S P9*7&QOVG5,G!:/*43;[-BS\W5Z.I9
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MYEN'@MO.(_;*O,9HV76==]_6-><KCE$QT4,\+00$$ &7*3 /*5[B-P9&V^$
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MS%]JMC""P1*U)^,CYW/&Y!H>JOLA7:*F+.=ZJ?6W?;T!33P$:?HI:7=WBHV
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MVJ !?" )/E+%3#.#+X@Z^Q660$$V&##XR'K[!A"G=QJ26W@#>-6-'4#J0:J
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MU1]DP2N2;O+D5J(;Y=,>]M_71#7]7W]/0F8I":5GOQ0>C3 RO(HI)ZW2[Y2
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MB#ML(IP17WN$V4VCXBL".=^^G)=91'R]"O/^JVI0Z(X[^(\?'VKQ/CGHB)9
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MM:K0^)$U';D*$8!#D]66%N]VW/IMYN7Z-"=\MU*:V9).X53]:7X%+4W8G3N
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M>*B?WL4-8!>1?_DTKCQ, 5N";:J/SZLK_:\E2[B\W9V'QUCAG;D$;[;JE%?
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ME363;!;9N3!'J$?P^;,9"FM#J6#R0)#,XE"]ZD(:_XQVQK6M==AB:ZN,:D!
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MO5EW-,AG +)[IZY8!^6E^N.YXF?=>*?G/\L\1./A )GU_OQ_(^/PYX6<[M8
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M5-O-2G\\45Y2+D$8P38VWJTU/86\05YM7A[[/<9PSBA$=/ [BI1"@^+[:OM
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M&%P^]6?NDRH2U@?LJ\+^_SO53()U=\\!/'^CW&0_*?>'M\<FQX@G;@=-KH$
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M]?8$ZV8Y(6>N8] ^U8U5)9XL[;H<.6X%IVQTHL#,-/]03J@;S7V@@7**CJI
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ME1N+<H$"*JKSY?7;M?H<;OL3K1J-DC847T.+L]XVI6J"0"GE[E48>^^H<T!
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MLT8^<:9T$JQ65Q*4(GM)0TCU;,C@/<*\!PWZS@F4']FL\"6Z 4SBFMLC>4%
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M[[7^>_>^=YQQS_G/6"]Y,QC)EV_.^<SR/D]"_4Y= $[I:^MI W1T=,!]VA]
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M/!78L;<;!R^TY/(\1.&'60BLH8LNR0P_K@>OJ&17SXY%HWN>IG6"?@=M)NT
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M4HF$E[S@U8NP!3#Y,ZSB,Q7(-=ZF L]@MR>L=JO_;$=&EALVTEU!<RT40;(
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M<"O^>A4,(H5TQ(9]71HXHI,A;2@[Y8BS9K;3Q)_1'8+Z[DHW@4\Q)+"#4)^
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M+2&R6[H!)B_2QA[/\V$]WSA"Z1+#F3PAHO(&#.,M&TRD 19KNJ6EE14INS:
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M 4N^!K4_9UT3/R);Y^R78E\CI>>[*/&-9D1W8_#2I"G!YA3GSV!AA&4!9$S
MUKE]+QPJMY!F_,'R9=N#\B#:UZ-''>\?,3I_9IH%L3Z7.MS\*%='V3SDVAJQ
M?=3&4&99BN(M71ZSB2P-\>"E\$F;M1<8;WK605$DE\DOMN#WF L,(/,C1@1Q
MCR+=6J#A,F/*NR(<B_(2PI7NT%X\*)4\:C&?&*8;8Z83<JKW>7,XGT"<!A\9
M2=4>U.#^!A\F;7R?)5Z$HW2K*2>K@E)WJ.=R=+TSDJEE;;Z_*84)#[\>GTU7
MO=C'DF(-OI6.QCX?",5R>7KZW!]CB/U8$4BIZ.%]/O;X5]+D<0_1VDLW^N?
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M61,^!B&S<@DY/E@1.T3K*D7TUJ4:A2?=Z6#G_:F[#V93^"&H/$M"EQ3#Y^B
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M@?8N+?)B2G6J0?[VD[?U-;>B]),E.4Y(L&- >E"K)T J/_]LP*6S(L< "G1
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MV $H;%J+R%=!V#)6M4RS+!]9\UYL+&N4JV;UX7#H]C6]>T*@64),0)Z\2GB
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MC* ^( ?0 =:;Z)U9+TC4,,6+#CB:00>\"X9JT0'%?KB#ES6H'BU3.B#1!G1
M1N]\ -HTH3=+&<*"B@_FU^4!SV"6]9=@U+.L=,"%R!;@ 74(M,,>2.U"#9J0
MU;AINEP1H-W]K[#??+O[:9!^&A#V,P;^#;WS)<2D#;AU%=&UI3],!Q!N:[JX
MX!(:-2*V?H];=,V<-).H.2UH7&^_WJ+SX[IKK@1@.PZ<#=4CBQ'L6D).#+G7
M:Q,[YUIKA^NMD$KM!-VIM_70UU6] 8;Y@NKG=KZBG\ICY6\=IE-]\ TF-A7#
M<A]'H5*P'"ODF_MUG[??DQ19O(\<;TEBU;YRTK\M\.V/T51[R]K,'+Z<*MD\
ME^F]6)B75692Z^ C0^_]AXB&A@V46X]\X](O2"6PB8N=*D/F)2A:_/+N^[YB
MJT"86!%JQ3FE0BKO:GW3&7W^D-+3?.SL#BIP&/84%JY"!U0B^]ZX*;$7F;!)
MM/ 1.1*MG/E/*JD^,5 ]T2=VYH?GZ3+1:YV);?[X$(9\90NY"CU)#F8$?(R&
M>^O1$1UAJY[\<73DR?QQ'R-S^V<6<=VB*D>8DE[79<_(N^+A9,F^T/KKE(?.
M.IIP7:+LEY0@PI8):]['"/YTX2K3(XO6 GH>=9I10,]Z(4*/C;(>&[3?S&VS
MSO,NG]_HU$0E)L]XYEW#YYH7DTJ5([:[.X,VE,P&1&@C#VT 42;?=M*K&<VU
M1 ["<T7RD=+CZSM0DRL&!4V7OZ@:F+OQOC*]?DU=[/NY9:H>@:NI;ZR%=@K.
M[H^;7<R=ZSN]&JA;7($_>7NUBD_LCE4HS,N51]?\IH"Y>G(!1HO::$31HOW2
M4&V&A +YH<I?)YR](/X4@\KO@_.5\4*2MNH?QCHMAL*;YASMLH=_:RRM*Q#\
M2%']]2)?H8_Z&\_+QT(EOES/G>R97:IPL0F99J:4J::O]*L?"^-AV3S#=:W!
MYWMUK<\"R[K(,8GRO)YO8NY!&1EI&1E&FVX1/*OWLI0O=A9:%9J3LW8J4"[>
M$]T[[A&BE\@F,USC1J2H4@:ICWB :>3M]SG)1;O$;QF^_J;Q?(1+3?SWQ./M
MX<B,EYW2^]5='*<?B7(=1FA)$9_1>D=42CIRY.-V9/4?$>_F\+9TB!.QE?C[
MSYY&M>DU55P[MG?*PSK_3T$6)*)1+&S./!%OPNY,XR9@6O?+:[PIH!.6V#D#
M/LZU*%.]>!UH@6=NZO1+15-'$.&>)B128D9W,W*GBY*Q&2%DL_@!:67[)@;W
M(&'A^[*P3$E[\\ON7 Z>=;5BU=!NI\[<%JF"CND-L,D>'W@T=>539<SHPF"*
MC%N)@($DQ0W,@_Q$!^17A<"XLO96QLL(+LVXHZ 7.. *A+->D;!TGW"\ F;O
M)Q_A@R;?EG//J\D^@34S>B\^)< 9U59?UG[B*&$XQ7X6_09R'&0'#V]4(<JW
MC%,=\'!!DR*K#F:7-'.^4GU7G[(>K].].^;1O \<ST]6XH^!FD#EF":N<11D
MA HAM+3@3BT1LQ92>KXDLD2)#E(TKSD-%=V.%U8J?6?:64=,$5?HF-1"X:LP
M(A*8/]V>FMV/65JM**PT,B=;!M^PR+WN?J6^)N91_2>!DN:<J1HPBT"?Y7K>
MF]9AI( ^5B_VG7N/NI<36R9V6]VSZF=5Q:8=ZT@NFYM)XE 95AK'XYJ'#/+R
MGO!R("V3#69!$:*:!(9A0K]M>C<P8VQ/?R?>T?#IZ:AV52[F*/S%*KQH#Y$I
M.N-IHM;V@M:. &H)SLJ'HT_1A,F+VU:$13B14_,^'<#*&0](Q;=]='"7LZ<,
M7-O'FET'*<9!%]+B#[\VJBV#A!^37]2:->:Z045F@D$MJFB7>.Z>FJJ \6GM
M;^-Q^[&A$R8LTC*?#M^CG1BPZB\VJQH=(D35)Y#R4&3NUE&/E1O&TL\B[P^@
M3OM&Y\AOE9P[=S[A^/2;,URNUMI."QYYEE<SDVV"-WW!IL93*M^R$&U#2^&6
M'NTU@\Y2N/RZPF&GTB"GDM\>M+YI<;(+@0L3&-GD'J<C3 Z?J9N21,?L5,OJ
M(@\L 5XREM8LCLW%>!N+LX_GU+Y-/9A=:L:-@V;D6Y#@]I!CU>1$/"H*&S J
MI*[<E24W:E@F'F"8K<=>QYQD=>XL,>YY2MHZD  C^1'T8^;(-W.IMQJ(X-B=
M#^6"/A#>'A>>0)O,L6WH>V0TEYBK-;^8$R"LR1QI3[E-E2,/$VXV90N0R[Z0
M%R?,R3#FY0.WHED/Q_6@9[=E.#HT)4W? Z[T%:LK+TD_&MDOU'-#Z" OLB59
MQ\NYZ648FEM:5 QTV>9K:9C'PE7EHBF_3#+RE?? &_4;;E15L@3!#@,4U;*7
M?_.M_@E15:]L8'9(2WU61MCHIYO<AOWCTB8/[Y*PLRJM\S\--S@^*GX_OP=R
MV1Q;,B3 UA(:=4 <^>2;>&/5UM/+94Z@B2UGHC-?4EO-<\WQ= FN']8)S-R9
MQ=+D!R02V<-5M=6$4^*-,H,\3;,2[5.S[/-MR(IK!!??KF?=-ZT5>0TL77L6
M1<:;I(V6@KT@9]#.P/ 6DN9H([^_XAWBI!\_EBJTLI(^9]5S*4_RB+U3?143
M\)WDO=?;59<]#;[9<?2M/IQ/N?4NIPY=9]\38B'I'D0I3=FM-:],> 1ZHKPQ
M5? "B9Q">B\L%YH/C.J$D]$4\;$_685@BDL0^E+RQ=GV_* 6]Y?E-+N;@QO'
M&MHKO.0RW,Z'=:N-1=IM/+XN<'87I7[X$?;DMAOLN3RO?X_.Z178\=V^8P8G
M^\:!-JZ6?3;EB<TZ0OH."8\:]W)8!,2IU2$RC.")(H-;T161;<:>JRT'&[D$
M#+[W@U/>2CHTVZPQ_T3H@&22/Z%/(%%$7)K]<>31F3AP)O06.9]@UXPXN@OG
M@*H3JJ*5;5Q:P5<Z//! _@F+0Y11A%BUKN/WM!.0MWTIXJ)DFWHR!Y^+\:\P
MSY@XQ\_?UI+B H8:=H5QZ7MQV9/%%)=H5&AZP44'/YW1.O?4Z=7@2B=WKV:9
MOY0A$H5(FV0)+FKVZ"O0*@ER*)':V*7.8#;!L#]/N@T<7J?1 0T/Z( SU+[3
M__Y">HSD1Z;&1,9OU*4#.F_J &&3^G2 <97/MD_@Z)H\<?7VX7LZP!G&[C]G
M6SE4O)/%O1X"-3_].8UK$6O"M [V?K!]^_-")&!7"YR6U9_UHNZT87I]'NOG
MNBJ^Q/&TAW$*WOFJS_+X:#O![)134#FR%&&)E$'H17Z$^F2TAHB%@HW%C-):
MP(%G-<(G<L5?=G@OFCWTG+@]D7H9T*&F#'+ C67OX9?B0JZ2^]JG68:T'A21
M[:S3>^5/.*7AGA@=ZEE8+)Q4>?CY=(3Y,9-N9&(F8-*A!18%*L4U<XDNBTH-
M?M-1=ZE-B]S(19>5#J'+SE6D^O?^[H[GWL2>E9HK5O_Y4YDJ0O%WFE8;HDDM
M0WB5D) '!%B;U>ZP'+?^![Z]6S7Q9>P3^^_UV8J$3BTEGJ%$[&N07[1[%8!/
M]FX*2$A]SK/7K. 5-2F="-*) 4],YH/9!9IY [P]?6-=742$%Q=7W59K-=#8
M/=+YR&9T&1?UL@LLDI\!J#[&P@^-0::_BI4CAM8W71=^)"P*BGQH83EOR!WW
MC+0T!'/^XW?3C$@+?3?MS]**XU06@9@1[^;9?8'XPRF!^&DCHXQ8?[O(GU7P
M/7L>I7,?KAK(>;Q2W$*UHV+0;+(A')9D^=G\\(K(=)M;*QKPZ'IC5Z=#Y+D3
MO*Z?KFQLS?[D>#DG[CT_4M6&QE:U3&LSUHG%4FW*RD9R"9.B8@,5OI7I N'$
MF-&UZ:=OSO!,0U.QJC/SSQ(\\K2JA,T'OBU]=O&LZY2U&5PPP;W++C26,MA'
MGDB5YV+_*KDRZ_-L)',4QF9CMM; 633#M=8TJTR$M9W4@+'ZI^%'8[3.(QMC
M/Y.=N];-?0=N)-=J+PS/2U4JO#E_K_99Q,P\[SK,$3%N]0-V5 M$2,9,7R2[
M2X1>5H:<4DG$HUD[4-;.IV-#;F=)6&@->0B5K7$-?=7FW#!I!E5NOE8V8:$:
M$ZJB,*WQ++>)\/@-J(U= =G6RG^7*6E!%]FI%9/'M/Z"Y0E#LY2R+H(<X=BP
MV<UX]#,$!U2!<#<6C[P*8EW=@C3I(,45A7^+1^]UB+6W//MB(;SG''[CE=]2
MC"U&L2 N%J$1ZV0$=@.SJR O\F["/#JT \*PCV<CH?7("6,^ZG3:!&6DZF8Q
M86\-,HN*!%9@VG[6/\DW*J"JD2V^V+@TWK#N.+-R^L[K<@I,V0;B%<U_5%7V
M]-$M9T2+R5A?"T2(JDY1>C0AXPAF!&I&ZU7_L/L)3N).3TIJ$M.>:O+HG;KU
M\\2]J]<?#W\@HDF[)60D1>BW*$O8W2%7JI.XBH9?]*[%?0[+O-1L!Q5'\>EG
MS[NCUBSTN_./AEG06 ]KGI!-9A&O& +29[B]CA"_F_P5XU^86M6/LRX+\- H
M4[VB6?#\>D74C\<R$+M,0[@VML"/MSA[72KO4N5>H1(#:X77],M_2&V->SJ2
M1BW:*G"W98(/>S$SFY$AS+11"-\BV6X6%VF)"BW>C7*S(^Q%8Z+DW#:$'.T"
M[DU.&+P/_5E2.9-9_))+<T0MY"Q5BBQ,X:)J$D=C=81-\#A><N3#H9VZK@#E
MB0:-J^=K$J'M6QTM[26%TE_O^94\;F7+FT%@76; :\2Y+CH@"L@)52"R080"
M5)GU!BMJ7,'ZOQ:S+ 2'<Y^GWA?2##=G/K?E%0'1)&=1]!VG50YC:<)0S:K*
MX30;0DC>UVF<M;$0NT4J'NR]-:;N^>-*[X)M(+?Q$P\?F1M*A]\<M_6H@VFJ
M+0\R;-W<K+9\*D@LEF^D.KH8-*OB$[*>0;-@L7GK-8L03JH='7""I=65O96I
M5[AOS=@0=X^OV.,L[6&11*I!'XN;YNXFQ))J]DN'AX9%"[I18;.(^"TR=]M!
M4=Y:H$FL[,5*/G[65[$B!ZJI,2>$;VS8KVBS=#"D4J.X,XBE\:*CK=0 %+4N
MSX73A;E=M.DO:V\*_;Z1+Z#3.OJK49U<0;E"M2,B,;&[. XJY)=/CZU=<*&3
MI?)P'/;%J%S;@M3ESX:%W59JS&$_+'?*8I1U2MB&YI2&+!<C+U>Y3+U[5NG;
M,)K7W_&J /ALN:=]].Y [?Z7VGWA2ER9>W2C1,CHM [Z\.-\;9TH$V$^^^*H
MPP ^@KMX8J(]FND645I._)Y.<$Z)L)3T)"J=O-J*8PZ1H9X?ENBO5U!M1@@N
M^XTT-X\K:TX]';2L3"3U-'PVW\KFW=]2V3@K*3[C\Q;6I(=G:&.G0W";$";\
M5C;SJ)8*E-=K]K<;_ -GPD- @;S@^U,0#\RT_3'/$UU5Y#W"@YFT\&E09#87
M42*Z8K7!LGU_5U[(ZM'&X,?*K.=7)DY4K5]=']O<ROKF/P-&Z*5JG(FLS+\H
M7K!5Z)[*ACOC3&VL,C&2U%SQ>9@M6!"D?@DE4R/307+"T@%>EE3]?N!)T%,N
M)O\ZO.B'V4/0C$1,!83).@HY@<%6-@1\GC:N5<A(*4WK$MB^RA0 NS+_[+1M
M4#Y5U?TX'="DU:A)OM'TN3%8!O],2+M,A;>8PZN%+?D7TYCHY%#ZTOH$P>7A
MX9<=7*S7.-1NQ&?"BHSBUD77E0O9OK_]\.V/FV7?=2=_OK_6S:,(N*M%:<-5
MPB)V@:^! E#%?"MR@@@8DZVI(S4@ER[PR<A1:^<=JX7]Y:1X] \!!Z!RP"/H
M)2?UF]@"Y4"3Z;JR!_55R>-N^%S^ 0V1%)>9.4%/Y2!C)]=,[W'YE(G@\1VY
M/#K@Z/POFJ!_E3XAAGJ<*-$JHORT*O81\2M1<>RG??)Q"UFD^;6,"WU'1F7+
M$SQJ&L4.BW2.(\91I$@B.%1GE$3>$2XYRW_T25YXOWW4]^4ZN^(UCTQ\ [H=
M5,'R P%'G-[!1>%.0>6)3"!A::O&LB].0+OD6R-+K\W,WG<V/^H?YM%XY2\@
MJ/Y\'X/?A,O2)*!W1BHHQMR&A.$O!=Z#5LN!+V1XD6^"SRB9L:G=NWI-..'N
M<1?L+%8]3AHG* 7RFVY8[PN)[S5"MPBT]SC]FNEQ?G*1_9Y1L*Q[Q)0K[T+=
MBR7)3S$4YJ8_SV0U$']M*;C=00#1C,!O0&NJ]G1 [@ ZIY9JU0:;>])P<3]W
M1Y2-QDBU!W\N0T@"NOU_O5T2=@,G0A/ZC1,(.;-J*T0\RFWCB/UF)#)T_\X3
MOWLK+9SJ9[^B4NB V2$0$_JW]2B,$"1/!J^<Y6KSUT*Q: BD7)I$?3+Y9&.Y
M!H6=?O8^SM5_Z/-P4F4CZB<U\1/:"OT/WV,H-,X<,B\=<&.QC@X(&X<U-P[2
M+NB J644!M\3A](!!WGQF\ &!A'<%],-J8*U? TY!OM5\^=^=A*$D$L3N4F0
MH87W^-$!+ P]&@XDGMY"+R FT?OGZ("')0US>^@MD+@C:F23[,/U W7 KXRC
MBG;1>/XRS_^])G E5;4^9(^F/Q_O0SMU^+$^B$"Y1NOX!77''W(;=0%+E@_:
MVBK0W0:@.GWV#@DM/]0@'?!/9_^VXA^>/&1=(=6#4FNC ];;6L(]"'YQGQK=
MJ? .H]@/\G*B%C8+J>9R&^LU67#QI,#D.W^W820(+[8 ZP+5P+9NP0H?31,I
MN'U@DA)XU8^J$3D#/F1/WZ1Q,3R$#?1?C_LT4(9F<<A(04E<NT;"TZ @.D!L
M2R_FT(VAC.Y1V>B '"\;!BBLH6?U_^M4_['D=5J!71!F$S8?<GOT+VWC=EC^
MJU%\@*=!,YF($UI>N63ST0>_*J*?$!;?UMJ_,K:]I6 5_>6MS"D=NT9]=9V/
MOL5:^E'J+U9-T^/6^2;Z?6(A/8O>IK,OGCGURF(>UC8NDT!"?VO,XCYRU#YD
MJV\#0DWL^X^=/B#786HW6]F++';77<Q'%DLJC62<Y#?F:US\3R6]S?$T_)3Z
M0G+&3>UL_U?RGLV(ED3^;]7 $:1/SC+GUJ/E09N?I-0[:Q;=][E+V!7$4YC%
MDUQV[?[B?805X&O(CIP+FJR=1I7FC[*X82#M->CNJQ$8Q#!\835IPC/AC]6[
MN(Y S8GZS44=Q5KR>&-8B]?D5XN\@5W6;]/W%%^UJYA>ZUA=<<Z/T_) 0F^,
MX$Q'=X,?6 \]NX?T^6ICX*5YY!>_IQ7S*J0(\@\+2O[%A$:T"YQW\]=YU;W\
M%N)IM,=T@%D)M3ZSOZJ(8?5M+IO#3[1SY-P6V-@!(H%J_W59^,9AQ*IE3?H$
M\U$NV<SBX\?5UA^Z-2J0:RF8 GQ!O1E>O?Z^J(H+5T'WZ/*;,05U]RM/=" -
M@PDI!RE_"63X/QB)]_3<9*IT?]Y%]#C<AC9JFZ<CT&V[#?DW[UNR)D_-F7!C
M7:XXV\H1]7)8HK*EE!TW?"P6C.]_PEYP:E$X\VXLPVC)K:W]BLQ5+A$7WVFN
MC);^5:'/@<=Z?M9GW+&J.999]HK'L-_AR4N <%0O8!%M#OL;G"G4.?>LWSQ>
MW8JJL%R%O4BH?#PU.3I-!_RD?JTCOT9!R%='6Y)7 ^NG14LSIZR</&UOCYAO
M98TGGI=X6C,Y_EAQ&V@Y1H"ML\SA(FM92.:OYV#\OP-M#2BBB&^35E;S228_
M$_B3[OIO0O(9Q/.?6\G0&I9LJ%6:=PD%B]#<(U<)S4*;- N*#AC0):,E0Y1O
M#3E&Y, V1J-6 W60GL7)MF,X(W</Z9JNB$0!!8YKXMQ]@? FR"GES0ALG;.H
MR,AN,-,AWE%HR;@^:>1Y?$D->PZ+TX^?O9S'0AAF_QL ?4!DD?!K4'=!UXG
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MTM#/BD?S9$%U0-IMT'!<R_Z_PTCNH);]-\=LT:&=6&VP:?F #UJ&HM<IG);
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M"V\YK:1Z'?I,T/XEXBI5B"6=1_Y[#9[R_K%CUTY\)/9\Z:+L0K_-98+::I>
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M7[I1TM((5"2-D0&[?FAJT,;*!AG@.'GSQ)(H.!I\.WC&FAK;4RY_T!*9]WG
M/GEP7,1&>DN&@<.8S] AO,=Y(T!\!/FZ7,6F-MYL3M[I7I[QVCFV101J&5V
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MTE4+J">V=34;C!H]\A"GD'C_:RM<SQ7[E=2T-G>X:_#Z/HY[R@<KP87?<UA
M\X4!YPX[&!T>8[,BJ\_77:XT,V?4F1.^[V^LOD),F'_#DA(>5VE]83:!!B]Y
M6MK*1[PR^H6"RD2S(L)HMTF)O)Y^^;Q]FIE01Y&=PE9(K;:@1/>'A)"@40VW
M)Y%[YA^^^Z$^]#;<E4-XYS:-%PSE.>OB;ZWAU/3!YTRH=,\)\\0KGFQ9I44C
M',J>3,R2[FJPF4P#+SCXP4@:)SF'6GOL'2:^_WA \ /TS?= 2JFTH@9F\K3
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M=M%Z'4TOC*.9]K(A:!WH;KBQ]#D=U\8XR);#:YP%SBBE9F6"TN@JAL5I >#
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MT*']>+LMB)9]%&)WFB8'CB7)C1(?-B*BFZ]A7!2FRE*,?TH;3ZQ8^-RZT=?
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MSQ.8$BZJ/[ES]:PK$V_<]G1=?,-*D_DUJ\34/S'=SP,B1I1#-ZJ@-TV:@\@
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MNSWYQ[8F[3R<;_4Q$Q)R\U("GFEU,P,;+(<:SY^0MOS 1+:>#5."[6+YI:Z
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M<$-:Y3OB(1AG2W1+:.9SAF4VG^PBF-"^KI/?5Z>"M#W@QQU7Q@]7N&Z]NTZ
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MZ(*)XAQ^^F9;_+5# EZYTJ]B=VK5Y'?2O7\'S>+[[?X'4$L! A0#%     @
M)$NA5K-[KE^<#   $7H  !$              ( !     '-A=F$M,C R,S S
M,S$N>'-D4$L! A0#%     @ )$NA5FIB26(""@  H(@  !4
M ( !RPP  '-A=F$M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( "1+H58C
M!+*[UA@  'Z8 0 5              "  0 7  !S879A+3(P,C,P,S,Q7V1E
M9BYX;6Q02P$"% ,4    "  D2Z%6V?/$9VE   "<U0, %0
M@ $),   <V%V82TR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ )$NA5F9[
MF[L.,   66D# !4              ( !I7   '-A=F$M,C R,S S,S%?<')E
M+GAM;%!+ 0(4 Q0    ( "1+H59+A9E%/6<! $^C&@ 5              "
M >:@  !S879A+3(P,C,P,S,Q>#$P<2YH=&U02P$"% ,4    "  D2Z%6:1GT
M_>F]  "(\@  &0              @ %6" ( <V%V82TR,#(S,#,S,7@Q,'%G
M,# Q+FIP9U!+ 0(4 Q0    ( "1+H58_:];-T_P  /\N 0 9
M  "  7;& @!S879A+3(P,C,P,S,Q>#$P<6<P,#(N:G!G4$L! A0#%     @
M)$NA5I,:NRD9)P$ )6T! !D              ( !@,,# '-A=F$M,C R,S S
M,S%X,3!Q9S P,RYJ<&=02P$"% ,4    "  D2Z%6*6<JM2 *   J9   &
M            @ '0Z@0 <V%V82TR,#(S,#,S,7AE>#,Q7S$N:'1M4$L! A0#
M%     @ )$NA5CJ,8#H3"@  \V(  !@              ( !)O4$ '-A=F$M
M,C R,S S,S%X97@S,5\R+FAT;5!+ 0(4 Q0    ( "1+H58-Z.>U!P<  %A/
M   8              "  6__! !S879A+3(P,C,P,S,Q>&5X,S)?,2YH=&U0
52P4&      P #  U P  K 8%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
